UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

(Rule 14a-101)

Proxy Statement Pursuant to Section 14(a) of the Securities

Exchange Act of 1934

Filed by the Registrant

 

Filed by a Party other than the Registrant

 

Check the appropriate box:

 

Preliminary Proxy Statement

Preliminary Proxy Statement

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

Definitive Proxy Statement

 

Definitive Additional Materials

Definitive Additional Materials

 

Soliciting Material Pursuant to §240.14a-12

Soliciting Material Pursuant to §240.14a-12

 

QUOTIENT LIMITED

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

 

No fee required

No fee required

Fee paid previously with preliminary materials

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

Fee paid previously with preliminary materials

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 


Table of Contentsimg148208479_0.jpg 

 

March 6, 2023

 

September 8, 2022

To our shareholders:

I am pleased to invite you to the 2022 Annual Generalextraordinary general meeting of shareholders (the "EGM"), which will also constitute a class meeting of holders of ordinary shares ("Ordinary Shares") in Quotient Limited ("Quotient", the "Company" or "we", "us" and "our") and a class meeting (the "Preference Class Meeting of Shareholders (the "Annual General Meeting" or “Annual Meeting”" and together with the EGM, the "Meetings") of Quotient Limited (“Quotient”,holders of preference shares ("Preference Shares") in the “Company” or "we", "us" and "our")Company to be held on October 31, 2022,April 25, 2023, at 11:00 a.m., local time, GMT, at the Radisson Blu Hotel, Zurich Airport, Rondellstrasse, Zurich Airport, 8058 Zurich, Switzerland.offices of Carey Olsen, 47 Esplanade, St Helier, Jersey JE1 0BD, Channel Islands. Information about the meeting isMeetings are presented on the following pages.

Details regarding admission to the meetingMeetings and the business that will be conducted are described in the accompanying notice of an extraordinary general meeting of the Company (which will also constitute a class meeting of holders of Ordinary Shares) (the "EGM Notice"), notice of class meeting of holders of Preference Shares (the "Preference Class Notice" and together with the EGM Notice, of Annual General Meeting (the "AGM Notice"the "Notices") and Proxy Statement.  

In accordancea proxy statement in connection with the “notice and access” rules and regulations adopted by the Securities and Exchange Commission (the "SEC"Meetings ("Proxy Statement"), instead of mailing a printed, paper copy of our proxy materials to each shareholder who holds shares in street name (the “full set delivery” option), we are furnishing proxy materials to those shareholders over the Internet (the “notice only” option). We believe the “notice only” process expedites shareholders’ receipt of proxy materials and reduces the costs and environmental impact of our Annual General Meeting. We will bear the entire cost of the solicitation.

On or about September 8, 2022,March 6, 2023, we will begin mailing athis notice, (the "Notice of Availability")proxy statement and proxy materials to our shareholders containing instructions on how to access onlinevote. Registered holders of Ordinary Shares and Preference Shares who are registered on our Proxy Statement and our Annual Reportregister of members at the close of business on Form 10-K for the fiscal year ended March 31, 2022, filed with the SEC on June 28, 2022 (our "Annual Report"),  vote online, and receive paper copies of these documents for shareholders who so select, as well as a link containing instructions on how to vote by telephone. Our Proxy Statement and the Annual Report are also available at https://quotientbd.com/page/investors.

All shareholders who do not receive a Notice of AvailabilityRecord Date will receive a printed, paper copy of our proxy materials by mail. If you received aOwners of Ordinary Shares held "in street name" on the Record Date, will receive either an electronic copy over e-mail or printed, paper copy by mail, of our proxy materials by mail, or you received a Notice of Availability by mail and have opted to receive a paper copy of our proxy materials by mail,materials. To vote your shares, please sign, date and mail the proxy card in the envelope provided. YouFor holders of Ordinary Shares, you may also vote your shares over the Internet or via a toll-freetoll free (in the United States) telephone number contained in the voting instructions or proxy card included with your proxy materials. Instructions regardingWe will bear the methodsentire cost of voting are contained in the Notice of Availability or proxy card.solicitation.

Our Proxy Statement is also available at https://quotientbd.com/page/investors.

Whether or not you plan to attend the meeting, your vote is important and we encourage you to review the proxy materials and vote your shares by proxy as soon as possible prior to the Annual General Meeting,Meetings, using the instructions provided in the proxy materials.

Thank you for your continued support of Quotient.Sincerely,

 

__________________________

Manuel O. Méndez

Director


TABLE OF CONTENTS

Quotient Shareholder Letter

1

Notice of an extraordinary general meeting of Quotient Limited which will also constitute a class meeting of the holders or Ordinary Shares

3

Notice of a Preference Class Meeting of Quotient Limited

5

Proxy Statement for Extraordinary General Meeting of Shareholders, Class Meeting of Holders of Ordinary Shares and Preference Class Meeting of Preference Shareholders

7

Accompanying Document - Merger Implementation Agreement

13

Accompanying Document - Constitutional Documents of Quotient Limited

35

Certificate signed under Article 127E(5) of the Companies (Jersey) Law 1991

78

Certificate signed under Article 127(6) of the Companies (Jersey) Law 1991

80


Table of Contents

img148208479_1.jpg 

Notice of an extraordinary general meeting of Quotient Limited (the "Company") which will also constitute a class meeting of the holders of Ordinary Shares (the "Notice")
to be held on April 25, 2023 at 11:00 a.m. GMT

DATE: April 25, 2023

TIME: 11:00 a.m. GMT

PLACE: Offices of Carey Olsen, 47 Esplanade, St Helier, Jersey JE1 0BD, Channel Islands

RECORD DATE: the close of business on March 3, 2023

PURPOSE OF MEETING: Passing the following special resolution.

SPECIAL RESOLUTION

Approval of the Merger Implementation Agreement

1)
THAT a merger implementation agreement dated [ , 2023] between the Company, Quotient Holdings Merger Company Limited and Quotient Holdings Finance Company Limited (the "Merger Implementation Agreement") and which contains, among other things, the terms and means of effecting a proposed merger ("Merger") of those parties under Article 18B (Mergers) of the Companies (Jersey) Law 1991 (the "Law") be hereby approved for all purposes, including (without limitation) for the purposes of Article 127F(1) of the Law and the directors of the Company (or a duly authorised committee thereof) be and are authorised to take all such action as they may consider necessary or desirable for the implementation of the Merger pursuant to the terms and subject to the conditions contained in the Merger Implementation Agreement.

Record Date

Beneficial owners of Quotient shares held in street name as well as holders of record, are entitled to vote only if they were a shareholder of Quotient at the close of business on March 3, 2023. Holders of Ordinary Shares of Quotient are entitled to one vote for each share held.

Attendance at the Extraordinary General Meeting and Class Meeting of holders of Ordinary Shares

As required by our organizational documents, we intend to hold the Extraordinary General Meeting in person. Whether or not you plan to attend the meeting, your vote is important, and we encourage you to review the proxy materials and vote as soon as possible using the instructions provided in the Notice. If you hold your shares in street name, you may also follow the instructions included in the proxy materials to vote and confirm your attendance by telephone or Internet.

Right to apply to the court

In terms of Article 127FB of the Law, any shareholder of the Company (i.e. a holder of record) has the right to apply to the court on the grounds that the merger would unfairly prejudice the interests of that shareholder.

An application may not be made more than 21 days after the merger has been approved by the shareholders.

If you beneficially own Ordinary Shares for which Cede & Co. is the registered holder (as nominee for The Depository Trust Company) you are not a shareholder / holder of record within the meaning of the Law. In order to make an application to the court pursuant to Article 127FB of the Law it would be necessary for you to cause your Ordinary Shares to be transferred directly to


you. You should contact the broker, bank, trustee or other nominee through which you hold Ordinary Shares in street name who should be able to advise you on process.

Where to Find More Information about the Resolutions and Proxies

Further information regarding the above resolution is set out in the Proxy Statement and other proxy materials, which are available at https://quotientbd.com/page/investors, all information as set out in the Proxy Statement is integral to this Notice and is constituted to form part of this Notice.

You are entitled to appoint one or more proxies to attend the Extraordinary General Meeting and vote on your behalf and your proxy need not also be a shareholder of the Company. Instructions on how to appoint a proxy are set out in the Proxy Statement and on the proxy card.

 

Sincerely,BY ORDER OF THE BOARD OF DIRECTORS

 

Heino von ProndzynskiManuel O. Méndez

Chairman of the Board of DirectorsDirector

Record shareholder: If your shares are registered directly in your name, please bring proof of such ownership.

Shares held in street name by a broker or a bank: If your shares are held for your account in the name of a broker, bank or other nominee, please bring a current brokerage statement, letter from your stockbroker or other proof of ownership to the meeting together with a proxy issued in your name should you wish to vote in person at the Extraordinary General Meeting.

This Notice of Extraordinary General Meeting and the Proxy Statement are being distributed on or about March 6, 2023.

Notice of 2023 Extraordinary General Meeting, the Proxy Statement and proxy card are available in the “Financials & Filings” section of our website at https://quotientbd.com/page/investors.


Table of Contents

img148208479_2.jpg 

Notice of a Preference Class Meeting of Quotient Limited (the "Company") (the "Notice")

To Be Held on April 25, 2023 immediately following EGM on April 25, 2023

DATE: April 25, 2023

TIME: Immediately following EGM on April 25, 2023

PLACE: Offices of Carey Olsen, 47 Esplanade, St Helier, Jersey JE1 0BD, Channel Islands

RECORD DATE: the close of business on March 3, 2023

PURPOSE OF MEETING: Passing the following special resolution.

SPECIAL RESOLUTION

Approval of the Merger Implementation Agreement

1)
THAT a merger implementation agreement dated [ , 2023] between the Company, Quotient Holdings Merger Company Limited and Quotient Holdings Finance Company Limited (the "Merger Implementation Agreement") and which contains, among other things, the terms and means of effecting a proposed merger ("Merger") of those parties under Article 18B (Mergers) of the Companies (Jersey) Law 1991 (the "Law") be hereby approved for all purposes, including (without limitation) for the purposes of Article 127F(1) of the Law and the directors of the Company (or a duly authorised committee thereof) be and are authorised to take all such action as they may consider necessary or desirable for the implementation of the Merger pursuant to the terms and subject to the conditions contained in the Merger Implementation Agreement.

Record Date

Preference shareholders on the Company's register of members are entitled to vote only if they were a preference shareholder of Quotient at the close of business on March 3, 2023. Holders of Preference Shares of Quotient are entitled to one vote for each share held.

Attendance at the Preference Shareholders Meeting

As required by our organizational documents, we intend to hold the Preference Class Meeting in person. Whether or not you plan to attend the meeting, your vote is important, and we encourage you to review the proxy materials and vote as soon as possible using the instructions provided in the Notice.

Right to apply to the court

In terms of Article 127FB of the Law, any shareholder of the Company has the right to apply to the court on the grounds that the merger would unfairly prejudice the interests of that shareholder.

An application may not be made more than 21 days after the merger has been approved by the shareholders.

Where to Find More Information about the Resolutions and Proxies

Further information regarding the above resolution is set out in the Proxy Statement and other proxy materials, which are available at https://quotientbd.com/page/investors, all information as set out in the Proxy Statement is integral to this Notice and is constituted to form part of this Notice.


You are entitled to appoint one or more proxies to attend the Preference Class Meeting and vote on your behalf and your proxy need not also be a shareholder of the Company. Instructions on how to appoint a proxy are set out in the Proxy Statement and on the proxy card.

BY ORDER OF THE BOARD OF DIRECTORS

Manuel O. Méndez

Director

Record shareholder: If your shares are registered directly in your name, please bring proof of such ownership.

This Notice of Preference Class Meeting and the Proxy Statement are being distributed on or about March 6, 2023.

Notice of 2023 Preference Class Meeting, the Proxy Statement and proxy card are available in the “Financials & Filings” section of our website at https://quotientbd.com/page/investors.


Table of Contents

img148208479_3.jpg 

PROXY STATEMENT

FOR

EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS, CLASS MEETING OF HOLDERS OF ORDINARY SHARES AND PREFERENCE CLASS MEETING OF PREFERENCE SHAREHOLDERS

The Board of Directors (the "Board") of QUOTIENT LIMITED ("Quotient", the "Company", or "we", "us" and "our") is soliciting proxies for use at (i) the Extraordinary General Meeting of Shareholders, which will constitute a class meeting of the holders of Ordinary Shares (the "EGM”) and (ii) a class meeting of the holders of Preference Shares Shareholders (the "Preference Class Meeting" and together with the EGM, the "Meetings") both to be held on April 25, 2023 (and at any adjournment or postponement of the Meetings). A notice of the EGM (the "EGM Notice"), notice of Preference Class Meeting (the "Preference Class Notice" and together with the EGM Notice, the "Notices"), and proxy materials will be distributed to shareholders who hold Ordinary Shares and Preference Shares of Quotient as of March 3, 2023 for the EGM and Preference Class Meeting, on or about March 6, 2023. Quotient Limited is a limited liability no par value company incorporated under the laws of Jersey, Channel Islands.

GENERAL INFORMATION

What am I voting on?

The ordinary shareholders will be voting on whether or not to approve the merger implementation agreement dated [____________, 2023] between the Company, Quotient Holdings Merger Company Limited and Quotient Holdings Finance Company Limited (the "Merger Implementation Agreement") which contains, among other things, the terms and means of effecting a proposed merger of the Company and Quotient Holdings Merger Company Limited under Article 18B (Mergers) of the Companies (Jersey) Law 1991 (the "Law"); and
The preference class shareholders will be voting on whether or not to approve the Merger Implementation Agreement which contains, among other things, the terms and means of effecting a proposed merger of the Company and Quotient Holdings Merger Company Limited under Article 18B (Mergers) of the Law.

What are the recommendations of the Board?

All shares represented by a properly executed proxy will be voted unless the proxy is revoked and, if a choice is specified, your shares will be voted in accordance with that choice. If no choice is specified but the proxy card is signed, the proxy holders will vote your shares according to the recommendations of the Board, which are included in the discussion of each matter later in this proxy statement. The Board recommends that you vote:

In each case, FOR approval of the Merger Implementation Agreement which contains, among other things, the terms and means of effecting a proposed merger of those parties under Article 18B (Mergers) of the Law be hereby approved for all purposes, including (without limitation) for the purposes of Article 127F(1) of the Law.

Who is entitled to vote?

For the special resolution to be voted on at the EGM, each ordinary shareholder is entitled to one vote for each Ordinary Share held.
For the special resolution to be voted on at the Preference Class Meeting, each preference shareholder is entitled to one vote for each Preference Share held.

For beneficial owners of Ordinary Shares held in street name, the record date for the EGM is the close of business on March 3, 2023. For registered shareholders, only registered shareholders whose names are included as current holders of Ordinary Shares or Preference Shares on our register of members at the close of business on March 3, 2023 will be entitled to vote. As of the close of business on March 3, 2023, there were:

21’055’012 Ordinary Shares outstanding; and
2’266’665 Preference Shares outstanding.

How do I vote by proxy in lieu of attending the Meetings?

You may vote by proxy by completing, dating and signing your proxy card and mailing it in the envelope provided. You must sign your name exactly as it appears on the proxy card. If you are signing in a representative capacity (for example, as officer of a corporation, guardian, executor, trustee or custodian), you must indicate your name and title or capacity.

Whether you submit your proxy by mail or for holders of Ordinary Shares, also via the Internet or by telephone, your proxy for the EGM must be received by 11:00 a.m. GMT on April 23, 2023 and for the Preference Class Meeting, by 11:30 a.m. GMT on April 23, 2023. For holders of Ordinary Shares, if you submit your proxy by Internet or telephone, you should not separately return your proxy card. Alternatively you may also vote in person at the Meetings or you may be represented by another person at the Meetings by executing a proxy designating that person. Whether or not you plan to attend the meeting, your vote is important, and we encourage you to vote by proxy using one of the other voting methods described above.

If you hold your interest in shares through a stock brokerage account or by a bank or other registered holder, you are considered the beneficial owner of shares held in “street name.” The street name holder will provide you with instructions that you must follow in order to have your shares voted. If you hold your shares in street name and you wish to vote in person at the Meetings, you must obtain a proxy issued in your name from the street name holder. As noted above, whether or not you plan to attend the meeting, your vote is important, and we encourage you to vote by proxy using one of the other voting methods described above.

May I change my mind after submitting a proxy?

If you are a registered shareholder, you may revoke your proxy before it is exercised by:

Written notice of revocation to our Head of Legal & Compliance, at Quotient Limited, Business Park Terre Bonne, Route de Crassier 13, 1262 Eysins, Switzerland, and execution of a later dated proxy relating to the same shares, delivered to our Head of Legal & Compliance, at or before the final vote at the meeting; or
Voting in person at the Meetings.

If you are a beneficial owner of shares held in street name, you may revoke prior and submit new, voting instructions by contacting your brokerage firm, bank or other registered holder.

What are broker non-votes?

A broker non-vote occurs when the broker that holds your shares in street name is not entitled to vote on a matter without instruction from you and you do not give any instruction. Unless instructed otherwise by you, brokers will not have discretionary authority to vote. It is important that you cast your vote for your shares to be represented.


What is the required vote?

Special Resolutions require a two-third majority of the members who (being entitled to do so) vote in person, or by proxy, at a Meeting in favor of that Resolution. Votes that are withheld, abstentions and broker non-votes are not counted as votes cast. All members are entitled to vote at their respective class meetings.

What will constitute a quorum for each Meeting?

EGM

A quorum will consist of two or more holders of Ordinary Shares present, in person or by proxy, who hold or represent shares between them of not less than 50% of the total Ordinary Shares in issue as of the date of the EGM.

Preference Class Meeting

A quorum will consist of two or more holders of Preference Shares present, in person or by proxy, who hold or represent shares between them of not less than 50% of the total Preference Shares in issue as of the date of the Preference Class Meeting.

How can I attend a Meeting?

As required by our organizational documents, we intend to hold the Meetings in person. Whether or not you plan to attend a meeting, your vote is important, and we encourage you to vote by proxy.

If you plan to attend a Meeting, whether you are a registered shareholder (i.e., a person who owns shares registered directly in his or her name) or a beneficial owners of shares held in street name, you will need proof of ownership to be admitted to a Meeting. For beneficial owners of shares held in street name by a broker, bank or other nominee, a recent brokerage statement or letters from the broker, bank or other nominee are examples of proof of ownership. If your shares are held in street name and you want to vote in person at a Meeting, you must obtain a written proxy from the broker, bank or other nominee holding your shares.

Can I access these proxy materials on the Internet?

This proxy statement is available in the “Financials & Filings” section of our website at https://quotientbd.com/page/investors

Can I get hard copies of the proxy materials?

Registered holders of our Ordinary Shares and Preference Shares as on the Record Date will be sent, by mail, this proxy statement and the related proxy card on or about March 6, 2023. If you hold your shares in street name as on the Record Date, you may request hard copies from your broker or agent, or you may contact our proxy solicitation provider, Okapi Partners LLC at 844-202-6026 (toll free in the USA) or +1 (212) 297 0720, to obtain hard copies of the proxy materials.

Who pays for this proxy solicitation and how much did it cost?

We will pay the cost for soliciting proxies for the Meetings. Quotient will distribute proxy materials and follow-up reminders by mail and electronic means. We have engaged Okapi Partners LLC (“Okapi”) at 1212 Avenue of the Americas, 24th Floor, New York, New York 10036 to assist with the solicitation of proxies. We will pay Okapi a fee of $9,000, plus reasonable out-of-pocket expenses. Certain Quotient employees, officers, and directors may also solicit proxies by mail, telephone, or personal visits. They will not receive any additional compensation for their services.

We will reimburse brokers, banks, and other nominees for their expenses in forwarding proxy materials to beneficial owners.

Where can I find voting results for the Meetings?

The voting results will be published in a current report on Form 8-K, which will be filed with the SEC no later than four business days after the Meetings.


PROPOSAL TO AUTHORIZE THE COMPANY ACTING BY ITS BOARD OF DIRECTORS TO EFFECT A PROPOSED MERGER BETWEEN THE COMPANY AND QUOTIENT HOLDINGS MERGER COMPANY LIMITED UNDER ARTICLE 18B (MERGERS) OF THE COMPANIES (JERSEY) LAW 1991

General

We are seeking shareholder approval to approve the terms of the Merger Implementation Agreement which contains, among other things, the terms and means of effecting a proposed merger ("Merger") of those parties under Article 18B (Mergers) of the Companies (Jersey) Law 1991 (the "Law").

The primary reason we are seeking shareholder approval of the Merger Implementation Agreement and the subsequent implementation of the Merger is to give effect to a comprehensive restructuring of the Company’s capital structure consistent with the terms and conditions of the Transaction Support Agreement entered into between (1) the Company and (2) the beneficial holders, or investment advisors or managers for the account of beneficial holders of: (i) senior secured notes issued under that certain indenture, dated as of October 14, 2016 (amended and restated, supplemented, or otherwise modified from time to time, the “Senior Secured Notes Indenture”), by and among the Company (as Issuer), the guarantors party thereto, and U.S. Bank Trust Company, National Association, as trustee and (ii) convertible notes issued under that certain indenture, dated as of May 26, 2021 (as amended, restated, amended and restated, supplemented, or otherwise modified from time to time, the “Convertible Notes Indenture” and together with the Senior Secured Notes Indenture, the “Indentures”), by and among the Company (as Issuer), the guarantors party thereto, and Wilmington Savings Fund Society, FSB, as trustee, initially dated December 5, 2022 and amended and restated as of January 9, 2023 (the "TSA"). The effect of which would provide funding to the Company and restructure the debt obligations of the Company.

The Board unanimously approved the TSA and therefore the Merger, on 6 December 2022.

The Board believes that the benefits to the Company outweigh the risks and recommends that you vote in favor of granting the Board the discretionary authority to effect the Merger.

Summary of the Merger

The merging bodies are the Company and Quotient Holdings Merger Company Limited, a company incorporated under the laws of Jersey with registered number 147409 and having its registered office at PO Box 536, 13-14 Esplanade, St Helier, Jersey, JE4 5UR ("MergerCo"). Upon the terms and conditions set out in the Merger Implementation Agreement, the Company will merge with MergerCo, the effect of which would result in the Company being the surviving company and MergerCo ceasing to be incorporated as a separate company.

It is further proposed that Manuel O. Méndez and Bradley Meyer will remain the directors of Quotient Limited following the Merger and that James Gaudin of Jersey (Channel Islands), be appointed as a director of Quotient Limited with effect from completion of the Merger.

Accompanying Documents

In accordance with Article 127F of the Law, this Proxy Statement is accompanied by the following:

a copy of the Merger Implementation Agreement;
a copy of the constitutional documents of the Company, we would like to inform you that the Articles of Association of Quotient Limited have not been amended or varied as a result of the Merger;
a copy of the certificate signed under Article 127E(5) of the Law certifying that each director of the Company has made full inquiry into the affairs of the Company and each director reasonably believes that the Company is, and will remain until the merger is completed, able to discharge its liabilities as they fall due; and
a copy of the certificate signed under Article 127E(6) of the Law certifying that in the opinion of each director who will be a director of the Company following the merger, the Company will be able to continue to carry on business and discharge its liabilities as they fall due: (a) on and immediately after the completion of the Merger; and (b) if later, until 12 months after the signing of this certificate.

A statement of the material interests in the Merger of the directors of the Company and MergerCo is set out below under the paragraph heading ‘Material Interests under Article 127F(2)(a)(v) of the Law’.


Reasons for the Merger

The Board believes that effecting the Merger is a necessary step to implement the restructuring as contemplated by the TSA, which would result in providing funding to the Company and help the Company to alleviate its debt obligations under the Indentures.

Effects of the Merger

If our shareholders approve the proposed Merger and the Board effects the implementation steps memo as set out in the TSA (the "implementation steps memo"), the effect of the Merger in accordance with the implementation steps memo will result in each shareholder of the Company (other than Quotient Holdings Finance Company Limited), whose name appears on the register of members of the Company, receiving a payment consideration of $0.01 for each share held (save for MergerCo whose Ordinary Shares and Preference Shares in Quotient Limited will be cancelled for no consideration) and each share subsequently cancelled in order to relieve the shareholders of the Company from any potential liability in the Company's winding up.

Procedure for Effecting the Merger

If the Merger is approved by our shareholders, the Board, in its sole discretion, would effect the Merger, taking into consideration the factors discussed above, and determine the procedure of effecting the Merger with the guidance of Jersey lawyers.

Material Interests under Article 127F(2)(a)(v) of the Law

The Company

Manuel O. Méndez and Bradley Meyer are directors of Quotient Holdings Merger Company Ltd.

Manuel O. Méndez is a shareholder of Quotient Ltd.

MergerCo

Manuel O. Méndez and Bradley Meyer are directors of Quotient Ltd.

James Gaudin does not have any material interest in the Merger.

Recommendation

THE BOARD RECOMMENDS THAT YOU VOTE “FOR” the authorization for the Company ACTING BY ITS BOARD OF DIRECTORSTO EFFECT THE MERGER BETWEEN THE COMPANY AND QUOTIENT HOLDINGS MERGER COMPANY LIMITED UNDER ARTICLE 18B (MERGERS) OF THE COMPANIES (JERSEY) LAW 1991


 


Table of Contents

 

 

Accompanying Document: Merger Implementation Agreement

Dated [________] 2023

(1)
Quotient Limited
(2)
Quotient Holdings Merger Company Limited
(3)
Quotient Holdings Finance Company Limited

MERGER IMPLEMENTATION AGREEMENT

In respect of the merger of Quotient Limited and Quotient Holdings Merger Company Limited

 



CONTENTS

Clause

1.DEFINITIONS AND INTERPRETATION

2.THE MERGER

3.CONDITIONS PRECEDENT TO CLOSING OF MERGER

4.UNDERTAKINGS

5.CONDUCT OF QUOTIENT BUSINESS

6.CONSIDERATION

7.ADMINISTRATIVE MATTERS RELATING TO THE MERGED COMPANY

8.WARRANTIES

9.TERMINATION

10.CONFIDENTIALITY

11.MISCELLANEOUS

12.GOVERNING LAW AND JURISDICTION

Schedule 1 - Indicative Merger Completion Timeline

Schedule 2 - MergerCo Resolutions

Schedule 3 - Notices of Quotient EGMs

Schedule 4 -

Part A - Quotient Warranties

Part B - MergerCo Warranties

SIGNATORIES



THIS AGREEMENT is dated [ ] 2023

PARTIES

(1)
QUOTIENT LIMITED, a company incorporated under the laws of Jersey with the registered number 109886, having its registered office at 28 Esplanade, St. Helier, Jersey, JE2 3QA (Quotient);
(2)
QUOTIENT HOLDINGS MERGER COMPANY LIMITED, a company incorporated under the laws of Jersey with the registered number 147409, having its registered office at 13-14 Esplanade, St. Helier, JE2 3QA, Jersey (MergerCo); and
(3)
QUOTIENT HOLDINGS FINANCE COMPANY LIMITED, an exempted company incorporated under the laws of the Cayman Islands with registration number 396578, having its registered office at 71 Fort Street, PO Box 500, Grand Cayman, KY1-1106 (FinanceCo).

BACKGROUND

(A) Quotient and MergerCo propose toundertake the Merger (as defined below).

(B) Upon the terms and conditions set forth in this Agreement, the Parties wish to effect the Merger so that Quotient continues as the survivor company for the purposes of the Law.

(C) The board of directors of Quotient and MergerCo have each determined that the Merger is in the best interests of Quotient and MergerCo and approved the Merger upon the terms and subject to the conditions set forth in this Agreement.

(D) FinanceCo is party to this Agreement for the purpose of providing the covenants at Clause 6.

Now, therefore, in consideration of the premises, and of the representations, warranties, covenants and agreements contained herein, the Parties agree as follows:

AGREED TERMS

1.
DEFINITIONS AND INTERPRETATION
1.1.
Definitions

In this Agreement, unless the context otherwise:

Application Date: means the date stated in the Indicative Merger Completion Timeline as the date for completion at Step 13.

BusinessDay: meansany day on which commercial banks are normally open for full banking business in Jersey.

CashConsiderationAmount: meansthe sum of US$0.01 payable to each Quotient Shareholder in accordance with Clause 6.

ClosingDate: meansthe date on which Closing occurs.

Closing: meanscompletion of the Merger in accordance with Article 127FM(2)(b) of the Law.

Conditions: meansthe conditions precedent to Closing as set out in Clause 3.1 and each individually is a Condition.

Court: meansthe Royal Court of Jersey.

Creditors: means, in respect of Quotient or MergerCo, all its actual, contingent and prospective creditors to whom notice of the proposed Merger must be sent in accordance with Article 127FC(1) of the Law.

GovernmentAuthority: meansany local, domestic, foreign or multinational court, arbitral tribunal, mediator, administrative agency or commission or other governmental or regulatory body, agency, instrumentality or authority including, without limitation, a taxing or other authority competent to impose any liability in respect of Tax or responsible for the administration and/or collection of Tax or enforcement of any law.

Greensill Claims: means all claims and legal remedies, regardless of nature, arising out of, in connection with or otherwise related to all shares of capital stock or other equity interests of Credit Suisse Virtuoso SICAV-SIF owned by or issued to Quotient.

Indicative Merger Completion Timeline: meansthe indicative timeline for the completion of the Merger agreed by the Parties and set out at Schedule 1.

JFSC: meansthe Jersey Financial Services Commission.

Law: meansthe Companies (Jersey) Law 1991, as amended.

Merger Consideration: means the consideration to be provided by FinanceCo as detailed in Clause 6.


Merger: meansthe merger under Part 18B of the Law of Quotient and MergerCo to be implemented on the terms and subject to the conditions set out in this Agreement (with or subject to any modification thereof or addition thereto, or condition approved or imposed by the Court, and in each case agreed to in writing by Quotient and MergerCo) further to which Quotient will continue as the survivor body.

MergerCo Directors: means the directors of MergerCo at the relevant time.

MergerCo Resolutions: the written resolutions, in the form at Schedule 2, to be passed by FinanceCo as the sole member of MergerCo to:

a)
approve the terms of this Agreement;
b)
approve the implementation of the Merger pursuant to the terms and subject to the conditions contained herein; and
c)
authorise the MergerCo Directors to take all such action as they may consider necessary or appropriate for giving full effect to the Merger.

MergerCo Shares: means the entire issued share capital of MergerCo from time to time and at the date of this Agreement being the 4,435,118 shares of USD0.01 each issued to FinanceCo.

Notices ofQuotient EGMs: means the notice of the Quotient EGM and the notice of the Quotient Preference Class Meeting in the form set out at Schedule 3.

Party: means a party hereto and “Parties” means more than one or all of them, and a reference to Party shall include any permitted assignee or successor to such party in accordance with the terms of this Agreement.

PostingDate: means the date of publication of the Quotient Shareholder Circular.

Quotient Directors: means the directors of Quotient at the relevant time.

Quotient EGMs: meansthe Quotient OrdinaryEGM and the Quotient Preference Class Meeting.

Quotient Group: means Quotient and its subsidiaries from time to time.

Quotient Resolutions: means the resolutions, as set out in the Notices of Quotient EGMs, to be proposed at the Quotient EGMs to:

a) approve the terms of this Agreement;

b) approve the implementation of the Merger pursuant to the terms and subject to the conditions contained herein; and

c) authorise the Quotient Directors to take all such action as they may consider necessary or appropriate for giving full effect to the Merger.

Quotient Ordinary EGM: meansthe extraordinary general meeting of the holders of Quotient Ordinary Shares (and any adjournment thereof) to be convened by the Notice of Quotient Extraordinary General Meeting to consider and if so determined pass the Merger Resolutions.

Quotient Ordinary Shares: means the ordinary shares of no par value in Quotient in issue from time to time.

Quotient Preference Class Meeting: means the extraordinary general meeting of the holders of Quotient Preference Shares (and any adjournment thereof) to be convened by the Notice of Merger Extraordinary General Meeting to consider and if so determined pass the Merger Resolutions.

Quotient Preference Shares: means the preference shares of no par value in Quotient in issue from time to time.

Quotient ShareholderCircular: means the circular to be issued by Quotient to the Quotient Shareholders incorporating, inter alia, the Notices of Quotient EGMs to approve the Quotient Resolutions.

Quotient Shareholders: means the members of Quotient whose names appear on the Register at the relevant time.

Quotient Shares: means the Quotient Ordinary Shares and Quotient Preference Shares.

Register: means the register of members of Quotient.

Registrar ofCompanies: means the registrar of companies in Jersey.

Retained Debt: means the US1,000,000.00 payable by Quotient to FinanceCo under, or in respect of, certain senior secured notes issued by Quotient pursuant to an indenture, dated 14 October 2016 (as amended, restated, amended and restated, supplemented, or otherwise modified from time to time) by and among the Issuer, the guarantors party thereto, and U.S. Bank Trust Company, National Association, as trustee.

Surviving Directors: means the persons who will be directors of Quotient with effect from Closing as set out at Clause 7.

Surviving Shares: means any Quotient Shares in issue immediately prior to Closing which are registered in the name of FinanceCo.


Tax: means all forms of taxation (other than deferred tax) and statutory, governmental, state, provincial, local government or municipal impositions, duties, contributions and levies, whether levelled by reference to income, profits, gains, net wealth, asset values, turnover, added value or otherwise.

1.2.
Interpretation

In this Agreement:

(a) except where the context otherwise requires, words denoting the singular include the plural and vice versa, words denoting a gender include every gender and references to persons include bodies corporate and unincorporate.

(b) references to “Background”, “Clauses”, “Annexes” and “Schedules” are, unless the context otherwise requires, references to recitals and clauses hereof and to annexes and schedules hereto.

(c) the Background and Schedules form part of this Agreement and shall have the same force and effect as if they were expressly set out in the body of this Agreement and any reference to this Agreement shall include the Background and Schedules.

(d) any reference to this Agreement or to any agreement or document referred to in this Agreement shall be construed as a reference to such agreement or document as amended, varied, modified, supplemented, restated, novated or replaced from time to time.

(e) any reference to any statute or statutory provision shall, unless the context otherwise requires, be construed as a reference to such statute or statutory provision as the same may have been, or may be, amended, varied, modified, extended, consolidated, supplemented, re-enacted or replaced and shall be deemed also to refer to any statutory instrument, regulation or order made thereunder.

(f) the word “may” shall be construed as being permissive and the word “shall” shall be construed as being mandatory.

(g) headings and the table of contents are inserted for convenience only and shall not affect the construction of this Agreement.

(h) any reference to a time of day is to Jersey time, unless otherwise specified in this Agreement.

(i) in construing this Agreement the so called “ejusdem generis” rule does not apply and, accordingly, the interpretation of general words is not restricted by (i) being preceded by words indicating a particular class of acts, matters or things, or (ii) being followed by particular examples.

(j) the words “subsidiary” and “subsidiary undertaking” shall have the same meaning in this Agreement as their respective definitions in the Law.

2.
THE MERGER
2.1.
On and subject to the terms of this Agreement, and subject to satisfaction or waiver of the Conditions, with effect from Closing and in accordance with Article 127FN of the Law:

(a) Quotient and MergerCo shall merge and continue as one merged body, with Quotient being the survivor company and MergerCo ceasing to be incorporated as a separate company;

(b) all MergerCo Shares in issue immediately prior to Closing shall be cancelled;

(c) all Quotient Shares in issue immediately prior to Closing, other than the Surviving Shares, shall be cancelled;

(d) all property and rights to which MergerCo and Quotient were entitled immediately before Closing shall become the property and rights of Quotient in accordance with Article 127FN of the Law; and

(e) Quotient shall become subject to all criminal and civil liabilities, and all contracts, debts and other obligations, to which each of MergerCo and Quotient were subject immediately before Closing and all actions and other legal proceedings which, immediately before Closing, were pending by or against MergerCo and/or Quotient, shall be continued by or against Quotient.

3.
CONDITIONS PRECEDENT TO CLOSING OF MERGER

3.1.
The Parties agree and acknowledge that the Merger is conditional upon satisfaction, approval or waiver of the following conditions or their satisfaction subject only to Closing:

(a) Quotient having given notice to all of its Creditors (if any) in accordance with Article 127FC(1) of the Law and having published the contents of such notice in accordance with Article 127FC(5) of the Law, and each applicable date as set out in Article 127FJ(3)(c) of the Law having passed;

(b) MergerCo having given notice to all of its Creditors (if any) in accordance with Article 127FC(1) of the Law and having published the contents of such notice in accordance with Article 127FC(5) of the Law, and each applicable date as set out in Article 127FJ(3)(c) of the Law having passed;

(c) all resolutions in connection with or required to approve and implement the Merger as set out in the Notices of Quotient EGMs and the MergerCo Resolutions and the Law having been duly passed by Quotient and MergerCo;

(d) the date as set out in Article 127FJ(3)(a) of the Law having passed (if applicable);

(e) the delivery to the Registrar of Companies of all documents required in accordance with Article 127FJ of the Law for the purposes of effecting the Merger; and

(f) there being no outstanding judgment, injunction, order or decree of a competent Government Authority which shall prohibit or frustrate the undertaking of the Merger.

4.
UNDERTAKINGS
4.1.
Each Party shall promptly co-operate with and provide all necessary information and other assistance reasonably required by any other Party in connection with the satisfaction of the Conditions.
4.2.
Quotient and MergerCo shall give notice and provide evidence reasonably satisfactory to the other Parties of the satisfaction of the relevant Conditions for which they are responsible and shall disclose to the other Party in writing promptly upon becoming aware of any matter, fact or circumstance which will or which would reasonably be expected to prevent any of the Conditions from being satisfied.
4.3.
Quotient undertakes to MergerCo that:

(a) it shall procure that each Quotient Director shall:

(i) sign the certificates required under Article 127E(5) of the Law prior to the Posting Date; and

(ii) sign the certificates required under Article 127FJ(4)(d) of the Law no later than 10 Business Days prior to the Application Date;

(b) it will procure that the Quotient Directors make reasonable enquiries to identify all its Creditors;

(c) it will send written notice of the proposed Merger to each of its Creditors (if any) at the time required by the Indicative Merger Completion Timeline and in the manner required under Article 127FC(1) of the Law;

(d) it will, within the time limit set out in Article 127FC(6) of the Law, and at the time required by the Indicative Merger Completion Timeline, publish the contents of the notice sent to its Creditors pursuant to 4.3(c) above at least once in a newspaper circulating in Jersey, even if no Quotient Creditors are identified;

(e) it will use all reasonable endeavours to ensure that the Survivor Directors shall sign the certificates required under Article 127E(6) of the Law;

(f) it will administer and minute the proceedings at the Quotient EGMs in accordance with the Law and its articles of association and it will notify MergerCo of the outcome of such meetings and provide with executed copies of such minutes as soon as possible thereafter;

(g) it will use all reasonable endeavours to ensure that:


(i) the Registrar of Companies in Jersey shall enter the details specified in Article 127FM(3) of the Law in the register in respect of MergerCo; and

(ii) the Registrar of Companies in Jersey shall enter the details specified in Article 127FM(4) of the Law in the register in respect of Quotient.

4.4.
MergerCo undertakes to Quotient that:

(a) it shall procure that each MergerCo Director shall:

(i) sign the certificates required under Article 127E(5) of the Law prior to the Posting Date; and

(ii) sign the certificates required under Article 127FJ(4)(d) of the Law no later than 10 Business Days prior to the Application Date;

(b) it will procure that MergerCo Directors make reasonable enquiries to identify all of its Creditors;

(c) it will send written notice of the proposed Merger to each of its Creditors (if any) at the time required by the Indicative Merger Completion Timeline and in the manner required under Article 127FC(1) of the Law;

(d) it will, within the time limit set out in Article 127FC(6) of the Law, and in line with the Indicative Merger Completion Timeline publish the contents of the notice to be given under (c) above at least once in a newspaper circulating in Jersey, even if no MergerCo Creditors are identified;

(e) it will use all reasonable endeavours to ensure that the Survivor Directors shall sign the certificates required under Article 127E(6) of the Law;

(f) it will provide Quotient with an executed copy of MergerCo Resolutions as soon as possible after they have been signed and dated; and

(g) it will use all reasonable endeavours to ensure that:

(i) the Registrar of Companies in Jersey shall enter the details specified in Article 127FM(3) of the Law in the register in respect of MergerCo; and

(ii) the Registrar of Companies in Jersey shall enter the details specified in Article 127FM(4) of the Law in the register in respect of Quotient.

4.5.
Each Party undertakes to use its reasonable endeavours to comply with the timelines outlined in the Indicative Merger Completion Timeline. Quotient or MergerCo may, subject to the requirements of the Law, request an extension to any timeline outlined in the Indicative Merger Completion Timeline with the consent of the other (such consent not to be unreasonably withheld or delayed).
5.
CONDUCT OF QUOTIENT BUSINESS
5.1.
Quotient undertakes to procure that during the period between the date of this Agreement and Closing each member of the Quotient Group shall carry on its business as a going concern in the ordinary and usual course.
5.2.
Quotient undertakes:

(a) to use all reasonable endeavours to procure the final resolution of all and any objections arising out of or in connection with Article 127FB, Article 127FE and/or Article 143 of the Law and/or customary law as quickly as possible; and

(b) in relation to clause 5.2(a)above, and without prejudice to its generality, to seek to resolve any application to the Court using wherever reasonably practicable any or all legal and/or procedural rights, remedies, mechanisms or devices, whether interlocutory or final, as may be available under the law of Jersey, the Royal Court Rules 2004 and/or any Practice Direction to expedite final resolution or abridge time as far as possible including but not limited to seeking to have any such application heard as a cause de brièveté.

6.
CONSIDERATION

6.1.
As consideration for Quotient entering into the Merger, the relevant Quotient Shareholders approving the Merger and the cancellation of Quotient Shares pursuant to Clause 2.1(c):

(a) FinanceCo shall promptly following Closing pay, or procure the payment of, the Cash Consideration Amount to each Quotient Shareholder whose name is on the Register at Closing other than MergerCo (for the avoidance of doubt whose Quotient Shares shall be cancelled in accordance with clause 2.1(c) above without any repayment of capital) or FinanceCo, in each case by means of a cheque sent to such Quotient Shareholder at the address shown on the Register at Closing;

(b) with effect from and conditional upon Closing, FinanceCo hereby irrevocably releases and discharges Quotient from any and all claims, demands, duties, obligations and liabilities it may have to the FinanceCo in respect of the Retained Debt; and

(c) FinanceCo hereby undertakes that:

(i) it shall hold harmless and not bring any actions, proceedings or claims against any relevant Quotient Shareholder where the action, proceeding or claim in any way relates to or concerns the Greensill Claims; and

(ii) to the fullest extent permitted by law, releases each Quotient Shareholder from any liability to Quotient for any loss or damage suffered or costs incurred arising, directly or indirectly, out of or in connection with the Greensill Claims, however such loss or damage is caused,

save where such Quotient Shareholder has acted fraudulently, dishonestly, negligently or with wilful misconduct.

6.2.
As consideration for the cancellation of MergerCo Shares pursuant to Clause 2.1(b), Quotient shall, on the date of this Agreement, pay to FinanceCo the amount of US$1.00 receipt of which is hereby acknowledged by FinanceCo.
7.
ADMINISTRATIVE MATTERS RELATING TO THE MERGED COMPANY

7.1. The Parties agree that James Harman Gaudin of 13-14 Esplanade, St. Helier, Jersey JE1 1BD shall become a director at Closing.

7.2. The Parties agree that, at Closing:

(a) the directors of Quotient shall therefore be:

(i) James Harman Gaudin of 13-14 Esplanade, St. Helier, Jersey JE1 1BD;

(ii) Manuel Mendez of Quotient Suisse SA, Business Park Terre Bonne, Route de Crassier 13, 1262 Eysins, Switzerland; and

(iii) Bradley Meyer of Ducera Partners, 11 Times Square, 36th Floor, New York, NY, USA.

(b) the secretary of Quotient shall remain JTC (Jersey) Limited of 28 Esplanade, St Helier, Jersey JE4 2QP.

(c) the registered office of Quotient shall remain at 28 Esplanade, St. Helier, Jersey, JE2 3QA.

(d) the date to which the first accounts of Quotient as surviving body shall be produced following the Closing Date shall remain as 31 March 2024.

(e) the registered number of Quotient shall remain as 109886.

7.3. No changes shall be made to the memorandum of association of Quotient or the Articles pursuant to the Merger and, save as set out in this Agreement, no other arrangements are necessary to provide for the continued management of Quotient following Closing.

8.
WARRANTIES
8.1.
Quotient warrants to MergerCo that each of the warranties set out at Part A of Schedule 4, is accurate in all respects at the date of this Agreement.

8.2.
MergerCo warrants to Quotient that each of the warranties set out at Part B of Schedule 4 is accurate in all respects at the date of this Agreement.
8.3.
Each warranty is separate and independent, and is not to be limited by reference to any other warranty or by anything in this Agreement.
9.
TERMINATION
9.1.
Except by operation of law, no Party nor FinanceCo shall be entitled to rescind or terminate this Agreement in any circumstances whatsoever (whether before or after Closing).
9.2.
Where this Clause applies pursuant to operation of law, this Agreement other than Clauses 1 (Definitions and Interpretation), 3 (Conditions precedent to Closing of the Merger), 12 (Confidentiality), 11.1 (Third Party Rights), 11.3 (Invalidity), 11.6 (Costs and Expense), 11.7 (Whole Agreement), 11.8 (Counterparts) and 14 (Governing Law) shall automatically terminate with immediate effect and each Party’s rights and obligations under this Agreement other than those specified above shall cease immediately on termination, provided that such termination shall not affect the rights and obligations of any Party existing before termination and shall be without prejudice to a Party’s right to claim damages or other compensation for failure by another Party to comply with its obligations under this Agreement. This Clause shall not exclude any liability for (or remedy in respect of) fraud or fraudulent misrepresentation.
10.
CONFIDENTIALITY
10.1.
Announcements

With the exception of the Quotient Shareholder Circulars, no announcement, communication or circular in connection with the existence or the subject matter of this Agreement or the Merger shall be made or issued by or on behalf of any Party or any member of Quotient’s Group after the date hereof without the prior written approval of the relevant other Party. This shall not affect any announcement, communication or circular (other than the Quotient Shareholder Circular) required by law or any governmental or regulatory body, court order or the rules of any relevant stock exchange, but then only to the extent so required and the Party with an obligation to make an announcement or communication or issue a circular shall consult with the other Parties insofar as is reasonably practicable before complying with such an obligation.

10.2. Confidentiality

(a) Subject to clause 10.2(b) each Party shall treat as strictly confidential and shall not disclose or use any information received or obtained as a result of entering into this Agreement (or any agreement entered into pursuant to this Agreement) that relates to:

(i) the provisions of this Agreement or any ancillary agreement; or

(ii) the other Party.

(b) Notwithstanding clause 10.2(a), a Party may disclose or use information if and to the extent:

(i) it is expressly permitted or provided for in this Agreement;

(ii) required by applicable law of any relevant jurisdiction or for the purposes of any legal proceedings;

(iii) required by any securities exchange or regulatory or Government Authority to which that Party is subject or submits, wherever situated, whether or not the requirement for information has the force of law;

(iv) that the disclosure is made to the professional advisers, and auditors on a need to know basis and provided they have a duty (whether contractual or otherwise) to keep such information confidential;

(v) that the information has come into the public domain through no fault of that Party; or

(vi) that the other Party has given prior written consent to the disclosure,

provided that any information disclosed pursuant to clause 10.2(b)(ii) or 10.2(b)(iii) shall be disclosed (where reasonably practicable and not otherwise prohibited by applicable law or regulation) only after notice has been given to the other Party of such requirement with a view to providing the other Party with the opportunity to contest such disclosure or use or otherwise agreeing to the content and timing of such disclosure.


11.
MISCELLANEOUS
11.1.
Third Party Rights

A person who is not a Party to this Agreement has no right to enforce any term of, or enjoy any benefit under, this Agreement and the rights of Parties to terminate, rescind or agree any variation, waiver or settlement under this Agreement are not subject to the consent of any person who is not a Party to this Agreement save that a relevant Quotient Shareholder may enforce and enjoy the benefit of Clause 6.1(c).

11.2.
Notices

(a) All notices with respect to this Agreement shall be delivered by hand or sent by first class post to the address of the addressee as set out in this Agreement or to such other address as the addressee may from time to time have notified for the purpose of this clause.

(b) Such notices shall be deemed to have been received:

(i) if sent by prepaid post, two Business Days after posting;

(ii) if delivered by hand, on the day of delivery; and

(iii) if sent by electronic means (including for the avoidance of doubt by email), on the day the notice was sent.

11.3.
Invalidity

Each of the provisions of this Agreement are severable. If any such provision is held to be or becomes invalid or unenforceable in any respect under the laws of any jurisdiction, it shall have no effect in that respect and the Parties shall use all reasonable efforts to replace it in that respect with a valid and enforceable substitute provision the effect of which is as close to its intended effect as possible.

11.4.
Variation

Any amendment of this Agreement (or of any other) shall be valid, effective and binding upon all Parties hereto (including any that have not explicitly agreed to it) if it is in writing and duly executed by or on behalf of all of the Parties to it.

11.5.
Assignment

(a) No Party may assign, hold on trust, transfer, sub-contract, delegate, charge or otherwise deal with all or any part of its rights or obligations under this Agreement without the prior written consent of the other Parties.

(b) The maximum liability of any Party for breach of this Agreement shall be limited to the liability that would have arisen in the absence of any assignment properly made in accordance with the terms of clause 11.5.

(c) Any purported assignment, declaration of trust, transfer, sub-contracting, delegation, charging or dealing in contravention of this clause 11.5 shall be ineffective.

11.6.
Costs and Expenses

Each Party shall bear its own costs and expenses in relation to the negotiation, preparation, execution and implementation of this Agreement, but this Clause 11.6 shall not prejudice any Party’s right to seek to recover costs in any litigation or other dispute resolution procedure arising in connection with this Agreement.

11.7.
Whole Agreement

(a) This Agreement contains the whole Agreement between the Parties relating to the subject matter of this Agreement at the date of this Agreement to the exclusion of any implied by law which may be excluded by contract and supersedes any previous written or oral agreement between the Parties in relation to matters dealt with in this Agreement.

(b) Each Party acknowledges that, in entering into this Agreement, it is not relying on any representation, warranty or undertaking not expressly incorporated into it.

(c) Each Party agrees and acknowledges that its only right and remedy in relation to any warranty made or given in clause 1 shall be for breach of the terms of this Agreement and each of the Parties waives all other rights and remedies (including those in tort or arising under statute) in relation to any such representation, warranty or undertaking.

(d) Nothing in this clause 11.7excludes or limits liability for fraud.

11.8.
Counterparts

This Agreement may be executed in any number of counterparts and by each Party on a separate counterpart each of which counterparts when so executed and delivered shall be an original but all such counterparts shall together constitute one and the same instrument.


12.
GOVERNING LAW AND JURISDICTION
12.1.
This Agreement and any dispute, claim or controversy (including non-contractual disputes, claims or controversies) arising out of or in connection with it or its subject matter (each a Disputes) shall be governed by and shall be construed in accordance with the laws of the Island of Jersey.
12.2.
Each Party irrevocably submits any Dispute to the exclusive jurisdiction of the Jersey courts and agrees not to object to the exclusive jurisdiction of the Court.

The signatures of the parties to this Agreement are situated after the Schedules to this Agreement.

IN WITNESS WHEREOF the Parties have duly executed this Agreement on the date stated at the beginning of it.


SCHEDULE 1

Indicative Merger Completion Timeline

QUOTIENT MERGER


INDICATIVE TIMELINE

This is a high-level indicative timeline for the merger between Quotient Limited (Quotient) and Quotient Holdings Merger Company Limited (MergerCo) (Merger) which is dependent on:

MergerCo having been redomiciled to Jersey before commencement of the Merger;
there being no comments received form the US Securities and Exchange Commission (SEC) following submission of the preliminary proxy statement;
there being no shareholder or creditor objections to the Merger; and
required approval being obtained from the Jersey Financial Services Commission (JFSC).

In the indicative timeline:

- “N” refers to the date that the notices and materials for the extraordinary general meeting of the holders of ordinary shares in Quotient (EGM) and the extraordinary general meeting of the holders of preference shares in Quotient (Pref Class Meeting) to approve the Merger are posted to shareholders;

- “D” refers to the date of the EGM and the Pref Class Meeting;

- "P" refers to the date that the notice to creditors is published in the Jersey Gazette; and

- “F” refers to the date which the Merger is completed following its registration by the JFSC.

Key dates are measured against these dates (e.g. 'D +10 days' is 10 days after the EGM).

S/N

Action

Timing

Indicative Date

Comments

1.

Drafting and finalizing the Merger Implementation Agreement

Prior to item 4 below

In advance of item 5 below

The timelines below assume that the Merger Implementation Agreement would be in agreed form prior to the board meetings of both Quotient and MergerCo/in advance of in advance of 3 March 2023

2.

In respect of Quotient and MergerCo, submission of Jersey Revenue form "Report to Comptroller on any entity being wound up/migrating" with all attachments being up to date management accounts of the Company and 'Distributions'

Prior to item 4 below

In advance of item 5 below

The JFSC routinely requires this on mergers notwithstanding the name of the form.

3.

In respect of Quotient and MergerCo, request for confirmation of no objection from Customer and Local Services Department

Prior to item 4 below

In advance of item 5 below


S/N

Action

Timing

Indicative Date

Comments

4.

Submission of the preliminary proxy statement

Prior to N

22 February 2023

SEC requires a minimum of 10 days to review the preliminary proxy statement

5.

Quotient board meeting to approve the terms of the Merger and circulation of the notice of the EGM and notice of the Pref Class Meeting

Prior to N

In advance of 3 March 2023

We expect this meeting to include the approval of the signing of statutory certificates.

Written resolution of the sole director of MergerCo approving the terms of the Merger

Given MergerCo has a sole shareholder and a sole director we should be able to co-ordinate timings to be in lockstep with Quotient as far as possible.

6.

Quotient directors to sign Art 127E(5) certificates

Prior to N

In advance of 3 March 2023

MergerCo director to sign Art 127E(5) certificates

7.

Posting of shareholder circularto Quotient Shareholders’ (which will contain the notice of the EGM and notice of the Pref Class Meeting)

N

6th March 2023

MergerCo has a sole shareholder and all necessary shareholder approval will be by written resolution.

8.

Quotient to send notice to creditors

No earlier than N and no later than 21 days after D

6th March 2023

MergerCo to send notice to creditors

In reality this is N/A as MergerCo has no creditors as such notices will not be sent to named persons

9.

Publication in Jersey Evening Post/Gazette of notice to creditors of both Quotient and MergerCo

P

Whichever is the sooner of 21 days after D or as soon as practicable after the last notice to creditors is sent out (as set out at 5. above)

25th April 2023

We would suggest publishing the notice in the Jersey Evening Post/Gazette so that the creditors and shareholder objection periods can run in parallel.

10.

EGM

D

25th April 2023

Pref Class Meeting


S/N

Action

Timing

Indicative Date

Comments

11.

End of Quotient creditor objection period

P + 21 days

16th May 2023

End of MergerCo creditor objection period

12.

End of Quotient shareholder objection period

D + 21 days

16th May 2023

End of MergerCo shareholder objection period

In reality this is N/A as MergerCo’s sole shareholder will consent.

13.

Delivery to the Registrar of all relevant documents as required under Article 127FJ of the Law

P + 21 days

(which should in any case be at least 10 Business Days prior to F to allow the Merger to take effect on F)

16th May 2023

14.

Closing of Merger

F

26th May 2023

Subject to engagement with JFSC on parties’ preferred timing for closing to be affected.



SCHEDULE 2

MergerCo Resolutions (Without Annexures)

QUOTIENT HOLDINGS MERGER COMPANY LIMITED

(A COMPANY INCORPORATED UNDER THE LAWS OF JERSEY WITH COMPANY NUMBER 147409)

(Company)

Written resolutions of the sole member of the Company

The undersigned, being the sole member of the Company who, at the date when the following resolutions (Resolutions) are deemed passed, would be entitled to vote on such Resolutions if the same were proposed at a general meeting of the Company, pursuant to Article 95 of the Companies (Jersey) Law 1991, as amended (Law) and the articles of association of the Company (Articles) HEREBY RESOLVE that the Resolution 1 be and are hereby approved as special resolutions of the Company and Resolutions 2 to 8 be and are hereby approved as ordinary resolutions such Resolutions being deemed to be passed when this instrument is signed:

Special Resolution

1.
THAT the merger agreement to be made amongst the Company, Quotient Limited a public limited liability no par value company formed under the laws of Jersey (Quotient) and Quotient Holdings Finance Company Limited, an Exempted Company incorporated in the Cayman Islands with limited (FinanceCo) on or about the date hereof (Merger Agreement), be and is approved for all purposes including, without limitation, Article 127F of the Law.

Ordinary Resolution

2.
THAT for the purpose of Article 127F(2)(a)(i) of the Law, we have received a copy of the Merger Agreement in the form set out at Annexure A hereto.
3.
THAT for the purpose of Article 127F(2)(a)(ii) of the Law, we acknowledge that the merged body will be Quotient as a survivor company and that the existing constitutional documents of Quotient, copies of which we have reviewed, will not be altered in connection with the proposed merger of the Company and Quotient (the Merger).
4.
THAT for the purpose of Article 127F(2)(a)(iv) of the Law, we acknowledge that we have received copies of the certificates of the directors of the Company signed under Article 127E(5) and by Manuel Mendez, Bradley Meyer and James Gaudin, being those persons who are proposed to be directors of Quotient following completion of the Merger, underArticle 127E(6), copies of which are set out at Annexure B hereto.
5.
THAT for the purpose of Article 127F(2)(a)(iv) of the Law, we acknowledge that the Company has not received any information from any other merging company under Article 127E(4)(b) of the Law and in particular that, as per the terms of the Merger Agreement, Article 127E(3) applies in relation to both the Company and Quotient.
6.
THAT for the purposes of Article 127F(2)(a)(v) of the Law, we acknowledge that [none of the directors of the Company or Quotient has any material interests in the Merger] as confirmed by the statement set out an Annexure C hereto provided by the Company.
7.
THAT for the purpose of Article 127F(2)(a)(vi) of the Law, we confirm we have received all information which we reasonably require to reach an informed decision on the Merger including copies of a Transaction Support Agreement dated 5 December 2022 (as amended and restated on 6 January 2023),a Master Transaction Agreement dated [16] February 2023 and a related Implementation Steps Memorandum.
8.
THAT for the purpose of Article 127F(2)(b) of the Law, we confirm we are aware of and have been alerted to our right to apply to the court under Article 127FB of the Law.

These Resolutions shall be deemed to be effective as from the date they are signed and shall be forwarded to the secretary of the Company for filing with the minutes of the meetings of the members of the Company and any other written resolution of the members of the Company.

Signed for and on behalf of

Quotient Holdings Finance Company Limited

Date



SCHEDULE 3.

Notices of Quotient EGMs

Notice of Annualan extraordinary general meeting of Quotient Limited (the "Company") which will also constitute a class meeting of the holders of Ordinary Shares (the "Notice")
to be held on April 25, 2023 at 11:00 a.m. GMT

DATE: April 25, 2023

TIME: 11:00 a.m. GMT

PLACE: Offices of Carey Olsen, 47 Esplanade, St Helier, Jersey JE1 0BD, Channel Islands

RECORD DATE: the close of business on March 3, 2023

PURPOSE OF MEETING: Passing the following special resolution.

SPECIAL RESOLUTION

Approval of the Merger Implementation Agreement

(1)
THAT a merger implementation agreement dated [ , 2023] between the Company, Quotient Holdings Merger Company Limited and Quotient Holdings Finance Company Limited (the "Merger Implementation Agreement") and which contains, among other things, the terms and means of effecting a proposed merger ("Merger") of those parties under Article 18B (Mergers) of the Companies (Jersey) Law 1991 (the "Law") be hereby approved for all purposes, including (without limitation) for the purposes of Article 127F(1) of the Law and the directors of the Company (or a duly authorised committee thereof) be and are authorised to take all such action as they may consider necessary or desirable for the implementation of the Merger pursuant to the terms and subject to the conditions contained in the Merger Implementation Agreement.

Record Date

Beneficial owners of Quotient shares held in street name as well as holders of record, are entitled to vote only if they were a shareholder of Quotient at the close of business on March 3, 2023. Holders of Ordinary Shares of Quotient are entitled to one vote for each share held.

Attendance at the Extraordinary General Meeting and Class Meeting of Shareholdersholders of Ordinary Shares

As required by our organizational documents, we intend to hold the Extraordinary General Meeting in person. Whether or not you plan to attend the meeting, your vote is important, and we encourage you to review the proxy materials and vote as soon as possible using the instructions provided in the Notice. If you hold your shares in street name, you may also follow the instructions included in the proxy materials to vote and confirm your attendance by telephone or Internet.

Right to apply to the court

In terms of Article 127FB of the Law, any shareholder of the Company (i.e. a holder of record) has the right to apply to the court on the grounds that the merger would unfairly prejudice the interests of that shareholder.

An application may not be made more than 21 days after the merger has been approved by the shareholders.

If you beneficially own Ordinary Shares for which Cede & Co. is the registered holder (as nominee for The Depository Trust Company) you are not a shareholder / holder of record within the meaning of the Law. In order to make an application to the court pursuant to Article 127FB of the Law it would be necessary for you to cause your Ordinary Shares to be transferred directly to you. You should contact the broker, bank, trustee or other nominee though which you hold Ordinary Shares in street name who should be able to advise you on process.

Where to Find More Information about the Resolutions and Proxies

Further information regarding the above resolution is set out in the Proxy Statement and other proxy materials, which are available at https://quotientbd.com/page/investors, all information as set out in the Proxy Statement is integral to this Notice and is constituted to form part of this Notice


You are entitled to appoint one or more proxies to attend the Extraordinary General Meeting and vote on your behalf and your proxy need not also be a shareholder of the Company. Instructions on how to appoint a proxy are set out in the Proxy Statement and on the proxy card.

BY ORDER OF THE BOARD OF DIRECTORS

Manuel O. Méndez

Director

Record shareholder: If your shares are registered directly in your name, please bring proof of such ownership.

Shares held in street name by a broker or a bank: If your shares are held for your account in the name of a broker, bank or other nominee, please bring a current brokerage statement, letter from your stockbroker or other proof of ownership to the meeting together with a proxy issued in your name should you wish to vote in person at the Extraordinary General Meeting.

This Notice of Extraordinary General Meeting and the Proxy Statement are being distributed on or about March 6, 2023.

Notice of 2023 Extraordinary General Meeting, the Proxy Statement and proxy card are available in the “Financials & Filings” section of our website at https://quotientbd.com/page/investors.



Notice of a Preference Class Meeting of Quotient Limited (the "Company") (the "Notice")

To Be Held on October 31, 2022 at the Radisson Blu Hotel, Zurich Airport, Rondellstrasse, Zurich Airport, 8058 Zurich, SwitzerlandApril 25, 2023 immediately following EGM on April 25, 2023

DATE: October 31, 2022April 25, 2023

TIME: 11:00 a.m., local timeImmediately following EGM on April 25, 2023

PLACE: The Radisson Blu Hotel, Zurich Airport, Rondellstrasse, Zurich Airport, 8058 Zurich, SwitzerlandOffices of Carey Olsen, 47 Esplanade, St Helier, Jersey JE1 0BD, Channel Islands

RECORD DATE: the close of business on August 31, 2022 (for beneficial owners of ordinary shares held in street name)March 3, 2023

PURPOSE OF MEETING: PresentingPassing the Company’s accountsfollowing special resolution.

SPECIAL RESOLUTION

Approval of the Merger Implementation Agreement

(1)
THAT a merger implementation agreement dated [ , 2023] between the Company, Quotient Holdings Merger Company Limited and Quotient Holdings Finance Company Limited (the "Merger Implementation Agreement") and which contains, among other things, the terms and means of effecting a proposed merger ("Merger") of those parties under Article 18B (Mergers) of the Companies (Jersey) Law 1991 (the "Law") be hereby approved for all purposes, including (without limitation) for the fiscal year ended March 31, 2022, together withpurposes of Article 127F(1) of the auditors’ reports on those accounts,Law and the directors of the Company (or a duly authorised committee thereof) be and are authorised to take all such action as they may consider necessary or desirable for the implementation of the Merger pursuant to the terms and subject to the conditions contained in the Merger Implementation Agreement.

Record Date

Preference shareholders on the Company's register of members are entitled to vote only if they were a preference shareholder of Quotient at the Annual Generalclose of business on March 3, 2023. Holders of Preference Shares of Quotient are entitled to one vote for each share held.

Attendance at the Preference Shareholders Meeting passing

As required by our organizational documents, we intend to hold the following ordinaryPreference Class Meeting in person. Whether or not you plan to attend the meeting, your vote is important, and special resolutionswe encourage you to review the proxy materials and transacting such other businessvote as may properly come beforesoon as possible using the Annual General Meeting:instructions provided in the Notice.

ORDINARY RESOLUTIONS

ElectionRight to apply to the court

In terms of directors

1) THAT Manuel O. Méndez be elected as a directorArticle 127FB of the Company.

2) THAT Thomas Aebischer be elected as a directorLaw, any shareholder of the Company.Company has the right to apply to the court on the grounds that the merger would unfairly prejudice the interests of that shareholder.

3) THAT Sophie Bechu

An application may not be electedmade more than 21 days after the merger has been approved by the shareholders.

Where to Find More Information about the Resolutions and Proxies

Further information regarding the above resolution is set out in the Proxy Statement and other proxy materials, which are available at https://quotientbd.com/page/investors, all information as set out in the Proxy Statement is integral to this Notice and is constituted to form part of this Notice.

You are entitled to appoint one or more proxies to attend the Preference Class Meeting and vote on your behalf and your proxy need not also be a directorshareholder of the Company. Instructions on how to appoint a proxy are set out in the Proxy Statement and on the proxy card.

BY ORDER OF THE BOARD OF DIRECTORS

[Manuel O. Méndez]

Director

4) THAT Isabelle BuckleRecord shareholder: If your shares are registered directly in your name, please bring proof of such ownership.

This Notice of Preference Class Meeting and the Proxy Statement are being distributed on or about March 6, 2023.


Notice of 2023 Preference Class Meeting, the Proxy Statement and proxy card are available in the “Financials & Filings” section of our website at https://quotientbd.com/page/investors.


SCHEDULE 4

Part A - Quotient Warranties

1.
Quotient has full power and authority to enter into, deliver and perform its obligations under this Agreement and all other documents to be elected asexecuted by it pursuant to or in connection with this Agreement.
2.
The obligations of Quotient under each document referred to in paragraph 1 above will, when executed, constitute valid and binding obligations of Quotient in accordance with their terms.
3.
The execution and delivery of, and the performance by Quotient of its obligations under this Agreement and all other documents to be executed by it pursuant to or in connection with this Agreement will not:
a.
conflict with or result in a directorbreach of any provision of Quotient’s memorandum and articles of association;
b.
conflict with, result in a breach of or constitute a default under any material agreement or instrument to which Quotient is a party;
c.
result in a breach of any law or regulation, or of any order, injunction, judgement or decree of any court, that applies to any member of the Company.Quotient Group; or
d.
require the consent of any person other than the shareholders of Quotient.

5) THAT Frederick HallsworthPart B - MergerCo Warranties

1.
MergerCo has full power and authority to enter into, deliver and perform its obligations under this Agreement and all other documents to be elected asexecuted by it pursuant to or in connection with this Agreement.
2.
The obligations of MergerCo under each document referred to in Part B paragraph 1 above will, when executed, constitute valid and binding obligations of MergerCo in accordance with its terms.
3.
The execution and delivery of, and the performance by MergerCo of its obligations under, this Agreement and all other documents to be executed by it pursuant to or in connection with this Agreement will not:
a.
conflict with or result in a directorbreach of any provision of the Company.

6) THAT Catherine Larue be elected asconstitutional documents of MergerCo;

b.
conflict with, result in a directorbreach of or constitute a default under any material agreement or instrument to which MergerCo is a party;
c.
conflict with or result in a breach of any law or regulation, or of any order, injunction, judgement or decree of any court, that applies to MergerCo; or
d.
require the Company.

7) THAT Heino von Prondzynski be elected as a directorconsent of the Company.

8) THAT Zubeen Shroff be elected as a director of the Company.

9) THAT John Wilkerson be elected as a director of the Company.

Compensation of our named executive officers ("say on pay")

10) THATany person other than the shareholders approve, on a non-binding, advisory basis, the compensation paid to the Company's named executive officers, as described in the "Executive Compensation - Compensation Discussion and Analysis" section of the Company's proxy statement (the "Proxy Statement") and the related compensation tables, notes and narrative discussion.MergerCo.

SIGNATORIES

SIGNED for and on behalf of

QUOTIENT LIMITED

)

)

)

By:

__________________________

Name:

Position:

Increase in shares available for issuance and removal of the "evergreen" provision under the 2014 Equity Plan

SIGNED for and on behalf of

QUOTIENT HOLDINGS MERGER

COMPANY LIMITED

)

)

)

By:

__________________________

Name:

Position:



SIGNED for and on behalf of

QUOTIENT HOLDINGS FINANCE

COMPANY LIMITED

)

)

)

By:

__________________________

Name:

Position:

11) THAT the fourth amended and restated 2014 Stock Incentive Plan (the "Fourth Amended and Restated 2014 Plan") be approved, which amends the Third Amended and Restated 2014 Stock Incentive Plan (the "2014 Plan") to (a) increase the number of ordinary shares authorized for issuance by 10’000’000 shares, and (b) remove the "evergreen" provision pursuant to which the aggregate number of shares authorized for issuance automatically increases each year.



Table of Contents

 

Auditors

12) THAT Ernst & Young LLP be re-appointedAccompanying Document: Constitutional Documents of Quotient Ltd.

Company no. 109886


COMPANIES (JERSEY) LAW 1991

A PUBLIC COMPANY LIMITED BY SHARES

MEMORANDUM

AND

ARTICLES OF ASSOCIATION

of

QUOTIENT LIMITED

Incorporating amendments passed by special resolution on October 31, 2022



Company no. 109886

COMPANIES (JERSEY) LAW 1991

A NO PAR VALUE PUBLIC LIMITED COMPANY

MEMORANDUM OF ASSOCIATION

OF

QUOTIENT LIMITED

(Adopted by written special resolution passed on 3rd April 2014)

Words and expressions contained in this Memorandum of Association have the same meanings as in the auditorsCompanies (Jersey) Law 1991, as amended.

1.
The name of the Company to hold office fromis Quotient Limited.

2.
The Company is a public company.

3.
The Company is a no par value company.

4.
There shall be no limit on the conclusionnumber of this meeting untilshares which may be issued by the conclusion ofCompany and if the Annual General Meetingshare capital structure of the Company tois at any time divided into separate classes of share there shall be held in 2023, thatno limit on the appointmentnumber of Ernst & Young LLP asshares of any class which may be issued by the Company’s independent registered public accounting firm for purposesCompany.

5.
The liability of United States securities law reporting for the fiscal year ending March 31, 2023 be ratified and that the directors be authorized to determine the fees to be paid to the auditors.

SPECIAL RESOLUTIONS

13) THAT the rights attaching to the common stocka member of the Company (ordinary shares) be and are hereby varied so thatis limited to the amount unpaid (if any) on such member's share or shares.



Company no. 109886

COMPANIES (JERSEY) LAW 1991

A NO PAR VALUE PUBLIC LIMITED COMPANY

ARTICLES OF ASSOCIATION

of

QUOTIENT LIMITED

(Adopted by a special resolution passed on 3rd April, 2014)


CONTENTS

1.PRELIMINARY 1

2.INTERPRETATION 1

3.SHAREs 7

4.RIGHTS ATTACHED TO SHARES 7

5.UNISSUED SHARES 7

6.REDEMPTION AND PURCHASE OF SHARES 8

7.COMMISSIONS AND BROKERAGE 8

8.TRUSTS NOT RECOGNISED 9

9.RENUNCIATION OF ALLOTMENT 9

10.VARIATION OF RIGHTS 9

11.ALTERATION OF SHARE CAPITAL 10

12.SHARE CERTIFICATES AND TITLE TO SHARES 11

13.CALLS ON SHARES 12

14.FORFEITURE AND LIEN 14

15.TRANSFER OF SHARES 16

16.UNCERTIFICATED SHARES 18

17.TRANSMISSION OF SHARES 21

18.UNTRACED SHAREHOLDERS 22

19.GENERAL MEETINGS 23

20.NOTICE OF GENERAL MEETINGS 23

21.PROCEEDINGS AT GENERAL MEETINGS 25

22.VOTING 27

23.VOTES OF MEMBERS 29

24.PROXIES AND CORPORATE REPRESENTATIVES 30

25.DTC SYSTEM VOTING ARRANGEMENTS 33

26.DIRECTORS 35

27.APPOINTMENT AND RETIREMENT OF DIRECTORS 36

28.ALTERNATE DIRECTORS 39

29.PROCEEDINGS OF DIRECTORS 40

30.DIRECTORS' INTERESTS AND CONFLICTS OF INTEREST 42

31.DIRECTORS' FEES 44

32.DIRECTORS' EXPENSES 45

33.BORROWING POWERS 45

34.GENERAL POWERS OF DIRECTORS 45

35.ASSOCIATE DIRECTORS 47

36.SECRETARY 48

37.THE SEAL 48

38.AUTHENTICATION OF DOCUMENTS 48

39.DIVIDENDS 49

40.RESERVES 52


41.CAPITALISATION OF RESERVES 52

42.RECORD DATES 55

43.REGISTER 55

44.MINUTES AND BOOKS 56

45.ACCOUNTS 56

46.AUDITORS 57

47.COMMUNICATIONS 57

48.WINDING UP 63

49.INDEMNITY AND INSURANCE 64


COMPANIES (JERSEY) LAW 1991

A PUBLIC COMPANY LIMITED BY SHARES

ARTICLES OF ASSOCIATION

OF

QUOTIENT LIMITED

(Adopted by a special resolution passed on 3rdApril, 2014)

1.
PRELIMINARY

This document comprises the articles of association of the Company. The regulations constituting the Standard Table in the Companies (Standard Table) (Jersey) Order 1992 shall not apply to the Company.

2.
INTERPRETATION
2.1.
In these Articles, unless the context requires otherwise:

"address" includes a number or address used for the purposes of sending or receiving documents or information by electronic means;

"these Articles" means these articles of association as amended or replaced from time to time;

"Auditors" means the auditors for the time being of the Company acting by itsor, in the case of joint auditors, any one of them;

"bankrupt" has the meaning given to it in the Interpretation (Jersey) Law 1954;

"Board" means the board of directors shall havefor the power to undertake a reverse stock split (consolidation) of all (but not some only)time being of the Company or the Directors present or deemed to be present at a duly convened meeting of the Directors at which a quorum is present, as the context requires;

"certificatedshare" means a share which is not an uncertificated share and references in these Articles to a share being held in "certificated form" shall be construed accordingly;

"cleardays" means, in relation to the giving of a notice, the period excluding the day on which a notice is given or deemed to be given and the day for which it is given or on which it is to take effect;

"CompaniesLaws" means the Law, the Uncertificated Securities Order, the Electronic Communications Law and all statutes adopted in Jersey (including any orders, regulations or other subordinate legislation made under such statutes) from time to time in force concerning companies in so far as they apply to the Company;

"communication" includes an electronic communication;

"Director" means a director for the time being of the Company;

"dividend" includes a bonus issue;

"DTC" means the Depositary Trust Company or any successor corporation;

"DTC Depositary" means Cede & Co. and/or any other custodian, depositary or nominee of DTC which holds Ordinary Shares under arrangements that facilitate the holding and trading of beneficial interests in such Ordinary Shares in the DTC System;

"DTC Proxy" means, in relation to any Ordinary Shares held by the DTC Depositary, any person who is, for the purposes of any general meeting or resolution, appointed a proxy (whether by way of instrument of proxy, power of attorney, mandate or otherwise) by:

(a) the DTC Depositary; or


(b) a proxy, attorney or other agent appointed by any other person whose authority is ultimately derived (whether directly or indirectly) from the DTC Depositary;

"DTC System" means the electronic system operated by DTC by which title to securities or interests in securities may be evidenced and transferred in dematerialised form;

"electronic communication" has the meaning given in the Electronic Communications Law;

"Electronic Communications Law" means the Electronic Communications (Jersey) Law 2000;

"electronic signature" has the meaning given in article 1(1) of the Electronic Communications Law;

"Group" means the Company and its subsidiaries from time to time;

"holder" means, in relation to any shares, the member whose name is entered in the Register as the holder of those shares;

"Jersey" means the island of Jersey;

"Law" means the Companies (Jersey) Law 1991;

"member" means a member of the Company;

"Memorandum of Association" means the document of the same name of the Company, as amended or replaced from time to time;

"month" means calendar month;

"NASDAQ" means the NASDAQ Global Market;

"NASDAQRules" means the rules of NASDAQ;

"Office" means the registered office for the time being of the Company;

"Operator" has the meaning given to "authorised operator" in the Uncertificated Securities Order;

"Operator-instruction" means a properly authenticated de-materialised instruction attributable to the Operator;

"ordinary resolution" means a resolution of the Company in general meeting passed by a simple majority of the votes cast at that meeting;

"Ordinary Shares" means ordinary shares in the capital of the Company;

"paid up" means paid up or credited as paid up;

"participating security" has the meaning given to it in the Uncertificated Securities Order;

"Register" means the register of members of the Company (and, unless the context requires otherwise, includes any overseas branch register) to be kept and maintained in accordance with these Articles and the Companies Laws;

"relevant system" means a computer based system and its related facilities and procedures that is provided by an Operator and by means of which title to units of a security can be evidenced and transferred, in accordance with the Uncertificated Securities Order, without a written instrument;

"Seal" means any common or official seal that the Company has and is permitted to have under the Companies Laws;

"special resolution" means a special resolution as defined in Article 90 of the Law;

"Transfer Office" means:

(a) in relation to the Register, the location in Jersey where the Register is kept and maintained; and


(b) where the Company keeps an overseas branch register in respect of any country, territory or place outside of Jersey, the location in that country, territory or place where that overseas branch register is kept and maintained;

"Uncertificated Securities Order" means the Companies (Uncertificated Securities) (Jersey) Order 1999 and any provisions of or under the Companies Laws which supplement or replace such order;

"uncertificated share" means a share title to which is recorded on the Register as being held in uncertificated form and references in these Articles to a share being held in "uncertificated form" shall be construed accordingly;

"United Kingdom" means the United Kingdom of Great Britain and Northern Ireland (and includes England, Scotland and Wales, whether or not for the time being forming part of the United Kingdom of Great Britain and Northern Ireland);

"USA" means the United States of America and its territories and possessions, including the District of Columbia; and

"year" means calendar year.

2.2.
In these Articles, unless the context requires otherwise:
2.2.1.
the expression "debenture" shall include debenture stock and the expression "debenture holder" shall include debenture stockholder;
2.2.2.
the expression "Secretary" means the secretary for the time being of the Company and includes any person appointed by the Board to perform any of the duties of the secretary including a joint, assistant or deputy secretary;
2.2.3.
the expression "officer" shall include, in relation to a body corporate, a director, alternate director, manager, executive officer and company secretary (including, in the case of the Company, the Directors, any alternate Directors, the Secretary and any executive officers of the Company who are not Directors) but shall not include auditors (being, in the case of the Company, the Auditors);
2.2.4.
the expressions "widow" and "widower" shall include the surviving civil partner of a deceased person;
2.3.
references to "writing" mean the representation or reproduction of words, symbols or other information in a legible form by any method or combination of methods, whether sent or supplied in electronic form or otherwise, and "written" shall be construed accordingly;
2.4.
references to a document or information being "sent", "supplied" or "given" to or by a person mean such document or information, or a copy of such document or information, being sent, supplied, given, delivered, issued or made available to or by, or served on or by, or deposited with or by that person by any method authorised by these Articles, and "sending", "supplying" and "giving" shall be construed accordingly;
2.5.
references to a document being "signed" or to "signature" include references to its being signed under hand or under Seal or by any other method and, in the case of an electronic communication, such references are to its being authenticated by electronic means as specified by the Board in accordance with these Articles or (where the Board has made no specification) to an electronic signature;
2.6.
references to a meeting shall not be taken as requiring more than one person to be present if any quorum requirement can be satisfied by one person;
2.7.
words importing the singular number include the plural and vice versa;
2.8.
words importing one gender include all genders and words importing persons include a body corporate;

2.9.
any word or expression defined in the Companies Laws on the adoption of these Articles shall, if not inconsistent with the subject or context and unless otherwise expressly defined in these Articles, bear the same meaning in these Articles except that "company" shall mean any body corporate;
2.10.
a reference to any statute or statutory instrument or any provision of a statute or statutory instrument includes any modification or re-enactment of that statute, statutory instrument or provision for the time being in force;
2.11.
any reference to:
2.11.1.
rights attaching to any share;
2.11.2.
members having a right to attend and vote at general meetings of the Company;
2.11.3.
dividends being paid, or any other distribution of the Company's assets being made, to members; or
2.11.4.
interests in a certain proportion or percentage of the issued share capital, or any class of share capital,
2.11.5.
shall, unless otherwise expressly provided by the Companies Laws, be construed as though any treasury shares held by the Company had to be cancelled;
2.11.6.
headings are inserted for convenience only and do not affect the construction of these Articles; and
2.11.7.
a special resolution shall be effective for any purpose for which an ordinary resolution is expressed to be required under any provision of these Articles.
2.12.
For the purposes of these Articles, unless the context requires otherwise:
2.13.
a document or information is sent or supplied in "electronic form" if it is sent or supplied:
2.13.1.
by electronic means (for example, by e-mail or fax); or
2.13.2.
by any other means while in an electronic form (for example, sending a disk by post), and references to "electronic copy" have a corresponding meaning;
2.14.
a document or information is sent or supplied by electronic means if it is:
2.14.1.
sent initially and received at its destination by means of electronic equipment for the processing (which expression includes digital compression) or storage of data; and
2.14.2.
entirely transmitted, conveyed and received by wire, by radio, by optical means or by other electromagnetic means,

and references to "electronic means" have a corresponding meaning;

2.15.
a document or information is sent or supplied in "hard copy form" if it is sent or supplied in a paper copy or similar form capable of being read, and references to "hard copy" have a corresponding meaning;
2.16.
a document or information authorised or required by these Articles to be sent or supplied in electronic form must be sent or supplied in a form, and by a means, that the sender or supplier reasonably considers will enable the recipient to read it and to retain a copy of it; and
2.17.
a document or information can be read only if:
2.17.1.
it can be read with the naked eye; or
2.17.2.
to the extent that it consists of images (for example photographs, pictures, maps, plans or drawings), it can be seen with the naked eye.
3.
SHAREs

The authorised share capital of the Company is as specified in the Memorandum of Association of the Company. No share issued by the Company shall have a nominal value.


4.
RIGHTS ATTACHED TO SHARES

Without prejudice to any rights for the time being attached to any existing shares or class of shares and subject to the provisions of the Company Laws, any share may be issued with such preferred, deferred or other special rights, or such restrictions, whether in regard to dividend, return of capital, transfer, voting, conversion or otherwise, as the Board may determine or otherwise as the Company may from time to time by special resolution determine.

5.
UNISSUED SHARES
5.1.
Subject to the provisions of the Companies Laws and these Articles, all unissued shares of the Company (whether forming part of the existing or any increased capital) shall be at the disposal of the Board which may allot (with or without conferring a right of renunciation), grant options over, offer or otherwise deal with or dispose of such shares to such persons, at such times and generally on such terms and conditions as the Board may determine. No share shall be issued at a discount.
5.2.
The Board may allot and issue shares in the Company to any person and without any obligation to offer such shares to the members (whether in proportion to the existing shares held by them or otherwise).
5.3.
The Company may issue fractions of shares in accordance with, and subject to the provisions of, the Law, provided that:
5.3.1.
a fraction of a share shall be taken into account in determining the entitlement of a member as regards dividends or on a winding up; and
5.3.2.
a fraction of a share shall not entitle a member to a vote in respect thereof.
6.
REDEMPTION AND PURCHASE OF SHARES
6.1.
Subject to the provisions of the Companies Laws:
6.1.1.
and to any rights attached to any existing shares, the Company may issue, or with the sanction of a special resolution convert any existing non-redeemable share (whether issued or not) into, a share which is to be redeemed, or is liable to be redeemed at the option of the Company or the holder;
6.1.2.
the Company may purchase, or may enter into a contract under which it will or may purchase, any of its own shares of any class (including any redeemable shares) and in relation thereto, neither the Company nor the Board shall be required to select the shares to be purchased rateably or in any other particular manner as between the holders of shares of the same class or as between them and the holders of shares of any other class or in accordance with the rights as to dividends or capital conferred by any class of shares; and
6.1.3.
the Company may hold as treasury shares any shares purchased or redeemed by it.
7.
COMMISSIONS AND BROKERAGE

The Company may exercise all powers of paying commissions and brokerage conferred or permitted by the Companies Laws. Subject to the provisions of the Companies Laws, any such commission or brokerage may be satisfied by the payment of cash, the allotment of fully or partly paid shares, the grant of an option to call for an allotment of shares or any combination of such methods.

8.
TRUSTS NOT RECOGNISED

Except as required by law, no person shall be recognised by the Company as holding any share upon any trust, and the Company shall not be bound by or compelled in any way to recognise (even when having notice thereof) any equitable, contingent, future or partial interest in any share, or any interest in any fractional part of a share, or (save as otherwise provided by these Articles or by law) any other right in respect of any share, except an absolute right to the entirety thereof in the registered holder.

9.
RENUNCIATION OF ALLOTMENT
9.1.
The Board may at any time after the allotment of any share but before any person has been entered in the Register as the holder:
9.1.1.
recognise a renunciation thereof by the allottee in favour of some other person and accord to any allottee of a share a right to effect such renunciation; and/or

9.1.2.
allow the rights represented thereby to be one or more participating securities, in each case upon and subject to such terms and conditions as the Board may think fit to impose.
10.
VARIATION OF RIGHTS
10.1.
Whenever the share capital of the Company is divided into different classes of shares, any of the special rights attached to any class may, subject to the provisions of the Companies Laws, be varied or abrogated (either whilst the Company is a going concern or during or in contemplation of a winding up) either:
10.1.1.
with the consent in writing of the holders of not less than two-thirds in number of the issued shares of the class (excluding any shares of that class held as treasury shares), which consent shall be in hard copy form or in electronic form sent to such address (if any) for the time being specified by or on behalf of the Company for that purpose or in default of any such specification to the Office; or
10.1.2.
with the sanction of a special resolution passed at a separate general meeting of the holders of the shares of the class, but not otherwise.
10.2.
To every such separate general meeting all the provisions of these Articles relating to general meetings of the Company and to the proceedings thereat shall apply mutatis mutandis, except that:
10.2.1.
any holder of shares of the class present in person or by proxy may demand a poll; and
10.2.2.
any holder of shares of the class shall, on a poll, have one vote in respect of every share of the class held by him.
10.3.
Article 10.1 shall apply to the variation or abrogation of the special rights attached to some (but not all) of the shares of such class as if the shares concerned and the remaining shares of such class formed separate classes, or to any scheme for the distribution (though not in accordance with legal rights) of assets in money or in kind in or before liquidation, or to any contract for the sale or disposal of the whole or any part of the Company's property or business determining the way in which as between the several classes of shareholders the purchase considerations shall be distributed, and generally to any alteration, contract, compromise or arrangement which the persons voting thereon could, if sui juris and holding all the shares of the class, consent to or enter into, and such resolution shall be binding upon all holders of shares of the class.
10.4.
Save as otherwise provided in these Articles, the special rights attached to any class of shares having preferential rights shall not unless otherwise expressly provided by the terms of issue thereof be deemed to be varied or abrogated by the creation or issue of further shares ranking as regards participation in the profits or assets of the Company or voting in some or all respects pari passu therewith but in no respect in priority thereto, or by any reduction of the capital paid up thereon, or by any purchase or redemption by the Company of its own shares.
11.
ALTERATION OF SHARE CAPITAL
11.1.
The Company may from time to time by special resolution alter its Memorandum of Association so as to increase or reduce the number of shares which is authorised to issue or consolidate or divide all or any part of its shares (whether issued or not) into fewer shares and may generally make such other alteration to its share capital as is from time to time permitted by Law. All new shares shall, save in so far as may be otherwise provided by the terms of issue thereof, be subject to the provisions of these Articles with reference to allotment, payment of calls, lien, transfer, transmission, forfeiture and otherwise.
11.2.
Whenever as a result of a consolidation, consolidation and sub-division or sub-division of shares any members would become entitled to fractions of a share, the Board may deal with the fractions as it thinks fit. In particular the Board may sell the shares representing the fractions for the best price reasonably obtainable to any person (including, subject to the provisions of the Companies Laws, the Company) and distribute the net proceeds of sale in due proportion among those members and the Board may authorise some person to transfer or deliver the shares to, or in accordance with the directions of, the purchaser. For the purposes of effecting the sale, the Board may arrange for the shares representing the fractions to be entered in the Register as certificated shares. The person to whom any shares are transferred or delivered shall not be bound to see to

the application of the purchase money nor shall his title to the shares be affected by any irregularity in, or invalidity of, the proceedings relating to the sale. Subject to the Companies Laws, when the Board consolidates or sub-divides shares, it can treat certificated and uncertificated shares which a member holds as separate shareholdings.
11.3.
The Company may reduce its capital accounts in any ways permitted by Law.
11.4.
Subject to the provisions of the Companies Laws and these Articles, the Company may make a distribution to its members from its stated capital account or any other reserve (whether of profit, capital or some other nature).
12.
SHARE CERTIFICATES AND TITLE TO SHARES
12.1.
Subject as follows, every person whose name is entered as a member in the Register in respect of any shares of any class in certificated form (except a person in respect of whom the Company is not by law required to issue a share certificate) shall be entitled without payment to a certificate therefor within two months after allotment (or such shorter period as the terms of issue shall provide), and upon the transfer thereof within two months after lodgement of transfer (not being a transfer which the Company is for any reason entitled to refuse to register and does not register) and, in the case of conversion thereof from uncertificated to certificated form, within two months of the date of conversion. Notwithstanding the foregoing, it shall be a term of issue of any shares in certificated form issued to a DTC Depositary that the Company shall not be required to issue a certificate in respect of such shares unless the DTC Depositary requests that such certificate be issued by notice to the Company, in which case the foregoing provisions shall apply mutatis mutandis save that the reference to the "allotment" of the relevant shares in the foregoing shall be a reference to the date that such notice is received by the Company. The Company shall not be bound to register more than four persons as the joint holders of a share and in the case of a share held jointly by several persons the Company shall not be bound to issue more than one certificate therefor and delivery of a certificate to any one of such persons shall be sufficient delivery to all.
12.2.
Every share certificate shall be signed under a Seal or signed by two Directors or by one Director and the Secretary and shall specify the number and class of the shares to which it relates and the amount or respective amounts paid up on the shares and (if required by the Companies Laws) the distinguishing numbers of such shares. The Board may by resolution decide, either generally or in any particular case or cases, that any signatures on any share certificates need not be autographic but may be applied to the certificates by some mechanical or other means or may be printed on them.
12.3.
Where a member transfers part only of the certificated shares comprised in a share certificate the old certificate shall be cancelled and a new certificate for the balance of such shares (to the extent that such balance is to be held in certificated form) issued in lieu without charge.
12.4.
Any two or more certificates representing certificated shares of any one class held by any member may at his request be cancelled and a single new certificate for such shares issued in lieu without charge.
12.5.
If any member shall surrender for cancellation a share certificate representing certificated shares held by him and request the Company to issue in lieu two or more share certificates representing such shares in such proportions as may be specified, the Board may, if it thinks fit, comply with such request.
12.6.
If a share certificate shall be damaged or defaced or alleged to have been lost, stolen or destroyed a new certificate representing the same certificated shares may be issued to the holder upon request subject to delivery up of the old certificate or (if alleged to have been lost, stolen or destroyed) compliance with such conditions as to evidence and indemnity and (in either case) the payment of any exceptional out-of-pocket expenses of the Company in connection with the request as the Board may think fit. Subject as aforesaid no charge will be made for a new share certificate issued to replace one that has been damaged, lost or destroyed.
12.7.
In the case of certificated shares held jointly by several persons any such request may be made by any one of the joint holders except where the certificate is alleged to be lost, stolen or destroyed.
13.
CALLS ON SHARES

13.1.
The Board may from time to time make calls upon the members in respect of any moneys unpaid on their shares and not by the terms of issue thereof made payable at fixed times. Each member shall (subject to receiving at least 14 clear days' notice specifying the time or times and place of payment) pay to or as directed by the Company at the time or times and place so specified the amount called on his shares.
13.2.
A call shall be deemed to have been made at the time when the resolution of the Board authorising the call was passed and may be made payable by instalments. A call may be wholly or in part revoked or postponed as the Board may determine.
13.3.
The joint holders of a share shall be jointly and severally liable to pay all calls in respect thereof. Subject to the Companies Laws, a person upon whom a call is made shall remain liable for calls made upon him, notwithstanding the subsequent transfer of the shares on which the call was made.
13.4.
If a sum called in respect of a share is not paid before or on the day appointed for payment thereof, the person from whom the sum is due shall pay interest on the sum from the day appointed for payment thereof to the time of actual payment at such rate as the Board in its absolute discretion may determine, together with all expenses that may have been incurred by the Company by reason of such non-payment, but the Board shall be at liberty in any case or cases to waive payment of such interest and expenses wholly or in part.
13.5.
Any sum which by the terms of issue of a share becomes payable upon allotment or at a fixed date shall for all the purposes of these Articles be deemed to be a call duly made and payable on the date on which by the terms of issue the same becomes payable. In the case of non-payment all the relevant provisions of these Articles as to payment of interest and expenses, forfeiture or otherwise shall apply as if such sum had become payable by virtue of a call duly made and notified.
13.6.
The Board may on the issue of shares differentiate between the holders as to the amount of calls to be paid and the times of payment.
13.7.
The Board may if it thinks fit receive from any member willing to advance the same all or any part of the moneys uncalled and unpaid upon the shares held by him and such payment in advance of call shall extinguish pro tanto the liability upon the shares in respect of which it is made and upon the money so received (until and to the extent that the same would but for such advance become payable) the Company may pay interest at such rate as may be agreed between the member paying such sum and the Board but any such advance payment shall not entitle the holder of the share to participate in respect of such amount in any dividend.
14.
FORFEITURE AND LIEN
14.1.
If a member fails to pay in full any call or instalment of a call on the day appointed for payment thereof, the Board may at any time thereafter serve a notice on him requiring payment of so much of the call or instalment as is unpaid together with any interest which may have accrued thereon and any expenses incurred by the Company by reason of such non-payment.
14.2.
The notice shall name a further day (not being less than 14 clear days from the date of service of the notice) on or before which and the place where the payment required by the notice is to be made, and shall state that in the event of non-payment in accordance therewith the shares on which the call was made will be liable to be forfeited.
14.3.
If the requirements of any such notice as aforesaid are not complied with, any share in respect of which such notice has been given may at any time thereafter, before payment of all calls and interest and expenses due in respect thereof has been made, be forfeited by a resolution of the Board to that effect. Such forfeiture shall include all dividends declared and other moneys payable in respect of the forfeited share and not actually paid before forfeiture. The Board may accept a surrender of any share liable to be forfeited.
14.4.
When any share has been forfeited, notice of the forfeiture shall be served upon the person who was before forfeiture the holder of the share but no forfeiture shall be invalidated by omission or neglect to give such notice.

14.5.
A share so forfeited or surrendered shall be deemed to be the property of the Company and may be sold, re-allotted or otherwise disposed of either to the person who was before such forfeiture or surrender the holder thereof or entitled thereto or to any other person upon such terms and in such manner as the Board thinks fit, and at any time before a sale, re-allotment or disposal the forfeiture or surrender may be cancelled on such terms as the Board thinks fit. The Board may, if necessary, authorise some person to transfer a forfeited or surrendered share to any such other person as aforesaid.
14.6.
A person whose shares have been forfeited or surrendered shall cease to be a member in respect of the shares (and shall, in the case of shares held in certificated form, surrender to the Company for cancellation the certificate for such shares) but shall notwithstanding the forfeiture or surrender remain liable to pay to the Company all moneys which at the date of forfeiture or surrender were presently payable by him to the Company in respect of the shares with interest thereon at such rate as the Board may in its absolute discretion determine from the date of forfeiture or surrender until payment, but the Board may waive payment of such interest either wholly or in part. The Board may enforce payment, without any allowance for the value of the shares at the time of forfeiture or surrender.
14.7.
The Company shall have a first and paramount lien on every share (not being a fully paid share) for all moneys payable to the Company (whether presently or not) in respect of such reverse stock split,share. The Company's lien on a share shall extend to all dividends or other moneys payable thereon or in respect thereof. The Board may waive any lien which has arisen and may resolve that any share shall for some limited period be exempt wholly or partially from the provisions of this Article.
14.8.
The Company may sell in such manner as the Board thinks fit any share on which the Company has a lien, but no sale shall be made unless the period for the payment or discharge of some part at least of the debt or liability in respect of which the lien exists shall have actually arrived nor until the expiration of 14 clear days after a notice stating and demanding payment or discharge thereof and giving notice of intention to sell in default shall have been given to the holder for the time being of the share or the person entitled thereto by reason of his death or bankruptcy.
14.9.
The net proceeds of such sale after payment of the cost of such sale shall be applied in or towards payment or satisfaction of the debts or liabilities in respect whereof the lien exists so far as the same are presently payable and any residue shall upon surrender (in the case of shares held in certificated form) to the Company for cancellation of the certificate for the shares sold and (in any case) subject to a like lien for debts or liabilities the period for the payment or discharge of which has not actually arrived as existed upon the shares prior to the sale be paid to the person entitled to the shares at the time of the sale. For giving effect to any such sale the Board may authorise some person to sign an instrument of transfer to transfer the shares sold to the purchaser.
14.10.
An affidavit that the declarant is a Director or the Secretary and that a share has been duly forfeited or surrendered or sold to satisfy a lien of the Company on a date stated in the affidavit shall be conclusive evidence of the facts therein stated as against all persons claiming to be entitled to the share. Such affidavit and the receipt of the Company for the consideration (if any) given for the share on the sale, re-allotment or disposal thereof together with the share certificate (in the case of shares in certificated form) delivered to a purchaser or allottee thereof shall (subject to the execution of an instrument of transfer if the same be required) constitute a good title to the share and the person to whom the share is sold, re-allotted or disposed of shall be registered as the holder of the share and shall not be bound to see to the application of the purchase money (if any) nor shall his title to the share be affected by any irregularity or invalidity in the proceedings in reference to the forfeiture, surrender, sale, re-allotment or disposal of the share.
15.
TRANSFER OF SHARES
15.1.
All transfers of shares which are in uncertificated form may be effected by means of a relevant system in accordance with the Companies Laws and the rules of the relevant system.
15.2.
A transfer of shares in certificated form may be effected by an instrument of transfer in any usual or common form or in any other form acceptable to the Board and may be under hand only. The instrument of transfer shall be signed by or on behalf of the transferor and (except in the case of

fully paid shares) by or on behalf of the transferee. The transferor shall remain the holder of the shares concerned until the name of the transferee is entered in the Register in respect thereof.
15.3.
The registration of transfers may be suspended at such ratiotimes and for such periods (not exceeding 30 days in any year) as the Board may from time to time determine either generally or in respect of any class of shares, save that the Board may not suspend the registration of transfers of any shares which are participating securities without the consent of the Operator.
15.4.
The Board may, in its absolute discretion, refuse to register any transfer of an uncertificated share where permitted by these Articles and the Companies Laws.
15.5.
The Board may, in its absolute discretion, refuse to register any instrument of transfer of a certificated share:
15.5.1.
which is not fully paid up; and
15.5.2.
on which the Company has a lien.
15.6.
The Board may decline to recognise any instrument of transfer relating to certificated shares unless the instrument:
15.6.1.
has been left at the Office, the Transfer Office or at such other place as the Board may decide, for registration;
15.6.2.
is accompanied by the certificate for the shares to be transferred and such other evidence (if any) as the Board may reasonably require to prove the title of the intending transferor or his right to transfer the shares; and
15.6.3.
is in respect of only one class of shares.
15.7.
Unless otherwise agreed by the Board in any particular case, the maximum number of persons who may be entered on the Register as joint holders of a share is four.
15.8.
For all purposes of these Articles relating to the registration of transfers of shares, the renunciation of the allotment of any shares by the allottee in favour of some other person shall be deemed to be a transfer and the Board shall have the same powers of refusing to give effect to such a renunciation as if it were a transfer.
15.9.
If the Board refuses to register a transfer then, within two months after the date on which:
15.9.1.
the transfer was lodged with the Company (in the case of shares held in certificated form); or
15.9.2.
the Operator-instruction was received by the Company (in the case of shares held in uncertificated form), the Board shall send to the transferee notice of the refusal together with (in the case of shares held in certificated form) the instrument of transfer.

15.10. Subject to Article 15.11, all instruments of transfer which are registered may be retained by the Company; and subject to the Companies Laws, the Company shall be entitled to destroy:

15.10.1.all instruments of transfer which have been registered at any time after the expiration of ten years from the date of registration thereof;

15.10.2. all dividend mandates and notifications of change of address at any time after the expiration of two years from the date of recording thereof;

15.10.3. all share certificates which have been cancelled at any time after the expiration of one year from the date of cancellation thereof;

15.10.4. all appointments of proxy which have been used for the purposes of a poll, at any time after the expiration of one year from the date of such use, and all appointments of proxy which have not been used for the purposes of a poll, at any time after one month from the end of the meeting to which the appointments of proxy relates and at which no poll was demanded; and


15.10.5. any other document on the basis of which any entry in the Register is made at any time after the expiry of 10 years from the date an entry in the Register was first made in respect of it,

and it shall conclusively be presumed in favour of the Company that every entry in the Register purporting to have been made on the basis of an instrument of transfer or other document so destroyed was duly and properly made and every instrument of transfer so destroyed was a valid and effective instrument duly and properly registered and every share certificate so destroyed was a valid and effective certificate duly and properly cancelled and every other document hereinbefore mentioned so destroyed was a valid and effective document in accordance with the recorded particulars thereof in the books or records of the Company.

15.11. Article 15.10 applies only to the destruction of a document in good faith and without notice of any claim (regardless of the parties thereto) to which the document might be relevant and nothing in Article 15.10 shall be construed as imposing upon the Company any liability in respect of the destruction of any such document earlier than as aforesaid or in any other circumstances which would not attach to the Company in the absence of Article 15.10.

15.12 References in Articles 15.10 and 15.11 to the destruction of any document include references to the disposal thereof in any manner.

15.13 No fee will be charged by the Company in respect of the registration of any instrument of transfer, probate, letters of administration, certificate of marriage or death, stop notice, power of attorney or other document relating to or affecting the title to any shares or otherwise for making any entry in the Register affecting the title to any shares.

16.
UNCERTIFICATED SHARES
16.1.
Subject to the Companies Laws, the Board may resolve that a class of shares is to become a participating security and may at any time determine that a class of shares shall cease to be a participating security.
16.2.
No provision of these Articles shall apply to shares of any class which are in uncertificated form to the extent that such Article is inconsistent with:
16.2.1.
the holding of shares of that class in uncertificated form;
16.2.2.
the transfer of title to shares of that class by means of a relevant system;
16.2.3.
any provision of the Uncertificated Securities Order; or
16.2.4.
the exercise of any powers or functions of the Company or the effecting by the Company of any actions by means of a relevant system.
16.3.
Any share of a class which is a participating security may be changed from an uncertificated share to a certificated share and from a certificated share to an uncertificated share in accordance with the Uncertificated Securities Order and the rules of any relevant system.
16.4.
For the purpose of effecting any action by the Company, the Board may determine that shares held by a person in uncertificated form shall be treated as a separate holding from shares held by that person in certificated form but shares of a class held by a person in uncertificated form shall not be treated as a separate class from shares of that class held by that person in certificated form.
16.5.
Unless the Board otherwise determines or the Uncertificated Securities Order or the rules of the relevant system concerned otherwise require, any shares issued or created out of or in respect of any uncertificated shares shall be uncertificated shares and any shares issued or created out of or in respect of any certificated shares shall be certificated shares.
16.6.
In relation to any share in uncertificated form:
16.6.1.
the Company may utilise the relevant system to the fullest extent available from time to time in the exercise of any of its powers or functions under the Companies Laws or these Articles or otherwise in effecting any actions and the Company may from time to time determine the manner in which such powers, functions and actions shall be so exercised or effected;

16.6.2.
the Company may, by notice to the holder of that share, require the holder to change the form of that share to certificated form within such period as may be specified in the notice; and
16.6.3.
the Company shall not issue a share certificate. The Company may by notice to the holder of any share in certificated form, direct that the form of such share may not be changed to uncertificated form for a period specified in such notice.
16.7.
Subject to the Companies Laws, the Board may lay down regulations not included in these Articles which (in addition to, or in substitution for, any provisions in these Articles):
16.7.1.
apply to the issue, holding or transfer of shares in uncertificated form;
16.7.2.
set out (where appropriate) the procedures for conversion and/or redemption of shares in uncertificated form; and/or
16.7.3.
the Board considers necessary or appropriate to ensure that these Articles are consistent with the Uncertificated Securities Order and/or the Operator's rules and practices.
16.8.
Any such regulations made by the Board pursuant to Article 16.6 will apply instead of any relevant provisions in these Articles which relate to the transfer, conversion and redemption of shares in uncertificated form or which are not consistent with the Uncertificated Securities Order, in all cases to the extent (if any) stated in such regulations. If the Board make any such regulations, Article 16.9 will (for the avoidance of doubt) continue to apply, when read in conjunction with those regulations.
16.9.
Any instruction given by means of a relevant system shall be a dematerialised instruction given in accordance with the Uncertificated Securities Order, the facilities and requirement of a relevant system and the Operator's rules and practices.
16.10.
Where the Company is entitled under the Companies Laws and the rules, procedures or practices of any relevant system or under these Articles to dispose of, forfeit, accept the surrender of, enforce a lien over, re-allot or sell, transfer or otherwise procure the sale of any shares which are held in uncertificated form, the Board shall have the power (subject to the Companies Laws and the rules, procedures or practices of the relevant system) to take such steps as the Board considers appropriate, by instruction by means of a relevant system or otherwise, to effect such disposal, forfeiture, surrender, enforcement, re-allotment sale or transfer and such powers shall (subject as aforesaid) include the right to:
16.10.1.
request or require the deletion of any computer based entries in the relevant system relating to the holding of such shares in uncertificated form; and/or
16.10.2.
alter such computer based entries so as to divest the registered holder of such shares of the power to transfer such shares to a person other than the transferee, purchaser or his nominee identified by the Company for this purpose; and/or
16.10.3.
require any holder of any uncertificated shares which are the subject of any exercise by the Company of any such entitlement, by notice to the holder concerned, to convert his holding of such uncertificated shares into certificated form within such period as may be specified in the notice prior to completion of any disposal, sale or transfer of such shares or direct the holder to take such steps as may be necessary to sell or transfer such shares; and/or
16.10.4.
otherwise rectify or change the Register in respect of any such shares in such manner as the Board considers appropriate (including, without limitation, by entering the name of the transferee into the Register as the next holder of such shares); and/or
16.10.5.
appoint any person to take such steps in the name of the holder of such shares as may be required to effect the conversion and/or transfer of such shares and such steps shall be effective as if they had been taken by the registered holder of the uncertificated shares concerned.
16.11.
The Company shall not issue to any person a certificate in respect of an uncertificated share.

17.
TRANSMISSION OF SHARES
17.1.
In the case of the death of a shareholder, the survivors or survivor where the deceased was a joint holder, and the executors or administrators of the deceased where he was a sole or only surviving holder, shall be the only persons recognised by the Company as having any title to his interest in the shares, but nothing in this Article shall release the estate of a deceased holder (whether sole or joint) from any liability in respect of any share held by him.
17.2.
Any guardian of an infant member, any curator bonis or guardian or other legal representative of a member under legal disability and any person becoming entitled to a share in consequence of the death or bankruptcy of a member or otherwise by operation of law may (subject as hereinafter provided) upon supplying the Company with such evidence as the Board may reasonably require to show his title to the share either require to be registered himself as a holder of the share by giving to the Company notice to that effect or transfer such share to some other person (in any case in the event of the share being in uncertificated form subject always to the Companies Laws and to the rules of any relevant system). All the limitations, restrictions and provisions of these Articles relating to the right to transfer and the registration of transfers of shares shall be applicable to any such notice or transfer as aforesaid as if the event giving rise thereto had not occurred and the notice or transfer were a transfer executed by such member.
17.3.
Save as otherwise provided by or in accordance with these Articles, a person becoming entitled to a share in consequence of any event giving rise to transmission by operation of law shall upon supplying the Company with such evidence as the Board may reasonably require to show his title to the share be entitled to the same dividends and other advantages as those to which he would be entitled if he were the registered holder of the share, but he shall not be entitled in respect thereof to exercise any right conferred by membership in relation to meetings of the Company until he shall have been registered as a member in respect of the share. Provided always that the Board may at any time give notice requiring such person to elect either to be registered himself or to transfer the share, and if within 60 days the notice is not complied with, the Board may in its absolute discretion withhold payment of dividends and other moneys payable in respect of such share until such time as the notice is complied with. Where two or more persons are jointly entitled by transmission to a share they shall for the purposes of these Articles be treated as if they were joint holders of such share registered in the order in which their names have been supplied to the Company or such other order as the person requiring to be registered may by notice to the Company have prescribed at that time.
18.
UNTRACED SHAREHOLDERS
18.1.
The Company shall be entitled to sell at the best price reasonably obtainable any share of a member or any share to which a person is entitled by transmission if and provided that:
18.1.1.
during a period of 12 years at least three cash dividends have become payable in respect of the share to be sold and have been sent by the Company in accordance with these Articles;
18.1.2.
during that period of 12 years no cash dividend payable in respect of the share has been claimed, no cheque, warrant, order or other payment for a dividend has been cashed, no dividend sent by means of a funds transfer system has been paid and no communication has been received by the Company from the member or the person entitled by transmission to the share;
18.1.3.
the Company has, at the expiration of the said period of 12 years by advertisement in at least one newspaper with a national circulation in the USA and in a newspaper circulating in the area in which the address on the Register or otherwise the last known postal address given by the member or the person entitled by transmission is located, given notice of its intention to sell such share; and
18.1.4.
the Company has not during the further period of three months after the date of publication of the advertisements (or the later publication date if the two advertisements are not published on the same day) and prior to the exercise of the power of sale received any communication from the member or person entitled by transmission.

18.2.
To give effect to any sale under Article 17.3 the Company may appoint any person to execute as transferor an instrument of transfer of such share and such instrument of transfer shall be as effective as if it had been executed by the registered holder of or person entitled by the transmission to such share. The Company shall account to the member or other person entitled to such share for the net proceeds of such sale by carrying all moneys in respect thereof to a separate account which shall be a debt of the Company and the Company shall be deemed to be a debtor and not a trustee in respect thereof for such member or other person. Moneys carried to such separate account may either be employed in the business of the Company or investments (other than shares of the Company or its holding company if any) as the Board may from time to time think fit. No interest shall be paid in respect of such moneys and the Company shall not be bound to account for any money earned thereon.
19.
GENERAL MEETINGS
19.1.
The Board shall convene and the Company shall hold general meetings as annual general meetings in accordance with the requirements of the Companies Laws.
19.2.
The Board may convene any other general meeting whenever it thinks fit and at such time and place as the Board may determine. On the request of members pursuant to the provisions of the Companies Laws, the Board shall convene a general meeting in accordance with the requirements of the Companies Laws.
19.3.
Subject to the Companies Laws, a resolution in writing signed by or on behalf of each member who would have been entitled to vote upon it if it had been proposed at a general meeting at which he was present shall be as effectual as if it had been passed at a general meeting properly convened and held and may consist of several instruments in the like form each signed by or on behalf of one or more of the members.
20.
NOTICE OF GENERAL MEETINGS
20.1.
An annual general meeting and any other general meeting (whether convened for the passing of an ordinary or a special resolution) shall be called by at least 14 clear days' notice.
20.2.
Notice of every general meeting shall be given to all members (other than those who under the provisions of these Articles or any restrictions imposed on any shares are not entitled to receive such notices from the Company), to each Director and to the Auditors provided that the Company may determine that only those persons entered on the Register at the close of business on a day determined by the boardCompany, such day being no more than 21 days before the day that notice of directorsthe meeting is sent, shall be entitled to receive such notice.
20.3.
The accidental omission to give notice of a meeting or to send any document or other information relating to the meeting to any person entitled to receive it, or the non-receipt of any such notice, document or information, whether or not the Company is aware of such omission or non-receipt, shall not invalidate the proceedings at any general meeting.
20.4.
Every notice calling a general meeting shall specify the place of the meeting and the time and date of the meeting, and there shall appear with reasonable prominence in every such notice a statement to the effect that a member is entitled to appoint one or more proxies (who need not be members) to exercise all or any of his rights to attend and to speak and vote at the meeting, provided that each proxy is appointed to exercise the rights attached to a different share or shares held by him.
20.5.
Every notice calling an annual general meeting shall specify the meeting as such.
20.6.
Every notice calling a general meeting at which business other than routine business is to be transacted shall specify the general nature of such business and, if any resolution is to be proposed as a special resolution, shall contain a statement to that effect.
20.7.
Routine business shall mean and include only business transacted at an annual general meeting of the following classes, that is to say:
20.7.1.
declaring dividends;
20.7.2.
considering and adopting the accounts, the reports of the Directors (if any) and Auditors and other documents required to be annexed to the accounts;

20.7.3.
appointing or re-appointing Directors to fill vacancies arising at the meeting on retirement;
20.7.4.
re-appointing the retiring Auditors unless they were last appointed otherwise than by the Company in general meeting;
20.7.5.
fixing the remuneration of the Auditors or determining the manner in which such remuneration is to be fixed;
20.7.6.
the grant, renewal, extension or variation of any authority for the Company to make purchases of shares in its own capital and to hold any shares so purchased as treasury shares; and
20.7.7.
the renewing or re-granting of an existing authority for a scrip dividend alternative.
20.8.
Any member present, either personally or by proxy, at any meeting of the Company without further approval or authorizationshall for all purposes be deemed to have received due notice of such meeting and, where requisite, of the shareholders (the "Reverse Stock Split"),purposes for which such power to be subject to the following conditions: (a) the ratio of the Reverse Stock Split must be a whole number between 1-for-10 and 1-for 40; (b) the Reverse Stock Split must be completed no later than the one year anniversary of the date of the Annual General Meeting; (c) with the exact ratio to be set within that range at the discretion of the board of directors, without further approval or authorization of the shareholders, and (d) to the extent the Reverse Stock Split causes any shareholder to hold a fractional number of shares, such fractions shall be dealt with in accordance with article 11.2 of the articles of association of the Company.

14) THAT the articles of association of the Company be and are hereby altered by the deletion of article 20.9 in its entirety and the insertion in its place of a new article 20.9 as follows:

"20.9meeting was convened.

20.9.
For the purposes of determining which persons are entitled to attend or vote at a meeting and how many votes such person may cast, the Company acting by its board of directors may specify a time in the notice of the meeting, such time being no more than 21 days before the day that notice of the meeting is sent, by which a person must be entered on the register of members in order to have the right to attend or vote at the meeting."
21.

Record Date

Beneficial owners of Quotient shares held in street name are entitled to vote only if they were a shareholder of Quotient at

PROCEEDINGS AT GENERAL MEETINGS
21.1.
No business (other than the close of business on August 31, 2022. Shareholders on Quotient's register of members 48 hours before the time the Annual General Meeting is to be held are also entitled to vote. Holders of ordinary shares of Quotient are entitled to one vote for each share held.

Attendance at the Annual General Meeting

As required by our organizational documents, we intend to hold the Annual General Meeting in person.  Whether or not you plan to attend the meeting, your vote is important, and we encourage you to review the proxy materials and vote as soon as possible using the instructions provided in the Notice.  If you hold your shares in street name, you may also follow the instructions included in the proxy materials to vote and confirm your attendance by telephone or Internet.

Where to Find More Information about the Resolutions and Proxies

Further information regarding the above business and resolutions is set out in the Proxy Statement and other proxy materials, which are available at https://quotientbd.com/page/investors.

You are entitled to appoint one or more proxies to attend the Annual General Meeting and vote on your behalf and your proxy need not also be a shareholder of the Company. Instructions on how to appoint a proxy are set out in the Proxy Statement and on the proxy card.

BY ORDER OF THE BOARD OF DIRECTORS

Heino von Prondzynski

Chairman


Table of Contents

IF YOU INTEND TO ATTEND THE MEETING IN PERSON, YOU WILL NEED PROOF THAT YOU OWN QUOTIENT SHARES AS OF THE RECORD DATE (FOR BENEFICIAL OWNERS OF SHARES HELD IN STREET NAME) OR 48 HOURS PRIOR TO THE TIME OF THE ANNUAL GENERAL MEETING (FOR RECORD HOLDERS) TO BE ADMITTED TO THE ANNUAL GENERAL MEETING.

Record shareholder: If your shares are registered directly in your name, please bring proof of such ownership.  

Shares held in street name by a broker or a bank: If your shares are held for your account in the nameappointment of a broker, bank or other nominee, please bring a current brokerage statement, letter from your stockbroker or other proof of ownership to the meeting together with a proxy issued in your name should you wish to vote in person at the Annual General Meeting.

This Notice of Annual General Meeting and the Proxy Statement are being distributed on or about September 8, 2022.

Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting tochairman) shall be Held on October 31, 2022

Our Annual Report on Form 10-K for the fiscal year ended March 31, 2022 (our "Annual Report"), notice of 2022 Annual General Meeting, the Proxy Statement and proxy card are available in the “Financials & Filings” section of our website at https://quotientbd.com/page/investors.


Table of Contents

TABLE OF CONTENTS

Page

GENERAL INFORMATION

2

MEETINGS OF THE BOARD OF DIRECTORS AND COMMITTEES OF THE BOARD

6

BOARD PRACTICES

9

RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

13

ELECTION OF DIRECTORS (RESOLUTIONS 1 TO 9)

15

COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS ("SAY ON PAY") (RESOLUTION 10)

18

FOURTH AMENDED AND RESTATED 2014 EQUITY PLAN (RESOLUTION 11)

20

NON-EMPLOYEE DIRECTOR COMPENSATION

24

REMUNERATION COMMITTEE REPORT

28

EXECUTIVE COMPENSATION

29

REPORT OF THE AUDIT COMMITTEE

44

APPOINTMENT OF AND PAYMENT TO AUDITORS (RESOLUTION 12)

46

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

47

PROPOSAL TO AUTHORISE THE COMPANY TO UNDERTAKE A REVERSE STOCK SPLIT (RESOLUTION 13)

49

PROPOSAL TO ALTER THE ARTICLES OF ASSOCIATION (RECORD DATE) (RESOLUTION 14)

55

OTHER INFORMATION

56

EXHIBIT A – 2014 STOCK INCENTIVE PLAN (FOURTH AMENDED AND RESTATED STOCK INCENTIVE PLAN)

57

i


Table of Contents

QUOTIENT LIMITED

PROXY STATEMENT

FOR

ANNUAL GENERAL MEETING OF SHAREHOLDERS

The Board of Directors (the "Board") of QUOTIENT LIMITED (“Quotient,” the “Company,” or “we”, “us” and “our”) is soliciting proxies for use at the 2022 Annual General Meeting of Shareholders to be held on October 31, 2022 (the "Annual General Meeting" or “Annual Meeting”), andtransacted at any adjournment or postponement of the Annual Meeting. A notice of the Annual Meeting and proxy materials will be distributed to shareholders who hold ordinary shares of Quotient as of August 31, 2022, the Record Date (as defined below) for the Annual Meeting, on or about September 8, 2022. Quotient Limitedgeneral meeting unless a quorum is a limited liability no par value company incorporated under the laws of Jersey, Channel Islands.

GENERAL INFORMATION

What am I voting on?

You will be voting on the following proposals at our Annual Meeting:

to elect nine directors;

to approve, on a non-binding, advisory basis, the compensation paid to our named executive officers;

to approve the Fourth Amended and Restated 2014 Stock Incentive Plan (the "Fourth Amended and Restated 2014 Plan"), which reflects amendments to the Third Amended and Restated 2014 Stock Incentive Plan (the "2014 Plan") to (a) increase the number of ordinary shares authorized for issuance by 10,000,000 shares, and (b) remove the "evergreen" provision pursuant to which the aggregate number of shares authorized for issuance automatically increases each year;

to re-appoint Ernst & Young LLP as the Company’s auditors, ratify their appointment as independent registered public accounting firm and to authorize the directors to determine the fees to be paid to the auditors; and

to vary the rights attaching to the common stock of the Company (ordinary shares) so that the Company acting by its board of directors shall have the power to undertake a reverse stock split (consolidation) of all of the ordinary shares in the capital of the Company in issue at the time of such reverse stock split, at such ratio as shall be determined by the board of directors of the Company, without further approval or authorization of the shareholders (the "Reverse Stock Split"), such power to be subject to the following conditions: (a) the ratio of the Reverse Stock Split must be a whole number between 1-for-10 and 1-for 40; (b) the Reverse Stock Split must be completed no later than the one year anniversary of the date of the Annual General Meetings; (c) with the exact ratio to be set within that range at the discretion of the board of directors, without further approval or authorization of the shareholders, and (d) to the extent the Reverse Stock Split causes any shareholder to hold a fractional number of shares, such fractions shall be dealt with in accordance with article 11.2 of the articles of association of the Company;

to alter the articles of association of the Company by the deletion of article 20.9 in its entirety and the insertion in its place of a new article 20.9 whereby for the purposes of determining which persons are entitled to attend or vote at a meeting and how many votes such person may cast, the Company acting by its board of directors may specify a time in the notice of the meeting, such time being no more than 21 days before the day that notice of the meeting is sent, by which a person must be entered on the register of members in order to have the right to attend or vote at the meeting.

to transact such other business as may properly come before the Annual Meeting.

What are the recommendations of the Board?

All shares represented by a properly executed proxy will be voted unless the proxy is revoked and, if a choice is specified, your shares will be voted in accordance with that choice. If no choice is specified but the proxy card is signed, the proxy holders will vote your shares according to the recommendations of the Board, which are included in the discussion of each matter later in this proxy statement. The Board recommends that you vote:

FOR the election of each of the nine nominees as directors;

2


Table of Contents

FOR the approval, on a non-binding, advisory basis, of the compensation paid to our named executive officers as described in the "Executive Compensation - Compensation Discussion and Analysis" of this proxy statement and the related compensation tables, notes and narrative discussion;

FOR the approval of the Fourth Amended and Restated 2014 Stock Incentive Plan (the "Fourth Amended and Restated 2014 Plan"), which reflects amendments to the Third Amended and Restated 2014 Stock Incentive Plan (the "2014 Plan") to (a) increase the number of ordinary shares authorized for issuance by 10,000,000 shares, and (b) remove the "evergreen" provision pursuant to which the aggregate number of shares authorized for issuance automatically increases;

FOR the re-appointment of Ernst & Young LLP as our auditors, ratification as our independent registered public accounting firm and the authorization of the directors to determine the fees to be paid to the auditors;

FOR the approval to vary the rights attaching to the common stock of the Company (ordinary shares) so that the Company acting by its board of directors shall have the power to undertake a reverse stock split (consolidation) of all of the ordinary shares in the capital of the Company in issuepresent at the time of such reverse stock split, at such ratio aswhen the meeting proceeds to business. The quorum for any general meeting shall be determined by the board of directors of the Company, without further approval or authorization of the shareholders (the "Reverse Stock Split"), such power to be subject to the following conditions: (a) the ratio of the Reverse Stock Split must be a whole number between 1-for-10 and 1-for 40; (b) the Reverse Stock Split must be completed no later than the one year anniversary of the date of the Annual General Meetings; (c) with the exact ratio to be set within that range at the discretion of the board of directors, without further approval or authorization of the shareholders, and (d) to the extent the Reverse Stock Split causes any shareholder to hold a fractional number of shares, such fractions shall be dealt with in accordance with article 11.2 of the articles of association of the Company;

and,

FOR the deletion of article 20.9 in its entirety from the articles of association of the Company and the insertion in its place of a new article 20.9 whereby for the purposes of determining which persons are entitled to attend or vote at a meeting and how many votes such person may cast, the Company acting by its board of directors may specify a time in the notice of the meeting, such time being no more than 21 days before the day that notice of the meeting is sent, by which a person must be entered on the register ofleast two members in order to have the right to attend or vote at the meeting.

In addition, the proxy holders may vote in their discretion with respect to any other matter that properly comes before the Annual Meeting.

Who is entitled to vote?

For each proposal to be voted on, each shareholder is entitled to one vote for each ordinary share.   For beneficial owners of ordinary shares held in street name, the record date for the Annual Meeting is the close of business on August 31, 2022 (the "Record Date"). Shareholders of record on our register of members 48 hours before the time the Annual Meeting is to be held are also entitled to vote.  As of the close of business on July 11, 2022, there were 135’683’559 ordinary shares outstanding.

How do I vote by proxy in lieu of attending the Annual Meeting?

If you received a printed, paper copy of our proxy materials by mail, or you received a Notice of Availability by mail and have opted to receive a paper copy of our proxy materials by mail, you may vote by proxy by completing, dating and signing your proxy card and mailing it in the envelope provided. You must sign your name exactly as it appears on the proxy card. If you are signing in a representative capacity (for example, as officer of a corporation, guardian, executor, trustee or custodian), you must indicate your name and title or capacity.

If you received a Notice of Availability by mail, you will not receive a printed, paper copy of the proxy materials unless you request to receive one. Instead, the Notice of Availability will instruct you as to how you may access and review all of the important information contained in the proxy materials. The Notice of Availability also instructs you as to how you may submit your proxy on the Internet and contains a link to instructions on how to submit your proxy by telephone. If you received a Notice of Availability by mail and would like to receive a paper copy of our proxy materials, including a proxy card, you should follow the instructions for requesting such materials included in the Notice of Availability.

If you vote via the Internet or by telephone, your vote must be received by 11:59 p.m., Eastern Time, on October 30, 2022. If you vote by Internet or telephone, you should not return your proxy card.

You may also vote in person at the Annual Meeting or you may be represented by another person at the Annual Meeting by executing a proxy designating that person.  Whether or not you plan to attend the meeting, your vote is important, and we encourage you to vote by proxy using one of the other voting methods described above.

3


Table of Contents

If your shares are held in a stock brokerage account or by a bank or other holder of record, you are considered the beneficial owner of shares held in “street name.” The street name holder will provide you with instructions that you must follow in order to have your shares voted.

If you hold your shares in street name and you wish to vote in person at the Annual Meeting, you must obtain a proxy issued in your name from the street name holder.  As noted above, whether or not you plan to attend the meeting, your vote is important, and we encourage you to vote by proxy using one of the other voting methods described above.

May I change my mind after submitting a proxy?

If you are a shareholder of record, you may revoke your proxy before it is exercised by:

Written notice of revocation to our Head of Legal & Compliance, at Quotient Limited, Business Park Terre Bonne, Route de Crassier 13, 1262 Eysins, Switzerland, and execution of a later dated proxy relating to the same shares, delivered to our Head of Legal & Compliance, at or before the final vote at the meeting; or

Voting in person at the Annual Meeting.

If you are a beneficial owner of shares held in street name, you may revoke prior and submit new, voting instructions by contacting your brokerage firm, bank or other holder of record.

What are broker non-votes?

A broker non-vote occurs when the broker that holds your shares in street name is not entitled to vote on a matter without instruction from you and you do not give any instruction. Unless instructed otherwise by you, brokers will not have discretionary authority to vote on any matter other than Resolution 12 - AUDITORS, which is considered to be routine for these purposes. It is important that you cast your vote for your shares to be represented on all matters.

What is the required vote?

To be approved, Resolutions 1 to 12 require a simple majority of the votes cast at the Annual Meeting in favor of each Resolution. Special Resolutions 13 and 14 require a two-third majority of the members who (being entitled to do so) vote in person, or by proxy, at the Annual Meeting in favor of each Resolution. If a director does not receive a majority of the vote for his or her election, then that director will not be re-elected to the Board and the Board may fill the vacancy with a different person, or the Board may reduce the number of directors to eliminate the vacancy. The vote on Resolution 10 - SAY ON PAY, is advisory and is not binding on our Board or the Company. Votes that are withheld with respect to the election of directors, abstentions and broker non-votes on the other matters are not counted as votes cast.

What will constitute the quorum for the Annual Meeting?

A quorum will consist of two or more shareholders present in person or by proxy who hold orare entitled to vote and who represent shares between them of not less than 50% of the total shares in issue as at the date of such general meeting.

21.2.
The chairman of the Board, failing whom a deputy chairman (to be chosen, if there be more than one, by agreement amongst them or, failing agreement, by lot) shall preside as chairman at a general meeting. If there be no such chairman or deputy chairman, or if at any meeting none be present within five minutes after the time appointed for holding the meeting or none be willing to act, the Directors present shall choose one of their number or, if no Director be present or if all the Directors present decline to take the chair, the members present shall choose one of their number to be chairman of the meeting.
21.3.
If within 15 minutes from the time appointed for a general meeting (or such longer period as the chairman of the meeting may think fit to allow) a quorum is not present, the meeting, if convened by or on the request of members pursuant to the provisions of the Companies Laws, shall be dissolved. In any other case it shall stand adjourned to the same day in the next week, at the same time and place, or to such day and at such time and place as the chairman of the meeting may determine, and if at such adjourned meeting a quorum is not present within 15 minutes from the time appointed for holding the meeting, the meeting shall be dissolved.
21.4.
The chairman of the meeting may at any time without the consent of the meeting adjourn any general meeting (whether or not it has commenced or a quorum is present), either indefinitely or to another time or place, where it appears to him that the members wishing to attend cannot conveniently be accommodated in the place appointed for the meeting or where the conduct of persons present prevents or is likely to prevent the orderly continuation of business or where an adjournment is otherwise necessary so that the business of the meeting may be properly conducted. In addition the chairman of the meeting may with the consent of any general meeting at which a quorum is present (and shall if so directed by the meeting) adjourn the meeting from time to time (or indefinitely) and from place to place, but no business shall be transacted at any adjourned meeting except business which might lawfully have been transacted at the meeting from which the adjournment took place. Where a meeting is adjourned indefinitely, the time and place for the adjourned meeting shall be fixed by the Board.
21.5.
When a meeting is adjourned for 30 days or more or indefinitely, not less than seven clear days' notice of the adjourned meeting (exclusive of the day on which it is served or deemed to be

served and of the day for which it is given) shall be given as in the case of the original meeting, but it shall not be necessary to specify in such notice the nature of the business to be transacted at the adjourned meeting. Save as aforesaid, it shall not be necessary to give any notice of an adjournment or of the business to be transacted at an adjourned meeting.
21.6.
In the case of any general meeting the Board may, notwithstanding the specification in the notice of the place of the general meeting (the "principal place") at which the chairman of the meeting shall preside, make arrangements for simultaneous attendance and participation at other places by members and proxies entitled to attend the general meeting but excluded from the principal place under the provisions of this Article. Such arrangements for simultaneous attendance at the meeting may include arrangements regarding the level of attendance at places other than the principal place provided that they shall operate so that any member and proxy excluded from attendance at the principal place is entitled to attend at one of the other places. For the purpose of all other provisions of these Articles any such meeting shall be treated as being held and taking place at the principal place.
21.7.
The Board may, for the purpose of facilitating the organisation and administration of any general meeting to which any of the arrangements referred to in Article 21.6apply, from time to time make arrangements, whether involving the issue of tickets (on a basis intended to afford to all members and proxies entitled to attend the meeting an equal opportunity of being admitted to the principal place) or the imposition of some random means of selection or otherwise as the Board shall in its absolute discretion consider to be appropriate, and may from time to time vary any such arrangements or make new arrangements in their place and the entitlement of any member or proxy to attend a general meeting at the principal place shall be subject to such arrangements as may be for the time being in force whether stated in the notice convening the meeting to apply to that meeting or notified to the members concerned subsequent to the notice convening the meeting.
21.8.
If it appears to the chairman that the meeting place specified in the notice convening the meeting is inadequate to accommodate all members entitled and wishing to attend, the meeting is duly constituted and its proceedings valid if the chairman is satisfied that adequate facilities are available to ensure that a member who is unable to be accommodated is able:
21.8.1.
to participate in the business for which the meeting has been convened;
21.8.2.
to hear all persons present who speak (whether by the use of microphones, loud-speakers, audio-visual communications equipment or otherwise), whether in the meeting place or elsewhere; and
21.8.3.
to be heard by all other persons present in the same way.
21.9.
The Board may make any arrangement and impose any restriction it considers appropriate to ensure the security of a meeting including, without limitation, the searching of a person attending the meeting and the restriction of the items of personal property that may be taken into the meeting place. The Board is entitled to refuse entry to a meeting to a person who refuses to comply with these arrangements.
21.10.
The Board may direct that members or proxies wishing to attend any general meeting should provide such evidence of identity and submit to such searches or other security arrangements or restrictions as the Board shall consider appropriate in the circumstances and shall be entitled in its absolute discretion to refuse entry to any general meeting to any member or proxy who fails to provide such evidence of identity or to submit to such searches or otherwise to comply with such security arrangements or restrictions or to eject any such member or proxy from any general meeting.
22.
VOTING
22.1.
At any general meeting a resolution put to the vote of the meeting shall be decided on a show of hands unless (before or immediately following the declaration of the result of the vote on a show of hands) a poll is duly demanded. Subject to the provisions of the Companies Laws, a poll may be demanded by either:
22.1.1.
the chairman of the meeting; or

22.1.2.
not less than five members present in person or by proxy and entitled to vote on the resolution; or
22.1.3.
a member or members present in person or by proxy and representing not less than 10 per cent. of the total voting rights of all the members having the right to vote on the resolution (excluding any voting rights attached to shares in the Company held as treasury shares); or
22.1.4.
a member or members present in person or by proxy and holding shares conferring a right to vote on the resolution being shares on which an aggregate sum has been paid up equal to not less than 10 per cent. of the total sum paid up on all the shares conferring that right (excluding any shares in the Company conferring a right to vote on the resolution which are held as treasury shares).
22.2.
A demand for a poll may, before the poll is taken, be withdrawn only with the consent of the chairman. A demand so withdrawn shall not be taken to have invalidated the result of a show of hands declared before the demand was made, which result shall be effective. Unless a poll is so demanded (and the demand is not withdrawn) a declaration by the chairman of the meeting that a resolution has been carried, or carried unanimously, or by a particular majority, or lost, and an entry to that effect in the minute of the meeting, shall be conclusive evidence of that fact without proof of the number or proportion of the votes recorded for or against such resolution.
22.3.
If a poll is duly demanded (and the demand is not withdrawn) it shall be taken in such manner (including the use of ballot or voting papers or tickets) as the chairman of the meeting may direct, and the result of the poll shall be deemed to be the resolution of the meeting at which the poll was demanded. The chairman of the meeting may (and if so directed by the meeting shall) appoint scrutinisers (who need not be members) and may adjourn the meeting to some place and time fixed by him for the purpose of declaring the result of the poll.
22.4.
A poll demanded on the election of a chairman or on a question of adjournment shall be taken forthwith. A poll demanded on any other question shall be taken either immediately or at such subsequent time (not being more than 30 days from the date of the meeting) and place as the chairman may direct. No notice need be given of a poll not taken immediately. The demand for a poll shall not prevent the continuance of the meeting for the transaction of any business other than the question on which the poll has been demanded.
22.5.
If an amendment is proposed to any resolution under consideration but is in good faith ruled out of order by the chairman of the meeting, the proceedings on the substantive resolution shall not be invalidated by any error in such ruling. With the consent of the chairman of the meeting, an amendment may be withdrawn before it is voted on. No amendment to a resolution duly proposed as a special resolution (other than a mere clerical amendment to correct a patent error) may in any event be considered or voted on. No amendment to a resolution duly proposed as an ordinary resolution (other than a mere clerical amendment to correct a patent error) may be considered or voted on unless either:
22.5.1.
at least 48 hours prior to the time appointed for holding the meeting or adjourned meeting at which such ordinary resolution is to be proposed notice of the terms of the amendment and intention to move the same has been delivered in hard copy form to the Office or to such other place as may be specified by or on behalf of the Company for that purpose or received in electronic form at such address (if any) for the time being specified by or on behalf of the Company for that purpose; or
22.5.2.
the chairman of the meeting in his absolute discretion decides that it may be considered or voted upon.
22.6.
If any votes shall be counted which ought not to have been counted, or might have been rejected, the error shall not vitiate the result of the voting unless it is pointed out at the same meeting, or at any adjournment thereof, and not in that case unless it shall in the opinion of the chairman of the meeting be of sufficient magnitude to affect the result of the voting.
23.
VOTES OF MEMBERS

23.1.
Subject to Article 20.9 and to any special rights or restrictions as to voting attached by or by virtue of these Articles to any shares or any class of shares, on a show of hands every member who is present in person and every proxy present who has been duly appointed by a member entitled to vote on the resolution shall have one vote and on a poll every member who is present in person or by proxy shall have one vote for every share of which he is the holder or in respect of which he has been appointed proxy (as applicable).
23.2.
In the case of joint holders of a share, the vote of the senior who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders. For this purpose seniority shall be determined by the order in which the names of the holders stand in the Register in respect of the joint holding.
23.3.
Where in Jersey or elsewhere an attorney, receiver, curator bonis or other person (by whatever name called) has been appointed by any court claiming jurisdiction in that behalf (whether in Jersey or elsewhere) to exercise power with respect to the property or affairs of any member on the ground (however formulated) of mental disorder, the Board may in its absolute discretion, upon or subject to production of such evidence as they may require, permit such attorney, receiver, curator bonis or other person to vote in person or by proxy on behalf of such member at any general meeting.
23.4.
No member shall, unless the Board otherwise determines, be entitled to be present or to vote at any general meeting either in person or by proxy or upon any poll or to exercise any other right conferred by membership in relation to meetings of the Company in respect of any shares held by him if any call or other sum presently payable by him to the Company in respect of such shares remains unpaid.
23.5.
No objection shall be raised as to the admissibility of any vote except at the meeting or adjourned meeting or poll at which the vote objected to is or may be given or tendered and every vote not disallowed at such meeting shall be valid for all purposes. Any such objection shall be referred to the chairman of the meeting whose decision shall be final and conclusive.
23.6.
On a poll a person present in person or by proxy and entitled to more than one vote need not use all his votes or cast all his votes in the same way.
24.
PROXIES AND CORPORATE REPRESENTATIVES
24.1.
A proxy need not be a member of the Company. A proxy shall be entitled to speak and vote on a show of hands.
24.2.
A member may appoint more than one person as his proxy in respect of the same meeting or resolution provided that the appointment of the proxy shall specify the number of shares in respect of which the proxy is appointed and only one proxy shall be appointed in respect of any one share. When two or more valid but differing appointments of proxy are delivered or received (regardless of its date or of the date of its signature) in respect of the Annual Meeting.

How can I attendsame share for use at the Annual Meeting?

As requiredsame meeting, the one which is last delivered or received shall be treated as replacing and revoking the others as regards that share. Subject to the Companies Laws, the Board may determine at its discretion when a proxy appointment shall be treated as delivered or received for the purposes of these Articles. If the Company is unable to determine which was last delivered or received, none of them shall be treated as valid in respect of that share.

24.3.
The appointment of a proxy shall be made in writing and shall be in any usual or common form or in any other form or forms which the Board may approve. Subject thereto, the appointment of a proxy may be:
24.3.1.
in hard copy form; or
24.3.2.
if the Company so agrees, in electronic form (including by our organizational documents, we intendmeans of a relevant system or a website).
24.4.
The appointment of a proxy, whether made in hard copy form or in electronic form, shall be executed or authenticated in such manner as may be approved by or on behalf of the Board from time to holdtime.

24.5.
The Board may, if it thinks fit (but subject to the Annual Meetingprovisions of the Companies Laws), at the Company's expense send forms of proxy in person.  Whether or not you plan to attendhard copy form for use at the meeting your vote is important, and we encourage youissue invitations in electronic form to vote by proxy.

If you plan to attend the Annual Meeting, whether you are record shareholders (i.e.,appoint a person who owns shares registered directlyproxy in his or her name with Continental Stock Transfer & Trust Company, Quotient’s transfer agent) or beneficial owners of shares held in street name, you will need proof of ownership to be admittedrelation to the Annual Meeting.

For beneficial ownersmeeting in such form as may be approved by the Board. The appointment of shares held in street name by a broker, bank or other nominee,proxy shall not preclude a recent brokerage statement or lettersmember from the broker, bank or other nominee are examples of proof of ownership. If your shares are held in street nameattending and you want to votevoting in person at the Annual Meeting, you must obtainmeeting or on the resolution concerned.

24.6.
The appointment of a proxy shall:
24.6.1.
if in hard copy form, be delivered by hand or by post to the Office or such other place as may be specified by or on behalf of the Company for that purpose:
24.6.1.1.
in the notice convening the meeting; or
24.6.1.2.
in any form of proxy sent by or on behalf of the Company in relation to the meeting,
24.6.1.3.
not less than 48 hours before the time appointed for holding the meeting or adjourned meeting at which the person named in the appointment proposes to vote; or
24.6.1.4.
if in electronic form, be received at any address specified by or on behalf of the Company for the purpose of receiving the appointment of a proxy in electronic form in:
24.6.1.4.1.
the notice convening the meeting; or
24.6.1.4.2.
any form of proxy sent by or on behalf of the Company in relation to the meeting; or
24.6.1.4.3.
any invitation to appoint a proxy issued by the Company in relation to the meeting,

not less than 48 hours before the time appointed for holding the meeting or adjourned meeting at which the person named in the appointment proposes to vote; or

24.6.1.5.
in either case, where a poll is taken more than 48 hours after it is demanded, be delivered or received as aforesaid after the poll has been demanded and not less than 24 hours before the time appointed for the taking of the poll; or
24.6.1.6.
if in hard copy form, where a poll is not taken forthwith but is taken not more than 48 hours after it was demanded, be delivered at the meeting at which the poll was demanded to the chairman of the meeting.

A proxy appointment which is not delivered or received in accordance with this Article shall be invalid. The Board may decide (in its absolute discretion), either generally or in any particular case, to treat a proxy appointment as valid, notwithstanding that the proxy appointment or any document or evidence has not been received in accordance with the requirements of these Articles.

24.7.
Where the appointment of a proxy is expressed to have been or purports to have been made, sent or supplied by a person on behalf of the holder of a share:
24.7.1.
the Company may treat the appointment as sufficient evidence of the authority of that person to make, send or supply the appointment on behalf of that holder;
24.7.2.
that holder shall, if requested by or on behalf of the Board at any time, send or procure the sending of any written authority under which the appointment has been made, sent or supplied or a copy of such authority certified notarially or in some other way approved by the Board, to such address and by such time as may be specified in the request (being a time no earlier than the time by which the appointment of proxy is required to be delivered or received) and, if the request is not complied with in any respect, the appointment may be treated as invalid; and
24.7.3.
whether or not a request under paragraph (b) of this Article has been made or complied with, the Company may determine that it has insufficient evidence of the authority of that person to make, send or supply the appointment on behalf of that holder and may treat the appointment as invalid.

24.8.
The appointment of a proxy to vote on a matter at a meeting confers on the proxy authority to demand, or join in demanding, a poll on that matter. The appointment of a proxy shall also, unless it provides to the contrary, be deemed to confer authority on the proxy to vote or abstain from voting as the broker, bankproxy thinks fit on any amendment of a resolution and on any procedural motion or resolution put to the meeting to which it relates and on any other business not referred to in the notice of meeting which may properly come before the meeting to which it relates. The appointment of a proxy shall, unless it provides to the contrary, be valid for any adjournment of the meeting as well as for the meeting to which it relates.
24.9.
Any member or other nominee holding yourperson which is a body corporate may, by resolution of its directors or other governing body, authorise a person to act as its representative at any meeting of the Company or at any separate meeting of the holders of any class of shares.

Can I access these proxy materials A person so authorised and present at any such meeting shall be entitled to exercise the same powers on behalf of the Internet?

This proxy statement and our Annual Report on Form 10-Kbody corporate which he represents as that body corporate could exercise if it were an individual member personally present, save that a Director, the Secretary or other person authorised for the fiscal year ended March 31, 2022 (our "Annual Report") are available at https://quotientbd.com/page/investors.

4


Table of Contents

Can I get hard copies of the proxy materials?

In accordance with rules adoptedpurpose by the SEC, instead of mailingSecretary may require such person to produce a printed, paper copy of our proxy materials to our shareholders who hold their shares in street name, we are furnishing proxy materials, including this Proxy Statement and our Annual Report to shareholders, by providing access to these documents on the Internet. Accordingly, on or about September 8, 2022, a Notice of Internet Availability of Proxy Materials (the “Notice of Availability”) will be sent to beneficial owners of our ordinary shares. The Notice of Availability provides you with instructions regarding the following: (1) viewing our proxy materials for the Annual Meeting on the Internet; (2) voting your shares after you have viewed our proxy materials; (3) requesting a papercertified copy of the resolution of authorisation before permitting him to exercise his powers. A body corporate shall for the purposes of these Articles be deemed to be present in person at any such meeting if the person so authorised by it is present at the meeting.

24.10.
A vote given or poll demanded by a proxy materials;or by the duly authorised representative of a body corporate shall be valid notwithstanding the previous determination of the authority of the person voting or demanding the poll unless notice of the determination was either delivered or received as mentioned in the following sentence at least three hours before the start of the meeting or adjourned meeting at which the vote is given or the poll demanded or (in the case of a poll taken otherwise than on the same day as the meeting or adjourned meeting) the time appointed for taking the poll. Such notice of determination shall be either by means of a document in hard copy form delivered to the Office or to such other place as may be specified by or on behalf of the Company in accordance with Article 24.5 or in electronic form received at the address (if any) specified by or on behalf of the Company in accordance with Article 24.5, regardless of whether any relevant proxy appointment was effected in hard copy form or in electronic form.
25.
DTC SYSTEM VOTING ARRANGEMENTS
25.1.
Subject to the Companies Laws, for the purpose of facilitating the giving of voting instructions for any general meeting by any person who holds, or holds interests in, beneficial interests in Ordinary Shares that are held and (4) instructing us to send our futuretraded in the DTC System:
25.1.1.
each DTC Proxy may appoint (whether by way of instrument of proxy, materials to you. We believepower of attorney, mandate or otherwise) more than one person as its proxy in respect of the delivery options allow us to provide our shareholders withsame general meeting or resolution provided that the instrument of appointment shall specify the number of shares in respect of which the proxy materials they need, while loweringis appointed and only one proxy may attend the costgeneral meeting and vote in respect of any one share;
25.1.2.
each DTC Proxy may appoint (by power of attorney, mandate or otherwise) an agent (including, without limitation, a proxy solicitation agent or similar person) for the purposes of obtaining voting instructions and submitting them to the Company on behalf of that DTC Proxy, whether in hard copy form or electronic form;
25.1.3.
each instrument of appointment made by a DTC Proxy or its agent shall, unless the Company is notified to the contrary in writing at least three hours before the start of the deliverymeeting (or adjourned meeting), be deemed to confer on the relevant proxy or agent the power and authority to appoint one or more sub-proxies or sub-agents or otherwise sub-delegate any or all of its powers to any person;
25.1.4.
the Board may accept any instrument of appointment made by a DTC Proxy or its agent as sufficient evidence of the materialsauthority of that DTC Proxy or agent or require evidence of the authority under which any such appointment has been made; and reducing
25.1.5.
the environmental impact of printing and mailing. If you chooseBoard may, to receive future proxy materials by email, you will receive an email next year with instructions containing a link to view those proxy materials and a linkgive effect to the intent of this Article:
25.1.5.1.
make such arrangements, either generally or in any particular case, as it thinks fit (including, without limitation, making or facilitating arrangements for the submission

to the Company of voting instructions on behalf of DTC Proxies, whether in hard copy form or electronic form);
25.1.5.2.
make such regulations, either generally or in any particular case, as it thinks fit, whether in addition to, or in substitution for, any other provision of these Articles; and
25.1.5.3.
do such other acts and things as it considers necessary or desirable (including, without limitation, approving the form of any instrument of appointment of proxy voting site. Your electionor agent, whether in hard copy form or electronic form).
25.2.
If any question arises at or in relation to receivea general meeting as to whether any person has been validly appointed as a proxy materialsor agent by emaila DTC Proxy or its agent to vote (or exercise any other right) in respect of any Ordinary Shares:
25.2.1.
if the question arises at a general meeting, the question will remainbe determined by the chairman of the meeting in effect until you terminate it.his sole discretion; or
25.2.2.
if the question arises otherwise than at a general meeting, the question will be determined by the Board in its sole discretion.

The decision of the chairman of the meeting or the Board (as applicable), which may include declining to recognise a particular appointment as valid, will, if made in good faith, be final and binding on all persons interested.

In addition, certain

26.
DIRECTORS
26.1.
The number of Directors shall not be less than two. The Board may from time to time vary the maximum number of Directors.
26.2.
A Director and an alternate Director shall not require a share qualification but nevertheless shall be entitled to attend and speak at any general meeting of the Company and at any separate meeting of the holders of recordany class of our ordinary shares will be sent, by mail, this proxy statement andin the related proxy card on or about September 8, 2022.

Who paysCompany.

26.3.
Any Director who is appointed to any executive office (including for this proxy solicitation and how much did it cost?

We will paypurpose the cost for soliciting proxies for the Annual Meeting. Quotient will distribute proxy materials and follow-up reminders by mail and electronic means. We have engaged Okapi Partners LLC (“Okapi”) at 1212 Avenueoffice of the Americas, 24th Floor, New York, New York 10036 to assist with the solicitation of proxies. We will pay Okapi a fee of $9’000, plus reasonable out-of-pocket expenses. Certain Quotient employees, officers, and directors may also solicit proxies by mail, telephone,chairman or personal visits. They willdeputy chairman whether or not receivesuch office is held in an executive capacity) or who serves on any additional compensation for their services.

We will reimburse brokers, banks, and other nominees for their expenses in forwarding proxy materials to beneficial owners.

How can I obtain the Company’s corporate governance information?

These documents are posted on Quotient’s website at www.quotientbd.com. Click on the tab “Investors” and then the caption “Corporate Governance.”

Corporate Governance Guidelines

Board Committee Charters

Code of Business Conduct and Ethics

Insider Trading Policy

Related Party Transaction Policy

Shareholder Communication Policy

Disclosure Procedure Policy

Where can I find voting results for this Annual Meeting?

The voting results will be published in a current report on Form 8-K,committee or who otherwise performs services which will be filed with the SEC no later than four business days after the Annual Meeting.

5


Table of Contents

MEETINGS OF THE BOARD OF DIRECTORS AND COMMITTEES OF THE BOARD

Per our Corporate Governance Guidelines, it is the sense of the Board of Directors that regular meetings at appropriate intervals are in general desirable for the performance of their responsibilities. In addition to regularly scheduled meetings, additional unscheduled meetings may be called upon appropriate notice at any time to address any special needs.  During the fiscal year ended March 31, 2022, the Board met fifteen times including four regularly scheduled meetings, and the audit committee met ten times including four regularly scheduled meetings. The remuneration committee met eight times including four regularly scheduled meetings, and the nominating and corporate governance committee met five times including four regularly scheduled meetings, during the fiscal year ended March 31, 2022. Attendance at Board and committee meetings exceeded 90% and no director attended less than 90% of the aggregate number of such Board and committee meetings for meetings that they were eligible to attend.

Our Board currently has three committees, as described below. Each committee has a separate written charter that is available on Quotient’s website at www.quotientbd.com.

Our business and affairs are managed under the direction of our Board. Our Board of Directors is currently composed of nine directors.  At each annual meeting of our shareholders, each of our directors must “retire,” and, if they wish to continue to serve as a director, they become subject to re-election to the Board by our shareholders.  

We are subject to the listing standards of Nasdaq, which require that, subject to specified exceptions and permitted phase-in periods, each member of a listed company’s audit, remuneration and nominating and corporate governance committees be independent. In addition, the listing standards of Nasdaq require that audit committee members satisfy independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and that the remuneration committee members satisfy independence criteria set forth in Rule 5605(d) of Nasdaq rules. The listing standards of Nasdaq further provide that a director will only qualify as an “independent director” if, in the opinion of that company’sthe Board that person does not haveare outside the scope of the ordinary duties of a relationship that would interfereDirector may be paid remuneration (in addition to any amounts receivable under Article 31) by way of salary, commission, bonus or otherwise (whether exclusive or inclusive of his remuneration (if any) under these Articles) as the Board may determine.

26.4.
A Director may hold any other office or place of profit under the Company (other than the office of auditor) in conjunction with his office of Director, and may act in a professional capacity to the Company, on such terms as to tenure of office, remuneration and otherwise as the Board may determine.
26.5.
The Board may establish and maintain, or procure the establishment and maintenance of, any pension or superannuation funds (whether contributory or otherwise) for the benefit of, and give or procure the giving of donations, gratuities, pensions, allowances and emoluments to, any persons who are or were at any time in the employment or service of the Company, or of any company which is a subsidiary of the Company or is allied to or associated with the exerciseCompany or any such subsidiary or of independent judgmentany of the predecessors in carrying outbusiness of the responsibilitiesCompany or any such other company as aforesaid, or who may be or have been Directors or officers of a director.

In addition, the listing standardsCompany or directors of Nasdaq require that a majorityofficers of any such other company as aforesaid and who hold or have held executive positions or agreements for services with the Company or any such other company as aforesaid, and the wives, husbands, civil partners, widows, widowers, families and dependants of any such persons, and also establish, subsidise and subscribe to any institutions, associations, societies, clubs or funds calculated to be for the benefit of, or to advance the interests and well-being of the Company or of any such other company as aforesaid, or of any such person as aforesaid, and make payments for or towards the insurance of any such person as aforesaid and subscribe or guarantee money for charitable or benevolent objects, or for any exhibition or for any public, general or useful object, and do any of the matters aforesaid either alone or in conjunction with any such other company as aforesaid. Subject to particulars with respect to the proposed payment being disclosed to the members of a listed company’s Boardthe Company and to the proposal being approved by the


Company by ordinary resolution, if the Companies Laws or the NASDAQ Rules (if applicable) shall so require, any Director who holds or has held any such executive position or agreement for services shall be independent. Our Board has determined that Messrs. Aebischer, Hallsworth, McDonough, von Prondzynski, Shroffentitled to participate in and Wilkerson, Mses.  Bechu, Buckle and Larue, are independent directors underretain for his own benefit any such donation, gratuity, pension, allowance or emolument.
26.6.
Subject to the applicable Nasdaq listing rules. In making these determinations, our Board considered the relationships that each such non-employee director has with our company and all other facts and circumstances that our Board deemed relevant in determining their independence, including beneficial ownership of our ordinary shares.

As previously announced in our proxy statement for our 2020 annual meetingprovisions of the shareholders, the NominatingCompanies Laws and Governance Committee has continued to evaluate the skillsets available across the Company Board of Directors and has also reflected upon shareholders’ voices from the votes at the Company’s 2020 and 2021 AGMs, as well as ongoing shareholder engagement activities.  This work has resulted in the Company adding or nominating new members to its Board of Directors and Committees, and in effectuating rotations of certain committee members and the appointment of new chairpersons to our three committees to be effective after the Annual General Meeting.

We believe these changes have brought and will continue to bring a fresh perspective and new experience and skill sets toArticles, the Board and our committees.  Unless otherwise noted, the disclosure that follows is based on the current composition of the Board and our committees. 

Audit Committee

Our audit committee is composed of Ms. Larue and Messrs. Aebischer, Hallsworth and Shroff, with Mr. Hallsworth serving as chairman of the committee. Our Board has determined that all these committee members meet the independence requirements of Rule 10A-3 under the Exchange Act and the applicable listing standards of Nasdaq.  Our Board has determined that Messrs. Hallsworth and Aebischer are “audit committee financial experts” within the meaning of SEC regulations and applicable listing standards of Nasdaq. The audit committee met ten times during the year ended March 31, 2022, including four regularly scheduled meetings.  Upon completion of the Annual General Meeting, if re-elected, Ms. Bechu will join the audit committee and the audit committee will be composed of Ms. Bechu and Larue and Messrs Aebischer and Hallsworth, with Mr. Aebischer serving as chairman of the committee.  The Board has determined that all these committee members meet the independence requirements of Rule 10A-3 under the Exchange Act and the applicable listing standards of Nasdaq.

The audit committee’s responsibilities include:

appointing, approving the compensation of, and assessing the qualifications, performance and independence of our independent registered public accounting firm;

6


Table of Contents

pre-approving audit and permissible non-audit services, and the terms of such services, to be provided by our independent registered public accounting firm;

reviewing the audit plan with the independent registered public accounting firm and members of management responsible for preparing our financial statements;

reviewing and discussing with management and the independent registered public accounting firm our annual and quarterly financial statements and related disclosures as well as critical accounting policies and practices used by us;

reviewing the adequacy of our internal control over financial reporting, financial and critical accounting practices and policies relating to risk assessment and management;

establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns;

reviewing and discussing with management and our independent registered public accounting firm our audited financial statements to be included in our Annual Report on Form 10-K;

monitoring our compliance with legal and regulatory requirements as they relate to our financial statements and accounting matters;

preparing the audit committee report required by the rules of the SEC to be included in our annual proxy statement;

reviewing the cyber-security risk management program and reporting to the Board regarding strategies for improvement;

reviewing and assessing the adequacy of the committee charter and submitting any changes to our Board for approval;

viewing all related party transactions for potential conflict of interest situations and approving all such transactions; and

reviewing and discussing with management and our independent registered public accounting firm our earnings releases and scripts.

Remuneration Committee

Our remuneration committee is composed of Messrs. McDonough, von Prondzynski and Shroff, with Mr. Shroff serving as chairman of the committee. Our Board has determined that all these committee members are independent as defined under the applicable listing standards of Nasdaq. The remuneration committee met eight times during the fiscal year ended March 31, 2022, including four regularly scheduled meetings.  Mr. McDonough will not stand for re-election at the 2022 Annual General Meeting.  Upon completion of the Annual General Meeting, if re-elected, the remuneration committee will be composed of Ms. Larue and Messrs. Hallsworth and von Prodzynski, with Mr. Hallsworth serving as chairman of the remuneration committee.

The remuneration committee’s responsibilities include:

determining and approving the remuneration of our chief executive officer and other named executive officers;

reviewing and approving corporate goals and objectives relevant to the compensation of our chief executive officer and other named executive officers;

evaluating the performance of our chief executive officer and other named executive officers in light of such corporate goals and objectives;

overseeing and administering our compensation and equity-based plans;

making recommendations to the Board about amendments to such plans and the adoption of any new employee incentive compensation plans;

appointing, compensating and overseeing the work of any compensation consultant, legal counsel or other advisor retained by the remuneration committee;

7


Table of Contents

conducting the independence assessment outlined in the rules of Nasdaq with respect to any compensation consultant, legal counsel or other advisor retained by the remuneration committee;

producing a remuneration committee report on executive compensation as required by the rules of the SEC to be included in our annual proxy statement;

reviewing our incentive compensation arrangements to determine whether they encourage excessive risk-taking;

reviewing at least annually the relationship between risk management policies and practices and compensation and evaluating compensation policies and practices that could mitigate any such risk;

annually reviewing and reassessing the adequacy of the committee charter in its compliance with the listing requirements of Nasdaq;

reviewing and establishing our overall management compensation philosophy and policy;

reviewing and approving our policies and procedures for the grant of equity-based awards; and

reviewing and making recommendations to our Board with respect to director compensation.

Nominating and Corporate Governance Committee

Our nominating and corporate governance committee is composed of Ms. Buckle and Messrs. von Prondzynski and Wilkerson, with Mr. von Prondzynski serving as chairman of the committee. Our Board has determined that these committee members are independent as defined under the applicable listing standards of Nasdaq. The committee met five times during the fiscal year ended March 31, 2022, including four regularly scheduled meetings.  Upon completion of the Annual General Meeting, if re-elected, the nominating and corporate governance committee will be composed of Ms. Buckle and Messrs von Prodzynski and Shroff, with Mr. Shroff serving as chairman of the nominating and corporate governance committee.

The nominating and corporate governance committee’s responsibilities include:

identifying individuals qualified to become members of our Board, consistent with criteria approved by our Board;

establishing a policy under which our shareholders may recommend a candidate to the nominating and corporate governance committee for consideration for nomination as a director;

recommending to our Board qualified individuals to serve as members of the committees of our Board;

developing, updating and recommending to our Board a set of corporate governance principles;

assisting the Board in developing and evaluating potential candidates for executive positions (including the chief executive officer) and overseeing the development of executive succession plans;

articulating to each director what is expected, including reference to the corporate governance principles and directors’ duties and responsibilities;

reviewing and recommending to our Board practices and policies with respect to directors;

reviewing and assessing the adequacy of the committee charter and submitting any changes to our Board for approval;

overseeing the systems and processes established by us to ensure compliance with our Code of Business Conduct and Ethics; and

performing an evaluation of the performance of the committee.

8


Table of Contents

BOARD PRACTICES

To help our shareholders better understand our Board practices, we are including the following description of current practices. The nominating and corporate governance committee periodically reviews these practices.

Size of the Board

Historically, the Board has consisted of eight directors and increased to nine directors in May 2022 and ten directors effective on September 1, 2022. We expect the size of the Board will return to nine directors at the Annual General Meeting, as a result of Mr. McDonough’s decision not to stand for re-election.  Our Memorandum and Articles of Association provide that our Board must consist of a minimum of two directors. The exact number of members on our Board will be determined from time to time appoint one or more of its body to be holder of any executive office (including, where considered appropriate, the office of chairman or deputy chairman or chief executive) on such terms and for such period as they may determine and, without prejudice to any claim for damages under any contract entered into in any particular case, may at any time revoke any such appointment.

26.7.
The appointment of any Director to the office of chairman or deputy chairman or managing or joint managing or deputy or assistant managing director or chief executive shall automatically terminate if he ceases to be a Director, but without prejudice to any claim by our full Board.  either the Company or the Director for damages for breach of any contract between him and the Company.
26.8.
The Board appointed Mr. Aebischer as directorappointment of any Director to any executive office shall automatically terminate if he ceases from any cause to be a Director, unless the contract or resolution under which he holds office shall expressly state otherwise, in which event such termination shall be without prejudice to any claim by either the Company or the Director for damages for breach of any contract between him and memberthe Company.
27.
APPOINTMENT AND RETIREMENT OF DIRECTORS
27.1.
At each annual general meeting each Director shall retire.
27.2.
A retiring Director shall be eligible for re-election.
27.3.
The Company at the meeting at which a Director retires under any provisions of these Articles may by ordinary resolution fill the vacated office by electing thereto the retiring Director or some other person eligible for appointment. In default the retiring Director shall be deemed to have been re-elected except in any of the audit committee effective asfollowing cases:
27.3.1.
where at such meeting it is expressly resolved not to fill the vacancy;
27.3.2.
where a resolution for the re-election of May 1, 2022,the retiring Director is put to the meeting and appointed Ms. Bechulost; or
27.3.3.
where the retiring Director has given notice to the Company that he is unwilling to be re-elected.
27.4.
The retirement shall not have effect until the conclusion of the meeting except where a resolution is passed to elect some other person in the place of the retiring Director or a resolution for his re-election is put to the meeting and lost and accordingly a retiring Director who is re-elected or deemed to have been re-elected (and his alternate, if any) will continue in office without break.
27.5.
The Company may by ordinary resolution remove any Director from office for cause notwithstanding any provision of these Articles or of any agreement between the Company and such Director, but without prejudice to any claim he may have for damages for breach of any such agreement. The vacancy arising upon the removal of a Director from office in accordance with the foregoing may be filled as a director effective as of September 1, 2022.  Mr. McDonough elected notcasual vacancy.
27.6.
Subject to stand for re-election at the 2022 Annual General Meeting.

Leadership Structure

Heino von Prondzynski, an independent, non-employee director, serves as the Chairmanprovisions of the Board. The Board recognizesCompanies Laws and of these Articles, if at any time the number of Directors falls below the minimum number fixed by or in accordance with these Articles or the Companies Laws, the Company may by ordinary resolution appoint any person or persons to be a Director, either to fill a casual vacancy or as (an) additional Director(s), in order that itthe number of Directors is importantequal to determine an optimal board leadership structurethe minimum number fixed by or in accordance with these Articles or the Companies Laws.

27.7.
Without prejudice to ensure the independent oversight of management as we continue to grow. We separate the roles of Chief Executive Officer and Chairmanpower of the Board in recognitionCompany to appoint any person to be a Director pursuant to these Articles but subject to the provisions of the differences between the two roles. The Chief Executive Officer is responsible for setting our strategic direction, day-to-day leadership,Companies Laws and performance, while the Chairman of the Board provides guidance to the Chief Executive Officer and presides over meetings of the full board of directors. We believe that this separation of responsibilities provides a balanced approach to management of our Board and oversight of us. However, no single leadership model is right for all companies and at all times. The Board recognizes that depending on the circumstances, other leadership models, such as combining the role of Chairman of the Board with the role of Chief Executive Officer, might be appropriate. Accordingly,these Articles, the Board may periodically review its leadership structure.

at any time appoint any person to be a Director Independence

The Board believeseither to fill a casual vacancy or as an additional Director, but so that a substantial majority of its members should be independent, non-employee directors. Only one member of the Board, Mr. Méndez, who serves as our Chief Executive Officer, is an employee of Quotient. The non-employee directors of the Company are Mses. Bechu, Buckle and Larue, and Messrs. Aebischer, Hallsworth, McDonough, von Prondzynski, Shroff and Wilkerson. The Board has determined that Messrs. Aebischer, Hallsworth, McDonough, von Prondzynski, Shroff and Wilkerson, Mses. Bechu, Buckle and Larue, are independent under the applicable Nasdaq listing rules.  In addition, the Board has determined that Ms. Larue and Messrs. Aebischer, Hallsworth and Shroff, each of whom serves on our audit committee, is independent under Rule 10A-3 under the Exchange Act. In particular, in making such determinations, the Board specifically considered Mr. Shroff’s role as managing director of Galen Partners and Mr. Wilkerson’s role as senior advisor to Galen Partners and the attribution to each of them of beneficial ownership of shares beneficially owned by Galen Partners, and determined that their service in such roles and the resulting attribution of beneficial ownership of our shares did not hinder their independence under applicable Nasdaq or Exchange Act rules.  Upon completion of the Annual General Meeting, if re-elected, Ms. Bechu will join the audit committee and the audit committee will be composed of Ms. Bechu and Larue and Messrs Aebischer and Hallsworth, with Mr. Aebischer serving as chairman of the committee.  The Board has determined that Ms. Bechu meets the independence requirements of Rule 10A-3 under the Exchange Act and the applicable listing standards of Nasdaq.

Audit Committee Financial Expert

The Board has determined that all of the current and nominee members of the audit committee are financially literate and that Mr. Hallsworth and Mr. Aebischer, are “audit committee financial experts” within the meaning of SEC regulations and applicable listing standards of Nasdaq.

Evaluation of Board Performance

The nominating and corporate governance committee coordinates an annual evaluation process by which the directors evaluate the Board’s and its committees’ performance and procedures. This self-evaluation leads to a full Board discussion of the results. The committees of the Board each conduct an annual evaluation of their committee’s performance and procedures.

As discussed above under “Meetings of the Board and Committees of the Board”, the Board evaluated our Board and committee composition, which resulted in the Company adding or nominating new members to its boardtotal number of Directors and Committees, andshall not at any time exceed the maximum number (if any) fixed by or in effectuating rotations of certain committee members and the appointment of new chairpersons to our three committees to be effective after the Annual General Meeting. The Board further undertook its annual evaluation process during the fiscal year ended March 31, 2022.

9


Table of Contents

Nomination of Directors – Skills and Experience

The nominating and corporate governance committee recommends individuals for membership on the Board. In making its recommendations, the nominating and corporate governance committee considers an individual’s independence based on Nasdaq independence requirements and the criteria determined by the Board.

The nominating and corporate governance committee considers not only a candidate’s qualities, performance and professional responsibilities, but also the composition of the Board and the challenges and needs of the Board at that time. The Board as a whole is constituted to be strong in its diversity and collective knowledge of accounting and finance, management and leadership, vision and strategy, business operations, business judgment, crisis management, risk assessment, industry knowledge, corporate governance and global markets.

The culture of the Board enables the Board to operate swiftly and effectively in making key decisions and when facing major challenges. Board meetings are conducted in an environment of trust, confidentiality, open dialogue, mutual respect and constructive commentary.

While the nominating and corporate governance committee does not have a formal policy on Board diversity, it views diversity in its broadest sense, which includes gender, ethnicity, education, experience and leadership qualities. The nominating and corporate governance committee will use the same process and criteria for evaluating all nominees, regardless of who submits the nominee for consideration.  In this regard, the nominating and corporate governance committee works with the Board, especially in conjunction with the annual Board and committee evaluations, to determine the appropriate diversity of professional experience, expertise, educational background and other qualifications in light of the Company’s business strategies.  As a group, our director nominees represent a broad range of these expertise, experience and skills.

Director Nominee Skills

Of 9 Nominees

Senior Leadership Experience

9

Financial Expertise

6

In-vitro diagnostic industry

7

Healthcare Industry Sales & Marketing

6

Strategic Transactions M&A

7

Capital markets

4

Public Company Board Experience

8

Research & Development IVD

3

The nominating and corporate governance committee also promotes the advancement of boardroom diversity and as a group, our director nominees embrace the below diversity range.

Board Diversity Matrix for Quotient Ltd. in relation with the Company’s nine director nominees for the 2022 Annual General Meeting

Country of Principal Executive Offices

Jersey (Channel Islands)

Foreign Issuer

Yes

Disclosure prohibited under home country law

Yes

Total number of nominee Directors

9

 

Female

Male

Non-Binary

Did not disclose gender

Part I: Gender Identity

Directors

3

6

-

-

Part II: Demographic Background

Underrepresented Individual in Home Country Jurisdiction

-

LGBTQ+

-

10


Table of Contents

Did Not Disclose Demographic Background

-

Shareholders are encouraged to submit the name of any candidate they believe to be qualified to serve on the Board, together with background information on the candidate, to the chair of the nominating and corporate governance committee. In accordance with procedures set forth in our Memorandum and Articles of Association, shareholders may propose, and the nominating and corporate governance committee will consider, nominees for election to the Board atthese Articles. Any Director so appointed


shall hold office only until the next annual general meeting and shall then retire (and be eligible for re-election) in accordance with the foregoing provisions.
27.8.
A resolution for the appointment of two or more persons as Directors by giving timely written noticea single resolution shall not be moved at any general meeting unless a resolution that it shall be so moved has first been agreed to our Headby the meeting without any vote being given against it; and any resolution moved in contravention of Legalthis provision shall be void.
27.9.
No person other than a Director retiring at the meeting shall, unless recommended by the Board for election, be eligible for appointment as a Director at any general meeting unless, during the period from (and including) the date that is 120 days before, to and Compliance, which must be received at our registered office no later than the close of business onincluding the date that is 90 days before, the first anniversary of the last annual general meeting of the Company, or August 1, 2022, and no earlierthere shall have been left at the Office notice signed by some member (other than the dateperson to be proposed) duly qualified to attend and vote at the meeting for which such notice is given of his intention to propose such person for election and also notice in writing signed by the person to be proposed of his willingness to be elected.
27.10.
The office of a Director shall be vacated in any of the following events, namely:
27.10.1.
if he shall become prohibited or disqualified by law or the NASDAQ Rules (if applicable) from acting as a Director;
27.10.2.
if he shall resign in writing under his hand left at the Office or if he shall tender his resignation and the Board shall resolve to accept the same;
27.10.3.
if he shall become bankrupt or shall make any arrangement with or compound with his creditors generally;
27.10.4.
if he is, or may be, suffering from mental disorder and either:
27.10.4.1.
he is admitted to hospital in pursuance of an application for admission for treatment under any statute relating to mental health; or
27.10.4.2.
an order is made by a Court having jurisdiction (whether in the Jersey or elsewhere) in matters concerning mental disorder for his detention or for the appointment of a receiver, curator bonis or other person to exercise powers with respect to his property or affairs.
27.10.5.
if he shall be absent from meetings of the Board for six months without leave (and his alternate Director, if any, shall not during such period have attended in his stead) and the Board shall resolve that his office be vacated;
27.10.6.
he shall be requested in writing by not less than two-thirds of the Directors then in office to resign; or
27.10.7.
if any contract with the Company relating to his appointment to any executive office is 120 daysterminated by the Company, unless the Board resolves that he should continue in office as a Director; or
27.10.8.
if he shall be removed from office as provided by Article 27.5.
28.
ALTERNATE DIRECTORS
28.1.
Any Director may appoint any person to be his alternate Director and may remove from office an alternate Director so appointed by him. Such appointment, unless the appointee has been previously approved by the Board or is another Director, shall have effect only upon and subject to being so approved.
28.2.
The appointment of an alternate Director shall terminate:
28.2.1.
if his appointor ceases to be a Director but, if a Director retires (whether in accordance with Article 26.8 or otherwise) but is reappointed or is deemed to be reappointed at the meeting at which he retires, any appointment by such Director of an alternate Director made by him which was in force immediately prior to his retirement shall continue after his reappointment; or

28.2.2.
on the happening of any event which if he were a Director would cause him to vacate his office as a Director; or
28.2.3.
if he resigns his office by notice to the Company.
28.3.
Any appointment or removal of an alternate Director shall be by notice to the Company by the Director making or revoking the appointment and shall take effect in accordance with the terms of the notice (subject to any approval required by Article 28.1) on receipt of such notice by the Company. Any such notice shall be in hard copy form or in electronic form sent to such address (if any) for the time being specified by or on behalf of the Company for that purpose or, in default of such specification, to the Office.
28.4.
An alternate Director shall be entitled to receive notice of all meetings of the Board.
28.5.
An alternate Director shall be entitled to attend and vote as a Director at any meeting of the Board at which the Director appointing him is not personally present and generally at such meeting to perform all functions of his appointor as a Director and for the purposes of the proceedings at such meeting the provisions of these Articles shall apply as if he were a Director. If his appointor is for the time being temporarily unable to act through ill-health, disability or any other reason his signature to any resolution under Article 29.7 of the Directors shall be as effective as the signature of his appointor. To such extent as the Board may from time to time determine in relation to any committee of the Board the provisions of Article 28.4 and this Article shall also apply to any meeting of any such committee of which his appointor is a member. An alternate Director shall not (save as aforesaid) have power to act as a Director nor shall he be deemed to be a Director for the purposes of these Articles.
28.6.
An alternate Director shall be an officer of the Company and shall alone be responsible to the Company for his own acts and defaults and he shall not be deemed an agent of or for the Director appointing him. An alternate Director may be interested in contracts, arrangements and other proposals with the Company, may be repaid expenses by the Company and shall be entitled to be indemnified by the Company to the same extent as if he were a Director, but he shall not be entitled to receive from the Company in respect of his appointment as alternate Director any remuneration except only such proportion (if any) of the remuneration otherwise payable to his appointor as such appointor may by notice to the Company from time to time direct.
28.7.
Where an alternate Director is the alternate of more than one Director and attends a meeting of the Board or a meeting of a committee of the Board which the Board has determined he is entitled to attend in his capacity as an alternate, he shall in the absence of more than one appointor have a separate vote for each appointor for whom he is attending (but he shall only count as one Director for the purposes of determining whether a quorum is present); if he is himself a Director his vote or votes as an alternate Director shall be in addition to his own vote as a Director.
29.
PROCEEDINGS OF DIRECTORS
29.1.
The Board may meet for the despatch of business, adjourn and otherwise regulate its proceedings as it thinks fit. Questions arising at any meeting shall be determined by a majority of votes. In the case of an equality of votes the chairman of the meeting shall not have a second or casting vote. A Director may, and the Secretary on the requisition of a Director shall, at any time summon a meeting of the Board. Any Director may waive notice of any meeting and any such waiver may be retrospective.
29.2.
Notice of a meeting of the Board shall be deemed to be properly given to a Director if given to him personally or by word of mouth or sent in hard copy form to him at his last known address or at any other address given by him to the Company for this purpose or sent in electronic form to the address (if any) notified by him to the Company for that purpose (which shall be deemed to include any email or other electronic address provided to him for his use by the Company).
29.3.
All or any of the Directors may participate in a meeting of the Board by any lawful means including by means of a conference telephone or any communication equipment which allows all persons participating in the meeting to hear and speak to each other at the same time. A person so participating shall be deemed to be present in person at the meeting and shall be entitled to vote and be counted in the quorum accordingly. Such a meeting shall be deemed to take place where

the largest group of those participating is assembled or, if there is no such group, where the chairman of the meeting then is.
29.4.
The quorum necessary for the transaction of the business of the Board shall be a majority of Directors in office at the time of the relevant meeting or such higher proportion of Directors as may be fixed by the Board. For the purposes of this Article an alternate Director shall be counted in a quorum, but so that not less than two individuals shall constitute the quorum. A meeting of the Board at which a quorum is present shall be competent to exercise all authorities, powers and discretions for the time being vested in or exercisable by the Board.
29.5.
The continuing Directors may act notwithstanding any vacancy in their number, but if and so long as the number of Directors is reduced below the minimum number fixed by or in accordance with these Articles the continuing Directors or Director may act for the purpose of filling up such vacancies or of summoning general meetings of the Company, but not for any other purpose. If there be no Directors or Director able or willing to act, then any two members may summon a general meeting for the purpose of appointing Directors.
29.6.
The Board may elect a chairman and, if thought fit, one or more deputy chairmen and determine the period for which each is to hold office. The chairman, failing whom a deputy chairman (to be chosen, if there be more than one, by agreement amongst them or failing agreement by lot), shall preside at all meetings of the Board, but if no chairman or deputy chairman shall have been elected, or if at any meeting none be present within five minutes after the time appointed for holding the meeting or none be willing to act, the Directors present may choose one of their number to be chairman of the meeting.
29.7.
A resolution in writing signed or approved by a majority of the Directors entitled to vote on that resolution shall be as valid and effective as a resolution passed at a meeting of the Directors duly convened and held. The resolution may be contained in one document (whether in hard copy or in electronic form) or in several documents (whether in hard copy or electronic form) each signed or approved by one or more of the Directors concerned. For this purpose:
29.7.1.
the signature or approval of an alternate director (if any) shall suffice in place of the signature of the Director appointing him; and
29.7.2.
the approval of a Director or alternate director shall be given in writing or by electronic means (including approval given in an email).
30.
DIRECTORS' INTERESTS AND CONFLICTS OF INTEREST
30.1.
Subject to Article 30.2:
30.1.1.
a Director who is in any way, directly or indirectly, interested in a proposed transaction or arrangement with the Company or any of its subsidiaries must declare the nature and extent of that interest to the other Directors before the first anniversaryCompany enters into the transaction or arrangement; and
30.1.2.
a Director who is in any way, directly or indirectly, interested in a transaction or arrangement that has been entered into by the Company or any of its subsidiaries must, unless the interest has already been declared pursuant to paragraph (a) of this Article, declare the nature and extent of that interest to the other Directors as soon as is practicable,

in each case in accordance with the requirements of the last annualCompanies Laws. If any such declaration under this Article proves to be, or becomes, inaccurate or incomplete, a further declaration must be made thereunder.

30.1.3.
Subject to the Companies Laws, a Director shall not be required to declare an interest:
30.1.4.
if the Director is not aware of the interest or of the transaction or arrangement in question (and, for this purpose, a Director is treated as being aware of matters of which he ought reasonably to be aware); or
30.1.5.
if the interest cannot reasonably be regarded as likely to give rise to a conflict of interest; or
30.1.6.
if, or to the extent that, the other Directors are already aware of the interest (and, for this purpose, the other Directors are treated as aware of anything of which they ought reasonably to be aware); or

30.1.7.
if, or to the extent that, the interest concerns the terms of his service contract that have been or are to be considered by a meeting of the Board or by a committee of the Board appointed for the purpose under these Articles.
30.2.
Subject to the provisions of the Companies Laws and provided that he has declared the nature and extent of any direct or indirect interest of his in accordance with Article 30.1, a Director, notwithstanding his office, may:
30.2.1.
be a party to or otherwise interested in any transaction or arrangement with the Company or in which the Company is directly or indirectly interested;
30.2.2.
hold any other office or place of profit with the Company (except that of auditor) in conjunction with the office of Director for such period and on such terms, including as to remuneration, as the Board may determine;
30.2.3.
act by himself or through a firm with which he is associated in a professional capacity for the Company or any of its subsidiaries or any company in which the Company is directly or indirectly interested (otherwise than as auditor) on such terms, including as to remuneration, as the Board may determine;
30.2.4.
be or become a director or other officer of, or employed by, or a party to any transaction or arrangement with, or otherwise interested (including by the holding of shares or other securities) in, any subsidiary of the Company or any company in which the Company is directly or indirectly interested; and
30.2.5.
be or become a director of any company in which the Company is not directly or indirectly interested if, at the time of his appointment as a director of that other company, such appointment cannot reasonably be regarded as giving rise to a conflict of interest.
30.3.
A Director shall not, by reason of his office or the fiduciary relationship thereby established, be liable to account to the Company for any remuneration or other benefit which he derives from any transaction or arrangement or from any office, employment, position or relationship or from any interest in any company which he is permitted to hold or enter into by virtue of Article 30.3 or otherwise pursuant to these Articles, nor shall the receipt of any such remuneration or other benefit constitute a breach of his duties under the Companies Laws or otherwise. No transaction or arrangement shall be liable to be avoided on the grounds of a Director having an interest therein (including deriving a benefit therefrom) if the interest is permitted under Article 30.3.
30.4.
A Director may, notwithstanding his interest, be counted in the quorum in relation to any resolution of the Board or a committee of the Board concerning any transaction or arrangement in which he is directly or indirectly interested and, subject to the provisions of Article 30.1, he may vote in respect of any such resolution.
30.5.
A Director may, notwithstanding his interest, be counted in the quorum in relation to any resolution of the Board or a committee of the Board concerning his own appointment (or the settlement or variation of the terms of, or the termination of, his own appointment) as the holder of any office or place of profit with the Company or any subsidiary of the Company or any company in which the Company is directly or indirectly interested, but he may not vote in respect of any such resolution.
30.6.
Where proposals are under consideration concerning the appointment (or the settlement or variation of the terms of the appointment or the termination of the appointment) of two or more Directors to offices or places of profit with the Company or any subsidiary of the Company or any company in which the Company is directly or indirectly interested, such proposals may be divided and considered in relation to each Director separately. In such a case, each of the Directors concerned shall be entitled to vote in respect of each resolution except that concerning his own appointment (or the settlement or variation of the terms, or the termination, of his own appointment).
31.
DIRECTORS' FEES

Without prejudice to Articles 26.3,26.4and 30.2, the Directors (other than alternate Directors) shall be entitled to receive by way of fees for their services as Directors such sum as the Board may from time to time determine. Any fees payable pursuant to this Article shall be distinct from any salary, remuneration or other


amounts payable to a Director pursuant to any other provisions of these Articles and shall accrue from day to day. For the purpose of this Article, the terms "sum" and "fees" include the issue of shares in the capital of the Company and/or the grant of options, warrants or other rights in or over such shares.

31.1.
DIRECTORS' EXPENSES

Each Director shall be entitled to be repaid all reasonable travelling, hotel and other expenses properly incurred by him in or about the performance of his duties as Director, including any expenses incurred in attending meetings of the Board or any committee of the Board or general meetings or separate meetings of the holders of any class of shares or of debentures of the Company.

32.
BORROWING POWERS

The Board may exercise all the powers of the Company to borrow money, and to mortgage or charge its undertaking, property and assets (present and future) and uncalled capital or any part thereof and to issue debentures and other securities whether outright or as collateral security for any debt, liability or obligation of the Company or of any third party.

32.1.
GENERAL POWERS OF DIRECTORS
32.2.
The business of the Company shall be managed by the Board, who may exercise all such powers of the Company as are not by the Companies Laws or by these Articles required to be exercised by the Company in general meeting, subject nevertheless to any regulations of these Articles, to the provisions of the Companies Laws and to such regulations, being not inconsistent with the aforesaid regulations or provisions, as may be prescribed by an ordinary resolution of the Company, but no regulation so made by the Company shall invalidate any prior act of the Board which would have been valid if such regulation had not been made. The general powers given by this Article shall not be limited or restricted by any special authority or power given to the Board by any other Article.
32.3.
The Board may delegate any of its powers to committees consisting of such person or persons (whether Directors or not) upon such terms and conditions and with such restrictions as it thinks fit provided that the majority of the members of the committee are Directors. Any such delegation (which may include authority to sub-delegate all or any of the powers so delegated) may be collateral with, or to the exclusion of, the powers which are the subject of the delegation (or sub-delegation). Any committees so formed shall in the exercise of the powers so delegated conform to any regulations which may from time to time be imposed by the Board and any or all of the powers so delegated may be altered, waived, withdrawn or revoked by the Board.
32.4.
The meetings and proceedings of any such committee consisting of two or more members shall be governed by the provisions of these Articles regulating the meetings and proceedings of the Directors, so far as the same are applicable.
32.5.
The Board may delegate any of its powers to any Director upon such terms and conditions and with such restrictions as they think fit. Any such delegation (which may include authority to sub-delegate all or any of the powers so delegated) may be collateral with, or to the exclusion of, the powers which are the subject of the delegation (or sub-delegation). Any or all of the powers so delegated may be altered, waived, withdrawn or revoked by the Board.
32.6.
The Board may establish any local boards or agencies for managing any of the affairs of the Company and may appoint any persons to be members of such local boards, or any managers or agents, and may fix their remuneration. The Board may delegate to any local board, manager or agent any of the powers, authorities and discretions vested in the Board, with power to sub-delegate, and may authorise the members of any local boards, or any of them, to fill any vacancies therein, and to act notwithstanding vacancies, and any such appointment or delegation may be made upon such terms and subject to such conditions as the Board may think fit, and the Board may remove any person so appointed, and may annul or vary any such delegation, but no person dealing in good faith and without notice of any annulment or variation shall be affected thereby.
32.7.
The Board may by power of attorney, mandate or otherwise appoint any person to be the agent of the Company on such terms (including terms as to remuneration) as it may decide and may delegate to any person so appointed any of its powers, authorities and discretions (with power to sub-delegate). The Board may remove any person appointed under this Article and may revoke or

vary the delegation, but no person dealing in good faith shall be affected by the revocation or variation.
32.8.
Any power of the Board to delegate any of its powers under these Articles (and the power to sub-delegate any of such powers) shall be effective in relation to the powers, authorities and discretions of the Board generally and shall not be limited by the fact that in certain Articles, but not in others, express reference is made to particular powers, authorities or discretions being exercised by the Board or by a committee of the Board.
32.9.
All acts done by or in pursuance of a resolution of any meeting of the Board or of a committee of the Board or by a person acting as a Director or alternate Director or as a member of a committee shall, notwithstanding that there was some defect in the appointment of any Director or alternate Director or member of a committee or that any such person was disqualified or had vacated office or was not entitled to vote, be as valid as if every such person had been duly appointed and was qualified and had continued to be a Director or alternate Director or member of a committee and had been entitled to vote.
32.10.
All cheques, promissory notes, drafts, bills of exchange and other negotiable or transferable instruments, and all receipts for moneys paid to the Company, shall be signed, drawn, accepted, endorsed or otherwise executed, as the case may be, in such manner as the Board shall from time to time determine.
32.11.
If any uncalled capital of the Company is included in or charged by any mortgage or other security, the Board may delegate to the person in whose favour such mortgage or security is executed, or to any other person in trust for him, the power to make calls on the members in respect of such uncalled capital, and to sue in the name of the Company or otherwise for the recovering of moneys becoming due in respect of calls so made and to give valid receipts for such moneys, and the power so delegated shall subsist during the continuance of the mortgage or security, notwithstanding any change of Directors, and shall be assignable if expressed so to be.
32.12.
The Board may from time to time elect a president of the Company and may determine the period for which he shall hold office. Such president may be either honorary or paid such remuneration as the Board in its discretion shall think fit, and need not be a Director but shall, if not a Director, be entitled to receive notice of and attend and speak, but not to vote, at all meetings of the Board.
33.
ASSOCIATE DIRECTORS

The Board may at any time and from time to time appoint any person (other than a Director) to any office or employment with the Company having a designation or title which includes the word "director" or attach to any existing office or employment with the Company such a designation or title and may at any time terminate any such appointment or the use of such designation or title. The inclusion of the word "director" in the designation or title of the office or employment of any person shall not imply that such person is, or is deemed to be, or is empowered in any respect to act as, a director of the Company for any of the purposes of the Companies Laws or these Articles. Subject as aforesaid, the powers and duties of any such person shall be determined by the Board.

34.
SECRETARY
34.1.
The Secretary shall be qualified in accordance with the provisions of the Companies Laws and shall be appointed by the Board on such terms and for such period as it may think fit. The Secretary may at any time be removed from office by the Board, but without prejudice to any claim for damages for breach of any contract between him and the Company. The Board may appoint one or more deputy or assistant secretaries.
34.2.
Any provision of the Companies Laws or of these Articles requiring or authorising a thing to be done by or to a Director and the Secretary shall not be satisfied by its being done by or to the same person acting both as Director and as, or in the place of, the Secretary.
35.
THE SEAL
35.1.
The Company may exercise the powers conferred by the Companies Laws with regard to seals and such powers shall be vested in the Board.
35.2.
The Board shall provide for the safe custody of every Seal.

35.3.
The Board may determine who (which person need not be an officer) shall sign any instrument to which a Seal is applied, either generally or in relation to a particular instrument or type of instrument, and may also determine, either generally or in any particular case, that such signatures shall be dispensed with.
35.4.
Unless otherwise decided by the Board:
35.4.1.
certificates for shares, debentures or other securities of the Company issued under Seal need not be signed; and
35.4.2.
every other instrument to which a Seal is applied shall be signed by at least one Director and the Secretary or by at least two Directors or by one Director in the presence of a witness who attests the signature.
36.
AUTHENTICATION OF DOCUMENTS
36.1.
Any officer or any person appointed by the Board for the purpose shall have power to authenticate and certify as true copies of and extracts from any document affecting the constitution of the Company (whether in hard copy form or in electronic form) and any resolution passed by the Company or the holders of any class of shares in the capital of the Company or the Board or any committee of the Board (whether in bard copy form or in electronic form), and any book, record, document relating to the business of the Company (whether in hard copy form or in electronic form and including without limitation the accounts). Where any books, records, documents or accounts are elsewhere than at the Office the local manager or other officer of the Company having the custody thereof shall be deemed to be a person appointed by the Board as aforesaid (whether in hard copy form or in electronic form and including without limitation the accounts). If certified as aforesaid, a document purporting to be a copy of a resolution, or an extract from the minutes of a meeting of the Company or Julyof the Board or any committee of the Board (whether in hard copy form or in electronic form) shall be conclusive evidence in favour of all persons dealing with the Company in good faith and relying thereon that such resolution has been duly passed or, as the case may be, that such minutes are or extract is true and accurate record of proceedings at a duly constituted meeting.
37.
DIVIDENDS
37.1.
Subject to the provisions of the Companies Laws, the Board may from time to time declare dividends and fix the time for payment thereof.
37.2.
Unless and to the extent that the rights attached to any shares or the terms of issue thereof otherwise provide, a dividend or any other money payable in respect of a share can be declared in any currency and paid in any currency or currencies. The Board shall have the power to decide the basis of conversion for any currency conversions that may be required and how any costs involved are to be met (including whether such costs shall be payable by the member) and to make such arrangements as it thinks fit to enable any dividend or other money payable in respect of a share to be paid in a currency or currencies other than that in which the dividend is declared or other money is expressed to be payable. The Board may deduct from the amount of any dividend or other money payable in respect of a share any fees, expenses, taxes or governmental charges payable by the member in respect of that dividend.
37.3.
Unless and to the extent that the rights attached to any shares or the terms of issue thereof all dividends shall (as regards any shares not fully paid throughout the period in respect of which the dividend is paid) be apportioned and paid pro rata according to the amounts paid on the shares during any portion or portions of the period in respect of which the dividend is paid. For the purposes of this Article no amount paid on a share in advance of call shall be treated as paid on the share.
37.4.
Subject to the provisions of the Companies Laws, if and so far as in the opinion of the Board the financial position of the Company justifies such payments, the Board may pay the fixed dividend on any class of shares carrying a fixed dividend expressed to be payable on fixed dates on the half-yearly or other dates prescribed for the payment thereof and may also from time to time pay interim dividends of such amounts and on such dates and in respect of such periods as it thinks fit. A resolution of the Board declaring any such dividend shall (once published with their authority) be irrevocable and have the same effect as if such dividend had been declared upon the

recommendation of the Board by an ordinary resolution of the Company. Provided the Board acts bona fide it shall not incur any responsibility to the holders of shares conferring a preference for any damage they may suffer by reason of the payment of any interim dividend on any shares having deferred or non-preferred rights.
37.5.
Subject to the provisions of the Companies Laws, where any asset, business or property is bought by the Company as from a past date the profits and losses thereof as from such date may at the discretion of the Board in whole or in part be carried to revenue account and treated for all purposes as profits or losses of the Company. Subject as aforesaid, if any shares or securities are purchased cum dividend or interest, such dividend or interest may at the discretion of the Board be treated as revenue, and it shall not be obligatory to capitalise the same or any part thereof.
37.6.
No dividend or other moneys payable on or in respect of a share shall bear interest as against the Company.
37.7.
The Board may retain any dividend or other moneys payable on or in respect of any share:
37.7.1.
on which the Company has a lien, and may apply the same in or towards satisfaction of the debts, liabilities, or engagements in respect of which the lien exists; or
37.7.2.
in respect of which any person is under the provisions as to the transmission of shares hereinbefore contained entitled to become a member, or which any person is under those provisions entitled to transfer, until such person shall become a member in respect of such shares or shall transfer the same.
37.8.
The Company may cease to send any cheque or warrant through the post for any dividend or other moneys payable on or in respect of any share if in respect of at least 2 2022.consecutive dividends payable on those shares the cheques or warrants have been returned undelivered or remain uncashed, or the cheque or warrant in respect of any one dividend has been returned undelivered or remains uncashed and reasonable enquiries have failed to establish any new address of the holder, but may recommence sending cheques or warrants in respect of dividends payable on those shares if the holder or person entitled thereto requests such recommencement by notice to the Company.
37.9.
All unclaimed dividends or other moneys payable on or in respect of a share may be invested or otherwise made use of by the Board for the benefit of the Company until claimed. The payment by the Board of any such dividend or other moneys into a separate account shall not constitute the Company a trustee in respect thereof and any dividend unclaimed after a period of 12 years from the date of declaration of such dividend or the date on which such dividend became due for payment shall be forfeited and shall revert to the Company, but the Board may at its discretion pay any such dividend or such other moneys or some part thereof to a person who would have been entitled thereto had the same not reverted to the Company.
37.10.
Subject to the Companies Laws, the Board may specify that payment of a dividend be made in whole or in part by the distribution of specific assets (and in particular of paid up shares or debentures of any other company). The Board shall have the power to decide how any costs relating to the distribution of such assets will be met, to sell all or a portion of such assets to fund the payment of any applicable taxes or governmental charges and generally to make such arrangements in connection with the distribution of such assets as it thinks fit. Where any legal, regulatory, technical or practical difficulty arises in regard to such distribution under the laws of, or the requirements of any relevant regulatory body or any stock exchange in, any jurisdiction, the Board may make such exclusions or arrangements to settle the same as it thinks expedient and may, in particular, authorise any person to sell and transfer any assets or fractions or ignore fractions altogether, fix the value for distribution purposes of such specific assets or any part thereof to be distributed and may determine that cash payments shall be made to any members upon the footing of the value so fixed in order to adjust the rights of all parties and may vest any such specific assets in trustees as may seem expedient to the Board. The Board may authorise any person to sign any instrument of transfer for the purposes of effecting a sale and transfer of any assets or fractions thereof pursuant to this Article.
37.11.
Any dividend or other moneys payable in cash or in respect of a share may be paid by cheque or warrant sent through the post to or left at the registered address of the member or

person entitled thereto (or, if two or more persons are registered as joint holders of the share or are entitled thereto in consequence of the death or bankruptcy of the holder, to any one of such persons) or to such person and such address as such member or person may by notice periodsdirect. Every such cheque or warrant shall be made payable to the order of the person to whom it is sent or to such persons as the holder or joint holders or person or persons entitled to the share in consequence of the death or bankruptcy of the holder may changeby notice direct and payment of the cheque or warrant by the banker upon whom it is drawn shall be a good discharge to the Company. Every such cheque or warrant shall be sent at the risk of the person entitled to the moneys represented thereby. In addition any such dividend or other moneys may at the discretion of the Board be paid by any bank or other funds transfer system or such other means and to or through such person as the holder or joint holders or person or persons entitled to the relevant share in consequence of the death or bankruptcy of the holder may by notice direct and the Company shall have no responsibility for any sums lost or delayed in the course of any such transfer or where it has acted on any such directions.
37.12.
In respect of shares in uncertificated form, where the Company is authorised to do so by or on behalf of the holder or joint holders in such manner as the Company shall from time to time consider sufficient, the Company may pay any such dividend, interest or other moneys by means of the relevant system (subject always to the facilities and requirements of that relevant system).
37.13.
If two or more persons are registered as joint holders of any share, or are entitled jointly to a share in consequence of the death or bankruptcy of the holder, any one of them may give effectual receipts for any dividend or other moneys payable or property distributable on or in respect of the share.
37.14.
The waiver in whole or in part of any dividend on any shares by any document shall be effective only if such document is signed by the shareholder (or the person entitled to the share in consequence of the death or bankruptcy of the holder or otherwise by operation of law) and delivered to the Company and if or to the extent that the same is accepted as such or acted upon by the Company.
38.
RESERVES

The Board may from time to time set aside out of the profits of the Company and carry to reserve such sums as they think proper which, at the discretion of the Board, shall be applicable for any purpose to which the profits of the Company may properly be applied and pending such application may either be employed in the business of the Company or be invested. The Board may from time to time designate the reserves or any part thereof for such purposes or in such manner as they think fit. The Board may also without placing the same to reserve carry forward any profits. In carrying sums to reserve and in applying the same the Board shall comply with the provisions of the Companies Laws.

39.
CAPITALISATION OF RESERVES
39.1.
The Company may in accordance with the procedures setCompanies Laws capitalise any sum standing to the credit of any of the Company's capital or revenue reserve funds or any sum standing to the credit of the profit and loss account (provided that such sum is not required for paying the dividends on any shares carrying a fixed cumulative preferential dividend) and appropriate the sum to be capitalised to the holders of shares in the proportions in which such sum would have been divisible amongst them had the same been a distribution of profits by way of dividend on the shares and to apply such sum on their behalf either in or towards paying up the amounts (if any) for the time being unpaid on any shares held by them respectively or in or towards paying up in full unissued shares or debentures of the Company, such shares or debentures to be allotted and distributed credited as fully paid up to and amongst them in the proportion aforesaid or partly in one way and partly in the other (and provided that any unrealised profits shall for the purposes of this Article only be applied in or towards the paying up of unissued shares to be allotted as fully paid) where, pursuant to this this Article, the Company capitalises any undistributed profits or reserves by applying them in or towards paying up issued shares in the Company which were not yet fully paid up or in paying up any previously unissued shares in the Company, the amount so applied shall, to the extent required by the Law, be credited to the stated capital account in respect of the class of share concerned.

39.2.
Subject to the Companies Laws, the Board may, in respect of any dividend or dividends, offer to holders of Ordinary Shares the right to elect to receive in lieu of such dividend (or part thereof) an allotment of additional Ordinary Shares credited as fully paid. In any such case the following provisions shall apply:
39.2.1.
the basis of allotment shall be determined by the Board so that each holder of Ordinary Shares is entitled to such number of new Ordinary Shares whose aggregate value is as nearly as possible equal to (but not greater than) the cash amount (disregarding any tax credit) of the dividend that such holder has elected to forgo. For this purpose, the value of an Ordinary Share shall be equal to the final reported per share closing price as quoted for the Ordinary Shares on NASDAQ, on the day on which quotations in respect of the Ordinary Shares are first given ex the relevant dividend and the four subsequent dealing days;
39.2.2.
the Board shall give notice to holders of Ordinary Shares of the right of election accorded to them and shall send with or following such notice forms of election and specify the procedure to be followed and the place at which and
39.2.3.
the latest date and time by which duly completed forms of election must be lodged in order to be effective;
39.2.4.
the dividend (or that part of the dividend in respect of which a right of election has been accorded) shall not be payable in cash on Ordinary Shares in respect of which an election has been made and in lieu thereof additional Ordinary Shares shall be allotted to the holders of such shares on the basis of allotment determined as aforesaid. For that purpose, the Board shall appropriate out of any amount for the time being standing to the credit of reserves or profit and loss account as the Board may determine a sum equal to the aggregate number of additional Ordinary Shares to be allotted on such basis and apply the same in our Memorandumpaying up in full the appropriate number of new Ordinary Shares on such basis;
39.2.5.
the additional Ordinary Shares so allotted shall rank pari passu in all respects with the fully paid Ordinary Shares then in issue save only as regards participation in the relevant dividend (or share election in lieu); and
39.2.6.
the Board may on any occasion determine that rights of election shall not be made available to any holders of Ordinary Shares with registered addresses in any territory where in the absence of a registration statement or other special formalities the circulation of an offer of rights of election would or might be unlawful, and in such event the provisions aforesaid shall be read and construed subject to such determination.
39.3.
Where Articles 41.1and/or 41.2 apply, the Board shall make all necessary appropriations, applications and allotments to give effect to such Articles. The Board shall have the power to decide how any costs relating to the distribution will be met and to sell all or a portion of Association. such shares or debentures to fund the payment of any applicable taxes or governmental charges and generally make such arrangements in connection with the distribution as it thinks fit. Without limiting the generality of the foregoing, the Board may:
39.3.1.
make such exclusions or arrangements as it thinks fit to settle any legal, regulatory, technical or practical difficulty arising in relation to the distribution under the laws of, or the requirements of any relevant regulatory body or any stock exchange in, any jurisdiction;
39.3.2.
make such arrangements as it thinks fit in the case of shares or debentures becoming distributable in fractions (including provisions whereby the benefit of fractional entitlements accrues to the Company rather than to the members concerned);
39.3.3.
authorise any person to enter, on behalf of all relevant members, into an agreement with the Company providing for the allotment to them respectively, credited as fully paid, of any further shares or debentures to which they may be entitled upon such capitalisation or (as the case may require) for the payment by the Company on their behalf, by the application thereto of their respective interests in such capitalised sum, of the amounts or any part of the amounts remaining unpaid on their existing shares and for matters incidental thereto and any agreement made under any such authority shall be effective and binding on all concerned; and

39.3.4.
authorise any person to sign any instrument of transfer for the purposes of effecting a sale and transfer of any shares or debentures or fractions thereof pursuant to this Article.
40.
RECORD DATES

Notwithstanding any other provision of these Articles, the Company or the Board may fix any date as the record date for any dividend, distribution, offer, allotment or issue and such record date may be on or any time before or after any date on which the dividend, distribution, offer, allotment or issue is declared, paid or made.

41.
REGISTER
41.1.
The Directors shall keep, or cause to be kept, at the Office or at the Transfer Office (but not, for the avoidance of doubt, at a place outside Jersey), the Register in the manner required by the Companies Laws. The Directors may rely upon the information provided to them from time to time by the Operator for the purposes of keeping the Register up to date in accordance with the Companies Laws. Except as provided by Article 43.2below, no counter-part or branch of the Register shall be maintained outside Jersey and no copy of the Register, list, record or information in respect of the members of the Company kept or maintained outside Jersey shall constitute the Register or any part of the Register. The Company shall not be bound to recognise any interest or right in respect of any share by virtue of it being contained or recorded in such copy of the Register or that list, record or information (as the case may be) kept or maintained outside Jersey.
41.2.
Subject to the provisions of the Companies Laws, the Company may keep an overseas branch register in any country, territory or place in respect of the members resident in such country, territory or place. The Board may make and vary such regulations as it may think fit in relation to the keeping of any such overseas branch register.
42.
MINUTES AND BOOKS
42.1.
The Board shall cause minutes to be made:
42.1.1.
of all appointments of officers made by the Board;
42.1.2.
of the names of the Directors present at each meeting of the Board and of any committee of the Board; and
42.1.3.
of all resolutions and proceedings at all meetings of the Company and of any class of members of the Company and of the Board and of committees of the Board.
42.2.
Any such notice must includeminutes if purporting to be signed by the namechairman of the nominee,meeting at which the proceedings took place, or by the chairman of the next following meeting, shall be sufficient evidence, without any further proof, of the facts therein stated.
42.3.
Any register, index, minute book, book of account or other book required by these Articles or the Companies Laws to be kept by or on behalf of the Company may be kept either by making entries in bound books or by recording them in any other manner. In any case in which bound books are not used, the Board shall take adequate precautions for guarding against falsification and for facilitating its discovery.
42.4.
Any register, index, minute book, book of account or other book or document of the Company shall always be open to the inspection of the officers of the Company. Subject as aforesaid no member of the Company or other person shall have any right of inspecting any book or document of the Company except as conferred by the Companies Laws or as ordered by a biographical sketchCourt of competent jurisdiction or as authorised by the Board and resume, contact informationthe Board shall (subject to the provisions of the Companies Laws) determine at what times and under what conditions any such right may be exercised.
43.
ACCOUNTS
43.1.
Accounting records sufficient to show and explain the Company's transactions and otherwise complying with the Companies Laws shall be kept at the Office or (subject to the provisions of the Companies Laws) at such other background materials on such nomineeplace as the nominatingBoard thinks fit.
43.2.
The Company shall send to each member of the Company and corporate governanceto the Auditors and to every other person who is entitled to receive notice of general meetings copies of the Company's annual

accounts, the Directors' report (if any) and the Auditors' report not less than 14 clear days before the date of the general meeting before which they are to be laid. Nothing in this Article shall require the Company to send a copy of those documents to any person who under these Articles is not entitled to be sent notices from the Company or of whose address the Company is unaware or to any holder of debentures of whose address the Company is unaware or to more than one of the joint holders of any shares or debentures. No accidental non-compliance with the provisions of this Article shall invalidate the proceedings at the meeting.
43.3.
Every account of the Company when audited and approved by the Company in general meeting shall be conclusive except as regards any error discovered therein within three months next after the approval thereof Whenever such an error is discovered within that period, the account shall forthwith be corrected and thereupon shall be conclusive.
44.
AUDITORS
44.1.
Auditors shall be appointed and their duties, powers, rights and remuneration regulated in accordance with the provisions of the Companies Laws.
44.2.
Subject to the provisions of the Companies Laws, all acts done by persons acting as Auditors shall, as regards all persons dealing in good faith with the Company, be valid, notwithstanding that there was some defect in their appointment or that they were at the time of their appointment not qualified for appointment.
44.3.
The Auditors shall be entitled to attend any general meeting and to receive all notices of and other communications relating to any general meeting which any member is entitled to receive, and to be heard at any general meeting on any part of the business of the meeting which concerns them as Auditors.
45.
COMMUNICATIONS
45.1.
Communications to be in writing
45.1.1.
Any notice or other communication to be given to or by any person pursuant to these Articles (other than a notice convening a meeting of the Board or of a committee of the Board) shall be in writing.
45.2.
Communications to the Company
45.2.1.
Subject to the Companies Laws and except where otherwise expressly stated in these Articles, any document or information to be sent or supplied to the Company (whether or not such document or information is required or authorised under the Companies Laws) shall be in hard copy form or, subject to Article 47.2.2, be sent or supplied in electronic form or by means of a website.
45.2.2.
Subject to the Companies Laws, a document or information may request.

Executive Sessions

Non-employee directors meet togetherbe given to the Company in electronic form only if it is given in such form and manner and to such address as may have been specified by the Board from time to time for the receipt of documents in electronic form. The Board may prescribe such procedures as it thinks fit for verifying the authenticity or integrity of any such document or information given to it in electronic form.

45.2.3.
A communication sent to the Company by electronic means shall not be treated as received by the Company if it is rejected by computer virus protection arrangements.
45.3.
Communications by the Company
45.3.1.
The Company may send or supply any document or information to a group during eachmember in hard copy form:
45.3.1.1.
personally; or
45.3.1.2.
by sending or supplying it by post in a pre-paid envelope addressed to the member at his registered address or by leaving it at that address in an envelope addressed to the member;
45.4.
Subject to the Companies Laws, a document or information may be sent or supplied by the Company in electronic form to any member who has agreed (generally or specifically) that a

document or information may be sent or supplied in electronic form and has not revoked that agreement. Where a document or information is sent or supplied by electronic means, it may only be sent or supplied to an address specified for that purpose by the member.
45.5.
A document or information may be sent or supplied by the Company to a member by being made available on a website if the member has agreed (generally or specifically), or pursuant to Article 47.7 below is deemed to have agreed, that documents or information can be sent or supplied to the member in that form and has not revoked such agreement. A document or information sent or supplied by means of a website must be made available in a form, and by a means, that the Company reasonably considers will enable the recipient:
45.5.1.
to read it; and
45.5.2.
to retain a copy of it.
45.6.
If a document or information is sent or supplied by means of a website, the Company must notify the intended recipient of:
45.6.1.
the presence of the document or information on the website;
45.6.2.
the address of the website; the place on the website where it may be accessed; and
45.6.3.
how to access the document or information.
45.7.
Any document or information made available on a website will be maintained on the website for the period of 28 days beginning with the date on which notification is given under Article 47.6 above, or such shorter period as may be decided by the Board. A failure to make a document or information available on a website throughout the period mentioned in this Article shall be disregarded if
45.7.1.
it is made available on the website for part of that period; and
45.7.2.
the failure to make it available throughout that period is wholly attributable to circumstances that it would not be reasonable for the Company to prevent or avoid.
45.8.
If a member has been asked individually by the Company to agree that the Company may send or supply documents or information generally, or specific documents or information, to the member by means of a website and the Company does not receive a response within a period of 28 days beginning with the date on which the Company's request was sent (or such longer period as the Board meeting, withoutmay specify), such member will be deemed to have agreed to receive such documents or information by means of a website in accordance with Article 47.5 above (save in respect of any documents or information as may be required to be sent in hard copy form pursuant to the Chief Executive OfficerCompanies Laws). A member can revoke any such deemed election in accordance with Article 47.9below.
45.9.
Any amendment or revocation of a notification given to the Company or agreement (or deemed agreement) under these Articles shall only take effect if in writing, signed (or authenticated by electronic means) by the member and on actual receipt by the Company thereof.
45.10.
Where these Articles require or permit a document to be authenticated by a person by electronic means, to be valid it must incorporate the electronic signature or personal identification details of that person, in such form as the Directors may approve, or be accompanied by such other evidence as the Directors may require to satisfy themselves that the document is genuine.
45.11.
In the case of joint holders of a share:
45.11.1.
all documents or information shall be given to the joint holder whose name stands first in the Register in respect of the joint holding and any document or information so given shall be deemed for all purposes given to all the joint holders; and
45.11.2.
anything to be agreed or specified in relation to any document or information to be given to them may be agreed or specified by any one of the joint holders and any such agreement or specification shall be deemed for all purposes to be agreed or specified by all the joint holders. The agreement or specification of the joint holder whose name stands first in the Register in respect of the joint holding shall be accepted to the exclusion of the agreement or specification of any of the other joint holders.

45.11.3.
If a member (or, in the case of joint holders, the person first named in the Register) has a registered address outside of Jersey, the Republic of Ireland, the United Kingdom or the USA but has notified the Company of an address within Jersey, the Republic of Ireland, the United Kingdom or the USA at which documents or information may be given to him, he shall be entitled to have documents or information given to him at that address or, where applicable, to be notified at that address of the availability of documents or information on a website. Alternatively, if a member has a registered address outside Jersey, the Republic of Ireland, the United Kingdom or the USA, he may give the Company an address for the purposes of communications in electronic form in which event, subject to these Articles, documents or information may, at the Company's absolute discretion, be sent to him at that address. Otherwise, no such member shall be entitled to receive any document or information from the Company.
45.11.4.
If on at least three consecutive occasions any document or information sent to a member by post at his registered address or his address at which documents or information may be given to him has been returned undelivered, such member shall not thereafter be entitled to receive any document or information from the Company until he shall have communicated with the Company and supplied the Company with a new registered address within Jersey, the Republic of Ireland, the United Kingdom or the USA or an address within Jersey, the Republic of Ireland, the United Kingdom or the USA at which documents or information may be given to him.
45.11.5.
If on at least two consecutive occasions the Company has attempted to send a document or information by electronic means to an address for the time being notified to the Company by a member for that purpose but the Company is aware that there has been a failure of delivery of such document or information, the Company shall, subject to the provisions of these Articles, thereafter send documents and information to such member by post at his registered address or his address at which documents or information may be given to him.
45.11.6.
The provisions of Articles 47.3 to 47.21 do not affect any provision of the Companies Laws requiring documents or information to be served on or given, sent, supplied or delivered to a member in a particular manner.
45.12.
Notice to persons entitled by transmission
45.13.
The Company may give a document or information to the person entitled by transmission to a share by sending it in any manner authorised by these Articles for the giving of a document or information to a member, addressed to that person by name or by the title of representative of the deceased or trustee of the bankrupt or representative by operation of law or by any similar description, at the address (if any) in Jersey, the Republic of Ireland, the United Kingdom or the USA supplied for that purpose by the person claiming to be so entitled. Until such an address has been supplied, a document or information may be given in any manner in which it might have been given if the death or bankruptcy or other event giving rise to the transmission of entitlement had not occurred.
45.14.
Record date for communications
45.15.
For the purposes of giving notices of meetings, or of sending or supplying other documents or other information, whether under the Companies Laws, any other applicable law or regulation, a provision in these Articles or any other employees in attendance. Mr. von Prondzynski, as our Board’s Chairman, presides over each executive sessioninstrument, the Company may determine that persons entitled to receive such documents or information are those persons entered on the Register at the close of business on a day determined by it. The day determined by the Company for the purposes of this Article may not be more than 21 days before the day that the notice of the Board. Theremeeting, document or other information is also an executive session during each committee meetinggiven.
45.16.
Evidence of service
45.16.1.
Any document or information:
45.16.1.1.
addressed to a member at his registered address or address at which committee members meet withoutdocuments or information may be given to him in Jersey, the Chief Executive OfficerRepublic of Ireland, the United Kingdom or the USA shall, if sent by post, be deemed to have been given to or received

by the intended recipient (where first class post is employed) on the day after the day on which it was posted or (where second class post is employed) on the second day after the day on which it was posted and, in proving service, it shall be sufficient to prove that an envelope containing the document or information was properly addressed, pre-paid and put into the post;
45.16.1.2.
not sent by post but addressed to a member but left at his registered address or address at which documents or information may be given to him in Jersey, the Republic of Ireland, the United Kingdom or the USA shall be deemed to have been given to or received by the intended recipient on the day on which it was so left;
45.16.1.3.
sent or supplied by electronic means shall be deemed to have been given to or received by the intended recipient on the day it was sent even if the Company subsequently sends a hard copy of such document or information by post. In proving service, it shall be sufficient to show that the document or information was properly addressed and sent;
45.16.1.4.
sent or supplied by the Company by means of a relevant system, that document or information shall be deemed to have been given to or received by the intended recipient when the Company or any sponsoring system-participant acting on its behalf sends the issuer's instruction relating to the document or information; and
45.16.1.5.
sent or supplied by being made available on a website shall be deemed to have been given to or received by the intended recipient on the day on which the document or information was first made available on the website or, if later, when the recipient received (or is deemed to have received) notification of the fact that the document or information was available on the website.
45.17.
A member present, either in person or by proxy, at any meeting of the Company shall be deemed to have been received due notice of the meeting and, where requisite, of the purposes for which the meeting was called.
45.18.
Proof that a notice contained in an electronic communication was sent in accordance with guidance issued by the Institute of Chartered Secretaries and Administrators shall be conclusive evidence that the notice was given.
45.19.
Any document or other information sent or supplied by the Company by any other means authorised in writing by the member concerned shall be deemed to have been received when the Company has carried out the action it has been authorised to take for that purpose.
45.20.
Notice binding on transferees
45.20.1.
Every person who, by operation of law, transfer or any other employeesmeans, becomes entitled to a share shall be bound by any notice in attendance. In addition, as required under Nasdaq listing standards, independent directors must meet together asrespect of that share which, before his name is entered in the Register, has been given to a groupperson from whom he derives his title.
45.21.
Notice during disruption of services
45.21.1.
If at any time by reason of the suspension, interruption or curtailment of postal services or the electronic communications system in Jersey, the Republic of Ireland, the United Kingdom or the USA, the Company is or would be unable effectively to convene a general meeting by notices sent through the post or by electronic means, notice of the general meeting may be given by a notice advertised in at least twiceone newspaper with a year.

Board’s Rolenational circulation in Risk Oversight

We faceeach of the United Kingdom and the USA. Such notice shall be deemed to have been duly served on all persons who are entitled to have notice of meetings sent to them at noon on the day when the advertisement (or, where applicable, the first of such advertisements) appears. In any such case, the Company shall send confirmatory copies of the notice by post or by electronic means if, at least seven clear days before the meeting, the posting of notices to addresses throughout Jersey, the Republic of Ireland, the United Kingdom or the USA or, as the case may be, the sending of such notices by electronic means again becomes practicable.

46.
WINDING UP

46.1.
The Board shall have power in the name and on behalf of the Company to present a petition to the Court for the Company to be wound up. Subject to any particular rights or limitations for the time being attached to any shares, as may be specified in these Articles or upon which such shares may be issued, if the Company is wound up, the assets available for distribution among the members shall be distributed to the members pro rata to the number of risks, including risks relatingshares held by each member at the time of the commencement of the winding up. If any share is not fully paid up, that share shall only carry the right to our business, operations, strategic direction and regulatory environment, as well as legal, financial, compliance, liability, information technology, ESG, cybersecurity and reputational risks. The Board takes an active role in risk oversight relatedreceive a distribution calculated on the basis of the proportion that the amount paid up on that share bears to the issue price of that share.

46.2.
If the Company both asshall be wound up (whether the liquidation is voluntary, under supervision, or by the Court) the liquidator (or the Directors, where no liquidator is appointed) may, with the authority of a full Board and through its committees. Whilespecial resolution, divide amongst the Company’s management is responsible for day-to-day managementmembers in specie the whole or any part of the various risks facingassets of the Company (whether or not the Boardassets shall consist of property of one kind or shall consist of properties of different kinds) and may for such purpose set such value as he deems fair upon any one or more class or classes of property and may subject to any special rights attached to any shares or the terms of issue thereof determine how such division shall be carried out as between the members or different classes of members. The liquidator (or the Directors, where no liquidator is responsibleappointed) may, with the like authority, vest any part of the assets in trustees upon such trusts for monitoring management’s actionsthe benefit of members as the liquidator with the like authority shall think fit, and decisions. The Board, as apprisedthe liquidation of the Company may be closed and the Company dissolved, but so that no contributory shall be compelled to accept any shares or other property in respect of which there is a liability.
47.
INDEMNITY AND INSURANCE
47.1.
Subject to the provisions of and to the extent permitted by the audit committee, determines that appropriate risk management and mitigation procedures are in place and that senior management takesCompanies Laws, the appropriate steps to manage all major risks.

Attendance at Shareholder Meetings

The Board does not have a formal policy regarding director attendance at shareholder meetings. Mr. von Prondzynski and Mr. Méndez attended the 2021 annual general meetingCompany may

47.1.1.
indemnify any officer of the shareholders.

As required by our organizational documents, we intend to hold the 2022 Annual General Meeting in person.

Governance Principles

The Board maintainsCompany (or of a formal statementsubsidiary) against any liability;

47.1.2.
indemnify an officer of Corporate Governance Guidelinesa company that sets forth the corporate governance practicesis a trustee of an occupational pension scheme for Quotient. The Corporate Governance Guidelines are available on our website at www.quotientbd.com. Click on the tab “Investors” and then the caption “Corporate Governance.”

Code of Business Conduct and Ethics

We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees including our principal executive officer and principal financial officer. A current copy(or former employees) of the code is posted onCompany (or of an associated body corporate) against liability incurred in connection with the investor sectioncompany's activities as trustee of our website, www.quotientbd.com. We intendthe scheme;

47.1.3.
purchase and maintain insurance against any liability for any officer referred to disclosein paragraph (a) or (b) above; and
47.1.4.
provide any amendmentofficer referred to in paragraph (a) or (b) above with funds (whether by loan or otherwise) to meet expenditure incurred or to be incurred by him in defending any criminal, regulatory or civil proceedings or in connection with an application for relief (or to enable any such officer to avoid incurring such expenditure).
47.2.
Subject to the code,Companies Laws, the powers given by Article 49.1 shall not limit any general powers of the Company to grant indemnities, purchase and maintain insurance or provide funds (whether by way of loan or otherwise) to any waivers of its requirements, on our website.

Corporate Responsibility

The Board is committed to being a good corporate citizen and seeks to identify and manage the material environmental, social and governance (“ESG”) risks and opportunities that are relevant to our activities.  The following is a description of our commitment to minimize the environmental impact of our products and operations. Our strategyperson in fiscal year 2022 was geared towards waste management and environmental management ISO certification under ISO 14001.  Our goal is to harmonize green standards at group level and we are building an ESG taskforceconnection with the mission to implement and improve our strategy in this area.

any legal or regulatory proceedings or applications for relief.

 

 


11


Table of Contents

 

 

Waste Management

We strive to reduce our waste, by employing continuous improvement initiatives such as our waste management process that focus on recyclable (and recycled) material and separates key waste categories according to their environmental impact. Our employees are trained onAccompanying document: Certificate under Article 127E(5) of the waste management process and may consult with our biological safety team on special wastes features.  We put in place appropriate containers to collect, sort and dispose of general waste.Companies (Jersey) Law 1991

 

ISO 14001 – Environmental management

During fiscal year 2022, we have applied for and were successfully certified in June 2022 to QUOTIENT LIMITED
(the ISO 14001 Environmental Management System for our manufacturing site in Switzerland.  We are committed to play a key role in achieving sustainable climate objectives. By being certified according to the ISO 14001 standards, we demonstrate our willingness to improve our environmental performance. We strive to do our best to protect our planet’s natural resources while also working towards our own environmental objectives.

"Environmentally friendly technologiesCompany")

We encourage the development and diffusion of environmentally friendly technologies to help our company reduce the use of raw materials leading to increased efficiency. Our Innovators’ Circle Studies aim at providing analytical data and measuring the impact of our MosaiQ platform workflow on the environment through measuring reagents and consumables consumptions, volume of water used, liquid and solid waste generated.Article 127E(5) Certificate

Communications with the Board

The Board believes thatConsidering that: (1) it is inproposed that the best interestsCompany merges with Quotient Holdings Merger Company Limited (the "Merger") under Part 18B (Mergers) of the Companies (Jersey) Law 1991 (the "Law"); and (2) a resolution has been passed by the directors of the Company and its shareholders to provide to every shareholder the ability to communicate with the Board as a whole, or with an individual director, through an established process for shareholder communication. The shareholder communication policy is posted on Quotient’s website at www.quotientbd.com. Click on the tab “Investors” and then the caption “Corporate Governance.”

12


Table of Contents

RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

The following is a description of transactions, since April 1, 2021, in which (a) we were a participant, (b) the amount involved exceeded $120,000 and (c) one or more of our executive officers, directors or 5% shareholders, or their immediate family members, each of whom we refer to as a “related person,” had a direct or indirect material interest. We refer to these as “related person transactions.”

Transition Agreement – Franz Walt

On February 23, 2021, we entered into a transition agreement with Mr. Franz Walt, our former Chief Executive Officer, and we agreed to make certain payments to Mr. Walt in consideration for his service to us, for his continued provision of services through his retirement date on May 24, 2021 and for up to 18 months following the retirement date to support the new Chief Executive Officer and to consult on special initiatives or other matters that may arise.  In recognition of Mr. Walt’s service to us, Mr. Walt received a single cash payment of $1,125,000 (equal to 18 months base salary). Mr. Walt was subject to non-competition restrictions during the 18-month consultancy.  In addition, the Transition Agreement provided that all options to acquire our ordinary shares held by Mr. Walt that were unvested asrespect of the retirement dateMerger (the "Resolution") under and that were scheduled to vest within 12 months following the retirement date remained outstanding and vested and became exercisable on their regularly scheduled vesting dates after the retirement date; all other options held by Mr. Walt that were unvested as of the retirement date were forfeited; and all options held by Mr. Walt that were vested as of the retirement date remained exercisable until May 24, 2022. Furthermore, all restricted share units (“RSUs”) and other awards with respect to our ordinary shares held by Mr. Walt that were unvested as of the retirement date and that were scheduled to vest within 12 months following the retirement date remained outstanding and vested on their regularly scheduled vesting dates after the retirement date; and all other RSUs held by Mr. Walt that were unvested as of the retirement date were forfeited. Mr. Walt was also entitled to receive all accrued and vested benefits under any other Company benefit plans, and any reimbursements to which Mr. Walt was entitled under current policies through the retirement date.

Registration Rights Agreement

On December 13, 2019, we entered into a registration rights agreement (the “Registration Rights Agreement”) with Heino von Prondzynski, our Chairman, Franz Walt, our former Chief Executive Officer, and Christopher Lindop, our former Chief Financial Officer, with respect to an aggregate of 105,000 ordinary shares owned by these individuals that were originally subscribed for by them in separate private placements that occurred in February 2017 and August 2018, respectively (the “registrable shares”). We refer to these individuals, in their capacities as parties to the Registration Rights Agreement, as the “holders.”  The purpose of the Registration Rights Agreement is to permit the public offer and resale of the registrable shares by the holders. In accordance with the terms of the Registration Rights Agreement, we filed with the SEC a shelf registration statement on Form S-3 to register the registrable shares to be sold by the holders from time to time (the “Shelf Registration Statement”), and we have agreed to use our reasonable best efforts to keep the Shelf Registration Statement continuously effective until the registrable shares are sold or otherwise cease to be registrable shares for purposesArticle 127E(1) of the Registration Rights Agreement orLaw and in accordance with Article 127E(5) of the agreement is otherwise terminated.

SupplementsLaw no notice has yet been given of a meeting of the Company as mentioned in that Article 127E(1), nor has a form of written special resolution (to approve the merger agreement) yet been provided to the 2016 Senior Secured Notes due 2025

On October 13, 2021, we received consents from allmembers of the holders of our 12% senior Secured Notes (the “Notes”) to certain amendmentsand to the indenture governingmembers holding each class of shares in the Notes.  Highbridge Capital Management, LLC and its affiliates, which beneficially own more than 5% of the Company’s ordinary shares, is a holder of the Notes and received its prorate share of the consent consideration paid to holders of the Notes, which amounted to (i) an aggregate of 932,772 of the Company’s ordinary shares, nil par value per share, and (ii) 5-year warrants to purchase an aggregate of 1,844,020 of the Company’s ordinary shares for $4 per share

In June 2022, the Company and holders of the Notes agreed additional amendments of the Notes.  In July 2022, Highbridge Capital Management, LLC and its affiliates will receive warrants to purchase Company’s ordinary shares at an exercise price of $0.75 per share.Company:

 

Employment Agreements

On January 3, 2020, we entered into an employment agreement with Mr. Buhler, our former Chief Financial Officer, which sets forthWe, being each of the terms and conditions under which Mr. Buhler served as our Chief Financial Officer.  On June 30, 2021, Peter Buhler notifieddirectors of the Company that he was resigning from his position as Chief Financial Officer to take a positionwho voted in favour of the Resolution HEREBY STATE for the purposes of and in accordance with another company.  Article 127E(5) of the Law that:He continued serving as our Chief Financial Officer through to October 31, 2021, and remained

1.
in accordance with Article 127E(2) of the Law, having made full inquiry into the affairs of the Company, to ensure a smooth transition until his employment agreement ended on December 31, 2021.

On February 23, 2021, we entered into an employment agreement with Mr. Méndez, which sets forth the terms and conditions under which Mr. Méndez will serve in the position of Chief Executive Officer effective April 1, 2021. The Employment Agreement was approved by the Board as well as the Remuneration Committee of the Board. The agreement has a four-year term and subject to certain circumstances set forth in the Employment Agreement, Mr. Méndez will work at our premises in Eysins, Switzerland.  The employment agreement with Mr. Méndez was subsequently amended on October 5 and October 15, 2021, as well as on January 12, 2022.

13


Table of Contents

On September 23, 2021, we entered into an employment agreement with Mr. El Khoury, which sets forth the terms and conditions under which Mr. El Khoury serves as our Chief Commercial Officer effective from October 5, 2021.

For additional information on our employment agreements with our executive officers, see “Executive Compensation—Agreements with our Executive Officers—Employment Agreements.”

Equity Awards

We have issued certain shares and granted share options, or multi-year, performance-based restricted share units, and/or restricted share units, or RSUs, to our executive officers and our directors.  For additional information, see “Executive Compensation—Outstanding Equity Awards at Fiscal Year End” and “Non-Employee Director Compensation.”

Change of Control

We are party to change of control agreements with our executive officers. For additional information, see “Executive Compensation—Agreements with our Executive Officers—Change of Control Agreements.”

Indemnification

We have entered into indemnification provisions or agreements with each of us reasonably believes that the Company is, and will remain until the Merger is completed, able to discharge its liabilities as they fall due; and

2.
the grounds for the statement at 1above are our executive officers and directors to indemnify them against certain liabilities and expenses arising from their being an officer or director (but specifically excluding any circumstance where they are determined to have violated their fiduciary duty to us). Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinionconsideration of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

Non-Employee Director Appointment Letters

We have entered into letters of appointment with certain of our non-employee directors. These letters set forth the main terms on which each of our non-employee directors serve on our Board. Continued appointment under the letter is contingent on continued satisfactory performance, re-nomination by the nominating and corporate governance committee and approval of the Board, re-election by the shareholders and anyall relevant statutory provisions and provisions of our articles of association relating to removal of a director.

Procedures for Approval of Related Party Transactions

Currently, under our Related Party Transaction Policy, our audit committee is charged with the primary responsibility for determining whether, based on the facts and circumstances a related person has a direct or indirect material interest in a proposed or existing transaction. To assist our audit committee in making this determination,known to us and the policy sets forth certain categories of transactions that are deemed not to involve a direct or indirect material interest on behalfcurrent intentions of the related person. If, after applying these categorical standards and weighing alldirectors regarding the business of the facts and circumstances, our audit committee determines that the related person would have a direct or indirect material interest in the transaction, the audit committee must review and either approve or reject the transaction in accordance with the terms of the policy. If any executive officer becomes aware of a related party transaction that the audit committee has not approved or ratified, he or she shall promptly inform the audit committee or such other person designated by the audit committee.

Composition of our Board of Directors and Director Independence

For information about the composition of our Board and director independence, please see “Meetings of the Board of Directors and Committees of the Board” and “Board Practices-Director Independence.”

Remuneration Committee Interlocks and Insider Participation

None of the members of our remuneration committee has at any time during the prior three years been one of our officers or employees. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the Board or remuneration committee of any entity that has one or more executive officers serving on our Board or remuneration committee.

Family Relationships

There is no family relationship between any director, executive officer or person nominated to become a director or executive director.

14


Table of Contents

ELECTION OF DIRECTORS (RESOLUTIONS 1 TO 9)

Messrs. Méndez, Aebischer, Hallsworth, von Prondzynski, Shroff, and Wilkerson, and Mses. Bechu, Buckle and Larue, who are the nine nominees for director, are each nominated for one-year or prorated terms expiring in 2023. The Board has been informed that each of these director nominees are willing to serve as a director. If a director does not receive a majority of the vote for his or her election then that director will not be elected to the Board and the Board may fill the vacancy with a different person, or the Board may reduce the number of directors to eliminate the vacancy.

The following sets forth information concerning the nine nominees for director. Messrs. Hallsworth, Shroff and Wilkerson were members of our Board immediately prior to our initial public offering in April 2014, and Mr. von Prondzynski was appointed to the Board shortly thereafter in September 2014.  Mses. Buckle and Larue were appointed to the Board, effective as of September 1, 2020; Mr. Méndez was appointed to the Board, effective as of April 1, 2021, Mr. Aebischer was appointed to the Board, effective as of May 1, 2022, and Ms. Bechu was appointed to the Board, effective as of September 1, 2022. Information below as to each such member’s tenure on the Board also reflects their tenure on the Board prior to our initial public offering.

Manuel O. Méndez Muñiz

Mr. Méndez, 54, joined the Board and was appointed Chief Executive Officer in April 2021.  From 2019 to 2021, Mr. Méndez served as the Senior Vice President and Chief Commercial Office at Quest Diagnostics Incorporated (NYSE: DGX), a leading global provider of diagnostic information services. From 2014 to 2019, Mr. Méndez held various roles, including Senior Vice President, Global Commercial Operations, Chief Commercial Officer and member of the Executive Committee, at QIAGEN N.V., a worldwide provider of Sample to Insight solutions for molecular testing. Mr. Méndez has also held a variety of senior leadership roles with Abbott Laboratories, Thermo Fisher Scientific Inc., OraSure Technologies, Inc. and bioMerieux. Mr. Méndez sits on the Advisory Boards of the Boston University College of Engineering, Forbes Business Council, and Alumni Society. He is also an executive member of the Latino Corporate Directors Association (LCDA).  Mr. Méndez received a Master of Business Administration degree from Northwestern University’s Kellogg School of Management and a Bachelor’s degree in biomedical engineering from Boston University.

The Board believes that Mr. Méndez is qualified to serve as a Director based upon his extensive leadership, executive, managerial, business and diagnostics and life science industry and market experience, along with his years of experience in the research and development of healthcare diagnostic products.

Thomas Aebischer

Mr. Thomas Aebischer, 61, was appointed as a Director effective May 1, 2022.  Since March 2021, Thomas Aebischer has been the chief financial officer of RWDC Ltd., a biotechnology company concentrated on innovative and cost-effective environmentally friendly biopolymer material solutions.  From January 2016 to December 2019, Mr. Aebischer served as Executive VP and CFO of LyondellBasell Industries, a company active in plastics, chemicals and refinement.  Mr. Aebischer also served as chief financial officer for the Holcim Group from 2011 to 2015. Before becoming chief financial officer, he worked in various positions for Holcim including as the chief financial officer for group companies from 1996 to 2010. Earlier in his career, Mr. Aebischer held positions as tax assessor and financial auditor. Mr. Aebischer has served as a director and member of the audit committee of Dormakaba (Switzerland) since October, 2021. Mr. Aebischer is a Swiss Certified Accountant and graduated from the Advanced Management Program at Harvard Business School.

The Board believes that Mr. Aebischer is qualified to serve as a Director based upon his extensive experience in global financial and capital markets, doubled with a highly strategic mindset as well as industry background experience.

Sophie Bechu

Ms. Sophie Bechu, 61, was appointed as a Director effective September 1, 2022.  Since September 2016, Sophie Bechu has been the Chief Operating Officer of Royal Philips, a medical technology company operating through diagnosis, treatment, connected care and personal health segments. Earlier in her career, Ms. Bechu held various positions at IBM across various international geographies, from December 1983 to August 2016, moving from Plant Strategy and Plant Controller in her early years to Vice President, Strategic Outsourcing, North America Delivery GTC in June 2015.  Ms. Bechu graduated in Engineering, Electronics, Automation from the École Supérieure d’Électricité, in Paris (France).

The Board believes that Ms Bechu is qualified to serve as a Director based upon her extensive experience in industry operations doubled with depth and knowledge of the medical technology sector.

15


Table of Contents

Dr. Isabelle Buckle

Dr. Isabelle Buckle, 60, was appointed as a Director in September 2020. Since 2014, Dr. Isabelle Buckle serves as Executive Vice-President of Technology Transfer and Industrial Partnership at Institut Pasteur, a private non-profit foundation with global outreach, dedicated to research, teaching and public health initiatives in the field of emerging viruses, infections, epidemics and diseases.  Dr. Buckle previously served as Global Vice President of Clinical Mass Spectrometry at Bruker Daltonics, CEO and Chairman at InGen Biosciences (an in vitro diagnostics group headquartered in France), Global Head European Pharma’s Accounts at Life Technologies (now part of Thermo Fisher Scientific), and Regional Director Head of Business Development at Ciphergen Biosystems Inc.  Dr. Buckle holds a Ph.D. in Biochemistry from the University Paris VII, Institut Pasteur.

The Board believes that Dr. Buckle is qualified to serve as a Director based upon her extensive scientific, commercial and business experience in the biotechnology sector, her scientific training and background as well as her operational experience in the field of emerging viruses and epidemics.

Frederick Hallsworth

Frederick Hallsworth, 69, was appointed as a Director in February 2011. Mr. Hallsworth spent 25 years with Arthur Andersen, becoming a partner in 1989. At Arthur Andersen, Mr. Hallsworth held a number of senior management positions, including Head of Corporate Finance, Head of Audit and Managing Partner of Cambridge, UK office of Arthur Andersen and Managing Partner and Head of Audit of Arthur Andersen, Scotland. He joined Deloitte in 2002, where he served as Senior Client Service Partner and Head of TMC Practice in Scotland until 2005. He is also currently a director of memsstar (2006 to present), CMA Scotland (2007 to present), and Offshore Renewable Energy Catapult (2015 to present). Former directorships include: Scottish Enterprise (2004-2010), Microvisk (2006-2012), Forth Dimension Displays (2007-2011), Elonics (2006-2010), Golden Charter (2009-2011), Infinite Data Storage plc (2005-2007), 3Way Networks (2005-2007), Innovata plc (2005-2007), Metaforic (2009-2014) and AT Communications plc (2008-2009). Mr. Hallsworth has been a Member of the Institute of Chartered Accountants of Scotland since 1978. Mr. Hallsworth received a Bachelor of Accountancy from Glasgow University 1974.

The Board believes that Mr. Hallsworth is qualified to serve as a Director based upon his extensive accounting experience and experience providing strategic direction to multiple life science and technology companies.

Dr. Catherine Larue

Dr. Catherine Larue, 66, was appointed as a Director in September 2020. Since 2020, Dr. Larue is the Founder and General Manager of CoDx, a consulting service in biotechnology.  From 2019 until 2020, Dr. Larue served as Director of External Affairs at the Integrated Biobank of Luxembourg, organised within the Luxembourg Institute of Health (LIH) and dedicated to supporting biomedical research, providing biospecimen and biobanking services and infrastructure for applied medical research. From 2012 to 2019, Dr. Larue served as CEO of the Integrated BioBank of Luxembourg (IBBL), being during the 2016-2017 period the CEO ad interim of the Luxembourg Institute of Health (LIH).  Dr. Catherine Larue began her career at Sanofi Pharmaceuticals in the cardiovascular R&D department before joining Sanofi Diagnostics Pasteur, at Minneapolis MN (USA) where she was responsible for Assay Development on Access instrument in the immunodiagnostic area. Dr. Larue also served as a Director of Business Unit at Bio-Rad Diagnostics, and was then appointed Vice-President Executive Biomarkers at Genfit. Dr. Larue authored 87 publications (h index 19) and filed 13 patents, while also creating and chairing the “Biomarkers Group” in the Competitiveness Bio-cluster (Medicen, Paris). She sits on the Scientific Advisory Board of EATRIS (since 2019) as well as on the Board of Directors of Fondation ARC (since 2018), Genfit and ITTM Inc (both since 2017). Dr. Larue holds a Ph.D. in Immunology from the University of Rouen and a Master in Business Administration from St John’s University and ISM Paris.

The Board believes that Dr. Larue is qualified to serve as a Director based upon her extensive experience in the diagnostics industry, her scientific background as well as her experience in providing strategic guidance to companies in the life sciences industry.

Heino von Prondzynski

Heino von Prondzynski, 72, was appointed as a director in September 2014 and as our Chairman in March 2018. He joined the Board as our Lead Independent Director in September 2014. Mr. von Prondzynski served as chief executive officer of Roche Diagnostics and as a member of the executive committee of F. Hoffman-La Roche Ltd., a Swiss based healthcare company that develops diagnostics and therapeutic products, from early 2000 to 2006, retiring from Roche at the end of 2006. From 1996 to 2000, Mr. von Prondzynski held several executive positions, including president of the vaccine business, at Chiron Corporation, a multinational biotechnology firm that developed biopharmaceuticals, vaccines and blood-testing products. Earlier in his career, Mr. von Prondzynski held sales and marketing and general management positions at Bayer AG, a German based maker of healthcare products, specialty materials and agricultural products. Mr. von Prondzynski also serves on the board of Epigenomics AG. Mr. von Prondzynski also has served as a director of Koninklijke Philips Electronics NV (2007-2019), Hospira, Inc. (2009-2015), Nobel Biocare Holding AG, Switzerland (2010- 2011) and Qiagen NV (2007-2013). Mr. von Prondzynski studied maths, geography and history at Westfälische Wilhelms University, Münster, Germany.

16


Table of Contents

The Board believes that Mr. von Prondzynski’s substantial history of leadership positions at major international healthcare companies allows him to provide a global business perspective to his service on the Board and makes him well qualified to serve on the Board.

Zubeen Shroff

Zubeen Shroff, 57, was appointed as a Director in July 2013.  Mr. Shroff is a Managing Director of Galen Partners, a leading healthcare growth equity firm founded in 1990. Mr. Shroff has over 25 years of experience working with entrepreneurs and their Boards of Directors in building high-growth healthcare companies. Mr. Shroff joined Galen in 1996 from The Wilkerson Group, where he was a Principal with a client base including pharmaceutical, diagnostics, device and biotech companies, plus a select number of venture capital firms. Prior to joining The Wilkerson Group, Mr. Shroff worked at Schering-Plough France, a manufacturer of healthcare products and medicines, where he helped launch their biotech product, alpha-Interferon, in several new indications. Mr. Shroff is currently serving as the Chair of WMC Health, a public benefit corporation, which provides healthcare services to Hudson Valley New York residents. He is a member of the Dean’s Advisory Board for Boston University School of Public Health. In addition, Mr. Shroff is a Fellow of the New York Academy of Medicine. Mr. Shroff has served on the board of directors of numerous privately held Galen portfolio companies. Mr. Shroff previously served on the public board of directors of Tactile Systems Technology, Inc. until May 2017, of Pet DrRx Corporation until July 2010, and of Encore Medical until June 2006. Mr. Shroff received a B.A; in Biological Sciences from Boston University and an M.B.A. from the Wharton School, University of Pennsylvania.

The Board believes that Mr. Shroff is qualified to serve as a Director based upon his extensive experience in providing strategic guidance to companies in the healthcare industry, particularly in the areas of medical devices, diagnostics, and capital equipment.

Dr. John Wilkerson

Dr. John Wilkerson, 79, was appointed as a Director in February 2012. Dr. Wilkerson co-founded Galen Partners in 1990 and currently serves as a Senior Advisor to Galen. Dr. Wilkerson has focused on healthcare throughout his career, beginning as a Group Product Director for Ortho-Clinical Diagnostics Inc. He was a Vice President covering medical device companies at Smith Barney before moving in 1980 to Channing, Weinberg & Co., Inc., a management consulting firm for pharmaceutical, diagnostic, medical device and biotechnology companies, which he acquired and renamed The Wilkerson Group.  The Wilkerson Group was subsequently acquired by IBM in 1996.

Dr. Wilkerson was previously a director of Sonacare Medical and was the Chairman of Atlantic Health Systems, a New Jersey hospital system. He is a trustee and former President of the Museum of American Folk Art and founder of the E.L. Rose Conservancy. Dr. Wilkerson received a Ph.D. from Cornell University.

The Board believes that Dr. Wilkerson is qualified to serve as a Director based upon his extensive experience providing strategic direction to companies in the life sciences industry, as well as his operational experience in the transfusion diagnostics industry.

The Board of Directors recommends a vote “FOR” each of the nine director nominees named above. If you complete the enclosed proxy card, unless you direct to the contrary on that card, the shares represented by that proxy will be voted FOR the election of all nine nominees.

17


Table of Contents

ADVISORY APPROVAL OF THE COMPENSATION PAID TO THE COMPANY'S NAMED EXECUTIVE OFFICERS (RESOLUTION 10)

Background

In accordance with Section 14A of the Exchange Act, we are providing our shareholders with the opportunity to cast a non-binding, advisory vote on the compensation paid to our named executive officers, or a “say on pay” proposal, as described in greater detail below. We believe it is appropriate to seek the views of our shareholders on our executive compensation program.  This vote will take place every year based on the results from the "say on frequency" vote during the annual general meeting of shareholders held on October 29, 2020.

Summary

Our executive compensation program is designed to focus executive behavior on achievement of both our annual and long-term objectives and strategy as well as align the interests of management to those of our shareholders.  Consequently, our executive compensation plan is comprised of four principal elements – salary, benefits, long-term equity interest and cash bonuses based on annual individual and corporate performance. Consistent with our strategic goals, we have designed and implemented a performance-based award that aligns equity compensation with outstanding returns to our shareholders over several years.  

When designing our executive compensation program, the remuneration committee periodically reviews commercially available, industry specific compensation data for: (i) companies in the global diagnostics industry; (ii) companies addressing the donor testing market; and (iii) companies in the European biotechnology industry, as a general guide for establishing its compensation practices and structures. The remuneration committee, along with the Board, also reviews and approves corporate objectives used in our executive compensation program to confirm that appropriate goals have been established and tracks performance against them.  On an annual basis the remuneration committee reviews tally sheets reflecting each named executive officer’s compensation history with respect to each element of compensation.

The COVID-19 global pandemic created a challenging environment for the Company to operate in.  Despite these challenges we achieved important milestones with respect to the development and commercialization of MosaiQ, maintained the continuity of our supply network and worked to ensure the safety of our employees.  We also made material achievements such as ensuring business continuity during a global pandemic with on-site operations continuing on all locations, development and regulatory approval (including obtaining the CE Mark of the MosaiQ expanded immuno-hematology microarray).  We believe the compensation paid to our named executive officers in fiscal 2022 reflects our strong pay-for-performance philosophy.

For additional information about our executive compensation program, please refer to the section of this proxy statement entitled "Executive Compensation - Compensation Discussion and Analysis" and the related compensation tables, notes and narrative discussion.

Proposal

In accordance with Section 14A of the Exchange Act, we are asking our shareholders to vote FOR the approval of the following resolution at the Annual Meeting:

“THAT the shareholders approve, on a non-binding, advisory basis, the compensation paid to the Company's named executive officers, as described in the "Executive Compensation - Compensation Discussion and Analysis" section of the Proxy Statement for the Company's 2022 Annual General Meeting and the related compensation tables, notes and narrative discussion.”

Effect of Proposal

The resolution above reflects a non-binding, advisory proposal. The approval or disapproval of this proposal by shareholders will not require our Board or our remuneration committee to take any action regarding our executive compensation practices. The final determination of the compensation of our executive officers remains with our Board and our remuneration committee. Our Board, however, values the opinions of our shareholders as expressed through their votes, as well as through other communications with us. Although the resolution is non-binding, our Board and our remuneration committee will carefully consider the outcome of this advisory vote, as well as shareholder opinions received from other communications, when making future executive compensation decisions.

18


Table of Contents

Required Vote

The approval, on a non-binding, advisory basis, of the compensation paid to our named executive officers as disclosed in the “Executive Compensation - Compensation Discussion and Analysis” section of this proxy statement and the related compensation tables, notes and narrative discussion requires the affirmative vote of a majority of votes cast at the Annual Meeting. This proposal is considered a non-routine matter under applicable rules. A broker, bank or other nominee may not vote without instructions on this matter, so there may be broker non-votes in connection with this proposal. Broker non-votes will have no effect on the result of the vote. If no contrary indication is made, returned proxies will be voted for the proposal.

The Board recommends a vote “FOR” this proposal. If you complete the enclosed proxy card, unless you direct to the contrary on that card, the shares represented by that proxy will be voted FOR the approval, on a non-binding, advisory basis, of the compensation paid to our named executive officers.

19


Table of Contents

Approval of the fourth Amended and Restated Stock Incentive Plan (the "Fourth Amended and Restated 2014 Plan") which amends the Third Amended and Restated 2014 Stock Incentive Plan (the "2014 Plan") to (a) increase the number of ordinary shares authorized for issuance by 10,000,000 shares, and (b) remove the "evergreen" provision pursuant to which the aggregate number of shares authorized for issuance automatically increaseS each year.

(Resolution 11)

Background and Purpose of the Proposal

The 2014 Plan was originally adopted by the Board on March 31, 2014 and approved by our shareholders on April 3, 2014, and has since been amended several times with the approval of our shareholders.  The use of share-based awards under the 2014 Plan continues to be a key element of our compensation program.

The 2014 Plan currently authorizes an aggregate of 6’249’273 ordinary shares for issuance in connection with awards and as of 30 June 2022, only 456,988 ordinary shares remained available.  

Given material declines in the Company's share price in recent months and the Company's belief that equity incentive compensation promotes alignment of the interests of Company management and stockholders, the Company is seeking stockholder approval for an additional fixed number of shares under the Plan.  The Company currently expects that the increased amount will enable it to fulfill the Company’s plans for executive compensation for 2022 and 2023. The additional shares would also permit the Company to settle certain awards previously granted to its chief executive officer in ordinary shares, rather than cash, as discussed further below, and also to potentially satisfy its commitments to its chief executive officer thereafter.  The proposed increase in available shares would be combined with the elimination of the existing Evergreen provision of the Plan.

Accordingly, shareholders are being asked to approve the Fourth Amended and Restated 2014 Plan, which provides for an increase in the number of ordinary shares authorized for issuance by 10,000,000 ordinary shares thereunder.  The shareholders are also being asked to approve the removal of the “evergreen” provision pursuant to which the aggregate number of shares authorized for issuance automatically increased each year by 0.75% of the number of ordinary shares issued and outstanding on the immediately preceding March 31.

If our shareholders approve this proposal, we intend to file, pursuant to the Securities Act, a registration statement on Form S-8 to register the 10,000,000 additional ordinary shares available for issuance pursuant to the Fourth Amended and Restated 2014 Plan. The increase of 10,000,000 ordinary shares was determined by the remuneration committee based on the number of ordinary shares currently available as well as our annual equity burn rates (which are discussed in more detail below), taking into account the effect of the removal of the "evergreen" provision which would no longer increase the shares reserved under the plan beginning in 2023 and thereafter.  The remuneration committee feels it important to have adequate ordinary shares available to appropriately compensate current and future employees.

In fiscal years 2022, 2021, and 2020, our annual equity burn rates (calculated by dividing the number of shares subject to equity awards granted during the year under the 2014 Plan by the weighted-average number of shares outstanding during the applicable year) under our 2014 Plan were .3%, .3%, and .2% respectively, or .27% on average.

Our expectations regarding our expected burn rates and the adequacy of the proposed aggregate share reserve under the Fourth Amended and Restated 2014 Plan are dependent on the price of our shares and hiring activity during the next few years, the vesting schedules and types of awards we grant, the amount of forfeitures of outstanding awards and that no future circumstances occur that may require us to change our current equity grant practices. Moreover, with the Company’s focus in fiscal year 2022 on hiring activity in key senior leadership positions our remuneration committee believes it is prudent to seek to have additional shares reserved and available for issuance under the Fourth Amended and Restated 2014 Plan. We cannot predict our future equity grant practices, the future price of our shares or future hiring activity with any degree of certainty at this time, and the share reserve under the Fourth Amended and Restated 2014 Plan could last for a shorter or longer time than estimated, provided always no awards may be granted under the Fourth Amended and Restated 2014 Plan after March 30, 2024

Summary of the Fourth Amended and Restated 2014 Plan

The following summary of the Fourth Amended and Restated 2014 Plan and the material changes to the 2014 Plan are qualified in their entirety by the actual text of the Fourth Amended and Restated 2014 Plan, which is attached to this proxy statement as Exhibit A.  The Fourth Amended and Restated 2014 Plan will provide us flexibility with respect to our ability to attract and retain the services of qualified employees, officers, directors, consultants and other service providers upon whose judgment, initiative and efforts the successful conduct and development of our business depends, and to provide additional incentives to such persons to devote their effort and skill to the advancement and betterment of our company, by providing them an opportunity to participate in the ownership of our company and thereby have an interest in its success and increased value.

20


Table of Contents

Company.

 

We confirm that we are amendingall the 2014 Plan to increasedirectors of the numberCompany who voted in favour of ordinary shares available for issuance under the Fourth Amended and Restated 2014 Plan, by 10’000’000 shares to an aggregate of 16’249’273 ordinary shares. The aggregate number of ordinary shares will be subject to adjustment in the event of a recapitalization, share split, share consolidation, reclassification, share dividend or other change in our capital structure, including the possible reverse stock split discussed in Special Resolution 13 in this proxy statement. To the extent that an award terminates, or expires for any reason, then any shares subject to the awardResolution.

This certificate may be used again for new grants. However, shares which are (i) not issued or delivered as a result of the net settlement of outstanding share appreciation rights, or SARs, or options, (ii) used to pay the exercise price related to outstanding options, (iii) used to pay withholding taxes related to outstanding options or SARs or (iv) repurchased on the open market with the proceeds from an option exercise, will not be available for re-grant under the Fourth Amended and Restated 2014 Plan.signed in counterpart.

 

Under the 2014 Plan, the number of ordinary shares reserved for issuance automatically increased on April 1 of each year, from April 1, 2021 through April 1, 2022, by 0.75% of the number of ordinary shares issued and outstanding on the immediately preceding March 31, or such lesser number of shares as determined by our Board or the remuneration committee.  As of April 1, 2022, we were authorized to issue an aggregate of 2’699’273 additional ordinary shares under the 2014 Plan as a result of such automatic annual increases. The Fourth Amended and Restated 2014 Plan will no longer contain the automatic annual increase of ordinary shares reserved for issuance beginning in 2023 and thereafter.

The Fourth Amended and Restated 2014 Plan will permit us to make grants of (i) incentive share options pursuant to Section 422 of the Code and (ii) nonqualified share options. Incentive share options may only be issued to our employees. Nonqualified share options may be issued to our employees, directors, consultants and other service providers. The option exercise price of each option granted pursuant to the Fourth Amended and Restated 2014 Plan will be determined by our remuneration committee and may not be less than 100% of the fair market value of the ordinary shares on the date of grant, subject to certain exceptions. The term of each option will be fixed by our remuneration committee and may not exceed ten years from the date of grant. All option grants under the Fourth Amended and Restated 2014 Plan will be made pursuant to a written option agreement.

The Fourth Amended and Restated 2014 Plan will permit us to sell or make grants of restricted shares. Restricted shares may be sold or granted to our employees, directors, consultants and other service providers (or of any current or future parent or subsidiary of our Company). Restricted shares issued under the Fourth Amended and Restated 2014 Plan will be sold or granted pursuant to a written restricted shares purchase agreement.

The Fourth Amended and Restated 2014 Plan will also permit us to issue SARs. SARs may be issued to our employees, directors, consultants and other service providers. The base price per share of ordinary shares covered by each SAR may not be less than 100% of the fair market value of the ordinary shares on the date of grant, subject to certain exceptions.  SAR grants under the Fourth Amended and Restated 2014 Plan will be made pursuant to a written SAR agreement.  Further, the Fourth Amended and Restated 2014 Plan will permit us to issue RSUs (including performance-based RSUs). RSUs may be issued to our employees, directors, consultants and other service providers. RSU grants under the Third Amended and Restated 2014 Plan will be made pursuant to a written RSU agreement.

As of March 31, 2022, 409 employees and 7 directors were eligible to participate in the 2014 Plan and will continue to be eligible to participate in the Fourth Amended and Restated 2014 Plan. The Fourth Amended and Restated 2014 Plan will be administered by our remuneration committee, which has the authority to control and manage the operation and administration of the 2014 Plan. In particular, the remuneration committee has the authority to determine the persons to whom, and the time or times at which, incentive share options, nonqualified share options, restricted shares, SARs or RSUs (including performance based RSUs) shall be granted, the number of shares to be represented by each option agreement or covered by each restricted share purchase agreement, SAR agreement or RSU agreement and the exercise price of such options and the base price of such SARs. In addition, our remuneration committee has the authority to accelerate the exercisability or vesting of any award, and to determine the specific terms, conditions and restrictions of each award. The remuneration committee is composed exclusively of individuals intended to be, to the extent provided by Rule 16b-3 of the Exchange Act, independent directors.

Unless provided otherwise within each written option agreement, restricted share purchase agreement, SAR agreement or RSU agreement as the case may be, the vesting of all options, restricted share, SARs and RSUs granted under the Fourth Amended and Restated 2014 Plan shall accelerate automatically in the event of a “change in control” (as defined in the Fourth Amended and Restated 2014 Plan) effective as of immediately prior to the consummation of the change in control unless such equity awards are to be assumed by the acquiring or successor entity (or parent thereof) or equity awards of comparable value are to be issued in exchange therefor or the equity awards granted under the Fourth Amended and Restated 2014 Plan are to be replaced by the acquiring entity with other incentives under a new incentive program containing such terms and provisions as our remuneration committee in its discretion may consider equitable.

Our Board may from time to time alter, amend, suspend or terminate the Fourth Amended and Restated 2014 Plan in such respects as our Board may deem advisable, provided that no such alteration, amendment, suspension or termination shall be made which shall substantially affect or impair the rights of any participant under any awards previously granted without such participant’s consent.

No awards may be granted under the Fourth Amended and Restated 2014 Plan after March 30, 2014.

21


Table of Contents

Federal Income Tax Consequences

The following discussion is for general information only and is intended to summarize briefly the U.S. federal tax consequences to participants arising from participation in the Fourth Amended and Restated 2014 Plan. This description is based on current law, which is subject to change (possibly retroactively). The tax treatment of participants in the Fourth Amended and Restated 2014 Plan may vary depending on the particular situation and therefore may be subject to special rules not discussed below. No attempt has been made to discuss any potential foreign, state or local tax consequences.

Incentive Options; Nonqualified Options; SARs

Participants will not realize taxable income upon the grant of a nonqualified stock option or a SAR. Upon the exercise of a nonqualified stock option or a SAR, a participant will recognize ordinary compensation income (subject to withholding) in an amount equal to the excess of (1) the amount of cash and the fair market value of the ordinary shares received, over (2) the exercise price (if any) paid. A participant will generally have a tax basis in any ordinary shares received pursuant to the exercise of a SAR, or pursuant to the cash exercise of a nonqualified stock option, that equals the fair market value of such shares on the date of exercise. We will be entitled to a deduction for federal income tax purposes that corresponds as to timing and amount with the compensation income recognized by a participant under the rules described above. Participants eligible to receive an incentive stock option will not recognize taxable income on the grant of an incentive stock option. Upon the exercise of an incentive stock option, a participant will not recognize taxable income, although the excess of the fair market value of the ordinary shares received upon exercise of the incentive stock option (“ISO Shares”) over the exercise price will increase the alternative minimum taxable income of the participant, which may cause such participant to incur alternative minimum tax. The payment of any alternative minimum tax attributable to the exercise of an incentive stock option would be allowed as a credit against the participant’s regular tax liability in a later year to the extent the participant’s regular tax liability is in excess of the alternative minimum tax for that year. Upon the disposition of ISO Shares that have been held for the requisite holding period (generally, at least two years from the date of grant and one year from the date of exercise of the incentive stock option), a participant will generally recognize capital gain (or loss) equal to the excess (or shortfall) of the amount received in the disposition over the exercise price paid by the participant for the ISO Shares. However, if a participant disposes of ISO Shares that have not been held for the requisite holding period (a “Disqualifying Disposition”), the participant will recognize ordinary compensation income in the year of the Disqualifying Disposition in an amount equal to the amount by which the fair market value of the ISO Shares at the time of exercise of the incentive stock option (or, if less, the amount realized in the case of an arm’s length disposition to an unrelated party) exceeds the exercise price paid by the participant for such ISO Shares. A participant would also recognize capital gain to the extent the amount realized in the Disqualifying Disposition exceeds the fair market value of the ISO Shares on the exercise date. If the exercise price paid for the ISO Shares exceeds the amount realized (in the case of an arm’s length disposition to an unrelated party), such excess would ordinarily constitute a capital loss. Generally, we will not be entitled to any federal income tax deduction upon the grant or exercise of an incentive stock option, unless a participant makes a Disqualifying Disposition of the ISO Shares. If a participant makes a Disqualifying Disposition, we will then be entitled to a tax deduction that corresponds as to timing and amount with the compensation income recognized by a participant under the rules described in the preceding paragraph.

Restricted Shares; RSUs

In general, a participant will recognize ordinary compensation income as a result of the receipt of shares pursuant to a restricted share award, in an amount equal to the fair market value of the shares when such shares are received; provided, however, that if the shares are not transferable and are subject to a substantial risk of forfeiture when received, a participant will recognize ordinary compensation income in an amount equal to the fair market value of the shares (1) when the shares first becomes transferable or no longer subject to a substantial risk of forfeiture in cases where a participant does not make an valid election under Section 83(b) of the Code or (2) when the shares are received in cases where a participant makes a valid election under Section 83(b) of the Code. A participant will generally not recognize taxable income at the time of grant of an award in the form of an RSU award denominated in shares, but rather, will generally recognize ordinary compensation income at the time he receives cash or shares.

A participant will be subject to withholding for federal, and generally for state and local, income taxes at the time he recognizes income under the rules described above for shares or cash received. Dividends that are received by a participant before the shares are taxed to the participant under the rules described in the preceding paragraph are taxed as additional compensation, not as dividend income. The tax basis in the ordinary shares received by a participant will equal the amount recognized by him as compensation income under the rules described in the preceding paragraph, and the participant’s capital gains holding period in those shares will commence on the later of the date the shares are received or the restrictions lapse.

We will be entitled to a deduction for federal income tax purposes that corresponds as to timing and amount with the compensation income recognized by a participant under the rules described above.

22


Table of Contents

New Plan Benefits and Grants to be Made Under the Fourth Amended and Restated 2014 Plan

In April 2022, the Company granted 500,000 Restricted Stock Units and 833,333 Performance Stock Units equal to a total aggregate value of 1,600,000 USD, to fulfil the equity award commitments to Mr. Méndez under his employment agreement (the 2022 Awards).  At the point of vesting the Company can choose to settle the 2022 Awards in cash or in equity if possible based on available equity pool, and with the requisite approval from the Board. The 2022 Awards are linked to the share price while retaining the usual vesting restrictions, even if settled in cash. The proposed increase in share availability under the Plan will permit the Company to settle these 2022 Awards using ordinary shares, rather than cash, should it wish to do so, and allow the Company to also potentially satisfy its commitments to its chief executive officer in subsequent years.

Consequences of Failing to Approve the Proposal

The Fourth Amended and Restated 2014 Plan will not be implemented unless it is approved by our shareholders. If the Fourth Amended and Restated 2014 Plan is not approved by our shareholders, the 2014 Plan will remain in effect in its present form. Failure of our shareholders to approve this proposal also will not affect the rights of existing award holders under the 2014 Plan or under any previously granted awards under the 2014 Plan.  Failure of our shareholders to approve this proposal may result in certain members of our management team not receiving future awards under the Company’s improved pay for performance compensation program.  In addition, in light of the comparatively small amount of ordinary shares that remain available for future grant under the 2014 Plan, we will be limited in our ability to continue to grant equity awards to our non-employee directors in accordance with our non-employee director compensation program, to implement the share incentive portion of our executive compensation program and to otherwise grant equity awards to our employees.

If at the time of vesting the Board does not provide approval for the 2022 Awards to be settled in equity, then the Company will pay to Mr. Méndez an amount in cash equal in value to the total number of units multiplied by the share price at the time of vest.

The Board recommends a vote “FOR” the approval of the Fourth Amended and Restated 2014 Plan, which amends the Third Amended and Restated 2014 Stock Incentive Plan (the "2014 Plan") to (a) increase the number of ordinary shares authorized for issuance by 10,000,000 shares, and (b) remove the "evergreen" provision pursuant to which the aggregate number of shares authorized for issuance automatically increases each year.

If you complete the enclosed proxy card, unless you direct to the contrary on that card, the shares represented by that proxy will be voted FOR approval of the Fourth Amended and Restated 2014 Plan.

23


Table of Contents

NON-EMPLOYEE DIRECTOR COMPENSATION

Eight out of nine of our director nominees are non-employee directors.  Six of these non-employee directors nominees are unaffiliated with our significant shareholders: Messrs. Aebischer, Hallsworth and von Prondzynski and Mses. Bechu, Buckle and Larue. We seek to maintain a director compensation program for our non-employee directors to enable us to attract and retain, on a long-term basis, high-caliber non-employee directors. Employee directors do not receive compensation in respect of their service as a director.

Pursuant to our director compensation program in effect from November 1, 2018 to October 31, 2020, the annual retainers were as set out below. As discussed in the notes to the table, the annual retainers for the chairman of our board of directors and all other directors comprised a cash component (except for directors affiliated with our significant shareholders) and an equity award component, and the annual retainers for committee chairpersons and committee members were paid in cash.

Board Member Compensation

Annual Retainer

Chairman

CHF 280,000(1)

Director

$ 200,000(2)

Committee Chairperson Compensation

Annual Retainer ($)

Audit Committee

24,000

Remuneration Committee

15,000

Nominating and Corporate Governance Committee

16,000

Committee Member Compensation

Annual Retainer ($)

Audit Committee

12,000

Remuneration Committee

8,000

Nominating and Corporate Governance Committee

8,000

(1)

CHF 120,000 (which equaled $130,406 based on the exchange rate in effect on July 22, 2021) was paid in cash in four equal quarterly installments on January 31, April 30, July 31 and October 31 of each year.  CHF 160,000 (which equaled $173,875 based on the exchange rate in effect on July 22, 2021) was paid in the form of RSUs to be issued immediately following each annual general meeting, which vest in four quarterly installments on January 31, April 30, July 31 and October 31 of each year.

(2)

$40,000 was paid in cash in twelve monthly installments to directors not affiliated with our significant shareholders, with the first installment beginning on November 30 of each year.  $120,000 was paid to all directors in the form of RSUs to be issued immediately following each annual general meeting, which vest in four quarterly installments on January 31, April 30, July 31 and October 31 of each year.  $40,000 was paid to all directors in the form of share options to purchase ordinary shares also issued immediately following each annual general meeting and which vest in equal installments on the first, second and third anniversary of the date of grant.

The foregoing compensation is in addition to reimbursement of all out-of-pocket expenses incurred by directors in attending meetings of the Board.

Effective as of November 1, 2020, the amounts for the annual retainers are as set out below. As discussed in the notes to the table, the annual retainers for the chairman of the board of directors and all other directors comprise a cash component (except for Directors affiliated with our significant shareholders) and an equity award component.  The annual retainers for committee chairpersons and committee members are paid in cash, except for directors affiliated with our significant shareholders who are paid in equity.

Board Member Compensation

Annual Retainer

Chairman

CHF 280,000(1)

Director

$ 150,000(2)

Committee Chairperson Compensation

Annual Retainer ($)

Audit Committee

24,000

Remuneration Committee

15,000

Nominating and Corporate Governance Committee

16,000

Committee Member Compensation

Annual Retainer ($)

Audit Committee

12,000

Remuneration Committee

8,000

Nominating and Corporate Governance Committee

8,000

24


Table of Contents

(1)

CHF 120,000 (which equaled $129,608based on the exchange rate in effect on March 31, 2022) is paid in cash in four equal quarterly installments on January 31, April 30, July 31 and October 31 of each year.  CHF 160,000 (which equaled $174,674 based on the exchange rate in effect on October 31, 2021) is paid in the form of RSUs to be issued immediately following each annual general meeting, which vest in four quarterly installments on January 31, April 30, July 31 and October 31 of each year.

(2)

All directors other than Mr. Shroff and Mr. Wilkerson are paid $40,000 in cash in twelve monthly installments with the first installment beginning November 30 of each year.  Until November 2019, Galen Partners beneficially owned more than 10% of the ordinary shares of the Company and was deemed by the board to be a significant shareholder of the Company.  As directors affiliated with Galen Partners, Mr. Shroff and Mr. Wilkerson were not entitled to receive the cash payment of $40,000 under the prior non-employee director compensation program.  In lieu of receiving a cash payment of $40,000 going forward, Mr. Shroff and Mr. Wilkerson have agreed to accept this payment in the form of RSUs. Accordingly, Mr. Shroff and Mr. Wilkerson receive $110,000, and all other directors receive $70,000, in the form of RSUs to be issued immediately following each annual general meeting, which vest in four quarterly installments on January 31, April 30, July 31 and October 31 of each year.  $40,000 is paid to all directors in the form of share options to purchase ordinary shares also issued immediately following each annual general meeting and which vest on the first anniversary of the date of grant.

The foregoing compensation is in addition to reimbursement of all out-of-pocket expenses incurred by directors in attending meetings of the Board.

Stock-based awards and option awards in the following table are computed in accordance with the valuation principles used in the Company’s financial statements to compute the fair value of each award on the date of grant.

 

 

Fiscal

Year

Ended

March 31,

 

Fees

earned

in cash

 

 

Stock-

based

awards (1)

 

 

Option

awards (2)

 

 

Non-equity

incentive

plan

compensation

 

 

Nonqualified

deferred

compensation

earnings

 

 

All other

compensation

 

 

Total

 

Heino von Prondzynski

 

2022

 

$

129,608

 

 

$

174,674

 

 

 

 

$

 

 

$

 

 

$

 

 

$

304,282

 

Isabelle Buckle

 

2022

 

$

48,000

 

 

$

70,000

 

 

$

40,000

 

 

$

 

 

$

 

 

$

 

 

$

158,001

 

Frederick Hallsworth

 

2022

 

$

64,000

 

 

$

70,000

 

 

$

40,000

 

 

$

 

 

$

 

 

$

 

 

$

174,001

 

Brian McDonough

 

2022

 

$

48,000

 

 

$

70,000

 

 

$

40,000

 

 

$

 

 

$

 

 

$

 

 

$

158,001

 

Catherine Larue

 

2022

 

$

52,000

 

 

$

70,000

 

 

$

40,000

 

 

$

 

 

$

 

 

$

 

 

$

162,001

 

Zubeen Shroff

 

2022

 

$

 

 

$

137,000

 

 

$

40,000

 

 

$

 

 

$

 

 

$

 

 

$

177,001

 

John Wilkerson

 

2022

 

$

 

 

$

118,000

 

 

$

40,000

 

 

$

 

 

$

 

 

$

 

 

$

158,001

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1)

Stock-based awards vest in four quarterly installments on January 31, April 30, July 31 and October 31 of each year.

(2)

Option Awards granted on or after October 29, 2020 vest in full on the first anniversary of the date of grant, on completion of the one year term of a Director.  Option Awards granted prior to October 29, 2020 vested in three equal installments on each first, second and third anniversary of the grant date.  Options have a term of ten years and will be forfeited if not exercised before the expiration of their term or upon non-reelection of a Non-Employee Director at an Annual General Meeting.

25


Table of Contents

The following table sets forth the share options held by the non-employee directors as of the fiscal year ended March 31, 2022.  All options are options to purchase ordinary shares:

Name

 

Grant Date

 

Number of

securities

underlying

exercisable

options

 

 

Number of

securities

underlying

unexercisable

options(1)

 

 

Option

exercise

price(2)

 

 

Option expiration

date

Frederick Hallsworth

 

August 31, 2012

 

 

20,014

 

 

 

 

 

$

1.44

 

 

August 31, 2022

 

 

April 29, 2014

 

 

5,000

 

 

 

 

 

$

8.00

 

 

April 29, 2024

 

 

October 31, 2014

 

 

5,025

 

 

 

 

 

$

9.95

 

 

October 31, 2024

 

 

October 31, 2015

 

 

7,505

 

 

 

 

 

$

11.62

 

 

October 31, 2025

 

 

October 31, 2016

 

 

8,726

 

 

 

 

 

$

5.73

 

 

October 30, 2026

 

 

October 31, 2017

 

 

9,597

 

 

 

 

 

$

5.21

 

 

October 30, 2027

 

 

October 31, 2018

 

 

6,240

 

 

 

 

 

$

6.41

 

 

October 31, 2028

 

 

October 31, 2019

 

 

5,438

 

 

 

2,720

 

 

$

7.78

 

 

October 31, 2029

 

 

October 29, 2020

 

 

13,611

 

 

 

 

 

$

4.55

 

 

October 29, 2030

 

 

October 31, 2021

 

 

 

 

 

 

24,040

 

 

$

2.53

 

 

October 31, 2031

Isabelle Buckle

 

September 1, 2020

 

 

1,448

 

 

 

723

 

 

$

4.81

 

 

September 1, 2030

 

 

September 1, 2020

 

 

6,930

 

 

 

13,860

 

 

$

4.81

 

 

September 1, 2030

 

 

October 29, 2020

 

 

13,611

 

 

 

 

 

$

4.55

 

 

October 28, 2030

 

 

October 31, 2021

 

 

 

 

 

24,040

 

 

$

2.53

 

 

October 30, 2031

John Wilkerson

 

April 29, 2014

 

 

3,500

 

 

 

 

 

$

8.00

 

 

April 28, 2024

 

 

October 31, 2014

 

 

5,025

 

 

 

 

 

$

9.95

 

 

October 30, 2024

 

 

October 31, 2015

 

 

7,505

 

 

 

 

 

$

11.62

 

 

October 30, 2025

 

 

October 31, 2016

 

 

8,726

 

 

 

 

 

$

5.73

 

 

October 30, 2026

 

 

October 31, 2017

 

 

9,597

 

 

 

 

 

$

5.21

 

 

October 30, 2027

 

 

October 31, 2018

 

 

6,240

 

 

 

 

 

$

6.41

 

 

October 30, 2028

 

 

October 31, 2019

 

 

5,438

 

 

 

2,720

 

 

$

7.78

 

 

October 30, 2029

 

 

October 29, 2020

 

 

13,611

 

 

 

 

 

$

4.55

 

 

October 28, 2030

 

 

October 31, 2021

 

 

 

 

 

24,040

 

 

$

2.53

 

 

October 30, 2031

Heino von Prondzynski

 

October 31, 2015

 

 

4,303

 

 

 

 

 

$

11.62

 

 

October 30, 2025

 

 

October 31, 2016

 

 

8,726

 

 

 

 

 

$

5.73

 

 

October 30, 2026

 

 

October 31, 2017

 

 

9,597

 

 

 

 

 

$

5.21

 

 

October 30, 2027

Brian McDonough

 

August 31, 2012

 

 

40,029

 

 

 

 

 

$

1.44

 

 

August 30, 2022

 

 

April 29, 2014

 

 

10,000

 

 

 

 

 

$

8.00

 

 

April 28, 2024

 

 

October 31, 2014

 

 

5,025

 

 

 

 

 

$

9.95

 

 

October 30, 2024

 

 

October 31, 2015

 

 

4,303

 

 

 

 

 

$

11.62

 

 

October 30, 2025

 

 

October 31, 2016

 

 

8,726

 

 

 

 

 

$

5.73

 

 

October 30, 2026

 

 

October 31, 2017

 

 

9,597

 

 

 

 

 

$

5.21

 

 

October 30, 2027

 

 

October 31, 2018

 

 

6,240

 

 

 

 

 

$

6.41

 

 

October 30, 2028

 

 

October 31, 2019

 

 

5,438

 

 

 

2,720

 

 

$

7.78

 

 

October 30, 2029

 

 

October 29, 2020

 

 

13,611

 

 

 

 

 

$

4.55

 

 

October 28, 2030

 

 

October 31, 2021

 

 

 

 

 

24,040

 

 

$

2.53

 

 

October 30, 2031

Catherine Larue

 

September 1, 2020

 

 

1,448

 

 

 

723

 

 

$

4.81

 

 

August 31, 2029

 

 

September 1, 2020

 

 

6,930

 

 

 

13,860

 

 

$

4.81

 

 

August 31, 2030

 

 

October 29, 2020

 

 

13,611

 

 

 

 

 

$

4.55

 

 

October 28, 2030

 

 

October 31, 2021

 

 

 

 

 

24,040

 

 

$

2.53

 

 

October 30, 2031

Zubeen Shroff

 

April 29, 2014

 

 

5,000

 

 

 

 

 

$

8.00

 

 

April 28, 2024

 

 

October 31, 2014

 

 

5,025

 

 

 

 

 

$

9.95

 

 

October 30, 2024

 

 

October 31, 2015

 

 

7,505

 

 

 

 

 

$

11.62

 

 

October 30, 2025

 

 

October 31, 2016

 

 

8,726

 

 

 

 

 

$

5.73

 

 

October 30, 2026

 

 

October 31, 2017

 

 

9,597

 

 

 

 

 

$

5.21

 

 

October 30, 2027

 

 

October 31, 2018

 

 

6,240

 

 

 

 

 

$

6.41

 

 

October 30, 2028

 

 

October 31, 2019

 

 

5,438

 

 

 

2,720

 

 

$

7.78

 

 

October 30, 2029

 

 

October 29, 2020

 

 

13,611

 

 

 

 

 

$

4.55

 

 

October 28, 2030

 

 

October 31, 2021

 

 

 

 

 

24,040

 

 

$

2.53

 

 

October 30, 2031

(1)

Option Awards granted on or after October 29, 2020 vest in full on the first anniversary of the date of grant, on completion of the one year term of a Director.  Option Awards granted prior to October 29, 2020 vested in three equal installments on each first, second and third anniversary of the grant date.  Options have a term of ten years and will be forfeited if not exercised before the expiration of their term or upon non-reelection of a Non-Employee Director at an Annual General Meeting.

26


Table of Contents

(2)

In certain cases, the option exercise prices are lower than the fair market value of the underlying securities on the date of grant. As part of the preparation for our initial public offering (which occurred in April 2014), the board of directors reviewed the fair value of our ordinary shares at the various dates in recent years when option and share awards were granted. This review resulted in certain instances in the board concluding that the fair value of the underlying securities was higher than the option exercise prices determined at the time. The resulting increase in compensation expense has been reflected in our financial statements.

The following table sets forth the RSUs held by the non-employee directors as of the fiscal year ended March 31, 2022. All RSUs convert into ordinary shares on a one-for-one basis.

Name

Grant Date

Number of

outstanding

securities

underlying the

award

Final Vesting Date

Frederick Hallsworth

October 31, 2021

13,834

October 31, 2022

Isabelle Buckle

October 31, 2021

13,834

October 31, 2022

John Wilkerson

October 31, 2021

23,320

October 31, 2022

Heino von Prondzynski

October 31, 2021

34,521

October 31, 2022

Brian McDonough

October 31, 2021

13,834

October 31, 2022

Catherine Larue

October 31, 2021

13,834

October 31, 2022

Zubeen Shroff

October 31, 2021

27,074

October 31, 2022

(1)

RSU awards vest in four quarterly installments on January 31, April 30, July 31 and October 31 of each year.  Vesting is subject to continued service through to the applicable vesting date.

27


Table of Contents

REMUNERATION COMMITTEE REPORT

The information contained in this remuneration committee report shall not be deemed to be “soliciting material” or “filed” with the SEC under the Securities Act or the Exchange Act. No portion of this remuneration committee report shall be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, through any general statement incorporating by reference in its entirety this Proxy Statement in which this report appears, except to the extent that Quotient Limited specifically incorporates this statement or a portion of it by reference.

The remuneration committee has reviewed and discussed the Executive Compensation Discussion and Analysis with management. Based on such review and discussions, the remuneration committee recommended to the Board that the Executive Compensation Discussion and Analysis be included in this Proxy Statement for the fiscal year ended March 31, 2022.

Respectfully submitted,

Zubeen Shroff (Chairperson)

Brian McDonough

Heino von Prondzynski

28


Table of Contents

EXECUTIVE COMPENSATION

Compensation Discussion and Analysis

Executive Summary

Our "named executive officers" for the fiscal year ended March 31, 2022 are Manuel O. Méndez, Ali Kiboro, and Mohammad El Khoury. This Compensation Discussion and Analysis explains our executive compensation program as it relates to our “named executive officers,” whose compensation information is presented in the following tables and discussion in accordance with the SEC rules.

Name

Position

/s/ Manuel O. Méndez

 

Chief Executive Officer/s/ Bradley Meyer

Ali KiboroMANUEL O. MéNDEZ
Director

Dated: February 17, 2023

 

Chief Financial OfficerBRADLEY MEYER

Mohammad El KhouryDirector

Chief Commercial OfficerDated: February 17, 2023

Our mission is to become the global leader for the development, manufacture and sale of transfusion diagnostics (blood grouping, serological disease screening and molecular disease screening), leveraging our proprietary MosaiQ™ technology platform. As MosaiQ is demonstrated to work for transfusion diagnostics, we will also seek to expand its utility elsewhere in the broader diagnostics market.

 

To achieve our mission, we must recruit, retain and motivate exceptional leaders with the ability to deliver superior results for our shareholders. The skills and knowledge built by the management team around MosaiQ, which represents a novel and highly disruptive technology platform for the broader diagnostics field, are unique and increasingly will become highly attractive to potential competitors. Retention of existing senior management and recruitment of additional senior managers to augment the existing team is therefore critical. Our executive compensation program is instrumental in achieving this objective.


 

Our executive compensation program is designed to focus executive behavior on achievement of both our annual and long-term objectives and strategy as well as align the interests of management to those of our shareholders. Consequently, our executive compensation plan is comprised of four principal elements – salary, benefits, long-term equity interest and cash bonuses based on annual individual and corporate performance. Consistent with our strategic goals, we have designed and implemented a performance-based award that aligns equity compensation with outstanding returns to our shareholders over several years.

Roles of the Remuneration Committee

General

It is the responsibility of the remuneration committee to administer the Company’s compensation practices, to ensure they are competitive, financially prudent and include incentives designed to appropriately drive performance. To achieve this, the remuneration committee periodically reviews commercially available, industry specific compensation data for: (i) companies in the global diagnostics industry; (ii) companies addressing the donor testing market; and (iii) companies in the European biotechnology industry, as a general guide for establishing its compensation practices and structures. The remuneration committee, along with the board of directors, also reviews and approves corporate objectives used in our executive compensation program to confirm that appropriate goals have been established and tracks performance against them and that compensation arrangements do not encourage excessive risk-taking.  On an annual basis the remuneration committee reviews tally sheets reflecting each named executive officer’s compensation history with respect to each element of compensation.

The remuneration committee conducts an annual review of performance and compensation during the first quarter of each fiscal year for the purpose of determining the compensation of named executive officers. As part of this review, the CEO submits recommendations to the remuneration committee relating to the compensation of the named executive officers (other than the CEO). Following a review of these recommendations, the remuneration committee approves the compensation of these named executive officers, with such modifications to the CEO's recommendations as the remuneration committee considers appropriate.

The remuneration committee's review of the CEO's compensation is subject to separate procedures. With input from members of the entire board, other than the CEO, the Chairman and the remuneration committee evaluate the CEO's performance and review the evaluation with him. Based on that evaluation and review, the remuneration committee then determines the CEO's compensation. The CEO is excused from meetings of the remuneration committee during voting or deliberations regarding his compensation.

29


Table of Contents

Peer Group Companies

The remuneration committee seeks to identify an executive compensation peer group of approximately fifteen to twenty companies that may compete with the Company for executive talent (“Peer Group Companies”). The remuneration committee has focused on creating a peer group that:

Represented companies working in the global diagnostics industry, companies addressing the donor testing market or companies in the European biotechnology industry;

Contains a mix of pre-commercial development companies and some commercial stage companies;

Captures comparable companies in terms of employee numbers and market capitalization; or

Have achieved or expect to achieve a growth profile comparable to that expected for the Company.

With the assistance of WTW, the remuneration committee’s independent compensation consultant, a full review of the peer group was completed in March 2020.  Based on the above criteria, the following companies were included in the peer group:

Company

Product Focus

Accelerate Diagnostics

In vitro diagnostics for hospital acquired and drug resistant infections

BioCartis Group NV

Molecular diagnostics

Cerus Corp

Pathogen inactivation for donor blood, plasma and platelets

Chembio Diagnostics

Diagnostics test kits for infectious disease

ChemoCentryx

Development of therapeutics for autoimmune diseases, inflammatory disorders and cancer.

Clinigen Group

Lifesciences tools and services

Cytokenetics

Development of muscle activators and muscle inhibitors

Epigenomics AG

Molecular diagnostics – cancer

Meridian Bioscience Inc.

Develops, manufacture, commercialization of a range of innovative diagnostics test kits

Myriad Genetics Inc.

Molecular diagnostics

Nanostring Technologies Inc.

Life science tools for translational research and molecular diagnostic products

Omega Diagnostics Group

Development of diagnostic products for allergy and autoimmune, food intolerance and infectious disease.

Oxford Biomedica

Biopharmaceutical company focused on the development and commercialization of gene-based medicines

Quidel Corp.

Provision of cellular based virology assays and molecular diagnostics testing systems

Senseonics Holdings

Development of diagnostic products for diabetes

Stratec

Design and manufacture of complex analyzer system solutions for invitro diagnostics

T2 Biosystems

Clinical diagnostics for sepsis

Zealand Pharma

Development of innovative peptide-based medicines

Oxford Immunotec Global was originally included in the Peer Group, but was removed after it was acquired by another company. The Remuneration Committee decided not to replace Oxford Immunotec Global and to keep the rest of the peer group unchanged with the remaining companies.

As noted above, the remuneration committee retained WTW as its independent compensation consultant. WTW does not perform any other consulting work or other services for the Company, reports directly to the remuneration committee and takes direction from the Chairman of the remuneration committee. The remuneration committee has assessed the independence of WTW pursuant to the rules prescribed by the SEC and has concluded that no conflict of interest existed in the financial year ended March 31, 2022 or currently exists that would prevent WTW from serving as an independent consultant to the remuneration committee.

Executive Compensation Programs

Overview and Objectives

Our executive compensation program for our named executive officers for fiscal years 2022 and 2023, each an Executive Compensation Program, was adopted on May 21, 2021 with respect to fiscal 2022 and June 13, 2022 with respect to fiscal 2023. Each year, the remuneration committee and the board of directors review the Executive Compensation Program for our named executive officers for the fiscal year to ensure that it is designed to achieve the following objectives:

30


Table of Contents

Focus executive behavior on achievement of our annual and long-term strategic objectives;

Provide a competitive compensation package that enables the Company to attract and retain, on a long-term basis, talented executives;

Provide a total compensation structure that the remuneration committee believes is at least comparable with the total compensation structure of Peer Group Companies for which we would compete for talent and which consists of a mix of base salary, equity and cash incentives; and

Align the interests of management and shareholders by providing management with long-term incentives through equity ownership.

The remuneration committee will continue to review the Executive Compensation Program in future years to ensure that it is closely aligned with the interests of shareholders and reflects our business needs.

Each Executive Compensation Program has four principal elements, namely base salary, benefits, short-term incentives and long-term incentives. A brief description of each element and their purpose at the Company is described below:

Compensation Element

Description

Purpose

Base Salary

Fixed cash compensation based on role, job scope, experience, qualification and performance.

To compensate for individual technical and leadership competencies required for a specific role and to provide economic security. Notice periods for named executive officers vary between two and 12 months.

Benefits

Competitive health, life assurance, disability and retirement benefits.

To promote health and wellness in the workforce and to provide competitive retirement planning and saving opportunities. Benefits vary depending on local employment practices and may include private health coverage, life insurance, a defined contribution pension scheme and/or provision of a company car. There are no enhanced benefits for named executive officers.

Short-term incentive

Annual cash incentive opportunity payable based on achievement of corporate objectives.

To incentivize management to meet and exceed annual performance metrics and deliver on commitments to shareholders.

Long-term incentive

Annual equity award.

To incentivize executive officers to increase shareholder value, reward long-term corporate performance and promote employee commitment through share ownership.  Further details regarding long-term incentives can be found below.

Our objective is to target total direct compensation for our named executive officers, including the annualized value of the incentive awards that are proposed to be granted in fiscal 2023 as part of our Executive Compensation Program, as follows: Base Salary & Benefits – 35%; Short-term Incentive – 25%; and Long-Term Incentive – 40%.

The amounts and mix attributable to base salary, short-term incentives and long-term incentives are determined by reference to market norms. Our aim is to align individual compensation with the objectives of the applicable Executive Compensation Program. While executive compensation mix is evaluated on an annual basis, we do not adhere to a rigid formula when determining the actual mix of compensation elements. Instead, our current policy is to balance the short-term and long-term focus of our compensation elements to reward short-term performance while emphasizing long-term value creation. These objectives are achieved by placing considerable weight on long-term, equity based compensation while offering cash and short-term compensation to attract and retain executive talent.

Determining Executive Compensation

The primary objective of our compensation philosophy is to design and support total remuneration packages aligned with strong business performance and long-term value creation for our shareholders.

31


Table of Contents

Each Executive Compensation Program in particular is designed with specific emphasis on accountability for the performance of the MosaiQ development and commercialization program in the short-term and shareholder return over the longer term. This alignment is created through several mechanisms:

Compensation Mechanism

Methodology

Pay Positioning

To attract and retain the best executives, all components of executive compensation are targeted between the market’s median and 75th percentile.

Performance Target Setting

We set goals that we consider to be ambitious but achievable for ourselves and for the Company aligned with our commitment to building long-term sustainable value for our shareholders.

Compensation Elements

Base Salary

Sets baseline pay level.

Annual Incentive Plan

Annual incentive payment that rewards performance relative to annual financial goals and/or MosaiQ development goals.

Stock Options, RSUs & PSUs

Long-term incentive with a three-year vesting period that rewards performance that enhances shareholder value.

Compensation Mix

Our compensation mix is weighted toward variable pay elements and long-term incentive pay elements.

By applying the above methodologies, named executive officers are compensated at between the market’s median and 75th percentile when we meet our performance targets, and deliver on the expectations we communicate to our shareholders.  Should our performance exceed expectations, our executives will be compensated above target, and vice versa. The significant weighting of long-term incentives ensures that the primary focus of our named executives is sustained long-term performance, while our short-term incentives motivate consistent annual achievement.

Long-Term Incentive Awards

We design our long-term incentive awards to:

Align management’s compensation opportunities with the interests of our shareholders;

Provide long-term compensation opportunities consistent with market practice; and

Incentivize and reward long-term value creation.

To achieve these objectives for fiscal 2022 and beyond, the remuneration committee revised the mix of equity awards for our named executive officers. From fiscal 2022, the total award value of long-term incentives expected to be granted to our management team including our Chief Executive Officer and other named executive officers, will be allocated as follows: 50% PSUs, 30% RSUs and 20% Stock Options.

The remuneration committee is responsible in its use of equity as long-term incentive compensation and regularly monitors the use of equity compensation for executives and the Company as a whole from a competitive standpoint. The remuneration committee believes that our equity awards, which in fiscal 2023 emphasizes performance shares for our most senior employees, including all of our named executive officers, reflect a strong focus on pay for performance in support of delivering on our corporate objectives.

Approach to Performance Share Awards

Performance shares encourage a long-term view and reinforce the link between financial results and rewards. Performance shares in fiscal 2023 will be based on a single three-year performance period and reward financial performance during that period. The value that they provide depends on the level of achievement of predefined performance goals. The remuneration committee will determine the payout under the agreed

32


Table of Contents

performance measure. No performance shares will be earned if a specified minimum performance level is not achieved. For performance above the threshold level, payment will vary with actual performance achieved, up to a maximum payment of 1.5 times the target level. Determination of the shares payable pursuant to each award is made after the end of the performance period.

Fiscal 2022 Executive Compensation

The following compensation packages have been put in place for the newly appointed CEO and other Named Executive Officers in fiscal year 2022:

On February 23, 2021, we entered into an Employment Agreement with Mr. Manuel O. Méndez, which sets forth the terms and conditions under which Mr. Méndez will serve in the position of Chief Executive Officer.  The agreement provided for a base salary of CHF 750,000 per annum, or approximately $815,040 based on the exchange rate in effect on July 22, 2021; eligibility to receive employee benefits that are customary for other senior executives of the Company located in Switzerland; eligibility to receive a discretionary annual cash bonus of up to CHF 750,000 based on the achievement of performance targets determined by the board, payable at no less than 80% of Mr. Méndez’s base salary for our fiscal year 2022; eligibility to receive annual Company equity awards comprised of (i) RSUs having a fair market value as of date of grant of $600’000, (ii) share options having a fair market value as of the date of grant equal to $400’000, and (iii) PSUs having a target fair market value as of date of grant of $1 million; subject to certain conditions, our payment to Mr. Méndez’s previous employer, Quest Diagnostics Incorporated (“Quest”), of $1,800,000 in a lump sum, in satisfaction of an obligation owed by Mr. Méndez to Quest; subject to the condition that Mr. Méndez forfeited a $960,000 cash bonus due to him by Quest as of March 31, 2021, our payment to him of a lump sum amount equivalent to such cash bonus; and our payment to him of a sign on bonus equal to $1,065,000.

In addition, in connection with the appointment of Mr. Méndez as our Chief Executive Officer, we granted the following awards to Mr. Méndez, which were issued outside of our 2014 Stock Incentive Plan and were approved by the remuneration committee and by the board of directors pursuant to the inducement grant exception under Nasdaq Rule 5635(c)(4), as an inducement that is material to Mr. Méndez’s entering into employment with us (i) RSUs equal in value to $3,333,333 based on the closing sales price of our ordinary shares on the Nasdaq Global Market on the date of grant (the “Sign-On RSUs”); and (ii) options equal in value to $1,666,667 with an exercise price equal to the closing sales price of our ordinary shares on the Nasdaq Global Market on the date of grant (the “Sign-On Share Options”); and in addition: (i) RSUs equal in value to $600,000, based on the closing sales price of our ordinary shares on the Nasdaq Global Market on the date of grant (the “First Annual RSUs”); (ii) options equal in value to $400,000 with an exercise price equal to the closing sales price of our ordinary shares on the Nasdaq Global Market on the date of grant (the “First Annual Share Options”); and (iii) performance-based restricted share units (“PSUs”) equal in value to $1,000,000 based on the closing sales price of our ordinary shares on the Nasdaq Global Market on the date of grant (the “First Annual PSUs”).

The RSUs, options and PSUs vest as following:

The Sign-On RSUs vest in three years, with 50% vesting on the first anniversary of the date of grant, and 25% vesting on each of the second and third anniversaries of the date of grant.

The Sign-On Share Options, the First Annual RSUs and the First Annual Share Options vest in three equal annual instalments on the first, second and third anniversaries of the date of grant.

The First Annual PSUs will vest on the third anniversary of the date of grant up to a maximum of 150% of the target fair market value of the First Annual PSUs, based on the level of achievement of specific performance criteria.

On October 5, 2021, we amended the employment agreement (the “Amendment”) with Mr. Méndez, dated February 23, 2021 (as previously amended, the “Employment Agreement”), to provide for (i) the surrender of Mr. Méndez’s entitlement to the guaranteed portion of his Discretionary Bonus for the Company’s fiscal year ending in 2022, which under the Employment Agreement is 600,000 Swiss Francs, (ii) the Company’s prompt payment in cash to Mr. Méndez of 600,000 Swiss Francs, net of social security cost deductions, to further support Mr. Méndez’s relocation to Switzerland. Mr. Méndez’s surrender of his entitlement to the guaranteed portion of his Discretionary Bonus does not affect his eligibility for additional bonus compensation that may be awarded by the Company’s Board of Directors in its sole discretion. The Amendment also confirms that, as provided in Mr. Méndez’s original Employment Agreement, the Company will reimburse Mr. Méndez, net of social security cost deductions, for all expenses incurred by Mr. Méndez in connection with his relocation to Switzerland, and that for relocation expenses incurred prior to the earlier of December 31, 2021 and Mr. Méndez’s move into his primary residence in Switzerland, such reimbursements will also be paid to Mr. Méndez net of tax deductions.

On October 15, 2021, we further amended the Employment Agreement to provide for the cancellation of 181,159 of the Company’s restricted stock units and 138,227 of the Company’s stock options previously granted to Mr. Méndez, and in lieu thereof the Company agreed to promptly pay to Mr. Méndez $1,000,000 in cash, net of social security and tax cost deductions, to further support Mr. Méndez’s relocation to Switzerland.

33


Table of Contents

On January 12, 2022, we amended the Employment Agreement to provide for (i) the payment by the Company to Mr. Méndez of a relocation allowance in the aggregate maximum amount of CHF 1’262’536 including an allowance of CHF 217’200 that will be payable to Mr. Méndez only if he acquires a primary residence in Switzerland by March 31, 2022, and (ii) the deletion from the Employment Agreement of all provisions under which Mr. Méndez otherwise would be entitled to payment or reimbursement of expenses incurred in connection with his relocation from the United States to Switzerland. The Amendment provided that various amounts previously paid by the Company on account of Mr. Méndez’s relocation expenses would be credited against the relocation allowance, leaving a balance that was payable to Mr. Méndez of CHF 261’700 only if Mr. Méndez acquired a primary residence in Switzerland by March 31, 2022. The Company paid the afore mentioned balance for the relocation allowance in March 2022 to Mr. Méndez net of deductions for social security costs and taxes.

On September 23, 2021, we entered into an employment agreement with Mr. El Khoury, which sets forth the terms and conditions under which Mr. El Khoury will serve as our Chief Commercial Officer effective from October 5, 2021.

The agreement provides for a sign-on bonus payment on the commencement date equal to AED 401,000 ($109,156), a base salary of AED 1,215,030 per annum (approximately $330,743) based on the exchange rate in effect on March 31, 2022; annual housing allowance in the amount of AED 300,000 ($81,663) per annum and paid each year in advance; annual transport allowance of AED 108,000 ($29,399) per annum, paid in 12 equal monthly instalments starting the month of the commencement date; eligibility to receive reimbursement up to an annual amount of Euros 25,000 ($28,035) upon the production of invoices towards the cost of comprehensive family worldwide medical insurance cover; eligibility to receive a discretionary annual cash bonus of up to sixty percent (60%) of the base salary based on the achievement of performance targets and personal objectives by Mr. El Khoury that are mutually agreed upon between the Company and Mr. El Khoury.  The annual discretionary cash bonus would be paid to Mr. El Khoury as soon as practicable, but in no event later than 120 days following the fiscal year to which it relates and always provided Mr. El Khoury is employed by the Company on the date of payment.

The agreement also provides that 100% of the first-year Quotient target bonus would be guaranteed, pro-rated by the number of months employed during fiscal year 2022 and that such exception would be strictly and only applicable to the period between Mr. El Khoury’s commencement date and last day of the fiscal year 2022.

In addition, in connection with the appointment of Mr. El Khoury as our Chief Commercial Officer, we granted the following awards to Mr. El Khoury, which were issued outside of our 2014 Stock Incentive Plan and were approved by the remuneration committee and by the board of directors pursuant to the inducement grant exception under Nasdaq Rule 5635(c)(4), as an inducement that is material to Mr. El Khoury’s entering into employment with us, effective on or about commencement date (i) RSUs equal in value to AED 3’207 679 ($873,431) based on the closing sales price of our ordinary shares on the Nasdaq Global Market on the date of grant (the “Sign-On RSUs”); and (ii) options equal in value to AED 1’652’441 ($449,949) with an exercise price equal to the closing sales price of our ordinary shares on the Nasdaq Global Market on the date of grant (the “Sign-On Share Options”). The Sign-On RSUs will vest 50% on the first anniversary of the grant date and the balance will vest pro rata on each of the second and third anniversaries of the grant date. The Sign-On Options will vest in three equal installments on each of the first, second and third anniversaries of the grant date.

The agreement finally provides that Mr. El Khoury will be eligible to participate in the Company Equity Plan in an amount having a grant date fair value of approximately USD 600’000, in accordance with the terms of the plan documents, award agreements, and any notices provided by the Company to Mr. El Khoury. The Annual Discretionary Equity Grant would normally be split 50% in Performance Share Units vesting on the third anniversary upon success of specific Corporate Goals, 30% in Restricted Stock Units vesting in three equal annual installments and 20% in Stock Options vesting in three equal annual installments, all of which based on annual performance criteria and the achievement of personal and corporate objectives by Mr. El Khoury, which shall be mutually agreed upon by and between the Company and Mr. El Khoury and assessed by Company in its sole discretion.

On October 9, 2021, we entered into an Employment Agreement with Ali Kiboro, which sets forth the terms and conditions under which Mr. Kiboro will serve in the position of Chief Financial Officer, effective as of November 1, 2021.  Pursuant to the Employment Agreement, Mr. Kiboro will, among others, be entitled to the following:

o

a base salary of Swiss Francs (CHF) 395,000 per annum ($426,628), which will be first subject to review in 2023 and on an annual basis thereafter, subject to increase by the Board in its sole discretion;

o

eligibility to receive employee benefits that are customary for other senior executives of the Company located in Switzerland;

o

eligibility to receive discretionary annual cash bonus of up to 60% of his base salary, subject to achievement of corporate performance goals and individual performance goals;

o

subject to the condition that Mr. Kiboro forfeits his yearly cash bonus due to him by Mr. Kiboro’s previous employer, Quest, our payment to him, in the first quarter of calendar year 2022, of a lump sum amount equivalent to the value lost for the current year through to the time of his departure from Quest; and

o

our payment to Mr. Kiboro of a “sign on” bonus equal to CHF 200,000 in the first quarter of calendar year 2022.

34


Table of Contents

In addition, in connection with the appointment of Mr. Kiboro as our Chief Financial Officer, on November 19, 2021, the Company granted the following awards to Mr. Kiboro, which were issued outside of our 2014 Stock Incentive Plan, as amended, and which were approved by the Board and the Remuneration Committee of the Board pursuant to the inducement grant exception under Nasdaq Rule 5635(c)(4), as an inducement that is material to Mr. Kiboro’s entering into employment with us: (i) performance restricted stock units (“PSUs”) equal in value to CHF 393,750 ($253,958) based on the closing sales price of our ordinary shares on the Nasdaq Global Market on the trading day immediately prior to the grant date (the “Sign-On PSUs”); (ii)restricted stock units (“RSUs”) equal in value to CHF 236,250 ($423,261) based on the closing sales price of our ordinary shares on the Nasdaq Global Market on the trading day immediately prior to the grant date (the “Sign-On RSUs”); and (iii) options equal in value to CHF 157,500 ($169,305) with an exercise price equal to the closing sales price of our ordinary shares on the Nasdaq Global Market on the trading day immediately prior to the grant date (the “Sign-On Share Options”). The Sign-On Share Options will have a term of ten years and will be forfeited if not exercised before the expiration of their term. In addition, in the event Mr. Kiboro’s employment is terminated, any Sign-On PSUs, Sign-On RSUs or Sign-On Share Options not vested shall be forfeited upon termination.

The number of shares underlying the Sign-On Share Options will be determined using a Black-Scholes calculation based on the closing sales price of the Company’s ordinary shares on the Nasdaq Global Market on the trading day immediately prior to the grant date.

The Sign-On PSUs will vest on the third anniversary of the date of grant up to a maximum of 150% of the target fair market value of the Sign-On PSUs, based on the level of achievement of specific performance criteria.  The Sign-On Share Options will vest in three equal annual installments on the first, second and third anniversaries of the date of grant.

Following the most recent shareholder advisory vote on executive compensation, the Company maintained its use of long-term incentives as set out previously. In fiscal 2022, the Company introduced the use of Performance Based long-term incentives to better align executive interests with those of shareholders. The Company also reviewed the time vesting of long-term incentives with all equity awards granted in fiscal 2022 to date having a three-year vesting period.

Fiscal 2023 Executive Compensation

In the context of a low share price with the consequence of long-term incentive equity awards consuming a high quantity of shares reserved under the 2014 Stock Incentive Plan, the Company decided that:

The annual long-term incentive equity awards to the Company chief executive officer would be granted with a possibility to settle the award in cash in case the number of shares available at vesting would not be sufficient for settlement in equity;

The long-term incentive equity awards to other named executive officers would be replaced, partially or totally, by cash deferred awards depending on the share price, and the availability of shares at the time of grant.

Our executive compensation is discussed in greater detail in the sections that follow. The remuneration committee will continue to evaluate our overall compensation structure and awards to ensure they are reflective of the performance of our executive officers and our Company and consistent with our compensation objectives.

35


Table of Contents

Summary Compensation Table

The following table summarizes information regarding the compensation for the fiscal years ended March 31, 2022 awarded to, earned by or paid to our named executive officers. See “Executive Compensation-Compensation Discussion and Analysis-Executive Summary” for more information regarding our named executive officers for the fiscal years ended March 31, 2022.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Name

and Principal Position

 

Fiscal Year

Ended

March 31,

 

Salary

 

 

Bonus

(1)

 

 

Performance Share Awards

(2)(3)

 

 

RSU Awards

(2)

 

 

Option Awards

(2)

 

 

All Other Compensation

 

Manuel Méndez

 

2022

 

$

810,053

 

 

$

1,218,150

 

 

$

1,000,000

 

 

$

3,266,666

 

 

$

1,733,337

 

 

$

8,189,709

 

Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ali Kiboro

 

2022

 

$

169,557

 

 

$

161,673

 

 

$

423,261

 

 

$

253,958

 

 

$

169,305

 

 

$

467,675

 

Chief Financial Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Mohammad El Khoury

 

2022

 

$

165,372

 

 

$

145,906

 

 

-

 

 

$

873,431

 

 

$

449,949

 

 

$

233,554

 

Chief Commercial Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1)

The bonus amount reported relates to the Fiscal 2022 bonus paid in June 2022

(2)

Reflects the value of share option and RSU awards granted to executive officers based on the grant date fair value of the awards. See note 9 to the Company’s audited consolidated financial statements for the fiscal year ended March 31, 2022, filed with the Company’s Annual Report on Form 10-K for assumptions made in the valuation.

(3)

Performance Share Awards are subject to 3-year vesting beginning at the date of grant, and subject to the achievement of Corporate revenue goals assessed at the end of Fiscal 2022

All other compensation was comprised of the following amounts for the fiscal year ended March 31, 2022:

 

 

Manuel Méndez

 

 

 

 

Ali Kiboro

 

 

 

 

Mohammad El Khoury

 

Sign-On Bonus

 

$

3,025,000

 

 

 

 

$

345,622

 

 

 

 

$

109,156

 

Relocation

 

$

1,434,550

 

 

 

 

$

92,054

 

 

 

 

 

 

 

Tax gross-Up

 

$

1,784,990

 

 

 

 

 

 

 

 

 

 

 

 

 

Pension Plan Contributions

 

$

118,167

 

 

 

 

$

22,437

 

 

 

 

 

 

 

Car/Transport Allowance

 

$

27,002

 

 

 

 

$

7,560

 

 

 

 

$

14,699

 

Housing Allowance

 

 

 

 

 

 

 

 

 

 

 

 

 

$

81,663

 

Make Whole Payment

 

$

1,800,000

 

 

 

 

 

 

 

 

 

 

 

 

 

Health Insurance

 

 

 

 

 

 

 

 

 

 

 

 

 

$

28,035

 

Total

 

$

8,189,709

 

 

 

 

$

467,675

 

 

 

 

$

233,554

 

(1)

Our payment to Mr. Méndez’s previous employer, Quest Diagnostics Incorporated (“Quest”), of $1,800,000 in a lump sum, in satisfaction of an obligation owed by Mr. Méndez to Quest. This one-time payment is not part of Mr. Méndez’s normal compensation and will not be repeated.

36


Table of Contents

Outstanding Equity Awards at Fiscal Year-End

Share Option Awards

The following table sets forth information regarding share option awards held by our named executive officers as of the fiscal year ended March 31, 2022. The Share Option Awards are options to purchase ordinary shares. For all 3 of our named executive officers, the Share Option Awards will vest in three equal installments on each of the first, second, and third anniversaries of the date of grant. Vesting of all options is subject to continued service through the applicable vesting date.

Name

Grant Date

Number of

securities

underlying

exercisable

options

 

Number of

securities

underlying

unexercisable

options

 

Option

exercise

price

 

Option expiration

date

Manuel Méndez

April 1, 2021

 

239,595

 

 

479,192

 

$

3.68

 

April 1, 2031

Ali Kiboro

November 19, 2021

 

 

 

 

123,267

 

$

2.08

 

November 20, 2031

Mohammad El Khoury

October 5, 2021

 

 

 

 

235,477

 

$

2.91

 

May 10, 2031

RSU Awards

The following table sets forth information regarding RSU awards held by our named executive officers as of the fiscal year ended March 31, 2022. For all 3 of our Named Executive Officers, 50% of the Sign-On RSUs shall vest on the first anniversary of the date of grant, and 25% of the Sign-On RSUs shall vest on each of the second and third anniversaries of the date of grant. Vesting of all RSU awards is subject to continued service through the applicable vesting date.

Name

Grant Date

Number of outstanding securities underlying the award

Final Vest Date

Manuel Méndez

April 1, 2021

471,014

April 1, 2024

Ali Kiboro

November 19, 2021

122,095

November 19, 2024

Mohammad El Khoury

May 10, 2021

300,148

October 5, 2024

Performance Share Awards

The following table sets forth information regarding Performance Share awards held by our named executive officers as of the fiscal year ended March 31, 2022. The Performance Share Awards shall vest on the third anniversary of the date of grant up to a maximum of 150% of the target fair market value of such Annual PSUs based on the level of achievement of performance goals and financial targets.Vesting of all Performance Share Awards is subject to continued service through the applicable vesting date.

Name

Grant Date

Number of outstanding securities underlying the award

Final Vest Date

Manuel Méndez

April 1, 2021

271,739

April 1, 2024

Ali Kiboro

November 19, 2021

203,491

November 19, 2024

37


Table of Contents

Agreements with Our Executive Officers

Employment Agreements

Manuel O. Méndez

Chief Executive Officer Agreement

In connection with Mr. Méndez’s appointment as our Chief Executive Officer, on February 23, 2021, we entered into an Employment Agreement with Mr. Méndez, which sets forth the terms and conditions under which Mr. Méndez will serve in this position. The Employment Agreement was approved by the Board as well as the Remuneration Committee of the Board. The agreement has a four-year term. Mr. Méndez will be required to devote the majority of his business time and energy to the Company and, subject to certain circumstances set forth in the Employment Agreement, will work at our premises in Eysins, Switzerland.

During the period of his employment and for a period of one year following any termination of his employment, Mr. Méndez will be obligated to refrain from engaging in competition with us, our subsidiaries and our affiliates. During the period of his employment and for a period of two years following any termination of his employment, Mr. Méndez will be obligated to refrain from soliciting any of our (or our subsidiaries’ or affiliates’) employees, suppliers or customers.

If we terminate Mr. Méndez’s employment other than for “Cause” (as defined in the Employment Agreement) or if Mr. Méndez terminates his employment for “Good Reason” (as defined in the Employment Agreement), then (i) all equity awards with respect to our ordinary shares held by Mr. Méndez at the time of such termination will vest and, in the case of any options, become exercisable, in accordance with their terms, (ii) Mr. Méndez will be entitled to receive, the base salary and certain employee benefits then in effect through and including the day of termination, (iii) Mr. Méndez will continue to receive payment of base salary during the twelve-month period following such termination, (iv) Mr. Méndez will receive a lump sum payment of a pro-rata portion of his discretionary annual cash bonus for the year of termination based on the achievement of applicable performance goals, and (v) we will pay to Mr. Méndez certain amounts related to his repatriation to the United States.

The Company has agreed to indemnify Mr. Méndez to the maximum extent permitted by our organizational documents and applicable law for any acts or decisions made in good faith while performing services for us.

The Company and Mr. Méndez have also entered into a change of control agreement (the “Change of Control Agreement”), substantially in the form of the change of control agreement entered into by the Company and former Company chief executive officer and previously filed as an exhibit to our Current Report on Form 8-K filed with the SEC on November 24, 2020.  The Change of Control Agreement will expire on April 1, 2024 and will automatically renew for successive one year terms unless the Board provides written notice of expiration of the Change of Control Agreement at least 90 days prior to April 1, 2024 or the applicable anniversary thereof. The purpose of the Change of Control Agreement is to establish certain protections for Mr. Méndez upon a qualifying termination of his employment in connection with a change of control of the Company.

Ali Kiboro

Chief Financial Officer Agreement

On October 9, 2021, we entered into an Employment Agreement with Ali Kiboro, which sets forth the terms and conditions under which Mr. Kiboro will serve in the position of Chief Financial Officer, effective as of November 1, 2021.  In connection with Mr. Kiboro’s appointment as our Chief Financial Officer.  The Employment Agreement was approved by the Board. The Employment Agreement has no specific term and continues until terminated in accordance with the terms therein. We may terminate Mr. Kiboro’s employment with or without “Cause” (as defined in the Employment Agreement). Mr. Kiboro is required to provide at least six months’ advance written notice to us if he terminates his employment. If we terminate Mr. Kiboro’s employment other than for Cause, we must provide six months’ advance written notice to Mr. Kiboro, and he will be entitled to receive, subject to certain conditions, the base salary and certain employee benefits then in effect through and including the day of termination. During the period of his employment and for a period of one year following any termination of his employment, Mr. Kiboro will be obligated to (i) refrain from engaging in competition with us, our subsidiaries and our affiliates; and (ii) refrain from soliciting any of our (or our subsidiaries’ or affiliates’) employees, suppliers or customers.

The Company has agreed to indemnify Mr. Kiboro to the maximum extent permitted by our organizational documents and applicable law for any acts or decisions made in good faith while performing services for us.  The Company and Mr. Kiboro have also entered into a change of control agreement. The purpose of the change of control Agreement is to establish certain protections for Mr. Kiboro upon a qualifying termination of his employment in connection with a change of control of the Company.

Mohammad El Khoury

Chief Commercial Officer

On September 23, 2021, we entered into an employment agreement with Mr. El Khoury, which sets forth the terms and conditions under which Mr. El Khoury serves as our Chief Commercial Officer effective from October 5, 2021.  We or Mr. El Khoury may voluntarily

38


Table of Contents

 

terminateAccompanying document: Certificate under Article 127E(6) of the employment agreement without cause subjectCompanies (Jersey) Law 1991

Article 127E(6) Certificate

in relation to six (6) months' advance written noticethe proposed merger of Quotient Limited and Quotient Holdings Merger Company Limited

In this certificate:

the "Companies"

means together Quotient Limited and Quotient Holdings Merger Company Limited, and "Company" shall be construed accordingly;

the "Law"

means the Companies (Jersey) Law 1991, as amended;

the "Merged Company"

means Quotient Limited;

the "Merger"

means the proposed merger of Quotient Limited and Quotient Holdings Merger Company Limited; and

the "Merger Implementation Agreement"

means the merger implementation agreement in respect of the Merger.

Considering that: (1) it is proposed that the Companies merge under Part 18B (Mergers) of the Law and the employment termMerged Company will expire onbe the final daybody resulting from the Merger; and (2) in accordance with Article 127E(6) of the monthLaw no notice has yet been given of a meeting of either Company as mentioned in whichArticle 127E(1) of the notice period expires.  Law, nor has a form of written special resolution to approve the Merger Agreement yet been provided to the members of and to the members holding each class of shares in either Company:

We, may immediately terminatebeing each of the employment agreement for "cause"persons who under Article 120127E(7) of the UAE Labour Law at any time without notice to Mr. El Khoury. In the event of a dismissal under Article 120must sign this certificate, being each of the UAE Labour Law, Mr. El Khoury would forfeit his entitlementpersons proposed to endbe the directors of service gratuity payment.  Otherwise and subject to Mr. El Khoury completing a minimumthe Merged Company as merged body in the form of one years’ service with us, he may become entitled to receive an amount by wayMerger Agreement HEREBY STATE for the purposes of end of service gratuity ("ESG") subject to and in accordance with Article 127E(6) of the UAE Labour Law.  The ESGLaw that:

1.
in the opinion of each of us, the Merged Company will be calculated with referenceable to Mr. El Khoury’s last monthly basic salarycontinue to carry on business and shall not include that portiondischarge its liabilities as they fall due: (a) on and immediately after the completion of his salary received as an allowancethe Merger; and (b) if later, until 12 months after the signing of this certificate; and
2.
the grounds for housing, travel, bonus, or any other typethe opinion at 1 above are our consideration of allowance or benefit in kind.  During the period of his employmentall relevant facts and for a period of one year following any termination of his employment, Mr. El Khoury will be obligatedcircumstances known to (i) refrain from engaging in competition with us our subsidiaries and our affiliates; and (ii) refrain from soliciting anycurrent intentions regarding the business of our (or our subsidiaries’ or affiliates’) employees, suppliers or customers.Thethe Merged Company and Mr. El Khoury have also entered into a CoC Agreement to establish certain protections for Mr. El Khoury upon a qualifying termination of his employment in connection with a change of controlhaving particular regard to: (a) the prospects of the Company.

Change of Control Agreements

We have entered into amended and restated change of control agreements, or CoC agreement, withMerged Company as merged body; (b) the following executive officers: Mr. Méndez, Mr. Kiboro, Mr. El Khoury and Ms. Bonasso. The purpose of the CoC agreements is to establish certain protections for certain of our officers upon a qualifying termination of their employment in connection with a change of control of us.

Each CoC agreement provides that, if we terminate the executive’s employment without “Cause” (as definedproposals in the respective CoC agreements) or the executive terminates his employment for “Good Reason” (as defined in the respective CoC agreements) and, in either case, such termination occurs no more than 24 months following a “Change of Control” (as defined in the respective CoC agreement), then, subject to the executive signing and not revoking a release and waiver of claims, the executive will receive a lump sum payment of the following:

any accrued obligations owed to the executive, which include: (i) any of the executive’s annual base salary earned through the effective date of termination that remains unpaid; (ii) any bonus payableMerger Agreement with respect to any fiscal year which ended priorthe management of the Merged Company's business; and (c) the amount and character of the financial resources that will, in the view of each person signing, be available to the effective dateMerged Company as merged body.

We confirm that we are all the persons who under Article 127E(7) of the executive’s termination of employment, which remains unpaid; and (iii) any expense reimbursement due to the executive on or prior to the date of termination which remains unpaid to the executive; and

a cash payment equal to 150% (except for the CoC agreements of Mr. Méndez which provide for 200%)Law must sign this certificate, being each of the sumpersons proposed to be the directors of the executive’s base salary plus target annual bonus in effect on the date of termination, without taking into effect any reductionmerged body in the executive’s annual base salary thatform of Merger Agreement.

This certificate may constitute “Good Reason” under the CoC Agreement.

Each CoC agreement expires on the third anniversary of the agreement and will automatically renew for successive one year terms unless the board provides written notice of expiration of the CoC agreement at least 90 days prior to the three year anniversary of the agreement or the further applicable anniversary thereof.be signed in counterpart.

 

39


Table of Contents

Equity and Incentive Plans

Our shareholders and board previously adopted the Enterprise Management Plan, or the 2012 Plan. In connection with the completion of our initial public offering in April 2014, we adopted the 2014 Stock Incentive Plan, and in October 2016, October 2018, and October 2020, our shareholders approved amendments and restatements of this plan at our annual general meetings of shareholders in 2016, 2018 and 2020 respectively. We refer to this plan, as so amended and restated, as the 2014 Plan.

The following table presents certain information about our equity compensation plans as of March 31, 2022:

 

 

Number of securities to

be issued upon exercise

of outstanding options

and rights (2)

 

 

Weighted

average

exercise price

of outstanding

options and

rights (3)

 

 

Number of

shares

remaining

available for

future issuance

 

Equity compensation plans approved

   by shareholders

 

 

1,843,460

 

 

$

6.83

 

 

 

1,409,812

 

Equity compensation plans not

  approved by shareholders (1)

 

 

4,383,308

 

 

$

3.19

 

 

 

 

(1)

On April 1, 2021, in connection with the appointment of Manuel O. Méndez as Chief Executive Officer, we granted Mr.

Méndez 857,015 options to purchase ordinary shares at an exercise price of $3.68 per share and 1,340,579 RSUs at a grant date price of $3.68 per share. During the quarter ended December 31, 2021, 138,227 of the stock options originally granted to Mr. Méndez and 181,159 of the outstanding RSUs were cancelled and cash settled in connection with an amendment to his employment agreement with the Company. On October 5, 2021, in connection with the appointment of Mohammad El Khoury as Chief Commercial Officer, we granted Mr. El Khoury 235,477 options to purchase ordinary shares at an exercise price $2.91 and 300,148 RSUs at a grant date price of $2.91 per share. On November 19, 2021, in connection with the appointment of Ali Kiboro as Chief Financial Officer, we granted Mr. Kiboro 123,267 options to purchase ordinary shares at an exercise price of $2.08 and 325,586 RSUs at a grant date price of $2.08. The grants were issued outside of our 2014 Plan pursuant to the inducement grant exception under Nasdaq Rule 5635(c)(4), as indicated under “Fiscal 2022 Executive Compensation”.  

(2)

Consists of options and restricted stock units granted under the 2012 and 2014 Plan. The Company’s Board of Directors has determined not to issue additional shares from the 2012 Plan.

(3)

The weighted-average exercise price is calculated based solely on the exercise prices of the outstanding options and does not reflect the shares that will be issued upon the vesting of outstanding RSU awards and PSU awards which have no exercise price.

As of March 31, 2022, the number of shares reserved for issuance, number of shares issued, number of shares underlying outstanding share options and number of shares remaining available for future issuance under the 2012 Plan and the 2014 Plan is set forth in the table below. Our board has determined not to make any further awards under the 2012 Plan.

Name of Plan

 

Number of securities to

be issued upon exercise

of outstanding options

and rights (3)

 

 

Weighted

average

exercise price

of outstanding

options

and rights (4)

 

 

Number of

shares

remaining

available for

future issuance

 

2012 Plan (1)

 

 

141,338

 

 

$

2.94

 

 

 

-

 

2014 Plan (2)

 

 

1,843,460

 

 

$

7.29

 

 

 

1,409,812

 

(1)

Outstanding awards comprise 141,338 options.

(2)

Outstanding awards comprise 663,025 RSUs and 1,180,435 options.

(3)

Consists of options and restricted stock units granted under the 2012 and 2014 Plan. The Company’s Board of Directors has determined not to issue additional shares from the 2012 Plan.

(4)

The weighted-average exercise price is calculated based solely on the exercise prices of the outstanding options and does not reflect     the shares that will be issued upon the vesting of outstanding RSU awards and PSU awards which have no exercise price.

On April 1, 2022 the number of shares reserved for issuance by the 2014 Plan increased by 769,585 shares.

40


Table of Contents

The following description of each of our share incentive plans is qualified by reference to the full text of those plans, which are incorporated by reference as exhibits to our Annual Report on Form 10-K.

2012 Plan

We adopted the Enterprise Management Plan, or the 2012 Plan, to enhance our ability to attract, retain and motivate employees expected to make important contributions to our Company by providing them with equity ownership opportunities and performance-based incentives. All of our employees were eligible to be granted share options under the 2012 Plan. The 2012 Plan was administered by our board. Subject to certain conditions, the 2012 Plan permits grants of enterprise management incentive options, or EMI options, under the terms of Schedule 5 to the UK Income Tax (Earnings and Pensions) Act 2003 (or ITEPA) for UK-based employees.

Share options granted pursuant to the 2012 Plan may be exercised upon the occurrence of certain events, including among other events, (i) in a sale of any shares of our share capital, which confers more than 50% of the total voting rights of all our issued shares; (ii) in the sale of all or substantially all of the undertakings of our Company and our subsidiaries, and (iii) in the event of a listing of our shares on any “Recognized Investment Exchange” as defined in Section 841(a) of the Corporation Taxes Act 2009. In the event our shares are listed, an option may be exercised, in three equal installments, on the first, second and third anniversaries of the date of the grant. Options must be exercised during an employee’s term of employment or service or within 40 days of termination of employment or service (or within one year in the case of termination on account of a participant’s death). The options lapse after specified periods upon the occurrence of applicable events, including, forty days after (i) the sale of any shares of our share capital which confers more than 50% of the total voting rights of all our issued shares or (ii) the sale of all or substantially all of the undertakings of our Company and our subsidiaries.

The maximum term of an option award is ten years.

Each option grant was documented through an option agreement. The exercise price per share of all options was determined by our board at the time of the grant.

Awards are non-transferable and our board retains discretion to amend, modify or terminate any outstanding award. Awards may be accelerated to become immediately exercisable in full or in part upon approval of our board.

In the event of certain changes in our capitalization, the number of shares available for issuance under the 2012 Plan, as well as the exercise price per share of each outstanding option, may be appropriately adjusted by our board. The 2012 Plan provides for certain exchange rights in the event of change in control and provides for conditional exercise in connection with a court-ordered reorganization of our Company or our amalgamation with any other company or companies.

As of March 31, 2022, under the plan there were 141,338 ordinary shares issuable upon the exercise of outstanding options, at a weighted-average exercise price of $2.94 per ordinary share.

Certain of our prior filings with the SEC referred to the 2012 Plan as the 2013 Plan.  In this proxy statement, we refer to the 2012 Plan as such because the first awards granted thereunder occurred in 2012.

2014 Plan

Our board and our shareholders have approved the 2014 Plan. The 2014 Plan provides us flexibility with respect to our ability to attract and retain the services of qualified employees, officers, directors, consultants and other service providers upon whose judgment, initiative and efforts the successful conduct and development of our business depends, and to provide additional incentives to such persons to devote their effort and skill to the advancement and betterment of our Company, by providing them an opportunity to participate in the ownership of our Company and thereby have an interest in its success and increased value.

We have reserved an aggregate of 5,479,688 ordinary shares for issuance under the 2014 Plan, which includes 3,550,000 ordinary shares reserved for issuance pursuant to the terms of the 2014 Plan, as amended, and 1,929,688 ordinary shares reserved for issuance as a result of automatic annual increases through April 1, 2021, as discussed further below.  This number is subject to adjustment in the event of a recapitalization, share split, share consolidation, reclassification, share dividend or other change in our capital structure, including the possible reverse stock split discussed in Special Resolution 13 in this proxy statement. To the extent that an award terminates, or expires for any reason, then any shares subject to the award may be used again for new grants. However, shares which are (i) not issued or delivered as a result of the net settlement of outstanding options or stock appreciation rights, or SARs, (ii) used to pay the exercise price related to outstanding options, (iii) used to pay withholding taxes related to outstanding options or SARs or (iv) repurchased on the open market with the proceeds from an option exercise, will not be available for re-grant under the 2014 Plan.

41


Table of Contents

The number of ordinary shares reserved for issuance automatically increases on April 1 of each year, from April 1, 2015 through April 1, 2023, by the lesser of 0.75% of the total number of our ordinary shares outstanding on March 31 of the preceding year, or such smaller amount as determined by our board. As at April 1, 2021, an additional 1,929,688 ordinary shares have been reserved for issuance under the 2014 Plan as a result of automatic increases. If adopted at the 2022 Annual General Meeting, the Fourth Amended and Restated 2014 Plan will no longer contain the automatic increase of ordinary shares reserved for issuance.  

The 2014 Plan permits us to make grants of (i) incentive share options pursuant to Section 422 of the Code and (ii) non-qualified share options. Incentive share options may only be issued to our employees. Non-qualified share options may be issued to our employees, directors, consultants and other service providers. The option exercise price of each option granted pursuant to the 2014 Plan will be determined by our remuneration committee and may not be less than 100% of the fair market value of the ordinary shares on the date of grant, subject to certain exceptions. The term of each option will be fixed by our remuneration committee and may not exceed ten years from the date of grant. All option grants under the 2014 Plan are made pursuant to a written option agreement.

The 2014 Plan permits us to sell or make grants of restricted shares. Restricted shares may be sold or granted to our employees, directors, consultants and other service providers (or of any current or future parent or subsidiary of our Company). Restricted shares issued under the 2014 Plan is sold or granted pursuant to a written restricted shares purchase agreement.

The 2014 Plan also permits us to issue SARs. SARs may be issued to our employees, directors, consultants and other service providers. The base price per share of ordinary shares covered by each SAR may not be less than 100% of the fair market value of the ordinary shares on the date of grant, subject to certain exceptions. SAR grants under the 2014 Plan are made pursuant to a written SAR agreement.

Further, the 2014 Plan permits us to issue RSUs. RSUs may be issued to our employees, directors, consultants and other service providers. RSU grants under the 2014 Plan are made pursuant to a written RSU agreement.

As of March 31, 2022, 409 employees and 7 directors were eligible to participate in the 2014 Plan.

The 2014 Plan is administered by our remuneration committee, which has the authority to control and manage the operation and administration of the 2014 Plan. In particular, the remuneration committee has the authority to determine the persons to whom, and the time or times at which, incentive share options, nonqualified share options, restricted shares, SARs or RSUs shall be granted, the number of shares to be represented by each option agreement or covered by each restricted share purchase agreement, SAR agreement or RSU agreement and the exercise price of such options and the base price of such SARs. In addition, our remuneration committee has the authority to accelerate the exercisability or vesting of any award, and to determine the specific terms, conditions and restrictions of each award. The remuneration committee will be composed exclusively of individuals intended to be, to the extent provided by Rule 16b-3 of the Exchange Act, independent directors.

Unless provided otherwise within each written option agreement, restricted share purchase agreement, SAR agreement or RSU agreement as the case may be, the vesting of all options, restricted share, SARs and RSUs granted under the 2014 Plan shall accelerate automatically in the event of a “change in control” (as defined in the 2014 Plan) effective as of immediately prior to the consummation of the change in control unless such equity awards are to be assumed by the acquiring or successor entity (or parent thereof) or equity awards of comparable value are to be issued in exchange therefor or the equity awards granted under the 2014 Plan are to be replaced by the acquiring entity with other incentives under a new incentive program containing such terms and provisions as our remuneration committee in its discretion may consider equitable.

Our board may from time to time alter, amend, suspend or terminate the 2014 Plan in such respects as our board of Directors may deem advisable, provided that no such alteration, amendment, suspension or termination shall be made which shall substantially affect or impair the rights of any participant under any awards previously granted without such participant’s consent.

No awards may be granted under the 2014 Plan after March 30, 2024.

As of March 31, 2022, there were 1,180,435 ordinary shares issuable upon the exercise of outstanding options, at a weighted-average exercise price of $7.29 per ordinary share and 663,025 RSUs outstanding under the plan.

42


Table of Contents

Share Ownership Guidelines

At its July 30, 2015 board meeting, the Company adopted guidelines to encourage ownership of shares of the Company by directors and named executive officers. Under these guidelines, directors and named executive officers have five years from the adoption of the guidelines (or if later, the date of employment, election or promotion, whichever applies) to achieve an ownership target as follows:

Award

Ownership Target:

Base Salary Multiple

 

 

Non-Employee DirectorsMANUEL O. MéNDEZ

Dated:

BRADLEY MEYER

Dated:

 

Dated:

Share value equal to or greater than three times annual retainer

 

 

CEO

Share value equal to or greater than six times base salary

Named executive officers (other than CEO)

Share value equal to or greater than two times base salary

JAMES GAUDIN
Dated:

 

Shares that count toward satisfaction of the ownership targets include:

Shares directly owned – individual, immediate family or trust (including without limitation shares purchased on the open market or acquired upon exercise of share options);

Vested restricted shares, restricted share units or deferred share units; and

“In the money” vested share options.

Shares that do not count towards the ownership targets include:

Unvested share options, restricted shares, restricted share units or deferred share units;

“Out of the money” vested share options; and

Performance restricted shares or performance equity units not yet vested.

Rule 10b5-1 Plans

As at March 31, 2022, certain of our directors have adopted 10b5-1 plans to permit sales of securities from time to time to fund tax obligations arising in connection with the vesting of equity awards.

Insured Pension Plan

We operate an insured pension plan in Switzerland for our Swiss employees.  The cost of this pension plan in the year ended March 31, 2022 was $2,300,000.  Mr. Méndez and Mr. Kiboro have participated in the plan since April and November 2021 respectively.  Further details can be found in the notes to our financial statements contained in our annual report on Form 10-K for the year ended March 31, 2022.

Hedging Policy

Our insider trading policy prohibits our employees and directors from hedging the value of our securities, engaging in hedging or similarly speculative transactions with respect to our securities, including prepaid variable forward contracts, equity swaps, collars and exchange funds.

43


Table of Contents

REPORT OF THE AUDIT COMMITTEE

The information contained in this report shall not be deemed to be “soliciting material” or “filed” or incorporated by reference in future filings with the SEC, or subject to the liabilities of Section 18 of the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference into a document filed under the Securities Act of 1933 or the Securities Exchange Act of 1934.

The audit committee currently consists of Ms. Larue and Messrs. Aebischer, Hallsworth and Shroff, with Mr. Hallsworth serving as chairman of the committee. Our Board has determined that Ms. Larue and Messrs. Aebischer, Hallsworth and Shroff meet the independence requirements of Rule 10A-3 under the Exchange Act and the applicable listing standards of Nasdaq. Our Board has determined that Mesrs. Aebischer and  Hallsworth are “audit committee financial experts” within the meaning of SEC regulations and applicable listing standards of Nasdaq.

The audit committee operates under a written charter adopted by the Board, which is evaluated annually. The charter of the audit committee is available on Quotient’s website at www.quotientbd.com. Click on the tab “Investors” and then the caption “Corporate Governance.”

The audit committee selects, evaluates and, where deemed appropriate, replaces Quotient’s independent registered public accountants. The audit committee also pre-approves all audit services, engagement fees and terms, and all permitted non-audit engagements, except for certain de minimis amounts.

Management is responsible for Quotient’s internal controls and the financial reporting process. Quotient’s independent registered public accountants are responsible for performing an audit of Quotient’s consolidated financial statements in accordance with the standards of the Public Company Accounting Oversight Board (United States). The audit committee’s responsibility is to monitor and oversee these processes.

In this context, the audit committee has reviewed Quotient’s audited financial statements for the fiscal year ended March 31, 2022 and has met and held discussions with management and Ernst & Young LLP (“E&Y”), the Company’s independent registered public accountants. Management represented to the audit committee that Quotient’s consolidated financial statements for fiscal 2022 were prepared in accordance with accounting principles generally accepted in the United States of America, and the audit committee discussed the consolidated financial statements with E&Y. The audit committee also discussed with E&Y the matters required to be discussed by the applicable requirements of the Public Accounting Oversight Board and the Securities and Exchange Commission.

The audit committee received the written disclosures and letter from E&Y required by the applicable requirements of the Public Company Accounting Oversight Board regarding E&Ys communications with the audit committee concerning its independence, and the audit committee discussed with E&Y the accounting firm’s independence.

Based upon the audit committee’s discussions with management and E&Y and the audit committee’s review of the representation of management and the report of E&Y to the audit committee, the audit committee recommended to the Board that the audited consolidated financial statements be included in Quotient’s Annual Report on Form 10-K for the fiscal year ended March 31, 2022, filed with the SEC.

The audit committee also considered whether non-audit services provided by E&Y were compatible with maintaining their independence and concluded that such non-audit services did not affect their independence.

Respectfully submitted,

Frederick Hallsworth, Chair

Thomas Aebischer

Catherine Larue

Zubeen Shroff

44


Table of Contents

 

 

Independent Registered Public Accountants’ Fees

Review of the Company’s Audited Financial Statements for the Fiscal Years ended March 31, 2022 and 2021

The audit committee approves Ernst & Young LLP’s and its affiliates audit and non-audit services in advance as required under Sarbanes-Oxley and SEC rules. Before the commencement of each fiscal year, the audit committee appoints the independent auditor to perform audit services that we expect to be performed for the fiscal year and appoints the auditor to perform audit-related, tax and other permitted non-audit services. In addition, our audit committee approves the terms of the engagement letter to be entered into by us with the independent auditor. The audit committee has also delegated to its chairman the authority, from time to time, to pre-approve audit-related and non-audit services not prohibited by law to be performed our independent auditors and associated fees, provided that the chairman shall report any decisions to pre-approve such audit-related and non-audit services and fees to our full audit committee at its next regular meeting.

The table below sets forth the fees paid to Ernst & Young LLP over the past two years in connection with its work for us. All such audit, audit-related and tax services were pre-approved by the audit committee, which concluded that the provision of such services by Ernst & Young LLP was compatible with the maintenance of that firm’s independence in the conduct of its auditing functions.

Fees billed by Ernst & Young LLP for the fiscal years ended March 31, 2022 and 2021 were as follows:


 

Fees

 

2022

 

 

2021

 

Audit fees (1)

 

$

1,017,500

 

 

$

962,000

 

Audit-related fees

 

 

0

 

 

 

0

 

Tax fees

 

 

0

 

 

 

0

 

All other fees

 

 

0

 

 

 

0

 

Total fees

 

$

1,017,500

 

 

$

962,000

 

(1)

Fees billed for audit services in 2022 and 2021 consisted of audit of our annual financial statements, review of our quarterly financial statements, statutory audits, consents, issuance of comfort letters, and review of documents filed with the SEC.

45


Table of Contents

APPOINTMENT OF AND PAYMENT TO AUDITORS (RESOLUTION 12)

The audit committee of our Board has appointed Ernst & Young LLP as our auditors. As required by law, shareholders are requested to re-appoint Ernst & Young LLP as the Company’s auditors for the period ending with the annual general meeting of the Company to be held in 2023. Shareholders are also requested to authorize the directors to determine the fees to be paid to the auditors. Shareholders are also requested to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for purposes of United States securities law reporting for the fiscal year ending March 31, 2023.

A representative of Ernst & Young LLP will be present at the Annual Meeting with the opportunity to make a statement if the firm desires and to respond to appropriate questions.

The Board recommends a vote “FOR” the re-appointment of Ernst & Young LLP as our auditors, to ratify their appointment as our independent registered public accounting firm and to authorize the directors to determine the fees to be paid to the auditors.

46


Table of Contents

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth information relating to the beneficial ownership of our ordinary shares as of July 5, 2022 for:

each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding ordinary shares;

each of our directors and director nominees;

each of our executive officers, including our NEOs; and

all directors, director nominees and executive officers, including our NEOs, as a group.

Beneficial ownership is determined in accordance with SEC rules. In general, under these rules a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise has or shares voting power or investment power with respect to such security. A person is also deemed to be a beneficial owner of a security if that person has the right to acquire beneficial ownership of such security within 60 days of July 5, 2022. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all ordinary shares held by that person.

Ordinary shares that a person has the right to acquire within 60 days of July 5, 2022 are deemed outstanding for purposes of computing the percentage ownership of such person’s holdings, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all directors and executive officers as a group. The beneficial ownership percentage of each shareholder is calculated on the basis of 135,683,559 ordinary shares outstanding as of July 5, 2022.

Except as indicated in footnotes to this table, we believe that the shareholders named in this table have sole voting and investment power with respect to all ordinary shares shown to be beneficially owned by them, based on information provided to us by such shareholders.

Unless otherwise indicated below, the address for each beneficial owner listed is c/o Quotient Limited, 28 Esplanade, St Helier, JE2 3QA, Jersey, Channel Islands.

Name and address of beneficial owner

 

Number of

ordinary shares

beneficially owned

 

 

Percentage of

ordinary shares

beneficially

owned

 

5% shareholders:

 

 

 

 

 

 

 

 

Galen Partners (1)

 

 

11,995,740

 

 

8.8%

 

Polar Capital LLP (2)

 

 

29,251,652

 

 

21.5%

 

Perceptive Advisors LLC (3)

 

 

16,200,818

 

 

11.9%

 

Highbridge Capital Management LLC (4)

 

 

27,654,951

 

 

20.3%

 

Pura Vida Investments, LLC (5)

 

 

21,481,683

 

 

15.8%

 

 

 

 

 

 

 

 

 

 

Executive officers, directors and director nominees:

 

 

 

 

 

 

 

 

Manuel Mendez (6)

 

 

722,928

 

 

*

 

Heino von Prondzynski (7)

 

 

428,505

 

 

*

 

Isabelle Buckle  (8)

 

 

65,043

 

 

*

 

Frederick Hallsworth (9)

 

 

307,311

 

 

*

 

Brian McDonough (10)

 

 

234,620

 

 

*

 

Catherine Larue (11)

 

 

69,213

 

 

*

 

Zubeen Shroff (12)

 

 

12,188,881

 

 

8.9%

 

John Wilkerson (13)

 

 

12,162,000

 

 

8.9%

 

Mohammad El Khoury (14)

 

 

50,000

 

 

*

 

Thomas Aebischer (15)

 

 

6,917

 

 

*

 

Ali Kiboro (16)

 

 

66,666

 

 

*

 

Sophie Bechu (17)

 

 

-

 

 

*

 

All Directors and Executive Officers as a group

 

 

14,317,639

 

 

10.5%

 

*

Denotes less than 1%.

47


Table of Contents

1.

The business address of Galen Partners is 680 Washington Blvd., Stamford, CT 06901. Includes 10,913,091 ordinary shares held of record by Galen Partners V LP, 931,945 ordinary shares held of record by Galen Partners International V LP, and 150,704 ordinary shares held of record by Galen Management, LLC (collectively, “Galen Partners”). John Wilkerson, David Jahns, and Zubeen Shroff exercise voting, investment and dispositive rights over our securities held of record by Galen Partners.

2.

Information based on a Schedule 13G/A filed with the SEC on February 14.2022 by Polar Capital LLP. The business address of Polar Capital LLP is 16 Palace Street, London SW1E 5JD. Includes 4,125,000 ordinary shares and 15,874,999 pre-funded warrants held of record by Polar Capital LLP as of June 29, 2022.

3.

Information based solely on a Schedule 13G/A filed with the SEC on February 14, 2022 by Perceptive Advisors LLC. The business address of Perceptive Advisors LLC is 51 Astor Place 10th Floor, New York, NY 10003.

4.

Information based on a Schedule 13G/A filed with the SEC on February 11,2022 by Highbridge Capital Management, LLC. The business address of Highbridge Capital Management, LLC is 277 Park Avenue, 23rd Floor, New York, NY 10172.  Includes 20,988,285 Ordinary Shares (including 419,673 Ordinary Shares issuable upon exercise of warrants and 13,227,509 Ordinary Shares issuable upon conversion of convertible notes). The convertible notes and exercisable warrants are each subject to a 9.90%beneficial ownership blocker and the percentage set forth in row (11) gives effect to such blockers. However, rows (6),(8) and (9) show the number of Ordinary Shares that would be issuable upon the conversion of the reported convertible notes and exercise of the reported warrants in full. Therefore, the actual number of Ordinary Shares beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported. Includes 6,666,666 pre-funded warrants held by Highbridge Capital Management LLC as of June 29, 2022.

5.

Information based on a Schedule 13G/A filed with the SEC on February 14.2022 by Pura Vida Investments LLC. The business address of Pura Vida Investments LLC  888 7th Avenue, 6th Floor, New York, NY 10106. Amount reported also includes 11,666,666 pre-funded warrants held of record by Pura Vida Investments LLC as of June 29, 2022.

6.

Comprises 416,667 ordinary shares and 239,595 share options held of record by Mr. Méndez.

7.

Comprises 405,879 ordinary shares and 22,626 share options held of record by Mr. von Prondzynski.

8.

Comprises 36,124 ordinary shares and 21,989 share options held of record by Ms. Buckle.

9.

Comprises 219,005 ordinary shares and 81,156 share options held of record by Mr. Hallsworth, and 3,150 shares held by Mr. Hallsworth’s wife

10.

Comprises 53,040 ordinary shares held by the McDonough-McGuire Joint Revocable Trust and 71,694 ordinary shares and 102,969 share options held of record by Mr. McDonough.

11.

Comprises 40,294 ordinary shares and 21,989 share options held of record by Ms. Larue

12.

Comprises the ordinary shares identified in footnote 1 and 118,461 ordinary shares and 61,142 options held of record by Mr. Shroff.  Mr. Shroff disclaims beneficial ownership of the ordinary shares identified in footnote 1, except to the extent of his proportionate pecuniary interest in such shares.

13.

Comprises the ordinary shares identified in footnote 1 and 94,958 ordinary shares, and 59,642 options held of record by Mr. Wilkerson.  Mr. Wilkerson disclaims beneficial ownership of the ordinary shares identified in footnote 1, except to the extent of his proportionate pecuniary interest in such shares.

14.

Comprises 50,000 ordinary shares held of record by Mr. El Khoury.

15.

Comprises 6,917 ordinary shares held of record by Mr. Aebischer.

16.

Comprises nil shares held of record by Mr. Kiboro.

17.

Comprises nil shares held of record by Ms. Bechu.

48


Table of Contents

PROPOSAL TO VARY THE RIGHTS ATTACHING TO THE COMMON STOCK OF THE COMPANY (ORDINARY SHARES) SO THAT THE COMPANY ACTING BY ITS BOARD OF DIRECTORS shall have the power TO UNDERTAKE a reverse stock split (consolidation) of ALL OF the ORDINARY SHARES IN THE CAPITAL OF THE Company IN ISSUE AT THE TIME OF SUCH REVERSE STOCK SPLIT, AT SUCH RATIO AS SHALL BE DETERMINED BY THE BOARD OF DIRECTORS OF THE COMPANY, WITHOUT FURTHER APPROVAL OR AUTHORIZATION OF THE SHAREHOLDERS (THE “REVERSE STOCK SPLIT”), SUCH POWER TO BE SUBJECT TO THE FOLLOWING CONDITIONS: (a) the ratio of the reverse stock split must be  a whole number between 1-for-10 and 1-for-40, (B) THE REVERSE STOCK SPLIT MUST BE COMPLETED NO LATER THAN the one year anniversary of the Annual General Meeting, (C) with the exact ratio to be set within that range at the discretion of the Board of Directors (the “Board”), without further approval or authorization of the shareholders, AND (D) to the extent the reverse stock split causes any shareholder to hold a fractional number of shares, SUCH FRACTIONS SHALL BE DEALT WITH IN ACCORDANCE WITH ARTICLE 11.2 OF THE ARTICLES OF ASSOCIATION OF THE COMPANY (RESOLUTION 13, PROPOSED AS A SPECIAL RESOLUTION)

General

We are seeking stockholder approval to grant the Company, acting by the Board, discretionary authority to effect a reverse stock split of the issued and outstanding shares of our common stock by a ratio of any whole number between 1-for-10 and 1-for-40 as determined by the Board, to take effect no later than the one year anniversary of the date of the Annual General Meeting (the “Reverse Stock Split”). One of the primary reasons we are seeking this stockholder approval to grant authority to effect the Reverse Stock Split, is that we believe it will enable us to regain compliance with the Nasdaq Capital Market listing requirements.

The Company is a no par value company established under the laws of Jersey, Channel Islands.  As such, under its constitutional documents there is no limit on the number of shares it is authorised to issue.  As a consequence, the Reverse Stock Split will not affect the number of shares the Company is entitled to issue, nor will it affect the relative voting power of the holders of our outstanding common stock (the holders of our preferred stock are not entitled to vote at general meetings of the Company). The Reverse Stock Split, if effected, would affect all of our holders of ordinary shares uniformly.

The Board unanimously approved to seek stockholder approval to vary the rights attaching to the common stock of the Company (ordinary shares) so that the Company acting by its board of directors shall have the power to undertake a Reverse Stock Split. If the proposal is approved by the stockholders, the Company will have the authority, acting by the Board in its sole discretion, without further action by the stockholders, to effect the Reverse Stock Split, subject to conditions as to (a) the ratio of the Reverse Stock Split, which must be a whole number between 1-for-10 and 1-for 40, (b) the timing of the Reverse Stock Split, which must be completed no later than the one year anniversary of the date of the Annual General Meeting, and (c) the manner in which any fractional share entitlements are dealt with, which must be dealt with in accordance with the existing provisions of the constitutional documents of the Company (which in summary permit the Board to deal with fractions as they see fit, including by aggregating them, selling them for cash and distributing the cash received to affected stockholders). Subject to the conditions above, the Board’s decision as to whether and when to effect the Reverse Stock Split, if approved by the stockholders, will be based on a number of factors, including prevailing market conditions, existing and expected trading prices for our common stock, actual or forecasted results of operations, and the likely effect of such results on the market price of our common stock.

A reverse stock split will also affect our outstanding stock options, restricted stock units and shares of common stock issued under our Amended and Restated 2014 Stock Incentive Plan (the « 2014 Equity Plan »), as well as our outstanding convertible notes, warrants and certain pre-existing rights to subscribe for common stock. Under these plans and pursuant to the terms of such securities and rights the number of shares of common stock deliverable upon exercise or grant must be appropriately adjusted and appropriate adjustments must be made to the purchase price per share to reflect the Reverse Stock Split. Under the 2014 Equity Plan, the number of Ordinary Shares (as defined under the 2014 Equity Plan) reserved and available for issuance under this Plan, including the number of additional Ordinary Shares available for issuance submitted for shareholders’ approval at the Company 2022 Annual General Meeting of the shareholders, must be adjusted accordingly. The Reverse Stock Split does not require any consent or approval of the holders of, or any variation to be made to the terms of, the Company's preferred stock.

The Reverse Stock Split is not being proposed in response to any effort of which we are aware to accumulate our shares of common stock or obtain control of the Company, nor is it a plan by management to recommend a series of similar actions to the Board or our stockholders.

There are certain risks associated with a reverse stock split, and we cannot accurately predict or assure the Reverse Stock Split will produce or maintain the desired results (for more information on the risks see the section below entitled “Certain Risks Associated with a

49


Table of Contents

Reverse Stock Split”). The Board believes that the benefits to the Company outweigh the risks and recommends that you vote in favor of granting the Board the discretionary authority to effect the Reverse Stock Split.

Reasons for the Reverse Stock Split

The Board believes that effecting the Reverse Stock Split would increase the price of our common stock which would, among other things, help us to:

meet certain listing requirements of the Nasdaq Global Market and the Nasdaq Capital Market;

appeal to a broader range of investors to generate greater interest in the Company; and

improve perception of our common stock as an investment security.

Meet Nasdaq Listing Requirements - Our common stock is listed on the Nasdaq Global Market under the symbol QTNT. On May 20, 2022, we received a deficiency letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), notifying us that, for the last 30 consecutive business days, the closing bid price for our common stock was below the minimum $1.00 per share required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we were given 180 calendar days, or until November 16, 2022 (“Compliance Date”), to regain compliance with Rule 5550(a)(2). As of the date of filing of this Proxy, we were not in compliance with Rule 5550(a)(2). If we do not regain compliance with Rule 5550(a)(2) by the Compliance Date and are not eligible for an additional compliance period at that time, the Nasdaq staff will provide written notification to us that our common stock will be subject to delisting. Although we believe that implementing the Reverse Stock Split is likely to lead to compliance with Rule 5550(a)(2), there can be no assurance that the closing share price after implementation of the Reverse Stock Split will succeed in restoring such compliance.

Appeal to a Broader Range of Investors to Generate Greater Investor Interest in the Company – An increase in our stock price may make our common stock more attractive to investors. Brokerage firms may be reluctant to recommend lower-priced securities to their clients. Many institutional investors have policies prohibiting them from holding lower-priced stocks in their portfolios, which reduces the number of potential purchasers of our common stock. Investment funds may also be reluctant to invest in lower-priced stocks. Investors may also be dissuaded from purchasing lower-priced stocks because the brokerage commissions, as a percentage of the total transaction, tend to be higher for such stocks. Moreover, the analysts at many brokerage firms do not monitor the trading activity or otherwise provide coverage of lower-priced stocks. Giving the Board the ability to effect the Reverse Stock Split, and thereby increase the price of our common stock, would give the Board the ability to address these issues if it is deemed necessary.

Improve the Perception of Our Common Stock as an Investment Security – The Board believes that effecting the Reverse Stock Split is one potential means of increasing the share price of our common stock to improve the perception of our common stock as a viable investment security. Lower-priced stocks have a perception in the investment community as being risky and speculative, which may negatively impact not only the price of our common stock, but also our market liquidity.

Certain Risks Associated with the Reverse Stock Split

Even if a reverse stock split is effected, some or all of the expected benefits discussed above may not be realized or maintained. The market price of our common stock will continue to be based, in part, on our performance and other factors unrelated to the number of shares outstanding.

Effects of the Reverse Stock Split

If our stockholders approve the proposed Reverse Stock Split and the Board elects to effect the Reverse Stock Split, our issued and outstanding shares of common stock, for example, would decrease at a rate of approximately one (1) share of common stock for every thirty (30) shares of common stock currently outstanding in a 1-for-30 split. The Reverse Stock Split would be effected simultaneously for all of our common stock, and the exchange ratio would be the same for all shares of common stock. The Reverse Stock Split would affect all of our stockholders uniformly and would not affect any stockholders’ percentage ownership interests in the Company, except to the extent that it results in a stockholder receiving cash in lieu of fractional shares. The Reverse Stock Split would not affect the relative voting or other rights that accompany the shares of our common stock, except to the extent that it results in a stockholder receiving cash in lieu of fractional shares. Common stock issued pursuant to the Reverse Stock Split would remain fully paid and non-assessable. The Reverse Stock Split would not affect our securities law reporting and disclosure obligations, and we would continue to be subject to the periodic reporting requirements of the Securities Exchange Act of 1934, as amended. We have no current plans to take the Company private. Accordingly, the Reverse Stock Split is not related to a strategy to do so.

50


Table of Contents

In addition to the change in the number of shares of common stock outstanding, the Reverse Stock Split would have the following effects:

Increase the Per Share Price of our Common Stock – By effectively condensing a number of pre-split shares into one share of common stock, the per share price of a post-split share is generally greater than the per share price of a pre-split share. The amount of the initial increase in per share price and the duration of such increase, however, is uncertain. The Board may utilize the Reverse Stock Split as part of its plan to maintain the required minimum per share price of the common stock under the Nasdaq listing standards.

The following table contains approximate information relating to our common stock, based on share information as of July 11, 2022:

 

 

 

 

After the Reverse Stock Split (2) (3)

 

    

Current

    

If Minimum 1:10
Ratio is Selected

    

If Maximum 1:40
Ratio is Selected

Common Stock issued and outstanding as of July 11, 2022 (1)

 

135’683’559

 

13,568,355

 

3,392,088

(1)

The Company has an unlimited number of shares available for issue.

(2)

Does not take into account that fractional shares resulting from the Reverse Split will be dealt with in accordance with the existing provisions of the constitutional documents of the Company.

(3)

Excludes shares of common stock reserved for issuance (i) upon the exercise of currently exercisable warrants and options; (ii) pursuant to awards granted under the 2014 Equity Plan; (iii) upon the conversion of convertible notes ; and (iv) upon the conversion of Preference Shares.

Require Adjustment to Currently Outstanding Securities Exercisable or Convertible into Shares of our Common Stock.  The Reverse Stock Split would effect a reduction in the number of shares of common stock issuable upon the exercise, conversion or settlement of our outstanding stock options, RSUs, convertible notes and warrants, as applicable, in proportion to the Reverse Stock Split ratio.  The conversion, exercise and purchase price of securities would likewise increase, as applicable, in proportion to the Reverse Stock Split ratio.

Require Adjustment to the Number of Shares of Common Stock Available for Future Issuance Under our Amended and Restated 2014 Equity Plan – In connection with any reverse stock split, the Board would also make a corresponding reduction in the number of shares available for future issuance under the foregoing plan so as to avoid the effect of increasing the number of authorized but unissued shares available for future issuance under such plans.

In addition, the Reverse Stock Split may result in some stockholders owning “odd lots” of less than one hundred (100) shares of common stock, which may be more difficult to sell and may cause those holders to incur greater brokerage commissions and other costs upon sale.

Procedure for Effecting Reverse Stock Split and Exchange of Stock Certificates

If the Reverse Stock Split is approved by our stockholders, the Board, in its sole discretion, would determine whether to implement the Reverse Stock Split, taking into consideration the factors discussed above, and, if implemented, determine the ratio of the Reverse Stock Split.

Effect on Beneficial Holders (i.e., Stockholders Who Hold in “Street Name”)

If the proposed Reverse Stock Split is approved and effected, we intend to treat common stock held by stockholders in “street name,” through a bank, broker or other nominee, in the same manner as stockholders whose shares are registered in their own names. Banks, brokers or other nominees will be instructed to effect the Reverse Stock Split for their customers holding common stock in “street name.” However, these banks, brokers or other nominees may have different procedures than registered stockholders for processing the Reverse Stock Split. If you hold shares of common stock with a bank, broker or other nominee and have any questions in this regard, you are encouraged to contact your bank, broker or other nominee.

Effect on Registered “Book-Entry” Holders (i.e., Stockholders That are Registered on the Transfer Agent’s Books and Records but do not Hold Certificates)

Some of our registered holders of common stock may hold some or all of their shares electronically in book-entry form with our transfer agent, Continental Stock Transfer & Trust Company. These stockholders do not have stock certificates evidencing their ownership of common stock. They are, however, provided with a statement reflecting the number of shares registered in their accounts. If a stockholder holds registered shares in book-entry form with our transfer agent, no action needs to be taken to receive post-reverse stock split shares or payment in lieu of fractional shares. If a stockholder is entitled to post-reverse stock split shares, a transaction statement will automatically be sent to the stockholder’s address of record indicating the number of shares of common stock held following the Reverse Stock Split.

51


Table of Contents

Fractional Shares

The Reverse Stock Split may result in certain stockholders of record (including CEDE & Co) holding fractional shares. Our constitutional documents contain a mechanism for dealing with such fractional shares, and if approved the Board will be obliged to deal with fractions in accordance with those provision.  In particular, the Board is empowered pursuant to those provisions to aggregate fractions, sell the whole shares resulting from such aggregation, and distribute the net proceeds to those stockholders who were entitled to fractional shares. Except for the right to receive the cash payment in lieu of fractional shares, stockholders will not have any voting, dividend or other rights with respect to the fractional shares they would otherwise be entitled to receive.

Stockholders should be aware that, under the escheat laws of the various jurisdictions where stockholders may reside, where we are domiciled, and where the funds will be deposited, sums due for fractional interests that are not timely claimed after the effective date of the Reverse Stock Split may be required to be paid to the designated agent for each such jurisdiction, unless correspondence has been received by us or the exchange agent concerning ownership of such funds within the time permitted in such jurisdiction. Thereafter, stockholders otherwise entitled to receive such funds will have to seek to obtain them directly from the state to which they were paid.

Accounting Matters

Net income or loss per share for all periods would increase proportionately as a result of the Reverse Stock Split since there would be a lower number of shares outstanding. We do not anticipate that any other material accounting consequences would arise as a result of the Reverse Stock Split.

No Appraisal Rights

Our stockholders are not entitled to appraisal rights with respect to the Reverse Stock Split, and we will not independently provide stockholders with any such right.

Certain Federal Income Tax Consequences of the Reverse Stock Split

The following summary describes certain U.S. federal income tax consequences of the Reverse Stock Split to holders of our common stock. This summary addresses the tax consequences only to a U.S. holder, which is a beneficial owner of our common stock that is either:

an individual citizen or resident of the United States;

a corporation, or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the United States or any state thereof or the District of Columbia;

an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or

a trust, if: (i) a court within the United States is able to exercise primary jurisdiction over its administration and one or more U.S. persons has the authority to control all of its substantial decisions or (ii) it was in existence before August 20, 1996 and a valid election is in place under applicable Treasury regulations to treat such trust as a U.S. person for U.S. federal income tax purposes.

This summary is based on the provisions of the Internal Revenue Code of 1986, as amended (the “Code”), U.S. Treasury regulations, administrative rulings and judicial authority, all as in effect as of the date of this proxy statement. Subsequent developments in U.S. federal income tax law, including changes in law or differing interpretations, which may be applied retroactively, could have a material effect on the U.S. federal income tax consequences of the Reverse Stock Split.

This summary does not address all of the tax consequences that may be relevant to any particular investor, including tax considerations that arise from rules of general application to all taxpayers or to certain classes of taxpayers or that are generally assumed to be known by investors. This summary also does not address the tax consequences to (i) persons that may be subject to special treatment under U.S. federal income tax law, such as banks, insurance companies, thrift institutions, regulated investment companies, real estate investment trusts, tax-exempt organizations, U.S. expatriates, persons subject to the alternative minimum tax, persons whose functional currency is not the U.S. dollar, partnerships or other pass-through entities, traders in securities that elect to mark to market and dealers in securities or currencies, (ii) persons that hold our common stock as part of a position in a “straddle” or as part of a “hedging transaction,” “conversion transaction” or other integrated investment transaction for federal income tax purposes or (iii) persons that do not hold our common stock as “capital assets” (generally, property held for investment).

This summary does not address backup withholding and information reporting. This summary does not address U.S. holders who beneficially own common stock through a “foreign financial institution” (as defined in Code Section 1471(d)(4)) or certain other non-U.S.

52


Table of Contents

entities specified in Code Section 1472. This summary does not address tax considerations arising under any state, local or foreign laws, or under federal estate or gift tax laws.

If a partnership (or other entity classified as a partnership for U.S. federal income tax purposes) is the beneficial owner of our common stock, the U.S. federal income tax treatment of a partner in the partnership will generally depend on the status of the partner and the activities of the partnership. Partnerships that hold our common stock, and partners in such partnerships, should consult their own tax advisors regarding the U.S. federal income tax consequences of the Reverse Stock Split.

General Tax Treatment of the Reverse Stock Split

The Reverse Stock Split is intended to qualify as a “reorganization” under Section 368 of the Code that should constitute a “recapitalization” for U.S. federal income tax purposes. Assuming the Reverse Stock Split qualifies as a reorganization, the Company should not recognize gain or loss. Further, assuming the Reverse Stock Split qualifies as a reorganization, a U.S. holder generally should not recognize gain or loss upon the exchange of our ordinary shares for a lesser number of ordinary shares, based upon the reverse stock split ratio. A U.S. holder’s aggregate tax basis in the lesser number of ordinary shares received in the Reverse Stock Split will be the same such U.S. holder’s aggregate tax basis in the shares of our common stock that such U.S. holder owned prior to the Reverse Stock Split. The holding period for the ordinary shares received in the Reverse Stock Split will include the period during which a U.S. holder held the shares of our common stock that were surrendered in the Reverse Stock Split. The United States Treasury regulations provide detailed rules for allocating the tax basis and holding period of the shares of our common stock surrendered to the shares of our common stock received pursuant to the Reverse Stock Split. U.S. holders of shares of our common stock acquired on different dates and at different prices should consult their tax advisors regarding the allocation of the tax basis and holding period of such shares.

A U.S. holder who receives cash in lieu of a fractional share of common stock pursuant to the Reverse Stock Split should be treated for U.S. federal income tax purposes as having received a fractional share pursuant to the Reverse Stock Split and then as having received cash in exchange for the fractional share and should generally recognize capital gain or loss equal to the difference between the amount of cash received and the U.S. holder's tax basis allocable to the fractional share. Any capital gain or loss will generally be long term capital gain or loss if the U.S. holder's holding period in the fractional share is greater than one year as of the effective date of the Reverse Stock Split.

THE FOREGOING IS A SUMMARY OF CERTAIN FEDERAL INCOME TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT, AND DOES NOT CONSTITUTE A TAX OPINION. EACH HOLDER OF OUR COMMON STOCK SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT AND FOR REFERENCE TO APPLICABLE PROVISIONS OF THE CODE.

Interests of Directors and Executive Officers

Our directors and executive officers have no substantial interests, directly or indirectly, in the matters set forth herein regarding the proposed Reverse Stock Split except to the extent of their ownership of shares of our common stock.

Reservation of Right to Abandon Reverse Stock Split

We reserve the right to abandon the Reverse Stock Split without further action by our stockholders at any time, even if the authority to effect the Reverse Stock Split has been approved by our stockholders at the Special Meeting. By voting in favor of the Reverse Stock Split, you are expressly also authorizing the Board to delay, not to proceed with, and abandon, the Reverse Stock Split if it should so decide, in its sole discretion, that such action is in the best interests of the Company.

Vote Required for Approval of this Proposal

The approval of the authorisation to the Company’s Board of Directors to effect a reverse stock split requires a two-third majority vote of the members who (being entitled to do so) vote in person, or by proxy, at the Annual Meeting in favor of each Resolution. Abstentions and broker non-votes are not counted as votes cast .

Recommendation

THE BOARD RECOMMENDS THAT YOU VOTE “FOR” the APPROVAL TO VARY THE RIGHTS ATTACHING TO THE COMMON STOCK OF THE COMPANY (ORDINARY SHARES) SO THAT THE COMPANY ACTING BY ITS BOARD OF DIRECTORS shall have the power TO UNDERTAKE a reverse stock split (consolidation) of ALL OF the ORDINARY SHARES IN THE CAPITAL OF THE Company IN ISSUE AT THE TIME OF SUCH REVERSE STOCK SPLIT, AT SUCH RATIO AS SHALL BE DETERMINED BY THE BOARD OF DIRECTORS OF THE COMPANY, WITHOUT

53


Table of Contents

FURTHER APPROVAL OR AUTHORIZATION OF THE SHAREHOLDERS (THE “REVERSE STOCK SPLIT”), SUCH POWER TO BE SUBJECT TO THE FOLLOWING CONDITIONS: (a) the ratio of the reverse stock split must be  a whole number between 1-for-10 and 1-for-40, (B) THE REVERSE STOCK SPLIT MUST BE COMPLETED NO LATER THAN the one year anniversary of the Annual General Meeting, (C) with the exact ratio to be set within that range at the discretion of the Board of Directors (the “Board”), without further approval or authorization of the shareholders, AND (D) to the extent the reverse stock split causes any shareholder to hold a fractional number of shares, SUCH FRACTIONS SHALL BE DEALT WITH IN ACCORDANCE WITH ARTICLE 11.2 OF THE ARTICLES OF ASSOCIATION OF THE COMPANY.

54


Table of Contents

PROPOSAL TO ALTER THE ARTICLES OF ASSOCIATION OF THE COMPANY TO DELETE ARTICLE 20.9 IN ITS ENTIRETY AND THE INSERTION IN ITS PLACE OF A NEW ARTICLE 20.9 (RESOLUTION 14, PROPOSED AS A SPECIAL RESOLUTION)

We are seeking stockholder approval to alter the articles of association of the Company to delete article 20.9 in its entirety and the insertion in its place of a new article 20.9 as follows:

"20.9For the purposes of determining which persons are entitled to attend or vote at a meeting and how many votes such person may cast, the Company acting by its board of directors may specify a time in the notice of the meeting, such time being no more than 21 days before the day that notice of the meeting is sent, by which a person must be entered on the register of members in order to have the right to attend or vote at the meeting."

The current article 20.9 provides that, for the purposes of determining which persons are entitled to attend or vote at a general meeting and how many votes such person may cast, the Company may specify a time in the notice of the general meeting, which may not be more than 48 hours before the time fixed for the meeting, by which a person must be entered on the register of members of the Company in order to have the right to attend or vote at that general meeting.

The proposed new article 20.9 alters the maximum time period specified in the current article 20.9 from "no more than 48 hours before the time fixed for the meeting" to "no more than 21 days before the day that notice of the meeting is sent ".

The principal reason for this amendment is to align with other time periods set out in the articles of association of the Company in respect of the record date for holders of record, including in respect of notice of general meetings (article 20.2) and record date for communications (article 17.15).

This amendment will not affect the process for setting a record date for the beneficial owners of the shares and will only apply to setting the record date for registered holders.  This will enable the Company acting by its board of directors, to align the record dates applicable to all holders, which we believe is customary for companies trading in the US markets.

Vote Required for Approval of this Proposal

The approval of proposal to alter the articles of association of the Company to delete article 20.9 in its entirety and the insertion in its place of a new article 20.9 requires a two-third majority vote of the members who (being entitled to do so) vote in person, or by proxy, at the Annual Meeting in favor of each Resolution. Abstentions and broker non-votes are not counted as votes cast.

Recommendation

THE BOARD RECOMMENDS THAT YOU VOTE FOR the deletion of article 20.9 in its entirety from the articles of association of the Company and the insertion in its place of a new article 20.9 whereby for the purposes of determining which persons are entitled to attend or vote at a meeting and how many votes such person may cast, the Company acting by its board of directors may specify a time in the notice of the meeting, such time being no more than 21 days before the day that notice of the meeting is sent, by which a person must be entered on the register of members in order to have the right to attend or vote at the meeting.

55


Table of Contents

OTHER INFORMATION

Quotient Mailing Address

The mailing address of our principal executive offices is: Quotient Limited, Business Park Terre Bonne, Route de Crassier 13, 1262 Eysins, Switzerland.

Shareholder Proposals for the 2023 annual meeting

In accordance with rules of the SEC, any shareholder proposal pursuant to Rule 14a-8 of the rules promulgated under the Exchange Act to be considered to be included in Quotient’s Proxy Statement for the 2023 Annual General Meeting of Shareholders must be received by our Head of Legal & Compliance (care of Quotient Suisse SA, Business Park Terre Bonne B1, Route de Crassier 13, 1262 Eysins (Switzerland)), on or before May 11, 2023 (120 days before the one-year anniversary of the expected mailing date).

If you wish to bring a matter before a general meeting outside the process described above, you may do so by following the procedures set forth in the Company’s Memorandum and Articles of Association and the Companies (Jersey) Law 1991, as amended.

Presentation of Accounts

Under Jersey law, the directors are required to present the accounts of the Company and the reports of the directors and auditors (if any) before shareholders at a general meeting. Therefore, the accounts of the Company for the fiscal year ended March 31, 2022 will be presented to the shareholders at the Annual Meeting.

Householding

Only one copy of each of our Notice of Availability or our proxy materials, as applicable, has been sent to multiple shareholders who share the same address and last name, unless we have received contrary instructions from one or more of those shareholders. This procedure is referred to as “householding.” We have been notified that certain intermediaries (brokers or banks) will also household our Notice of Availability or proxy materials. We will deliver promptly, upon oral or written request, separate copies of the Notice of Availability or proxy materials to any shareholder at the same address. If you wish to receive separate copies of the Notice of Availability or proxy materials, or if you do not wish to participate in householding in the future, you may write to our Head of Legal & Compliance, at Quotient Limited, Business Park Terre Bonne, Route de Crassier 13, 1262 Eysins, Switzerland or +41 22 545 82 57. You may contact your broker or bank to make a similar request. Shareholders sharing an address who now receive multiple copies of our Notice of Availability or proxy materials may request delivery of a single copy of each document by writing or calling us at the address or telephone number above or by contacting their broker or bank (provided the broker or bank has determined to household proxy materials).

Other Business

Management does not know of any other matters to be brought before the Annual Meeting except those set forth in the notice thereof. If other business is properly presented for consideration at the Annual Meeting, it is intended that the proxies will be voted by the persons named therein in accordance with their judgment on such matters.

56


Table of Contents

EXHIBIT A - QUOTIENT LIMITED

2014 STOCK INCENTIVE PLAN

As adopted on March 31, 2014, amended and restated on October 28, 2016, further amended and restated on October 31, 2018, October 29, 2020[, and October 31, 2022]

WHEREAS, on April 3, 2014, the shareholders of the Company approved the adoption of the 2014 Stock Incentive Plan (the "2014 Plan"), which provided for an initial limit of 1,500,000 Ordinary Shares in terms of the number of Ordinary Shares authorized for issuance (the "Original Initial Limit") and 3,000,000 in terms of the maximum number of Ordinary Shares that may be issued upon the exercise of Incentive Options.

WHEREAS, on October 28, 2016, at the annual meeting of shareholders of the Company, the shareholders of the Company approved the adoption of the Amended and Restated 2014 Stock Incentive Plan (the "Amended and Restated 2014 Plan"), which reflected amendments to the 2014 Plan to increase by 750,000 both the Original Initial Limit (the "Amended and Restated Original Limit") and the maximum number of Ordinary Shares that may be issued upon the exercise of Incentive Options.

WHEREAS, pursuant to Section 4.1 of each of the 2014 Plan and the Amended Restated 2014 Plan, on April 1 of each year from 2015 through 2022, the number of Ordinary Shares authorized for issuance under the 2014 Plan and the Amended and Restated 2014 Plan automatically increased by an aggregate of 2,699,273 additional Ordinary Shares (comprised of 170,205 additional Ordinary Shares that were authorized on April 1, 2015, 200,000 additional Ordinary Shares that were authorized on April 1, 2016, 200,000 additional Ordinary Shares that were authorized on April 1, 2017, 200,000 additional Ordinary Shares that were authorized for issuance on April 1, 2018, 200,000 additional Ordinary Shares that were authorized on April 1, 2019, 200,000 additional Ordinary Shares that were authorized for issuance on April 1, 2020, 759,483 additional Ordinary Shares that were authorized for issuance on April 1, 2021, and 769,585 additional Ordinary Shares that were authorized for issuance on April 1, 2022) (collectively, the "Prior Evergreen Increases to the Initial Limit").

WHEREAS, on October 31, 2018, at the annual meeting of shareholders of the Company, the shareholders of the Company approved the adoption of the Second Amended and Restated 2014 Stock Incentive Plan, which reflected amendments to the Amended and Restated 2014 Plan to increase by 550,000 both the Amended and Restated Original Limit and the maximum number of Ordinary Shares that may be issued upon the exercise of Incentive Options.

WHEREAS, on October 29, 2020, at the annual meeting of shareholders of the Company, the shareholders of the Company approved the adoption of the Third Amended and Restated 2014 Stock Incentive Plan (the "Plan"), which reflected amendments to the Second Amended and Restated 2014 Plan to increase by 750,000 both the Second Amended and Restated Initial Limit and the maximum number of Ordinary Shares that may be issued upon the exercise of Incentive Options and to modify the "evergreen" provision so that, on April 1, 2021, and each April 1 thereafter until April 1, 2023, the number of Ordinary Shares reserved and available for issuance under the Plan shall be increased by three quarters of one percent (0.75%) of the number of Ordinary Shares issued and outstanding on the immediately preceding March 31 or such lesser number of Ordinary Shares as determined by the Administrator.

WHEREAS, on [October 31, 2022], at the annual meeting of shareholders of the Company, the shareholders of the Company approved the adoption of the Fourth Amended and Restated 2014 Stock Incentive Plan (the “Plan”), which reflected amendments to the Third Amended and Restated 2014 Plan to (i) ) increase the number of ordinary shares authorized for issuance by 10’000’000 shares, and (ii) remove the "evergreen" provision pursuant to which the aggregate number of shares authorized for issuance automatically increases each year.

ARTICLE 1.

PURPOSES OF THE PLAN

1.1Purposes.

The purposes of the Plan are (a) to enhance the Company's ability to attract and retain the services of qualified employees, officers, directors, consultants and other service providers upon whose judgment, initiative and efforts the successful conduct and development of the Company's business largely depends, and (b) to provide additional incentives to such persons or entities to devote their utmost effort and skill to the advancement and betterment of the Company, by providing them an opportunity to participate in the ownership of the Company and thereby have an interest in the success and increased value of the Company.

57


Table of Contents

ARTICLE 2.

DEFINITIONS AND INTERPRETATION

For purposes of this Plan, terms not otherwise defined herein shall have the meanings indicated below:

2.1Administrator.  "Administrator" means the Board or, if the Board delegates responsibility for any matter to the Committee, the term Administrator shall mean the Committee.

2.2Affiliated Company.  "Affiliated Company" means: with respect to Incentive Options, any "parent corporation" or "subsidiary corporation" of the Company, whether now existing or hereafter created or acquired, as those terms are defined in Sections 424(e) and 424(f) of the Code, respectively; and with respect to Nonqualified Options, Restricted Stock, Restricted Stock Units and Stock Appreciation Rights, any entity described in paragraph (a) of this Section 2.2, plus any other company, corporation, limited liability company ("LLC"), partnership or joint venture, whether now existing or hereafter created or acquired, with respect to which the Company beneficially owns more than fifty percent (50%) of: (1) the total combined voting power of all outstanding voting securities or (2) the capital or profits interests of an LLC, partnership or joint venture.

2.3Amended and Restated 2014 Plan.  "Amended and Restated 2014 Plan" means the Amended and Restated 2014 Stock Incentive Plan of the Company.

2.4Base Price.  "Base Price" means the price per Ordinary Share for purposes of computing the amount payable to a Participant who holds a Stock Appreciation Right upon exercise thereof.

2.5Board.  "Board" means the Board of Directors of the Company.

2.6Cause.  "Cause" means, with respect to a Participant, the occurrence of any of the following events: (i) such Participant's commission of any felony or any crime involving fraud, dishonesty or moral turpitude; (ii) such Participant's attempted commission of, or participation in, a fraud or act of dishonesty against the Company; (iii) such Participant's intentional, material violation of any contract or agreement between the Participant and the Company or of any statutory duty owed to the Company; (iv) such Participant's unauthorized use or disclosure of the Company's confidential information or trade secrets; or (v) such Participant's gross misconduct.

2.7Change in Control.  "Change in Control" means:

(a)The acquisition, directly or indirectly, in one transaction or a series of related transactions, by any person or group (within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended) of the beneficial ownership of securities of the Company possessing more than fifty percent (50%) of the total combined voting power of all outstanding securities of the Company; provided, however, that a Change in Control shall not result upon such acquisition of beneficial ownership if such acquisition occurs as a result of a public offering of the Company's securities or any financing transaction or series of financing transactions;

(b)A merger or consolidation in which the Company is not the surviving entity, except for a transaction in which the holders of the outstanding voting securities of the Company immediately prior to such merger or consolidation hold as a result of holding Company securities prior to such transaction, in the aggregate, securities possessing more than fifty percent (50%) of the total combined voting power of all outstanding voting securities of the surviving entity (or the parent of the surviving entity) immediately after such merger or consolidation;

(c)A reverse merger in which the Company is the surviving entity but in which the holders of the outstanding voting securities of the Company immediately prior to such merger hold, in the aggregate, securities possessing less than fifty percent (50%) of the total combined voting power of all outstanding voting securities of the Company or of the acquiring entity immediately after such merger; or

(d)The sale, transfer or other disposition (in one transaction or a series of related transactions) of all or substantially all of the assets of the Company, except for a transaction in which the holders of the outstanding voting securities of the Company immediately prior to such transaction(s) receive as a distribution with respect to securities of the Company, in the aggregate, securities possessing more than fifty percent (50%) of the total combined voting power of all outstanding voting securities of the acquiring entity immediately after such transaction(s).

Notwithstanding the foregoing, if (i) a transaction does not qualify as a change in control event within the meaning of Section 409A of the Code and (ii) treating such transaction as a Change in Control would cause, give rise to or otherwise result in a failure to satisfy the distribution requirements of Section 409A(a)(2)(A) of the Code (to the extent the Plan and the applicable Option Agreement, Restricted Stock Agreement, Restricted Stock Unit Agreement, or Stock Appreciation Right Agreement are not exempt therefrom), then such transaction will not be deemed a Change in Control.

58


Table of Contents

2.8Code.  "Code" means the United States Internal Revenue Code of 1986, as amended from time to time.

2.9Committee.  "Committee" means a committee of two or more members of the Board appointed to administer the Plan, as set forth in Section 9.1.

2.10Company.  "Company" means Quotient Limited, a public no par value limited liability company incorporated in Jersey, Channel Islands, with registered number 109886, or any entity that is a successor to the Company.

2.11Continuous Service.  Unless otherwise provided in the Option Agreement, Restricted Stock Agreement, Restricted Stock Unit Agreement, or Stock Appreciation Right Agreement, the terms of which may be different from the following, "Continuous Service" means (a) Participant's employment by either the Company or any Affiliated Company, or by a successor entity following a Change in Control, which is uninterrupted except for vacations, illness (not including permanent Disability), or leaves of absence which are approved in writing by the Company or any of such other employer corporations, as applicable, (b) service as a member of the Board until the Participant resigns, is removed from office, or Participant's term of office expires and he or she is not reelected, or (c) so long as the Participant is engaged as a Consultant or other Service Provider.  Notwithstanding the foregoing, if (i) a termination, leave of absence, resignation, expiration or other cessation of engagement or employment does not qualify as a separation from service from the Company within the meaning of Section 409A of the Code and (ii) treating such termination, leave of absence, resignation, expiration or other cessation of engagement or employment as a termination of Continuous Service would cause, give rise to or otherwise result in a failure to satisfy the distribution requirements of Section 409A(a)(2)(A) of the Code or Section 457A of the Code (to the extent the Plan and the applicable Option Agreement, Restricted Stock Agreement, Restricted Stock Unit Agreement, or Stock Appreciation Right Agreement are not exempt therefrom), then such termination, leave of absence, resignation, expiration or other cessation of engagement or employment will not be deemed a termination of Continuous Service.

2.12Disability.  "Disability" means permanent and total disability as defined in Section 22(e)(3) of the Code.  The Administrator's determination of a Disability or the absence thereof shall be conclusive and binding on all interested parties.

2.13Effective Date.  "Effective Date" means the date on which the Plan was originally adopted by the Board, as set forth on the first page hereof.

2.14Exchange Act.  "Exchange Act" means the United States Securities and Exchange Act of 1934, as amended.

2.15Exercise Price.  "Exercise Price" means the subscription price per Ordinary Share (as applicable) payable by the Optionee to the Company upon exercise of an Option.

2.16Fair Market Value.  "Fair Market Value" on any given date means the value of one Ordinary Share, determined as follows:

(a)If the Ordinary Shares are then listed or admitted to trading on The NASDAQ Stock Market or another stock exchange which reports closing sale prices, the Fair Market Value shall be the closing sale price on the date of valuation on The NASDAQ Stock Market or principal stock exchange on which the Ordinary Shares are then listed or admitted for trading, or, if no closing sale price is quoted on such day, then the Fair Market Value shall be the closing sale price of the Ordinary Shares on The NASDAQ Stock Market or such exchange on the next preceding day on which a closing sale price is reported.

(b)If the Ordinary Shares are not then listed or admitted to trading on The NASDAQ Stock Market or a stock exchange which reports closing sale prices, the Fair Market Value shall be the average of the closing bid and asked prices of the Ordinary Shares in the over the counter market on the date of valuation.

(c)If neither (a) nor (b) is applicable as of the date of valuation, then the Fair Market Value shall be determined by the Administrator in good faith using any reasonable method of evaluation in a manner consistent with the valuation principles under Section 409A of the Code, which determination shall be conclusive and binding on all interested parties.

2.17FINRA Dealer.  "FINRA Dealer" means a broker-dealer that is a member of the Financial Industry Regulatory Authority.

2.18Incentive Option.  "Incentive Option" means any Option designated and qualified as an "incentive stock option" as defined in Section 422 of the Code.

2.19Incentive Option Agreement.  "Incentive Option Agreement" means an Option Agreement with respect to an Incentive Option.

59


Table of Contents

2.20Insider Trading Policy.  "Insider Trading Policy" means the insider trading policy of the Company, as adopted by the Board and then in effect.

2.21New Incentives.  "New Incentives" shall have the meaning set forth in Section 10.1(b) hereof.

2.22Nonqualified Option.  "Nonqualified Option" means any Option that is not an Incentive Option.  To the extent that any Option designated as an Incentive Option fails in whole or in part to qualify as an Incentive Option, including, without limitation, for failure to meet the limitations applicable to a 10% Shareholder or because it exceeds the annual limit provided for in Section 5.8 below, it shall to that extent constitute a Nonqualified Option.

2.23Nonqualified Option Agreement.  "Nonqualified Option Agreement" means an Option Agreement with respect to a Nonqualified Option.

2.24Option.  "Option" means any option to subscribe for or purchase Ordinary Shares granted pursuant to this Plan.

2.25Option Agreement.  "Option Agreement" means the written agreement entered into between the Company and the Optionee with respect to an Option granted under this Plan.

2.26Optionee.  "Optionee" means any Participant who holds an Option.

2.27Ordinary Shares.  "Ordinary Shares" means the ordinary shares of no par value in the capital of the Company and "share of Common Stock" and "shares of Common Stock" mean any one or more of such shares (as the context may require), in each case subject to adjustment pursuant to Section 4.2.

2.28Participant.  "Participant" means an individual or entity that holds Options, Restricted Stock, Restricted Stock Units or Stock Appreciation Rights under this Plan.

2.29Performance Criteria.  "Performance Criteria" means the criteria that the Administrator may select from time to time for purposes of establishing the performance goals or objectives applicable to the vesting of any Incentive Option, Nonqualified Option, Restricted Stock, Restricted Stock Units or Stock Appreciation Rights granted under the Plan and may be applicable to the Company, an Affiliated Company, a division, business unit or product of the Company or any Affiliated Company, or any combination of the foregoing, and which may be stated as an absolute amount, a target percentage over a base percentage or absolute amount, or the occurrence of a specific event), any of which may be measured either in absolute terms or as compared to any incremental increase or as compared to results of a peer group.

2.30Plan.  "Plan" means this Second Amended and Restated 2014 Stock Incentive Plan of the Company.

2.31Prior Evergreen Increases to the Initial Limit. "Prior Increases to the Initial Limit" means two million six hundred ninety-nine thousand two hundred seventy-three (2,699,273) Ordinary Shares.

2.32Purchase Price.  "Purchase Price" means the subscription or purchase price (as applicable) per share of Restricted Stock or share underlying a Restricted Stock Unit.

2.33Restricted Stock.  "Restricted Stock" means Ordinary Shares issued pursuant to Article 6 hereof, subject to any restrictions and conditions as are established pursuant to such Article 6.

2.34Restricted Stock Agreement.  "Restricted Stock Agreement" means the written agreement entered into between the Company and a Participant evidencing the grant of Restricted Stock under the Plan.

2.35Restricted Stock Unit.  "Restricted Stock Unit" means a right to receive Ordinary Shares or an amount equal to the Fair Market Value of the underlying Ordinary Shares pursuant to Article 8 hereof, subject to any restrictions and conditions as are established pursuant to such Article 8.

2.36Restricted Stock Unit Agreement.  "Restricted Stock Unit Agreement" means the written agreement entered into between the Company and a Participant evidencing the grant of Restricted Stock Unit under the Plan.

2.37Securities Act.  "Securities Act" means the United States Securities Act of 1933, as amended.

60


Table of Contents

2.38Service Provider.  "Service Provider" means a consultant or other person or entity the Administrator authorizes to become a Participant in the Plan and who provides services to (i) the Company, (ii) an Affiliated Company, or (iii) any other business venture designated by the Administrator in which the Company or an Affiliated Company has a significant ownership interest.

2.39Shares.  "shares" includes Ordinary Shares.

2.40Shareholder.  "shareholder" includes a "member" within the meaning given to such term by the Articles of Association of the Company at the relevant time.

2.41Stock.  "stock" includes Ordinary Shares.

2.42Stock Appreciation Right.  "Stock Appreciation Right" means a right issued pursuant to Article 7, subject to any restrictions and conditions as are established pursuant to Article 7, that is designated as a Stock Appreciation Right.

2.43Stock Appreciation Right Agreement.  "Stock Appreciation Right Agreement" means the written agreement entered into between the Company and a Participant evidencing the grant of Stock Appreciation Rights under the Plan.

2.4410% Shareholder.  "10% Shareholder" means a person who, as of a relevant date, owns or is deemed to own (by reason of the attribution rules applicable under Section 424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or of an Affiliated Company.

2.45Fourth Amended and Restated Initial Limit.  "Fourth Amended and Restated Initial Limit" means thirteen million five hundred fifty thousand (13’550’000) Ordinary Shares.

2.462014 Plan. "2014 Plan" means the 2014 Stock Incentive Plan of the Company.

2.47United States.  "United States" means the United States of America and (as the context requires) and State of the United States of America.

2.48In this Plan, unless the context otherwise requires:

(a)references to persons shall include individuals, bodies corporate (wherever incorporated), unincorporated associations and partnerships, and references to a company or a corporation are to a body corporate wherever incorporated;

(b)the headings are inserted for convenience only and shall not affect the construction of this Plan;

(c)the singular shall include the plural and vice versa and references to one gender include all genders;

(d)references to Sections, paragraphs and Exhibits are to sections and paragraphs of sections of and exhibits to this Plan;

(e)general words shall not be given a restrictive meaning by reason of the fact that they are followed by particular examples intended to be embraced by the general words;

(f)any reference to an enactment, statutory provision or treaty is a reference to it as it may have been amended, modified, consolidated or re‑enacted as at the date of this Plan and shall include any orders and regulations made pursuant thereto;

(g)references to any Jersey legal term for any action, remedy, method of judicial proceeding, legal document, legal status, court, official or any other legal concept shall, in respect of any jurisdiction other than Jersey, be deemed to include the legal concept which most nearly approximates in that jurisdiction to the Jersey legal term;

(h)references to United States statutes, ordinances, regulations or any other instruments having the force of law therein shall be interpreted as if the Company was incorporated in the United States and subject to such provisions, to the extent the same does not contravene any laws of Jersey or the United States;

(i)where pursuant to this Plan the Company is said to be authorised or empowered to exercise any authorities, discretions or powers pursuant to any United States statutes, ordinances, regulations or any other instruments, the Company shall also be authorised and empowered to exercise any similar or analogous authorities, discretions or powers pursuant to the laws of Jersey;

61


Table of Contents

(j)any references to this Plan to a legal remedy or legal concept under United States law shall be construed as the legal remedy or legal concept under Jersey law which most closely reflects the same; and

(k)references to time are to the time in New York.

The Exhibits shall form part of this plan.

ARTICLE 3.

ELIGIBILITY

3.1Incentive Options.  Only employees of the Company or of an Affiliated Company (including members of the Board if they are employees of the Company or of an Affiliated Company) are eligible to receive Incentive Options under the Plan.

3.2Nonqualified Options; Restricted Stock; Restricted Stock Units; and Stock Appreciation Rights.  Employees of the Company or of an Affiliated Company, members of the Board (whether or not employed by the Company or an Affiliated Company), and Service Providers are eligible to receive Nonqualified Options, Restricted Stock, Restricted Stock Units and Stock Appreciation Rights under the Plan.

3.3Performance Goals

(a)Performance Thresholds.  The performance goals or objectives applicable to the vesting of any Incentive Option, Nonqualified Option, Restricted Stock, Restricted Stock Units or Stock Appreciation Rights granted under the Plan may include a threshold level of performance below which no payment shall be made (or no vesting shall occur), levels of performance at which specified payments shall be made (or specified vesting shall occur), and a maximum level of performance above which no additional payment shall be made (or at which full vesting shall occur).

(b)Adjustments.  Unless the Committee provides otherwise at the time of establishing the performance goals, for each fiscal year of the Company, the Committee shall have the authority to make equitable adjustments to the performance goals or objectives applicable to the vesting of any Incentive Option, Nonqualified Option, Restricted Stock, Restricted Stock Units or Stock Appreciation Rights granted under the Plan in recognition of unusual or non recurring events affecting the Company or an Affiliated Company or the financial statements of the Company or an Affiliated Company and may provide for objectively determinable adjustments to any of the Performance Criteria described above for one or more of the items of gain, loss, profit or expense: (i) determined to be extraordinary or unusual in nature or infrequent in occurrence, (ii) related to the disposal of a segment of a business, (iii) related to a change in accounting principles, applicable laws or regulations, (iv) related to discontinued operations that do not qualify as a segment of a business, and (E) attributable to the business operations of any entity acquired by the Company during the fiscal year.

3.4Deferrals.  To the extent permitted by applicable law, the Administrator, in its sole discretion, may determine that the delivery of Ordinary Shares or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Option, Restricted Stock, Restricted Stock Units or Stock Appreciation Right may be deferred and may establish programs and procedures for deferral elections to be made by Participants.  Deferrals by Participants will be made only in accordance with Section 409A of the Code, and only if the Committee determines in good faith that the deferral is permissible under Section 457A of the Code.  Consistent with Sections 409A and 457A of the Code, the Administrator may provide for distributions while a Participant is providing Continuous Service to the Company.

62


Table of Contents

ARTICLE 4.

PLAN SHARES

4.1Shares Subject to the Plan.  As of [•], [2022], the maximum number of Ordinary Shares reserved and available for issuance under this Plan shall initially be equal to the sum of (i) the Fourth Amended and Restated Initial Limit and (ii) the Prior Evergreen Increases to the Initial Limit, subject to adjustment as to the number and kind of shares pursuant to Section 4.2 or such lesser number of Ordinary Shares as determined by the Administrator.  Subject to such overall limitation, the maximum aggregate number of Ordinary Shares that may be issued in the form of Incentive Options shall not exceed the lesser of (x) the sum of (i) the Fourth Amended and Restated Initial Limit and (ii) the Prior Evergreen Increases to the Initial Limit, cumulatively increased as provided in the foregoing sentence or (y) 5,050,000 shares, in each case subject to adjustment as provided in Section 4.2.  For purposes of this limitation, in the event that (a) all or any portion of any Options or Stock Appreciation Rights granted under the Plan can no longer under any circumstances be exercised, (b) any Ordinary Shares are reacquired by the Company pursuant to an Option Agreement, other than Ordinary Shares surrendered for purposes of payment of the Exercise Price or applied or delivered in satisfaction of a tax withholding obligation, or (c) all or any portion of any Restricted Stock or Restricted Stock Unit granted under the Plan is forfeited or can no longer under any circumstances vest, then the Ordinary Shares allocable to or covered by the unexercised or unvested portion of such Options, Stock Appreciation Rights, Restricted Stock, or Restricted Stock Units or the Ordinary Shares so reacquired shall again be available for grant or issuance under the Plan.  To the extent a Stock Appreciation Right (or portion thereof) is settled in cash as provided in Section 7.6, such Stock Appreciation Right (or portion thereof) shall be deemed to reduce the number of Ordinary Shares available for grant or issuance under the Plan.  The shares available for issuance under the Plan may be unissued Ordinary Shares or Ordinary Shares reacquired by the Company by way of repurchase or redemption.

4.2Changes in Capital Structure.  In the event that the outstanding Ordinary Shares are hereafter increased or decreased or changed into or exchanged for a different number or kind of shares or other securities of the Company by reason of a recapitalization, stock split, reverse stock split (consolidation), reclassification or redesignation, stock dividend (bonus issue), or other similar change in the capital structure of the Company, then appropriate adjustments shall be made to the aggregate number and kind of shares subject to this Plan, the number and kind of shares and the price per share subject to or covered by outstanding Option Agreements, Restricted Stock Agreements, Restricted Stock Unit Agreement, or Stock Appreciation Right Agreements and the limit on the number of shares under Section 3.3, all in order to preserve, as nearly as practical, but not to increase, the benefits to Participants.

ARTICLE 5.

OPTIONS

5.1Grant of Stock Options.  The Administrator (or pursuant to Section 9.2, an officer of the Company) shall have the right to grant pursuant to this Plan, Options subject to such terms, restrictions and conditions as the Administrator may determine at the time of grant.  Such conditions may include, but are not limited to, continued employment or the achievement of specified performance goals or objectives established by the Administrator with respect to one or more Performance Criteria, which require the Administrator to certify whether and the extent to which such Performance Criteria were achieved.

5.2Option Agreements.  Each Option granted pursuant to this Plan shall be evidenced by an Option Agreement which shall specify the number of shares subject thereto, vesting provisions relating to such Option, the Exercise Price per share, and whether the Option is an Incentive Option or Nonqualified Option.  As soon as is practical following the grant of an Option, an Option Agreement shall be duly executed and delivered by or on behalf of the Company to the Optionee to whom such Option was granted.  Each Option Agreement shall be in such form and contain such additional terms and conditions, not inconsistent with the provisions of this Plan, as the Administrator shall, from time to time, deem appropriate.  Each Option Agreement may be different from each other Option Agreement.

5.3Exercise Price.  The Exercise Price per Ordinary Share covered by each Option shall be determined by the Administrator, subject to the following: (a) the Exercise Price of an Incentive Option shall not be less than 100% of Fair Market Value on the date the Incentive Option is granted, (b) the Exercise Price of a Nonqualified Option shall not be less than 100% of Fair Market Value on the date the Nonqualified Option is granted, and (c) if the person to whom an Incentive Option is granted is a 10% Shareholder on the date of grant, the Exercise Price shall not be less than 110% of Fair Market Value on the date the Incentive Option is granted.  However, an Option may be granted with an Exercise Price lower than that set forth in the preceding sentence if such Option is granted pursuant to an assumption or substitution for another option in a manner satisfying the provisions of Sections 409A and 424 of the Code.

63


Table of Contents

5.4Payment of Exercise Price.  Payment of the Exercise Price shall be made upon exercise of an Option and may be made, in the discretion of the Administrator, subject to any legal restrictions, by: (a) cash; (b) check (cheque); (c) provided that a public market for the Ordinary Shares exists, a "same day sale" commitment from the Optionee and a FINRA Dealer whereby the Optionee irrevocably elects to exercise the Option and to sell a portion of the shares so purchased to pay for the Exercise Price and whereby the FINRA Dealer irrevocably commits upon receipt of such shares to forward the Exercise Price directly to the Company; (f) any combination of the foregoing methods of payment; or (g) any other consideration or method of payment as shall be permitted by applicable law.

5.5Term and Termination of Options.  The term and provisions for termination of each Option shall be as fixed by the Administrator, but no Option may be exercisable more than ten (10) years after the date it is granted.  An Incentive Option granted to a person who is a 10% Shareholder on the date of grant shall not be exercisable more than five (5) years after the date it is granted.

5.6Date of Grant.  The date of grant of an Option will be the date on which the Administrator makes the determination to grant such Options, unless a later date is otherwise specified by the Administrator.  The Option Agreement and a copy of this Plan will be delivered to the Optionee within a reasonable time after the granting of the Option.

5.7Vesting and Exercise of Options.

(a)Each Option shall vest and become exercisable in one or more installments at such time or times and subject to such conditions, including without limitation the achievement of specified performance goals or objectives established with respect to one or more Performance Criteria as shall be determined by the Administrator.

(b)Except as otherwise provided in the Option Agreement, following the termination of the Participant's Continuous Service (i) due to Disability, Incentive Options held by such Optionee on the date of termination (to the extent then exercisable) may be exercised in whole or in part at any time within one year of the date of termination (but in no event after the Expiration Date) (ii) due to death, Incentive Options held by such Optionee on the date of death (to the extent then exercisable) may be exercised in whole or in part by the Optionee's heirs or estate at any time prior to the final expiration of the Incentive Option, as set forth in the applicable Stock Option Agreement.

5.8Annual Limit on Incentive Options.  To the extent required for "incentive stock option" treatment under Section 422 of the Code, the aggregate Fair Market Value (determined as of the time of grant) of the Ordinary Shares with respect to which Incentive Options granted under this Plan and any other plan of the Company or any Affiliated Company become exercisable for the first time by an Optionee during any calendar year shall not exceed $100,000.

5.9Nontransferability of Options.  Except as otherwise provided in this Section 5.9, (a) Incentive Options shall not be assignable or transferable except by will, the laws of descent and distribution or pursuant to a domestic relations order entered by a court in settlement of marital property rights, (b) Nonqualified Options shall not be assignable or transferable except by will, the laws of succession, bankruptcy, descent and distribution or pursuant to a domestic relations order or other equivalent order entered by a court in settlement of marital property rights, and (c) during the life of the Optionee, Options shall be exercisable only by the Optionee.  At the discretion of the Administrator and in accordance with rules it establishes from time to time, Optionees may be permitted to transfer some or all of their Nonqualified Options to one or more "family members," which is not a "prohibited transfer for value," provided that (a) the Optionee (or such Optionee's estate or representative) shall remain obligated to satisfy all income or other tax withholding obligations associated with the exercise of such Nonqualified Option; (b) the Optionee shall notify the Company in writing that such transfer has occurred and disclose to the Company the name and address of the "family member" or "family members" and their relationship to the Optionee, and (c) such transfer shall be effected pursuant to transfer documents in a form approved by the Administrator.  For purposes of the foregoing, the terms "family members" and "prohibited transfer for value" have the meaning ascribed to them in the General Instructions to Form S‑8 (or any successor form) promulgated under the Securities Act.

5.10Non‑Employee Directors.

(a)[Reserved]

(b)Each non‑employee director shall be granted Options issued immediately following the annual general meeting with value and vesting dates consistent with the then current non-employee director compensation program in place at the date of grant, based on the Fair Market Value of the Ordinary Shares at the date of grant (the "Annual Nonqualified Option Grant").  To the extent a non‑employee director commences service on the Board on a date other than the date of an annual meeting of shareholders, the Annual Nonqualified Option Grant shall be pro‑rated based upon the number of full months of service on the Board prior to such annual meeting of shareholders (up to a maximum of twelve (12) months), divided by twelve (12).  The exercise price of the Nonqualified Options described in this Section 5.10(b) shall be at Fair Market Value on the date of grant.  

64


Table of Contents

5.11Rights as a Shareholder.  An Optionee or permitted transferee of an Option shall have no rights or privileges as a shareholder with respect to any shares covered by an Option until such Option has been duly exercised in accordance with the terms of the relevant Option Agreement.

5.12Unvested Shares.  The Administrator shall have the discretion to grant Options that are exercisable for unvested Ordinary Shares on such terms and conditions as the Administrator shall determine from time to time.

5.13Notice of Disqualifying Disposition of Incentive Option Shares.  If a Participant sells or otherwise disposes of any of the Ordinary Shares acquired pursuant to the exercise of an Incentive Option on or before the later of (i) the date two (2) years after the date of grant of such Incentive Option, or (ii) the date one (1) year after the date of exercise of such Incentive Option, such Participant shall immediately notify the Company in writing of such disposition.

5.14Compliance with Code Sections 409A and 457A.  Notwithstanding anything in this Article 5 to the contrary, to the extent that any Option is subject to Code Section 409A or Code Section 457A, the Option is intended to be structured to satisfy the requirements of Code Section 409A or Code Section 457A (as applicable), or an applicable exemption, as determined by the Administrator.

ARTICLE 6.

RESTRICTED STOCK

6.1Issuance and Sale of Restricted Stock.  The Administrator shall have the right to issue shares of Restricted Stock subject to such terms, restrictions and conditions as the Administrator may determine at the time of grant.  Such conditions may include, but are not limited to, continued employment or the achievement of specified performance goals or objectives established by the Administrator with respect to one or more Performance Criteria, which require the Administrator to certify whether and the extent to which such Performance Criteria were achieved.  The Purchase Price of Restricted Stock (which may be zero) shall be determined by the Administrator.

6.2Restricted Stock Agreements.  A Participant shall have no rights with respect to the shares of Restricted Stock covered by a Restricted Stock Agreement until the Participant has paid the full Purchase Price, if any, to the Company in the manner set forth in Section 6.3 hereof and has executed and delivered to the Company the applicable Restricted Stock Agreement.  Each Restricted Stock Agreement shall be in such form, and shall set forth such terms, conditions and restrictions of the Restricted Stock, not inconsistent with the provisions of this Plan, as the Administrator shall, from time to time, deem appropriate.  Each Restricted Stock Agreement may be different from each other Restricted Stock Agreement.

6.3Payment of Purchase Price.  Subject to any legal restrictions (including the Sarbanes-Oxley Act of 2002), payment of the Purchase Price, if any, may be made, in the discretion of the Administrator, by: (a) cash; (b) check (cheque); (c) the Participant's promissory note in a form and on terms acceptable to the Administrator; (d) the cancellation of indebtedness of the Company to the Participant; (e) the waiver of compensation due or accrued to the Participant for services rendered; (f) any combination of the foregoing methods of payment; or (g) any other consideration or method of payment as shall be permitted by applicable law.

6.4Vesting of Restricted Stock.  Each share of Restricted Stock shall vest in one or more installments at such time or times and subject to such conditions, including without limitation continued employment or the achievement of specified performance goals or objectives established with respect to one or more Performance Criteria as shall be determined by the Administrator.

6.5Rights as a Shareholder.  Upon complying with the provisions of Section 6.2 hereof, a Participant shall have the rights of a shareholder with respect to Restricted Stock, including voting and dividend rights, subject to the terms, restrictions and conditions set forth in the relevant Restricted Stock Agreement.

6.6Dividends.  If payment for shares of Restricted Stock is made by promissory note, any cash dividends paid with respect to the Restricted Stock may be applied, in the discretion of the Administrator, to repayment of such note.

6.7Compliance with Code Sections 409A and 457A.  Notwithstanding anything in this Article 6 to the contrary, to the extent that any award of Restricted Stock is subject to Code Section 409A or Code Section 457A, such award of Restricted Stock must be structured to satisfy the requirements of Code Sections 409A or 457A (as applicable), or an applicable exemption, as determined by the Administrator.

65


Table of Contents

ARTICLE 7.

STOCK APPRECIATION RIGHTS

7.1Grants of Stock Appreciation Rights.  The Administrator shall have the right to grant pursuant to this Plan, Stock Appreciation Rights subject to such terms, restrictions and conditions as the Administrator may determine at the time of grant.  Such conditions may include, but are not limited to, continued employment or the achievement of specified performance goals or objectives established by the Administrator with respect to one or more Performance Criteria, which require the Administrator to certify whether and the extent to which such Performance Criteria were achieved.

7.2Stock Appreciation Right Agreements.  A Participant shall have no rights with respect to the Stock Appreciation Rights covered by a Stock Appreciation Right Agreement until the Participant has executed and delivered to the Company the applicable Stock Appreciation Right Agreement.  Each Stock Appreciation Right Agreement shall be in such form, and shall set forth the Base Price and such other terms, conditions and restrictions of the Stock Appreciation Right Agreement, not inconsistent with the provisions of this Plan, as the Administrator shall, from time to time, deem appropriate.  Each such Stock Appreciation Right Agreement may be different from each other Stock Appreciation Right Agreement.

7.3Base Price.  The Base Price per Ordinary Share covered by each Stock Appreciation Right shall be determined by the Administrator and will be not less than 100% of Fair Market Value on the date the Stock Appreciation Right is granted.  However, a Stock Appreciation Right may be granted with a Base Price lower than that set forth in the preceding sentence if such Stock Appreciation Right is granted pursuant to an assumption or substitution for another stock appreciation right in a manner satisfying the provisions of Section 409A of the Code.

7.4Term and Termination of Stock Appreciation Rights.  The term and provisions for termination of each Stock Appreciation Right shall be as fixed by the Administrator, but no Stock Appreciation Right may be exercisable more than ten (10) years after the date it is granted.

7.5Vesting and Exercise of Stock Appreciation Rights.  Each Stock Appreciation Right shall vest and become exercisable in one or more installments at such time or times and subject to such conditions, including without limitation the achievement of specified performance goals or objectives as shall be determined by the Administrator.

7.6Amount, Form and Timing of Settlement.  Upon exercise of a Stock Appreciation Right, the Participant who holds such Stock Appreciation Right will be entitled to receive payment from the Company in an amount equal to the product of (a) the difference between the Fair Market Value of an Ordinary Share on the date of exercise over the Base Price per Ordinary Share covered by such Stock Appreciation Right and (b) the number of Ordinary Shares with respect to which such Stock Appreciation Right is being exercised.  Payment in respect thereof will be made no later than thirty (30) days after such exercise, provided that such payment will be made in a manner such that no amount of compensation will be treated as deferred under Treasury Regulation Section 1.409A-1(b)(5)(i)(D) or Section 457A of the Code.  Such payment may, in the discretion of the Administrator, be in cash, Ordinary Shares of equivalent Fair Market Value as of the date of exercise, or a combination of both, except as specifically provided in the Stock Appreciation Right Agreement.

7.7Rights as a Shareholder.  Holders of Stock Appreciation Rights shall have no rights or privileges as a shareholder with respect to any Ordinary Shares covered thereby unless and until they become owners of Ordinary Shares following settlement in respect of such Stock Appreciation Rights, in whole or in part, in Ordinary Shares, pursuant to the terms, restrictions and conditions set forth in the relevant Stock Appreciation Rights Agreement.

7.8Restrictions.  Stock Appreciation Rights may not be sold, pledged or otherwise encumbered or disposed of and shall not be assignable or transferable except by will, the laws of descent and distribution or pursuant to a domestic relations order entered by a court in settlement of marital property rights, except as specifically provided in the Stock Appreciation Right Agreement or as authorized by the Administrator.

7.9Unvested Shares.  The Administrator shall have the discretion to grant Stock Appreciation Rights that may be exercised or settled for unvested Ordinary Shares on such terms and conditions as the Administrator shall determine from time to time.

7.10Compliance with Code Sections 409A and 457A.  Notwithstanding anything in this Article 7 to the contrary, to the extent that any award of Stock Appreciation Rights is subject to Code Section 409A or Code Section 457A, such award of Stock Appreciation Rights is intended to be structured to satisfy the requirements of Code Sections 409A or 457A (as applicable), or an applicable exemption, as determined by the Administrator.

66


Table of Contents

ARTICLE 8.

RESTRICTED STOCK UNITS

8.1Grants of Restricted Stock Units.  The Administrator shall have the right to grant pursuant to this Plan, Restricted Stock Units subject to such terms, restrictions and conditions as the Administrator may determine at the time of grant.  Such conditions may include, but are not limited to, continued employment or the achievement of specified performance goals or objectives established by the Administrator with respect to one or more Performance Criteria, which require the Administrator to certify whether and the extent to which such Performance Criteria were achieved.  The Purchase Price of Restricted Stock Unit (which may be zero) shall be determined by the Administrator.

8.2Restricted Stock Unit Agreements.  A Participant shall have no rights with respect to the Restricted Stock Units covered by a Restricted Stock Unit Agreement until the Participant has executed and delivered to the Company the applicable Restricted Stock Unit Agreement.  Each Restricted Stock Unit Agreement shall be in such form, and shall set forth such terms, conditions and restrictions of the Restricted Stock Unit Agreement, not inconsistent with the provisions of this Plan, as the Administrator shall, from time to time, deem appropriate.  Each such Restricted Stock Unit Agreement may be different from each other Restricted Stock Unit Agreement.

8.3Payment of Purchase Price.  Subject to any legal restrictions (including the Sarbanes-Oxley Act of 2002), payment of the Purchase Price, if any, may be made, in the discretion of the Administrator, by: (a) cash; (b) check (cheque); (c) the Participant's promissory note in a form and on terms acceptable to the Administrator; (d) the cancellation of indebtedness of the Company to the Participant; (e) the waiver of compensation due or accrued to the Participant for services rendered; (f) any combination of the foregoing methods of payment; or (g) any other consideration or method of payment as shall be permitted by applicable law.

8.4Vesting of Restricted Stock Units.  The Restricted Stock Units shall vest in one or more installments at such time or times and subject to such conditions, including without limitation continued employment or the achievement of specified performance goals or objectives established with respect to one or more Performance Criteria as shall be determined by the Administrator.

8.5Rights as a Shareholder.  Holders of Restricted Stock Units shall have no rights or privileges as a shareholder with respect to any Ordinary Shares covered thereby unless and until they become owners of Ordinary Shares following settlement in respect of such Restricted Stock Units, in whole or in part, in Ordinary Shares, pursuant to the terms, restrictions and conditions set forth in the relevant Restricted Stock Unit Agreement.  Notwithstanding the foregoing, the Restricted Stock Unit Agreement may provide dividend equivalent rights to a holder of Restricted Stock Units.

8.6Restrictions.  Restricted Stock Units may not be sold, pledged or otherwise encumbered or disposed of and shall not be assignable or transferable except by will, the laws of descent and distribution or pursuant to a domestic relations order entered by a court in settlement of marital property rights, except as specifically provided in the Restricted Stock Unit Agreement or as authorized by the Administrator.

8.7Compliance with Code Sections 409A and 457A.  Notwithstanding anything in this Article 6 to the contrary, to the extent that any award of Restricted Stock is subject to Code Section 409A or Code Section 457A, such award of Restricted Stock must be structured to satisfy the requirements of Code Sections 409A or 457A (as applicable), or an applicable exemption, as determined by the Administrator.

ARTICLE 9.

ADMINISTRATION OF THE PLAN

9.1Administrator.  Authority to control and manage the operation and administration of the Plan shall be vested in the Board, which may delegate such responsibilities in whole or in part to the Committee.  Each of the members shall meet the independence requirements under the then applicable rules, regulations or listing requirements adopted by The NASDAQ Stock Market or the principal exchange on which the Ordinary Shares is then listed or admitted to trading.  Members of the Committee may be appointed from time to time by, and shall serve at the pleasure of, the Board.  The Board may limit the composition of the Committee to those persons necessary to comply with the requirements of Section 16 of the Exchange Act.  As used herein, the term "Administrator" means the Board or, with respect to any matter as to which responsibility has been delegated to the Committee, the term Administrator shall mean the Committee.

9.2Delegation to an Officer.  To the extent authorized by applicable law, the Board may delegate to one or more officers of the Company the authority to do one or both of the following: (a) designate employees (other than officers) of the Company or any of its subsidiary corporations to be recipients of Incentive Options, Nonqualified Options, Restricted Stock, Restricted Stock Units, or Stock Appreciation Rights and (b) determine the number of Ordinary Shares to be subject to such Options, Stock Appreciation Rights or Restricted Stock Units or to be issued as Restricted Stock and granted to such employees (other than officers) of the Company or any of its subsidiary corporations; provided, however, that the resolutions of the Board regarding such delegation shall specify that grants of Plan awards to employees pursuant to this Section 9.2 shall be consistent with specific parameters approved in advance by the Committee.

67


Table of Contents

9.3Powers of the Administrator.  In addition to any other powers or authority conferred upon the Administrator elsewhere in this Plan or by law, the Administrator shall have full power and authority: (a) to determine the persons to whom, and the time or times at which, Incentive Options, Nonqualified Options, Restricted Stock, Restricted Stock Units or Stock Appreciation Rights shall be granted, the number of shares to be represented by each Option Agreement, Restricted Stock Agreement, Restricted Stock Unit Agreement, or Stock Appreciation Right Agreement, and the Exercise Price of such Options, the Purchase Price of the Restricted Stock and Restricted Stock Units, and the Base Price of such Stock Appreciation Rights; (b) to interpret the Plan; (c) to create, amend or rescind rules and regulations relating to the Plan; (d) to determine the terms, conditions and restrictions contained in, and the form of, Option Agreements, Restricted Stock Agreements, Restricted Stock Unit Agreements, and Stock Appreciation Right Agreements; (e) to determine the identity or capacity of any persons who may be entitled to exercise a Participant's rights under any Option Agreement, Restricted Stock Agreement, Restricted Stock Unit Agreement, or Stock Appreciation Right Agreement under the Plan; (f) to correct any defect or supply any omission or reconcile any inconsistency in the Plan or in any Option Agreement, Restricted Stock Agreement, Restricted Stock Unit Agreement, or Stock Appreciation Right Agreement; (g) to accelerate the vesting of any Option, Restricted Stock, Restricted Stock Units, or Stock Appreciation Right; (h) to extend the expiration date of any Option Agreement or Stock Appreciation Right Agreement; (i) to amend outstanding Option Agreements, Restricted Stock Agreements, Restricted Stock Unit Agreement, or Stock Appreciation Right Agreements to provide for, among other things, any change or modification which the Administrator could have included in the original agreement or in furtherance of the powers provided for herein; and (j) to make all other determinations necessary or advisable for the administration of this Plan, but only to the extent not contrary to the express provisions of this Plan.  Any action, decision, interpretation or determination made in good faith by the Administrator in the exercise of its authority conferred upon it under this Plan shall be final and binding on the Company and all Participants.  Notwithstanding any term or provision in this Plan, the Administrator shall not have the power or authority, by amendment or otherwise to extend the expiration date of an Option or Stock Appreciation Right beyond the original expiration date of such Option or Stock Appreciation Right.

9.4Repricing Prohibited.  Subject to Section 4.2, and except in connection with a corporate transaction involving the Company (including, without limitation, any stock dividend, stock split, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, split‑up, spin‑off, combination, or exchange of shares), neither the Committee nor the Board shall amend the terms of outstanding awards to reduce the Exercise Price of outstanding Options or the Base Price of outstanding Stock Appreciation Rights or cancel outstanding Options or Stock Appreciation Rights in exchange for cash, for Options with an Exercise Price that is less than the Exercise Price of the original Options, or for Stock Appreciation Rights with a Base Price that is less than the Base Price of the original Stock Appreciation Rights, in each case without approval of the Company's shareholders, evidenced by a majority of votes cast.

9.5Limitation on Liability.  No employee of the Company or, subject to applicable laws, member of the Board or Committee shall be subject to any liability with respect to duties under the Plan unless the person acts fraudulently or in bad faith.  To the extent permitted by law, the Company shall indemnify each member of the Board or Committee, and any employee of the Company with duties under the Plan, who was or is a party, or is threatened to be made a party, to any threatened, pending or completed proceeding, whether civil, criminal, administrative or investigative, by reason of such person's conduct in the performance of duties under the Plan.

ARTICLE 10.

RESTRICTIONS; EXTENSIONS

10.1Recovery.  All Options, Stock Appreciation Rights and Restricted Stock Units, or any Ordinary Shares or cash issued or awarded pursuant to the exercise of Options, Stock Appreciation Rights or Restricted Stock Units, and all Restricted Stock will be subject to recoupment in accordance with any clawback or recovery policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company's securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law.  In addition, the Administrator may impose such other clawback, recovery or recoupment provisions in an Option, Stock Appreciation Right, Restricted Stock Unit Agreement, or Restricted Stock Agreement as the Administrator determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired Ordinary Shares or other cash or property upon the occurrence of an event constituting Cause.  No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for "good reason" or "constructive termination" (or similar term) under any agreement with the Company.

10.2Termination for Cause.  Except as explicitly provided otherwise in a Participant's Stock Option Agreement or Stock Appreciation Right Agreement or other individual written agreement between the Company or any Affiliated Company and the Participant, if a Participant's Continuous Service is terminated for Cause, the Option or SAR will terminate immediately upon such Participant's termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the date of such termination of Continuous Service.  "Cause" will have the meaning ascribed to such term in any written agreement between the Participant and the Company defining such term and, in the absence of such agreement, shall mean Cause as defined in this Plan.  The determination that a termination of the Participant's Continuous Service is either for Cause or without Cause will be made by the Administrator, in its sole discretion.  Any determination by the Administrator that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Options or Stock Appreciation Rights held by such Participant will have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose.

68


Table of Contents

10.3Extension of Termination Date.

(a)If the exercise of an Option or Stock Appreciation Right following the termination of the Participant's Continuous Service (other than for Cause and other than upon the Participant's death or Disability) would be prohibited at any time solely because the issuance of Ordinary Shares would violate the Securities Act, then the Option or Stock Appreciation Right will terminate on the earlier of (i) the expiration of a total period of time (that need not be consecutive) equal to the applicable post termination exercise period after the termination of the Participant's Continuous Service (as set forth in the applicable award agreement) as extended for any period of time during which the exercise of the Option or Stock Appreciation Right would violate the Securities Act, and (ii) the final expiration of the Option or Stock Appreciation Right as set forth in the applicable Stock Option Agreement or Stock Appreciation Right Agreement.

(b)Unless otherwise provided in a Participant's Option Agreement or Stock Appreciation Right Agreement, if the sale of any Ordinary Share received on exercise of an Option or Stock Appreciation Right following the termination of the Participant's Continuous Service (other than for Cause) would violate the Company's Insider Trading Policy (assuming, for this purpose, that Participant's Continuous Service had not terminated and thus the provisions of the Insider Trading Policy continued to apply to Participant), then the Option or Stock Appreciation Right will terminate on the earlier of (i) the expiration of a period of time (that need not be consecutive) equal to the applicable post‑termination exercise period after the termination of the Participant's Continuous Service (as set forth in the applicable award agreement) as extended for any period of time during which the sale of the Ordinary Shares received upon exercise of the Option or Stock Appreciation Right would violate the Insider Trading Policy (assuming, for this purpose, that Participant's Continuous Service had not terminated and thus the provisions of the Insider Trading Policy continued to apply to Participant) if, and only if, such violation of the Insider Trading Policy arose during the unmodified post‑termination exercise period, or (ii) the final expiration of the term of the Option or Stock Appreciation Right as set forth in the applicable Stock Option Agreement or Stock Appreciation Right Agreement.

ARTICLE 11.

CHANGE IN CONTROL

11.1Options and Stock Appreciation Rights.  In order to preserve a Participant's rights with respect to any outstanding Options or Stock Appreciation Rights in the event of a Change in Control of the Company:

(a)Vesting of all outstanding Options and Stock Appreciation Rights shall accelerate automatically effective as of immediately prior to the consummation of the Change in Control unless the Options or Stock Appreciation Rights are to be assumed by the acquiring or successor entity (or parent thereof) or new options, stock appreciation rights or New Incentives are to be issued in exchange therefor, as provided in subsection (b) below.

(b)Vesting of outstanding Options or Stock Appreciation Rights shall not accelerate if and to the extent that: (i) the Options or Stock Appreciation Rights (including the unvested portion thereof) are to be assumed by the acquiring or successor entity (or parent thereof) or new options or stock appreciation rights of comparable value and containing such terms and provisions as the Administrator in its discretion may consider equitable are to be issued in exchange therefor pursuant to the terms of the Change in Control transaction, or (ii) the Options or Stock Appreciation Rights (including the unvested portion thereof) are to be replaced by the acquiring or successor entity (or parent thereof) with other incentives of comparable value containing such terms and provisions as the Administrator in its discretion may consider equitable under a new incentive program ("New Incentives").  If outstanding Options or Stock Appreciation Rights are assumed, or if new options or stock appreciation rights of comparable value are issued in exchange therefor, then each such Option, new option, Stock Appreciation Right or new stock appreciation right shall be appropriately adjusted, concurrently with the Change in Control, to apply to the number and class of securities or other property that the Participant would have received pursuant to the Change in Control transaction in exchange for the shares that would have been issued upon exercise of the Option or Stock Appreciation Right had the Option or Stock Appreciation Right been exercised immediately prior to the Change in Control and, with respect to Stock Appreciation Rights, payments in respect of such Stock Appreciation Right been made in shares, and appropriate adjustment also shall be made to the Exercise Price or Base Price such that the aggregate Exercise Price of each such Option or new option or Base Price of each Stock Appreciation Right or new stock appreciation right shall remain the same as nearly as practicable and in a manner satisfying the provisions of Sections 409A and 424 of the Code.

(c)If any Option or Stock Appreciation Right is assumed by an acquiring or successor entity (or parent thereof) or a new option or stock appreciation right of comparable value or New Incentive is issued in exchange therefor pursuant to the terms of a Change in Control transaction, then, if so provided in an Option Agreement or Stock Appreciation Right Agreement, the vesting of the Option, new option, Stock Appreciation Right, new stock appreciation right or New Incentive shall accelerate if and at such time as the Participant's service as an employee, director, officer, consultant or other Service Provider to the acquiring or successor entity (or a parent or subsidiary thereof) is terminated involuntarily or voluntarily under certain circumstances within a specified period following consummation of the Change in Control, pursuant to such terms and conditions as shall be set forth in the Option Agreement or Stock Appreciation Right Agreement.

69


Table of Contents

(d)If vesting of outstanding Options or Stock Appreciation Rights will accelerate pursuant to subsection (a) above, the Administrator in its discretion may provide, in connection with the Change in Control transaction, for the purchase or exchange of each Option or Stock Appreciation Right for an amount of cash or other property having a value equal to (i) with respect to each Option, the amount (or "spread"), if any, by which, (x) the value of the cash or other property that the Optionee would have received pursuant to the Change in Control transaction in exchange for the shares issuable upon exercise of the Option had the Option been exercised immediately prior to the Change in Control, exceeds (y) the Exercise Price of the Option, and (ii) with respect to each Stock Appreciation Right, the value of the cash or other property that the Participant would have received had the Stock Appreciation Right been exercised immediately prior to the Change in Control.

(e)The Administrator shall have the discretion to provide in each Option Agreement and Stock Appreciation Right Agreement other terms and conditions that relate to (i) vesting of such Option or Stock Appreciation Right in the event of a Change in Control and (ii) assumption of such Options or Stock Appreciation Rights or issuance of comparable securities or New Incentives in the event of a Change in Control.  The aforementioned terms and conditions may vary in each Option Agreement and Stock Appreciation Right Agreement, and may be different from and have precedence over the provisions set forth in Sections 10.1(a) - 10.1(d) above.

(f)Outstanding Options and Stock Appreciation Rights shall terminate and cease to be exercisable upon consummation of a Change in Control except to the extent that the Options or Stock Appreciation Rights are assumed by the successor entity (or parent thereof) pursuant to the terms of the Change in Control transaction.

(g)If outstanding Options or Stock Appreciation Rights will not be assumed by the acquiring or successor entity (or parent thereof), the Administrator shall cause written notice of a proposed Change in Control transaction to be given to the Participants who hold Options and Stock Appreciation Rights not less than fifteen (15) days prior to the anticipated effective date of the proposed transaction.

11.2Restricted Stock and Restricted Stock Units.  In order to preserve a Participant's rights with respect to any outstanding Restricted Stock or Restricted Stock Units, in the event of a Change in Control of the Company:

(a)All Restricted Stock and Restricted Stock Units shall vest in full effective as of immediately prior to the consummation of the Change in Control, except to the extent that in connection with such Change in Control, the acquiring or successor entity (or parent thereof) provides for the continuance or assumption of Restricted Stock Agreements or Restricted Stock Unit Agreements or the substitution of new agreements of comparable value covering shares of a successor corporation (with appropriate adjustments as to the number and kind of shares) or cash or other property.

(b)The Administrator in its discretion may provide in any Restricted Stock Agreement and Restricted Stock Unit Agreement that if, upon a Change in Control, the acquiring or successor entity (or parent thereof) assumes such Restricted Stock Agreement or Restricted Stock Unit Agreement, or substitutes new agreements of comparable value and containing such terms and provisions as the Administrator in its discretion may consider equitable covering shares of a successor corporation (with appropriate adjustments as to the number and kind of shares) or cash or other property, then the Restricted Stock or Restricted Stock Units or any substituted shares, cash or property covered thereby shall immediately vest in full, if the Participant's service as an employee, director, officer, consultant or other Service Provider to the acquiring or successor entity (or a parent or subsidiary thereof) is terminated involuntarily or voluntarily under certain circumstances within a specified period following consummation of a Change in Control, pursuant to such terms and conditions as shall be set forth in the Restricted Stock Agreement or Restricted Stock Unit Agreement.

(c)If vesting of outstanding Restricted Stock or Restricted Stock Units will accelerate pursuant to subsection (a) above, the Administrator in its discretion may provide, in connection with the Change in Control transaction, for the purchase or exchange of each Restricted Stock or Restricted Stock Units for an amount of cash or other property having a value equal to the value of the cash or other property that the Participant would have received had the Restricted Stock or Restricted Stock Units vested immediately prior to the Change in Control.

(d)The Administrator shall have the discretion to provide in each Restricted Stock Agreement or Restricted Stock Unit Agreement other terms and conditions that relate to (i) vesting of such Restricted Stock or Restricted Stock Units in the event of a Change in Control and (ii) assumption of such Restricted Stock Agreements or Restricted Stock Unit Agreements or issuance of substitute new agreements of comparable value in the event of a Change in Control.  The aforementioned terms and conditions may vary in each Restricted Stock Agreement or Restricted Stock Unit Agreement, and may be different from and have precedence over the provisions set forth in Sections 10.2(a) - 10.2(c) above.

70


Table of Contents

11.3Dissolution or Liquidation.  Except as otherwise provided in an Option Agreement, Restricted Stock Agreement, Restricted Stock Unit Agreement, or Stock Appreciation Right Agreement, in the event of a dissolution, liquidation or winding up of the Company, all outstanding Options, Stock Appreciation Rights, and Restricted Stock Units will terminate immediately prior to the completion of such dissolution or liquidation, and the Ordinary Shares subject to the Company's repurchase rights or subject to a forfeiture condition under an award of Restricted Stock or Restricted Stock Units or pursuant to early exercise of an Option, may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such award is providing Continuous Service; provided, however, that the Administrator may, in its sole discretion, cause some or all Options, Restricted Stock, Restricted Stock Units and Stock Appreciation Rights to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such awards have not previously expired or terminated) before the dissolution, liquidation or winding up is completed but contingent on its completion.

11.4Compliance with Sections 409A and 457A of the Code.  Notwithstanding anything else provided in this Article 11, in the case of any Option, Restricted Stock, Restricted Stock Unit or Stock Appreciation Right that constitutes a deferral of compensation within the meaning of Section 409A or 457A of the Code, the Committee will not accelerate the payment of such Option, Restricted Stock, Restricted Stock Unit or Stock Appreciation Right unless it determines in good faith that such accelerated payment is permissible under Sections 409A or 457A of the Code, as applicable.

ARTICLE 12.

AMENDMENT AND TERMINATION OF THE PLAN

12.1Amendments.  The Board may from time to time alter, amend, suspend or terminate this Plan in such respects as the Board may deem advisable.  No such alteration, amendment, suspension or termination shall be made which shall substantially affect or impair the rights of any Participant under an outstanding Option Agreement, Restricted Stock Agreement, Restricted Stock Unit Agreement, or Stock Appreciation Right Agreement without such Participant's consent.  The Board may alter or amend the Plan to comply with requirements under the Code relating to Incentive Options or other types of options which give Optionees more favorable tax treatment than that applicable to Options granted under this Plan as of the date of its adoption.  Upon any such alteration or amendment, any outstanding Option granted hereunder may, if the Administrator so determines and if permitted by applicable law, be subject to the more favorable tax treatment afforded to an Optionee pursuant to such terms and conditions.  The Board may also adopt amendments of the Plan relating to certain nonqualified deferred compensation under Section 409A or Section 457A of the Code and/or ensuring the Plan or any awards granted under the Plan are exempt from, or compliant with, the requirements for nonqualified deferred compensation under Section 409A or Section 457A of the Code, subject to the limitations, if any, of applicable law.

12.2Foreign Participants.  The Board may from time to time adopt such procedures and sub‑plans as are necessary or appropriate to permit participation in the Plan by Employees, Directors or Service Providers who are foreign nationals or employed outside Jersey, Channel Islands (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Option Agreement, Restricted Stock Agreement, Restricted Stock Unit Agreement, or Stock Appreciation Right Agreement that are required for compliance with the laws of the relevant foreign jurisdiction).

12.3Plan Termination.  Unless this Plan shall theretofore have been terminated, the Plan shall terminate on the tenth (10th) anniversary of the Effective Date and no Options, Restricted Stock, Restricted Stock Units, or Stock Appreciation Rights may be granted under the Plan thereafter, but Option Agreements, Restricted Stock Agreements, Restricted Stock Unit Agreements, and Stock Appreciation Right Agreements then outstanding shall continue in effect in accordance with their respective terms.

ARTICLE 13.

TAXES

13.1Withholding.  The Company shall have the power to withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy any applicable Federal, state, and local tax withholding requirements with respect to any Options, Restricted Stock, Restricted Stock Units, or Stock Appreciation Rights.  To the extent permissible under applicable tax, securities and other laws, the Administrator may, in its sole discretion and upon such terms and conditions as it may deem appropriate, permit a Participant to satisfy his or her obligation to pay any such tax by (a) directing the Company to apply Ordinary Shares to which the Participant is entitled as a result of the exercise of an Option or Stock Appreciation Right or vesting of a Restricted Stock or Restricted Stock Unit or (b) delivering to the Company Ordinary Shares owned by the Participant.  The Ordinary Shares so applied or delivered in satisfaction of the Participant's minimum tax withholding obligation shall be valued at their Fair Market Value as of the date of measurement of the amount of income subject to withholding.

71


Table of Contents

13.2Compliance with Section 409A of the Code.  Options, Restricted Stock, Restricted Stock Units, and Stock Appreciation Rights to individuals subject to taxation in the United States will be designed and operated in such a manner that they are either exempt from the application of, or comply with, the requirements of Section 409A of the Code such that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable under Section 409A of the Code, except as otherwise determined in the sole discretion of the Administrator.  The Plan and each Option Agreement, Restricted Stock Agreement, Restricted Stock Unit Agreement, and Stock Appreciation Right Agreement is intended to meet the requirements of Section 409A of the Code and will be construed and interpreted in accordance with such intent, except as otherwise determined in the sole discretion of the Administrator.  To the extent that an Option, Restricted Stock, Restricted Stock Units, or Stock Appreciation Right or grant, payment, settlement or deferral thereof is subject to Section 409A of the Code such Option, Restricted Stock, Restricted Stock Units, or Stock Appreciation Right will be granted, paid, settled or deferred in a manner that will meet the requirements of Section 409A of the Code, such that the grant, payment, settlement or deferral thereof will not be subject to the additional tax or interest applicable under Section 409A of the Code.  Notwithstanding the generality of the preceding sentence, to the extent any grant, payment, settlement or deferral of an Option Agreement, Restricted Stock Agreement, Restricted Stock Unit Agreement, or Stock Appreciation Right Agreement subject to Section 409A is subject to the requirement under Section 409A(a)(2)(B)(i) of the Code that such grant, payment, settlement or deferral be delayed until six (6) months after Participant's separation from service if Participant is a specified employee within the meaning of the aforesaid section of the Code at the time of such separation from service, then such grant, payment, settlement or deferral will not be made before the date which is six (6) months after the date of such separation from service (or, if earlier, the date of death of such Participant).

(a)Compliance with Section 457A of the Code.  Options, Restricted Stock, Restricted Stock Units, and Stock Appreciation Rights to individuals subject to taxation in the United States will be designed and operated in such a manner that they are either exempt from the application of, or comply with, the requirements of Section 457A of the Code such that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable under Section 457A of the Code, except as otherwise determined in the sole discretion of the Administrator.  The Plan and each Option Agreement, Restricted Stock Agreement, Restricted Stock Unit Agreement, and Stock Appreciation Right Agreement is intended to meet the requirements of Section 457A of the Code and will be construed and interpreted in accordance with such intent, except as otherwise determined in the sole discretion of the Administrator.  To the extent that an Option, Restricted Stock, Restricted Stock Unit or Stock Appreciation Right or grant, payment, settlement or deferral thereof is subject to Section 457A of the Code such Option, Restricted Stock, Restricted Stock Unit or Stock Appreciation Right will be granted, paid, settled or deferred in a manner that will meet the requirements of Section 457A of the Code, such that the grant, payment, settlement or deferral thereof will not be subject to the additional tax or interest applicable under Section 457A of the Code, and may contain terms compliant with the following limitations: Options and Stock Appreciation Rights subject to Section 457A of the Code will be settled in Ordinary Shares only.  In no event will any Option or Stock Appreciation Right be settled in cash;

(b)A Participant's continued service with the Company, a parent of the Company or a subsidiary will be required in order for Options, Restricted Stock, Restricted Stock Unit and Stock Appreciation Rights subject to Section 457A of the Code to vest.  In no event will any Options, Restricted Stock, Restricted Stock Unit and Stock Appreciation Rights subject to Section 457A of the Code provide for vesting (1) upon voluntary termination, (2) solely on the basis of achievement of performance goals or objectives, or (3) following termination of a Participant's employment or service relationship with the Company;

(c)The Ordinary Shares underlying Restricted Stock and Restricted Stock Units subject to Section 457A of the Code in which the Participant vests (whether as a result of the normal vesting schedule or as a result of accelerated vesting) will be issued on the applicable vesting date for those shares or as soon thereafter as administratively practicable, but in no event later than the close of the calendar year in which such vesting date occurs or (if later) the fifteenth day of the third calendar month following such vesting date; and

(d)Options or Stock Appreciation Rights subject to Section 457A of the Code in which the Participant vests (whether as a result of the normal vesting schedule or as a result of accelerated vesting) must be exercised no later than the close of the calendar year in which such vesting date occurs or (if later) the fifteenth day of the third calendar month following such vesting date.

Notwithstanding the provisions of Section 13.3, the Committee may, when appropriate, grant Options, Restricted Stock, Restricted Stock Units and Stock Appreciation Rights pursuant to this Plan to individuals subject to taxation in the United States with terms that do not comply with the provisions of Code Section 457A, subjecting such individual to early income recognition under Code Section 457A attributable to such Options, Restricted Stock, Restricted Stock Units or Stock Appreciation Rights.  Similarly, the Committee may, when appropriate, amend the Options, Restricted Stock, Restricted Stock Units or Stock Appreciation Rights made pursuant to this Plan to add terms that do not comply with the provisions of Code Section 457A, subjecting holder of the Options, Restricted Stock, Restricted Stock Units or Stock Appreciation Rights to early income recognition under Code Section 457A attributable to such Options, Restricted Stock, Restricted Stock Units or Stock Appreciation Rights.

72


Table of Contents

ARTICLE 14.

MISCELLANEOUS

14.1Benefits Not Alienable.  Other than as provided above, benefits under this Plan may not be assigned or alienated, whether voluntarily or involuntarily.  Any unauthorized attempt at assignment, transfer, pledge or other disposition shall be without effect.

14.2No Enlargement of Employee Rights.  This Plan is strictly a voluntary undertaking on the part of the Company and shall not be deemed to constitute a contract between the Company and any Participant to be consideration for, or an inducement to, or a condition of, the employment of any Participant.  Nothing contained in the Plan shall be deemed to give the right to any Participant to be retained as an employee of the Company or any Affiliated Company or to interfere with the right of the Company or any Affiliated Company to discharge any Participant at any time.  The Company will have no duty or obligation to any Participant to advise such holder as to the time or manner of exercising any right under any outstanding awards under the Plan.  Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Option or any other form of award under the Plan or a possible period in which such Option or other award may not be exercised.  The Company has no duty or obligation to reduce the tax consequences of any award granted to a Participant under the Plan.

14.3Application of Funds.  The proceeds received by the Company from the sale of Ordinary Shares pursuant to Option Agreements, Restricted Stock Unit Agreements or Restricted Stock Agreements, except as otherwise provided herein, will be used for general corporate purposes.

14.4Annual Reports.  During the term of this Plan, the Company will furnish to each Participant who does not otherwise receive such materials, copies of all reports, proxy statements and other communications that the Company distributes generally to its shareholders or as otherwise required by applicable law.

14.5Adoption and Shareholder Approval.  This Plan will become effective on the Effective Date and will be approved by the shareholders of the Company (excluding Ordinary Shares issued pursuant to this Plan), consistent with applicable laws, within twelve (12) months before or after the Effective Date.  Upon the Effective Date, the Administrator may grant Options, Restricted Stock, Restricted Stock Units or Stock Appreciation Rights pursuant to this Plan; provided, however, that: (a) no Option or Stock Appreciation Right may be exercised prior to initial shareholder approval of this Plan; (b) no Option or Stock Appreciation Right granted pursuant to an increase in the number of Ordinary Shares approved by the Administrator shall be exercised prior to the time such increase has been approved by the shareholders of the Company; (c) in the event that initial shareholder approval is not obtained within the time period provided herein, all Options, Restricted Stock, Restricted Stock Units or Stock Appreciation Rights shall be canceled, any Ordinary Shares issued pursuant to any such Options, Restricted Stock, Restricted Stock Units or Stock Appreciation Rights shall be canceled and any purchase of such Ordinary Shares issued hereunder shall be rescinded; and (d) Options, Restricted Stock, Restricted Stock Units or Stock Appreciation Rights granted pursuant to an increase in the number of Ordinary Shares approved by the Administrator which increase is not approved by shareholders within the time then required and any Ordinary Shares issued pursuant to any such Options, Restricted Stock, Restricted Stock Units or Stock Appreciation Rights shall be canceled, and any purchase of Ordinary Shares subject to any such Options, Restricted Stock, Restricted Stock Units or Stock Appreciation Rights shall be rescinded.

14.6Electronic Delivery.  Any reference herein to a "written" agreement or document shall include any agreement or document delivered electronically or posted on the Company's intranet.

14.7Governing Law.  The Plan shall be governed by and construed in accordance with the laws of Jersey without reference to the principles of conflicts of laws thereof.

73


Table of Contents

Proxy – Quotient Limited

 

Proxy Solicited by Board of Directors for the AnnualExtraordinary General Meeting of Shareholders – October 31, 2022April 25, 2023

 

The Chairman of the EGM, Quotient Head of Legal & Compliance, and any director of Quotient Limited, and Quotient Chief Financial Officer, or any of them, each with the power of substitution, are hereby authorized to represent and vote the shares of the undersigned, with all the powers which the undersigned would possess if personally present, at the AnnualExtraordinary General Meeting of Shareholders of Quotient Limited to be held on October 31, 2022April 25, 2023 or at any postponement or adjournment thereof.

 

Shares represented by this proxy will be voted as directed by the shareholder. If no such directions are indicated, the Proxies will have authority to vote FOR all director nominees and FOR Proposals 10 through 14.Proposal 1.

 

PLEASE MARK, SIGN, DATE, AND RETURN THIS PROXY CARD

PROMPTLY USING THE ENCLOSED ENVELOPE.

 

 

Important Notice Regarding the Availability of Proxy Materials for the AnnualExtraordinary General Meeting of Shareholders

of Quotient Limited to be held on October 31, 2022.April 25, 2023. The 2022Notice and Proxy Statement and our Annual Report on Form 10-K for the

fiscal year ended March 31, 2022, Extraordinary General Meeting of Shareholders, are available at www.okapivote.com/Quotient

CONTINUED AND TO BE SIGNED AND DATED ON REVERSE SIDE.

 

SEE REVERSE SIDE

 

SEE REVERSE SIDE

 

 

 

 

▲ PLEASE DETACH ALONG PERFORATED LINE AND MAIL IN THE ENVELOPE PROVIDED. ▲

 

 

Electronic Voting Instructions

You can vote by Internet or telephone!

Available 24 hours a day, 7 days a week!

 

 

 

Instead of mailing your proxy, you may choose one of the two voting methods outlined below to vote your proxy.

 

 

 

Proxies submitted by Internet or telephone must be received by 11:59 p.m.00 a.m., EasternGreenwich Mean Time on October 30, 2022.April 23, 2023.

 

 

 

img148208479_4.jpg 

 

Vote by Internet

 

 

 

• Log on to the Internet and go to www.OkapiVote.Com/QTNT

 

 

 

• Follow the steps outlined on the secure website.

 

 

 

img148208479_5.jpg 

 

Vote by telephone

 

 

 

• At NO CHARGE to you, call toll free (888) 391-6465 within the USA, US territories & Canada any time on a touch tone telephone.

 

 


Table QUOTIENT LIMITED

(the "Company")

FORM OF PROXY

EXTRAORDINARY GENERAL MEETING OF THE COMPANY WHICH ALSO CONSTITUTES A CLASS MEETING OF HOLDERS OF ORDINARY SHARES OF THE COMPANY (EGM)

I/We …………………………………………………………………………………………………………

of Contents…………………………………………………………………………………………………………

(Please insert full name(s) and address(es) in block capitals.)

being a member/members of the Company holding ………………………………………………………… shares hereby appoint ………………………………………………………… of ………………………………………………………… or failing him/her the duly appointed Chairman of the EGM, Quotient Head of Legal & Compliance, any director of Quotient Limited, and Quotient Chief Financial Officer, or any of them, each with the power of substitution, as my/our proxy, to attend and vote for me/us on my/our behalf at the EGM to be held on April 25, 2023 at 11:00 a.m. GMT and at any adjournment thereof,

Using a black ink pen, mark your votesI/We instruct my/our proxy to vote on the resolutions proposed at the meeting as indicated on this form with an "X", or the relevant number of shares (see note 4 below), as shown in this example. Please do not write outside the designated areas.follows:

Annual General Meeting Proxy Card

A – Proposals – The Board of Directors unanimously recommends a vote “FOR” the nominees for Director in Proposals 1-9 and “FOR” the approval of Proposals 10 through 14.

Mark here to vote as the Board recommends.S/N

Special Resolution

Mark here to vote FORallFor

Mark here to withhold vote from allAgainst

Vote Withheld

1.

     nominees.

     nominees.

ElectionTHAT a merger implementation agreement dated [ , 2023] between the Company, Quotient Holdings Merger Company Limited and Quotient Holdings Finance Company Limited (the "Merger Implementation Agreement") and which contains, among other things, the terms and means of Directors until the next Annual General Meetingeffecting a proposed merger (“Merger”) of the Company:

☐ Company and Quotient Holdings Merger Company Limited under Article 18B (Mergers) of the Companies (Jersey) Law 1991 (the "ForLaw") be hereby approved for all EXCEPT– To withhold authoritypurposes, including (without limitation) for the purposes of Article 127F(1) of the Law and the directors of the Company (or a duly authorised committee thereof) be and are authorised to votetake all such action as they may consider necessary or desirable for a nominee, write the

01 – Manuel O. Méndez 02 – Isabelle Buckle                03 – Frederick Hallsworth     04 – Catherine Larue

05 – Thomas Aebischer     06 – Heino von Prondzynski   07 – Zubeen Shroff                08 – John Wilkerson  09 – Sophie Bechu

     name implementation of such nominee below.

the Merger pursuant to the terms and subject to the conditions contained in the Merger Implementation Agreement.

 

 

 


Please tick to indicate your voting preference above. If you do not complete this section, your proxy will vote or abstain at his/her discretion, as he/she will on any other business that may be raised at the EGM.

Signature(s) ………………………………………………………………………………………………

Full Name ……………………………………………………………………………..................

(Please insert in block capitals.)

Date ………………………………………………2023


NOTES

1.
A proxy need not be a member. Please insert the name of the person(s) who you wish to be appointed as your proxy or proxies in the space provided. If you leave this section blank the Chairman of the EGM, Quotient Head of Legal & Compliance, any director of Quotient Limited, and Quotient Chief Financial Officer, or any of them, each with the power of substitution, will be appointed as your proxy and authorized to represent and vote your shares, with all the powers which you would possess if personally present.
2.
A member may appoint more than one person as his proxy in respect of the same meeting or resolution provided that the appointment of the proxy shall specify the number of shares in respect of which the proxy is appointed and only one proxy shall be appointed in respect of any one share.
3.
If this form is returned without an indication as to how the proxy shall vote, the proxy will exercise his/her discretion as to whether he/she votes on the specified resolutions and on any other business (including on a motion to amend a resolution, to propose a new resolution or to adjourn the meeting) which may properly come before the EGM. If instruction is given to abstain from voting in respect of any resolution, this instruction will be deemed to be neither a vote for or against the resolution.
4.
If you wish your proxy to cast all of your votes for or against a resolution, you should insert an "X" in the appropriate box. If you wish your proxy to cast only certain votes for and certain votes against, insert the relevant number of shares in the appropriate box.
5.
This form of proxy is for use by members only. Any member or other person which is a body corporate may, by resolution of its directors or other governing body, authorise a person to act as its representative at any EGM. Such representative may be required to produce a certified copy of the resolution of authorisation he/she is permitted to exercise his/her powers.
6.
To be valid, this form must be completed and returned (together with any power of attorney or other authority (if any) under which it is signed or a notarially certified copy of such power or authority) to Okapi Partners LLC, 1212 Avenue of the Americas, 17th floor, New York, NY 10036 (United States of America), to the attention of Teresa Huang. This instrument of proxy must be deposited not less than forty-eight hours before the time appointed for the EGM.
7.
Any alterations made to this form must be initialled by you.
8.
The completion and return of this form will not prevent you from attending the EGM and voting in person should you so wish. Please refer to the further guidance provided in the proxy statement if you wish to attend the EGM in person.

 


Proxy – Quotient Limited

Proxy Solicited by Board of Directors for the Preference Class Meeting of Preference Shareholders ("Preference Class Meeting") – April 25, 2023

The Chairman of the Preference Class Meeting, Quotient Head of Legal & Compliance, any director of Quotient Limited, and Quotient Chief Financial Officer, or any of them, each with the power of substitution, are hereby authorized to represent and vote the shares of the undersigned, with all the powers which the undersigned would possess if personally present, at the Preference Class Meeting of Quotient Limited to be held on April 25, 2023 or at any postponement or adjournment thereof.

Shares represented by this proxy will be voted as directed by the shareholder. If no such directions are indicated, the Proxies will have authority to vote FOR Proposal 1.

PLEASE MARK, SIGN, DATE, AND RETURN THIS PROXY CARD

PROMPTLY USING THE ENCLOSED ENVELOPE.

Important Notice Regarding the Preference Class Meeting of Quotient Limited to be held on April 25, 2023. The Notice and Proxy Statement for the Preference Class Meeting, are available at www.okapivote.com/Quotient

CONTINUED AND TO BE SIGNED AND DATED ON REVERSE SIDE.

10. A non-binding, advisory vote on the compensation paid to the Company’s named executive officers, as described in the “Executive Compensation - Compensation Discussion and Analysis” section of the Company’s proxy statement and the related compensation tables, notes and narrative discussion.

11. Proposal to approve the Fourth Amended and Restated 2014 Stock Incentive Plan (the "Fourth Amended and Restated 2014 Plan"), which reflects amendments to the Third Amended and Restated 2014 Stock Incentive Plan (the "2014 Plan") to (a) increase the number of ordinary shares authorized for issuance by 10’000’000 shares, and (b) remove the "evergreen" provision pursuant to which the aggregate number of shares authorized for issuance automatically increases each year.

FOR AGAINST ABSTAIN

FOR AGAINST ABSTAIN

12. Proposal to re-appoint Ernst & Young LLP as the Company’s auditors from the conclusion of this meeting until the next Annual General Meeting of the Company to be held in 2023, to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm and to authorize the directors to determine the fees to be paid to the auditors.

13. Proposal to vary the rights attaching to the common stock of the Company (ordinary shares) so that the Company acting by its board of directors shall have the power to undertake a reverse stock split (consolidation) of all of the ordinary shares in the capital of the Company in issue at the time of such reverse stock split, at such ratio as shall be determined by the board of directors of the Company, without further approval or authorization of the shareholders (the "Reverse Stock Split"), such power to be subject to the following conditions: (a) the ratio of the Reverse Stock Split must be a whole number between 1-for-10 and 1-for 40; (b) the Reverse Stock Split must be completed no later than the one year anniversary of the date of the Annual General Meetings; (c) with the exact ratio to be set within that range at the discretion of the board of directors, without further approval or authorization of the shareholders, and (d) to the extent the Reverse Stock Split causes any shareholder to hold a fractional number of shares, such fractions shall be dealt with in accordance with article 11.2 of the articles of association of the Company.

FOR AGAINST ABSTAIN

FOR AGAINST ABSTAIN

14. Proposal to delete article 20.9 in its entirety from the articles of association of the Company and to insert in its place of a new article 20.9 whereby for the purposes of determining which persons are entitled to attend or vote at a meeting and how many votes such person may cast, the Company acting by its board of directors may specify a time in the notice of the meeting, such time being no more than 21 days before the day that notice of the meeting is sent, by which a person must be entered on the register of members in order to have the right to attend or vote at the meeting.

FOR AGAINST ABSTAIN

B. – Authorized Signatures – This section must be completed for your vote to be counted. – Date and Sign Below.

Please sign exactly as name appears hereon. When joint tenants hold shares, both should sign. When signing as attorney, executor, administrator, trustee, or guardian, please give full title as such. If a corporation, please sign in full corporate name by president or other authorized officer. If a partnership, please sign in partnership name by authorized person.

Date (mm/dd/yyyy) – Please print date below.SEE REVERSE SIDE

 

Signature 1 –Please keep signature within the box.

Signature 2 –Please keep signature within the box.

/                       /

SEE REVERSE SIDE

 

 

 

▲ PLEASE DETACH ALONG PERFORATED LINE AND MAIL IN THE ENVELOPE PROVIDED. ▲

 

 


QUOTIENT LIMITED

(the "Company")

FORM OF PROXY

PREFRENCE CLASS MEETING OF THE COMPANY (the Meeting)

I/We …………………………………………………………………………………………………………

of …………………………………………………………………………………………………………

(Please insert full name(s) and address(es) in block capitals.)

being a member/members of the Company holding ………………………………………………………… shares hereby appoint ………………………………………………………… of ………………………………………………………… or failing him/her the duly appointed Chairman of the Meeting, Quotient Head of Legal & Compliance, any director of Quotient Limited, and Quotient Chief Financial Officer, or any of them, each with the power of substitution, as my/our proxy, to attend and vote for me/us on my/our behalf at the Meeting to be held on April 25, 2023 immediately following the EGM of April 25, 2023 and at any adjournment thereof,

I/We instruct my/our proxy to vote on the resolutions proposed at the meeting as indicated on this form with an "X", or the relevant number of shares (see note 4 below), as follows:

Special Resolution

For

Against

Vote Withheld

THAT a merger implementation agreement dated [__________, 2023] between the Company, Quotient Holdings Merger Company Limited and Quotient Holdings Finance Company Limited (the "Merger Implementation Agreement") and which contains, among other things, the terms and means of effecting a proposed merger (“Merger”) of the Company and Quotient Holdings Merger Company Limited under Article 18B (Mergers) of the Companies (Jersey) Law 1991 (the "Law") be hereby approved for all purposes, including (without limitation) for the purposes of Article 127F(1) of the Law and the directors of the Company (or a duly authorised committee thereof) be and are authorised to take all such action as they may consider necessary or desirable for the implementation of the Merger pursuant to the terms and subject to the conditions contained in the Merger Implementation Agreement.


Please tick to indicate your voting preference above. If you do not complete this section, your proxy will vote or abstain at his/her discretion, as he/she will on any other business that may be raised at the Meeting.

Signature(s) ………………………………………………………………………………………………

Full Name ……………………………………………………………………………..................

(Please insert in block capitals.)

Date ………………………………………………2023


NOTES

1.
A proxy need not be a member. Please insert the name of the person(s) who you wish to be appointed as your proxy or proxies in the space provided. If you leave this section blank the Chairman of the Meeting, Quotient Head of Legal & Compliance, any director of Quotient Limited, and Quotient Chief Financial Officer, or any of them, each with the power of substitution, will be appointed as your proxy and authorized to represent and vote your shares, with all the powers which you would possess if personally present.
2.
A member may appoint more than one person as his proxy in respect of the same meeting or resolution provided that the appointment of the proxy shall specify the number of shares in respect of which the proxy is appointed and only one proxy shall be appointed in respect of any one share.
3.
If this form is returned without an indication as to how the proxy shall vote, the proxy will exercise his/her discretion as to whether he/she votes on the specified resolutions and on any other business (including on a motion to amend a resolution, to propose a new resolution or to adjourn the meeting) which may properly come before the Meeting. If instruction is given to abstain from voting in respect of any resolution, this instruction will be deemed to be neither a vote for or against the resolution.
4.
If you wish your proxy to cast all of your votes for or against a resolution, you should insert an "X" in the appropriate box. If you wish your proxy to cast only certain votes for and certain votes against, insert the relevant number of shares in the appropriate box.
5.
This form of proxy is for use by members only. Any member or other person which is a body corporate may, by resolution of its directors or other governing body, authorise a person to act as its representative at any Meeting. Such representative may be required to produce a certified copy of the resolution of authorisation he/she is permitted to exercise his/her powers.
6.
To be valid, this form must be completed and returned (together with any power of attorney or other authority (if any) under which it is signed or a notarially certified copy of such power or authority) to Okapi Partners LLC, 1212 Avenue of the Americas, 17th floor, New York, NY 10036 (United States of America), to the attention of Teresa Huang. This instrument of proxy must be deposited not less than forty-eight hours before the time appointed for the Meeting.
7.
Any alterations made to this form must be initialled by you.
8.
The completion and return of this form will not prevent you from attending the Meeting and voting in person should you so wish. Please refer to the further guidance provided in the proxy statement if you wish to attend the Meeting in person.